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The readers are receiving this outstanding book which documents major 
advancements in the field of ocular oncology. Ocular oncology services are 
typically provided by highly trained subspecialists. However, general oph-
thalmologists also need to be sufficiently familiar with early signs, diagnos-
tics, and treatment options to ensure timely management of oncological eye 
conditions which may progress into vision and life-threatening diseases. 
Several years of collaborative work have brought together more than 25 
authors comprising ophthalmic oncologists, ophthalmic plastic and recon-
structive surgeons, vitreo-retinal surgeons, ocular pathologists, and radiation 
oncologists from many internationally renowned healthcare institutions 
around the world.
This book was designed to describe symptoms, diagnostic, and treatment 
approaches for oncologic conditions. It includes indications, pre- and postop-
erative care, and surgical techniques required to manage various eye cancer 
ailments with the help of ample illustrations. The text provides a detailed 
approach to treatment for common and rare diseases and summarizes the key 
points required for performing the surgeries. The video atlas, comprising of 
more than 20 well-edited videos, is a valuable opportunity to review the 
actual surgical steps and enables the readers to understand the procedures in 
a comprehensive manner. The learning experience of the user is significantly 
enhanced by these easy-to-follow tutorials.
This book is fully in line with the strategic goals of the International 
Council of Ophthalmology (ICO) to improve patient’s lives and eyesight by 
improving education and knowledge. General ophthalmologists, ocular 
oncologists, fellows, and residents as well as students in training will all stand 
to benefit from this unique collaborative effort. The truly international coop-
eration, the open-access nature and availability of the book everywhere in the 
world, and this up-to-date resource as a guiding tool in the field of surgical 
ophthalmic oncology make it a special delight for the ICO.
Peter Wiedemann, MD
Ivo Kocur, MD
International Council of Ophthalmology
San Francisco, CA, USA
Foreword
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Ophthalmic oncologists care for the rare and unusual tumors of the eye, lids, 
and orbit. Around the world, there exist fewer than 300 known eye cancer 
surgeons. In fact, there are almost 40 countries with no fellowship-trained eye 
cancer specialist and many more that are underserved.
In 2015, the first Eye Cancer Working Day was held at the Curie Institute 
in Paris, France. During that meeting, Drs. Honavar and Finger recognized 
the opportunity to address the needs of the millions of eye cancer patients 
who do not have access to subspecialty care. It was proposed that a book 
containing preferred practice guidelines with surgical videos be published in 
an open-access format to offer ophthalmic surgeons guidance in underserved 
and unserved countries.
After almost 2.5 years of work, this book is a result of collaborative efforts 
of more than 25 authors which include ophthalmic oncologists, ophthalmic 
plastic and reconstructive surgeons, vitreoretinal surgeons, ocular patholo-
gists, and radiation oncologists from various renowned centers spread over in 
total of five continents. We have enjoyed this unique opportunity to work with 
all the contributors in collaboration.
With the help of ‘The Eye Cancer Foundation’, this project has materialized into a 
textbook and video atlas of surgical techniques involved in managing diseases 
related to ophthalmic oncology. We are hopeful that it would be a valuable resource 
for general ophthalmologists, surgeons as well as fellows and trainees around the 
world who encounter these diseases in the care of their patients. (Paul T. Finger, 
MD, Chief Executive Officer of the Eye Cancer Foundation (ECF))
The layout of this book has been organized so that it is simple to use as a 
quick reference. This book covers tumors of the eyelid, cornea, conjunctiva, 
and orbit as well as intraocular tumors. A chapter dedicated to ophthalmic 
radiation therapy has been added to describe the eye sparing methods of treat-
ment. It provides vital key points regarding radiation physics to be considered 
by ophthalmic oncologists during radiation treatment planning. Ophthalmic 
pathology is an integral part of ophthalmic oncology. A chapter on pathology 
has been included to guide the operating surgeons with the essential guide-
lines regarding specimen collection, transport, and interpretation of pathol-
ogy report.
This book was designed to include indications, pre- and postoperative 
care, and surgical techniques required to manage the various eye cancer ail-
ments with the help of ample illustrations. The text provides a detailed 
approach to treatment and summarizes the key points required for performing 
Preface
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the surgeries, whereas the video atlas gives an opportunity to review the 
actual surgical steps as a guiding tool. The atlas comprising of more than 20 
well-edited videos would enable the readers to understand the procedures in 
a more comprehensive manner.
However, we understand that this reference is not a complete compilation 
of all the existent surgical techniques involved in ophthalmic oncology. The 
authors aim to provide preferred practice guidelines from their own experi-
ence. The surgical techniques may vary between different centers, countries, 
and areas of the world. We sincerely hope that this book would be able to 
guide the practitioners from underserved countries with even limited resources 
to manage the diseases which will allow them to adhere to the oncological 
principles and achieve optimal outcomes.
Pune, India Sonal S. Chaugule 
Hyderabad, India Santosh G. Honavar 
New York, NY, USA Paul T. Finger 
Preface
ix
We gratefully acknowledge the important role of Dr. Paul T. Finger and “The 
Eye Cancer Foundation (ECF)” for supporting the concept of a Collaborative 
Open Access Surgical Textbook (COAST) at the First Eye Cancer Working 
Day held at the Curie Institute, Paris, France, in 2015. There, Dr. Santosh 
G. Honavar and colleagues presented COAST as a method to help eye care 
professionals in unserved and underserved areas of the world. The project 
would not have been possible without ECF’s generous contributions. In addi-
tion, we heartily thank the ECF board, trustees, and donors for underwriting 
this open-access effort. We also recognize the encouragement from the lead-
ership of the International Council of Ophthalmology (ICO). All have sup-
ported the idea behind this book and gave constant encouragement during its 
execution.
However, it would not have been possible without all our contributors ful-
filling their roles as authors in a timely manner. Their willingness as well as 
enthusiasm to create what has become a relevant and novel ophthalmic oncol-
ogy resource for ophthalmologists and trainees in developing and under-
served areas around the world has been very impressive. We must also 
acknowledge the reviewers who kindly offered their input for completion of 
chapters, including Drs. Sonal S. Chaugule, Carol Karp, Daniel Rootman, 
Steffen Heegaard, and Vikas Khetan. We thank them for donating their time 
and expertise in reviewing all the chapters.
We are also grateful to the wonderful team of editors at Springer with 
whom Dr. Sonal S.  Chaugule has shepherded this work from inception to 




Part I  Eyelid Tumors
 1  Overview of Eyelid Tumors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   3
Usha Singh and Raghavendra Rao Kolavali
 2  Biopsy Techniques for Eyelid Tumours . . . . . . . . . . . . . . . . . . . . .  11
Albert Wu, Shyamala C. Huilgol, and Dinesh Selva
 3  Excision of Eyelid Tumors: Principles and Techniques . . . . . . . .  15
Gangadhara Sundar and Fairooz P. Manjandavida
 4  Principles and Techniques of Eyelid Reconstruction . . . . . . . . . .  33
Francesco Bernardini and Brent Skippen
 5  Sentinel Lymph Node Biopsy for Conjunctival  
and Ocular Adnexal Tumors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
Sonal S. Chaugule and Bita Esmaeli
Part II  Conjunctival and Corneal Tumors
 6  Overview and Classification of Conjunctival  
and Corneal Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  69
Raksha Rao and Carol L. Shields
 7  Surgical Techniques for Conjunctival  
and Corneal Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  75
Raksha Rao and Carol L. Shields
Part III  Intraocular Tumors
 8  Overview of Intraocular Tumours . . . . . . . . . . . . . . . . . . . . . . . . .  87
Ido Didi Fabian and Mandeep S. Sagoo




Part IV  Orbital Tumors
 10  Overview and Imaging of Orbital Tumors . . . . . . . . . . . . . . . . . . 107
Zeynel A. Karcioglu
 11  Surgical Techniques for Orbital Tumors . . . . . . . . . . . . . . . . . . . . 117
Zeynel A. Karcioglu
Part V  Enucleation and Exenteration
 12  Enucleation and Exenteration . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Santosh G. Honavar and Raksha Rao
 13  Orbital Implants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Kasturi Bhattacharjee, Manab Jyoti Barman, and Sripurna 
Ghosh
Part VI  Ophthalmic Radiotherapy
 14  Ophthalmic Radiotherapy: Plaques and Implants  . . . . . . . . . . . 147
Paul T. Finger, Mark J. Rivard, Sonal S. Chaugule, P. Mahesh 
Shanmugam, Svetlana Saakyan, Hatem Krema, Mandeep S. 
Sagoo, and Wolfgang A. G. Sauerwein
Part VII  Ocular Pathology
 15  Ocular Pathology  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Hardeep Singh Mudhar
 Appendices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
 Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
Contents
xiii
Manab  Jyoti  Barman, DO, DNB Ocular Oncology  Services, Sri 
Sankaradeva Nethralaya, Guwahati, India
Francesco Bernardini, MD Oculoplastica Bernardini, Genoa, Italy
Kasturi Bhattacharjee, MS, DNB, FRCS Department of Orbit, Ophthalmic 
Plastic and Reconstructive Surgery, Sri Sankaradeva Nethralaya, Guwahati, 
India
Sonal  S.  Chaugule, MBBS, MS Ophthalmic Plastic Surgery, Orbit and 
Ocular Oncology, PBMA’s H V Desai Eye Hospital, Pune, India
Bita Esmaeli, MD, FACS Orbital Oncology and Ophthalmic Plastic Surgery 
Service, Department of Plastic Surgery, The University of Texas M.  D. 
Anderson Cancer Center, Houston, TX, USA
Ido Didi Fabian, MD Goldschleger Eye Institute, Sheba Medical Center, 
Tel-Aviv University, Tel-Aviv, Israel
International Centre for Eye Health, London School of Hygiene and Tropical 
Medicine, London, UK
Paul T. Finger, MD, FACS, LFAAO The Eye Cancer Foundation, Inc., The 
New  York Eye Cancer Center, New York University School of Medicine, 
New York, NY, USA
Sripurna  Ghosh Department of Orbit, Ophthalmic Plastic and 
Reconstructive Surgery, Sri Sankaradeva Nethralaya, Guwahati, India 
Dan  S.  Gombos, MD, FACS Section of Ophthalmology, Department of 
Head & Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA
Santosh G. Honavar, MD, FACS Ocular Oncology Service and National 
Retinoblastoma Foundation, Centre for Sight, Hyderabad, India
Shyamala  C.  Huilgol, MBBS (Hons), FACD Dermatology Department, 
Royal Adelaide Hospital, Adelaide, SA, Australia
Zeynel  A.  Karcioglu, MD Department of Ophthalmology, University of 
Virginia, Charlottesville, VA, USA
Raghavendra  Rao  Kolavali, MS Department of Ophthalmology, Post 
Graduate Institute of Medical Education and Research, Chandigarh, India
Contributors
xiv
Hatem  Krema, MD, MSc, FRCS Department of Ophthalmology and 
Vision Sciences, Princess Margaret Hospital, Toronto, ON, Canada
Fairooz  P.  Manjandavida, MD Department of Oculoplasty and Ocular 
Oncology, Horus Specialty Eye Care, Bangalore, India
Hardeep  Singh  Mudhar, BSc, PhD, MBBChir, FRCpath National 
Specialist Ophthalmic Pathology Service (NSOPS), Department of 
Histopathology, Royal Hallamshire Hospital, Sheffield, UK
Raksha Rao, MS, FICO Department of Orbit and Ophthalmic Oncology, 
Narayana Nethralaya, Bangalore, India
Mark J. Rivard, PhD, FAAPM Department of Radiation Oncology, Brown 
University School of Medicine, Providence, RI, USA
Svetlana  Saakyan, MD Department of Ocular Oncology, Moscow 
Helmholtz Research Institute of Eye Diseases, Moscow, Russia
Mandeep S. Sagoo, MB, PhD, FRCA (Ed), FRCOphth Ocular Oncology 
Service, Moorfields Eye Hospital and Retinoblastoma Service, Royal London 
Hospital, UCL Institute of Ophthalmology, London, UK
Wolfgang  A.  G.  Sauerwein, MD Department of Radiation Oncology, 
Strahlenklinik, University Hospital Essen, Essen, Germany
Dinesh  Selva, MBBS, DHSc, FRACS, PhD, FAICO Ophthalmology 
Department, Royal Adelaide Hospital, Adelaide, SA, Australia
P. Mahesh Shanmugam, MBBS, DO, FRCSEd, PhD, FAICO Vitreoretinal 
and Oncology Service, Sankara Eye Hospital, Bangalore, India
Carol  L.  Shields, MD Ocular Oncology Service, Wills Eye Hospital, 
Thomas Jefferson University, Philadelphia, PA, USA
Usha Singh, MS Department of Ophthalmology, Advanced Eye Center, Post 
Graduate Institute of Medical Education and Research, Chandigarh, India
Brent  Skippen, MBBS (HONS), B Med Sci, MPH Department of 
Ophthalmology, Wagga Wagga Rural Referral Hospital, Wagga Wagga, 
NSW, Australia
Gangadhara  Sundar, DO, FRCSEd, FAMS, AB(USA) Orbit and 
Oculofacial Surgery/Ophthalmic Oncology, Department of Ophthalmology, 
National University Hospital, National University of Singapore, Singapore, 
Singapore
Department of Pediatrics, National University Hospital, Singapore, Singapore





3© The Author(s) 2019 
S. S. Chaugule et al. (eds.), Surgical Ophthalmic Oncology, 
https://doi.org/10.1007/978-3-030-18757-6_1
Overview of Eyelid Tumors
Usha Singh and Raghavendra Rao Kolavali
 Overview and Epidemiology
Eyelid is a common place for skin cancer to 
occur and constitute 5–10% of all skin can-
cers. Eyelid neoplasms comprise a variety of 
benign and malignant growths (Table  1.1). 
Significant majority of these growths are benign 
in nature and constitute 82–98% of all neoplasms 
(Table 1.2). There is wide, racial, and probable 
geographical variation reported in the incidence 
of the various eyelid tumors. Eyelid malignancies 
vary in distribution and presentation. The most 
common malignant eyelid tumor in western lit-
erature is basal cell carcinoma (BCC) compris-
ing 86–91% incidence among the Caucasians [7, 
12]. However, in one of the largest series from 
China and India this incidence is much lower, 
consequently sebaceous gland carcinoma (SGC) 
constitutes 32% of all eyelid tumors [6, 13]. In 
studies from Asian countries [2, 14, 15] it is the 
sebaceous gland carcinoma which constitutes the 
majority (67–77%). The mean age for benign 
tumor is lower than that of malignant tumors. 
Epithelial tumor and dermoid cysts are the most 
common eyelid tumor in children [16]. Malignant 
eyelid tumor in children is extremely rare. When 
it presents, is usually a part of a systemic process, 
genetic defects or following radiation treatment 
[17, 18]. Merkel cell carcinomas (MCC) of the 
eyelid are rare neuroendocrine tumor constitut-
ing 5–20% of the head and neck tumor, predomi-
nantly in Caucasians [19].
 Classification of Eyelid Tumors
Eyelid tumors can arise from various histological 
layers eyelid is composed of. Eyelid tumors are 
classified as benign or malignant or according to 
the tissue or cell of origin (Tables 1.2, 1.3 and 1.4). 
They can be subdivided into non- melanocytic and 
melanocytic tumors. Benign epithelial prolifera-
tions such as squamous papilloma, pseudoepi-
theliomatous hyperplasia, seborrheic keratosis, 
keratoacanthoma cysts and nevi are common. 
Among the malignant, BCC (Figs. 1.1 and 1.2) is 
the most common in Caucasians and SGC among 
the Asians (Fig. 1.3), followed by squamous cell 
carcinoma (SCC) and malignant melanoma (MM) 
(Figs. 1.4, 1.5, 1.6, 1.7 and 1.8). The large major-
ity of BCC (93%) was seen in 71% of females 
[2] SGC has predilection for the upper lid [20]. 
Merkel cell cancer has higher prevalence in men. 
Primary malignant melanomas of the eyelid skin 
are rare and account for 0.2–13% of all reported 
U. Singh (*) 
Department of Ophthalmology, Advanced Eye 
Center, Post Graduate Institute of Medical Education 
and Research, Chandigarh, India 
R. R. Kolavali 
Department of Ophthalmology, Post Graduate 
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Table 1.2 Eyelid tumors originating from epidermis
Subtypes Benign Premalignant Malignant
Non-melanocytic Squamous cell papilloma Actinic(solar) keratosis Basal cell carcinoma
Seborrheic keratosis Intraepithelial neoplasia Squamous cell 
carcinoma









Melanocytic Ephelis or freckles Congenital dysplastic 
nevus
Lentigo simplex Lentigo maligna (melanotic 
freckle of Hutchinson)
Melanoma arising from 
nevi
Solar Lentigo Melanoma arising in 
lentigo maligna







Oculodermal nevus of Ota
Eyelid tumors arising from adnexal and cystic lesions
Sebaceous gland 
tumors
Sebaceous gland hyperplasia – Sebaceous gland 
carcinomaSebaceous gland adenoma
Sweat gland and 
lacrimal gland 
tumors
Syringoma Sweat gland (eccrine) 
adenocarcinoma
Papillary syringadenoma Mucinous sweat gland 
adenocarcinoma
Eccrine spiradenoma Apocrine gland 
adenocarcinoma
Eccrine acrospiroma Adenoid cystic 
carcinoma
Porocarcinoma
Eyelid tumors arising from hair follicle












Other benign cystic lesion
1 Overview of Eyelid Tumors
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Xanthelasma Malignant fibrous histiocytoma













Smooth muscle Leiomyoma Leiomyosarcoma
Angiomyoma
Skeletal muscle Rhabdomyoma Rhabdomyosarcoma
Table 1.4 Eyelid tumors arising from vascular, perivascular, neural, lipomatous, cartilage, bone lymphoid tumors, 
hamartomas, and choristomas
Benign Malignant
Vascular Nevus flammeus (port wine stain) Angiosarcoma
Papillary endothelial hyperplasia Lymphangiosarcoma
Capillary hemangioma Kaposi’s sarcoma
Cavernous hemangioma
Venous hemangioma




Perivascular Hemangiopericytoma Malignant hemangiopericytoma
Glomus tumor Malignant glomus tumor
Neural Traumatic neuroma Malignant peripheral nerve sheath 
tumor





















Fig. 1.1 (a) Basal cell carcinoma involving the lower lid. 
(b) Ulcerative basal cell carcinoma involving the medial 
canthus. (c) Basal cell carcinoma involving the upper lid 
with central necrotic area. (d) Morpheaform type of basal 
cell carcinoma involving the lower lid
Fig. 1.2 Extensive basal cell carcinoma involving both 
medial canthi, nose and cheek
Fig. 1.3 Sebaceous gland carcinoma misdiagnosed as 
chalazion and surgically intervened
1 Overview of Eyelid Tumors
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cases [2, 7]. They occur 20 years later than other 
non-melanoma tumor and have 2.6 times predilec-
tion for the lower lid. Eyelids can also be involved 
by secondary and metastatic lesions.
All primary carcinomas of the eyelid can be 
classified based on their clinical and histologi-
cal presentation using the TNM [tumor, nodes 
(lymph), metastasis] by AJCC (8th Ed) classifi-
cation system [21]. TNM staging describes the 
size of tumor, number and location of regional 
lymph nodes which have malignant cells in them 
and whether the malignant cells have spread or 
metastasized to another part of the body. The 
TNM classification of eyelid carcinomas reflects 
both morbidity and mortality risks in order to pro-
vide useful guidelines for patient management.
Fig. 1.4 Malignant melanoma involving lower lid and 
conjunctiva
Fig. 1.5 Extensive malignant melanoma involving both 
the eyelids in a patient with xeroderma pigmentosa Fig. 1.6 Rapidly growing squamous cell carcinoma of 
the eyelid and extending to the orbit
a b
Fig. 1.7 (a) Kissing nevus in a young adolescent girl. (b) Nevi involving the upper lid in a young adult with a history 
of recent growth. (c) Nevus involving the lid margin in a young adult. (d) Keratoacanthoma





Fig. 1.8 (a) Squamous papilloma of the lower eyelid. (b) Lymphangioma diffusely involving the lids and orbit. (c) 
Extensive Xanthelesma involving all four lids
c d
Fig. 1.7 (continued)
1 Overview of Eyelid Tumors
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Biopsies of eyelid lesions can be performed to 
establish the diagnosis and may identify high- risk 
histological tumour subtypes. This may influence 
management, especially when there is a signifi-
cant cosmetic impact of excising a large lesion, 
when non-surgical management can be used or 
when planning Mohs surgery. Another use is 
establishing tumour boundaries through mapping 
biopsies. A biopsy may also assist in determin-
ing whether tumour recurrence has occurred fol-
lowing previous treatment [1]. The main types 
of biopsy are excisional, incisional, punch and 
shave biopsies. A biopsy may be performed with 
the intention of excising a lesion, for example, 
in the case of a very small basal cell carcinoma 
(BCC) where the clinician feels confident about 
the diagnosis. It should be borne in mind that 
biopsies can occasionally provide an inaccurate 
or incomplete diagnosis due to sampling errors. 
In one study of periocular BCC with aggressive 
subtypes (n  =  51), biopsy failed to identify an 
aggressive component in 52% of cases [2].
 Preoperative Considerations
Although biopsies are generally straightforward 
procedures, the patient’s medical history should first 
be reviewed [1, 3]. General medical history, allergies 
and medications should be noted. Smoking and med-
ical conditions may impair healing. Antiplatelets, 
anticoagulants, bleeding disorders and hypertension 
increase the risk of haemorrhage. Informed consent 
should be obtained and complications explained 
such as haemorrhage, infection, scarring, ectropion 
and pain. The lesion may be outlined with a skin 
marker pen before the procedure to help identify the 
lesion following injection of local anaesthesia [1, 
3]. A photo with the biopsy site marked and mea-
surements to fixed landmarks such as the canthi or 
lacrimal puncta are essential for later accurate locali-
sation, especially for smaller lesions which may be 
very difficult to find after the biopsy.
 Biopsy Techniques
The main techniques utilised in the periocular area 
are excisional, incisional, punch, snip, curette and 
shave biopsies. Techniques are selected based on 
lesion characteristics, possible diagnosis, loca-
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tion and surgeon preference. For instance, a snip 
biopsy may be used for a pedunculated lesion, or 
a shave biopsy for an elevated lid margin lesion. 
One study of periocular tumours (n = 20) found 
that incisional biopsy had an accuracy rate of 95% 
[4]. Similarly, the accuracy rate of punch biop-
sies in identifying periocular tumours has been 
reported to be 67–85% [4–6]. Shave biopsy may 
produce a better cosmetic outcome than a deeper 
biopsy which may leave a notch in the eyelid if the 
lesion proves to be benign. However, shave biopsy 
is not recommended in certain scenarios such as 
differentiating keratoacanthoma-type squamous 
cell carcinoma (SCC) from invasive SCC [1, 3] or 
in suspected melanoma where tumour thickness is 
an important prognostic factor.
 Equipment Required for Biopsy
• Skin preparation materials
• Local anaesthetic with adrenaline 1:100,000
• Forceps
• Scalpel/scissors
• Cautery or other method of haemostasis
• Formalin container(s)
Other equipment can be added as needed, such 
as disposable punch, blade for shave biopsy and 
suturing equipment. An eye shield may be used 
to prevent eye injury.
 Incisional Biopsy Technique  
(Video 2.1)
 1. Aseptic skin preparation.
 2. Inject local anaesthetic with adrenaline around 
the lesion.
 3. Using a scalpel blade (No. 11 blade often use-
ful for small lesions), aim to sample a piece of 
tumour and some adjacent normal tissue. 
Avoid sampling ulcerated areas which may 
only provide necrotic tissue and not provide a 
diagnosis. Also avoid keratinised/crusted 
areas and remove overlying crust with irriga-
tion/soaking if necessary. An elliptical exci-
sion can also be performed.
 4. Place specimen in formalin.
 5. Cauterise wound or use pressure.
 6. Close wound with sutures if necessary but 
small defects can be left to heal by secondary 
intention [1, 7, 8].
 Punch Biopsy Technique (Video 2.2)
 1. Aseptic skin preparation.
 2. Inject local anaesthetic with adrenaline around 
the lesion.
 3. Using thumb and index finger, stretch the skin 
on either side of the lesion away from the 
lesion. This produces an oval defect which 
facilitates wound closure. Align the oval 
defect with skin tension lines.
 4. Insert punch into lesion perpendicular to skin 
with a twisting motion. Aim to sample a non- 
central part of the lesion away from the mar-
gin. Take care not to injure the globe. Consider 
using an eye shield.
 5. Remove the punch perpendicular to skin, 
leaving behind the whole biopsy specimen.
 6. Using forceps, grasp an edge of the specimen 
gently to avoid crush artefact, and lift the speci-
men out. The specimen may also be lifted out 
using a needle, a skin hook or a suture passed 
through the specimen. This step may be made 
easier by pushing down on surrounding skin to 
raise the lesion relative to the surrounding skin.
 7. Cut the base of the specimen with scissors or 
scalpel.
 8. Place specimen in formalin.
 9. Consider cautery. Haemostasis may also be 
achieved with sutures and slight pressure. 
Suture closure produces a better cosmetic out-
come but is not always necessary [1, 3, 4, 6, 9].
 Shave Biopsy Technique (Video 2.3)
 1. Aseptic skin preparation.
 2. Inject local anaesthetic with adrenaline intra-
dermally, raising the lesion from the surround-
ing skin.
 3. Stretch the skin. When a lesion has limited 
elevation, the skin may be bunched up to 
A. Wu et al.
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increase elevation. With raised lesions, for-
ceps may be used to lift the lesion.
 4. A scalpel is often used on the eyelid. The blade 
is used to saw through the lesion horizontally 
along the skin or the eyelid margin. Razor 
blades are used elsewhere on the body but are 
difficult to use on or near the eyelid margin.
 5. Place specimen in formalin.
 6. Apply light pressure, chemical haemostasis or 
cautery. Wound re-epithelialisation occurs in 
around 1 week [1, 3, 7, 8].
 Snip Biopsy
Lift the lesion with forceps to snip the base with 
scissors. The lesion should not be pulled too far, 
resulting in removal of more skin at the base than 
necessary. Light pressure may be sufficient for 
haemostasis [1].
 Curette Biopsy
Curette biopsy may be used for soft superficial 
lesions, including seborrhoeic keratosis, actinic 
keratosis and some BCC.  Stretch the surround-
ing skin, and scoop down through the lesion with 
the curette. Avoid this method on lax skin of 
the eyelid as the curette may tear the skin while 
attempting to remove the tumour. Light pressure, 
chemical haemostasis or electrodessication can 
be used [1].
 Communication with Pathologist
The pathology request form and specimen con-
tainer should be labelled with patient identifying 
details, date and biopsy site. Ensure the specimen 
is in the container. The request form should also 
include details of the requesting clinician, type 
of biopsy (diagnostic or excisional), and relevant 
clinical information such as suspected clinical 
diagnosis and previous treatments to the biopsy 
site. A diagram or clinical photograph may be 
included. Specific questions may be included on 
the request form, and the case may be discussed 
with the pathologist if required [1]. The clinician 
should record all specimens sent to the pathologist, 
and follow up and act upon pathology results in a 
timely manner.
 Postoperative Care
Vaseline may be applied to the wound site. 
Topical antibiotics should not be routinely used. 
The site should be cleaned regularly, and medi-
cal advice should be sought if signs of infection 
develop.
 Conclusion
Biopsy of the eyelid is an important skill which 
assists in diagnosis and management of eyelid 
tumours. The main techniques are excisional, 
incisional, punch and shave biopsies, and are 
selected depending on the clinician’s preference 
and characteristics of the lesion.
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Excision of Eyelid Tumors: 
Principles and Techniques
Gangadhara Sundar and Fairooz P. Manjandavida
Lesions of the eyelid, benign or malignant, 
have physical, esthetic and psychological con-
sequences and may on occasion be vision and 
life threatening. An overview of common and 
rare conditions affecting the eyelids and a con-
ceptual approach has been described earlier. 
When the diagnosis is in doubt or when extensive 
reconstruction or nonsurgical treatment is being 
considered, an incisional biopsy of the lesion 
for histopathological confirmation is indicated, 
which has been described earlier.
Excision of lesions are often performed after 
an initial diagnosis has been established, thereby 
being therapeutic [1–3]. Not infrequently, it may 
be performed as both a diagnostic and therapeutic 
procedure, especially when preoperative clinical 
diagnosis is certain, and reconstruction is straight-
forward with minimal morbidity. In malignant 
lesions, wide excisions are performed, which are 
usually therapeutic followed by reconstruction. 
Oncological principles for eyelid malignancy 
are the same as in other malignant neoplasms 
involving skin and adnexa. The surgical aim 
should be complete excision with adequate mar-
gin clearance to minimize recurrence, metastasis, 
and mortality. Therefore, clinically confirmed 
malignant eyelid tumors are often excised with 
margin control either with frozen section control 
or by Moh’s micrographic surgery followed by 
formal histopathological confirmation with per-
manent fixed section [4–6]. Where frozen section 
facility is unavailable, a wider excision may be 
performed with margin control with permanent 
histology and secondary with delayed primary 
reconstruction after histopathological confirma-
tion of clear margins. Moh’s micrographic sur-
gery is a good alternative where available which 
helps secure clear margins before a delayed 
primary reconstruction [7]. Conjunctival map 
biopsy is performed in the presence of suspected 
intraepithelial invasion of conjunctiva, especially 
in sebaceous gland carcinoma of eyelid [8].
On occasion, a therapeutic excision of an eyelid 
tumor, typically infiltrative and aggressive malig-
nant neoplasms, e.g., sebaceous gland adenocarci-
noma, melanoma, and Merkel cell carcinoma, may 
be combined with sentinel lymph node biopsy or 
a modified radical regional (cervical) lymph node 
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dissection, with adjuvant  external beam therapy. 
The surgeon should thus not only be aware of 
the indications, but also be familiar with various 
techniques of excision and reconstruction. They 
should preferably work in multidisciplinary teams 
comprising pathologists, head and neck surgeons, 
Moh’s micrographic surgeons, medical and radia-
tion oncologists. Reconstruction, when performed, 
should not only be functional but should also be 
esthetically acceptable, with minimal donor site 
and host site morbidity and minimal downtime.
In general, small benign lesions may be 
excised with maximal tissue preservation. Unless 
typical of inflammatory lesions like a chalazion, 
it is recommended to submit the excised lesions 
for histopathological examination. Superficial 
benign epidermal lesions, especially when diag-
nosis is certain, may also be managed with tissue 
destructive techniques, e.g., fulguration, elec-
trodessication, etc. [2]
When malignant lesions are excised, a “no 
touch” technique should be employed to avoid 
host tissue seeding. Excision should be per-
formed as precisely and delicately as possible 
with the least tissue destructive technique and 
maximal hemostasis. It is essential to respect 
and preserve the anatomical vital structures  – 
medial canthal tendon, lateral canthal tendon, 
levator aponeurosis, lacrimal sac, etc. The 
nature of the underlying lesion also determines 
the margin of resection, e.g., benign lesion, 
maximal skin and subcutaneous tissue sparing; 
basal cell carcinoma, minimal 2–4 mm margin 
depending on the morphological variants; squa-
mous cell carcinoma/sebaceous gland adenocar-
cinoma, 4–5 mm margin; and melanoma, up to 
10  mm margin is recommended as the current 
standard of care. The commonly used instru-
ments in various excision techniques are shown 
in Fig. 3.1.
Fig. 3.1 Instrument tray. Instruments, starting lower left: 
1, Metzenbaum scissors; 2, Westcott scissors; 3, 
Castroviejo needle holder; 4, tissue forceps; 5 and 6, 
Bishop-Harmon forceps; 7, Adson tissue forceps; 8, 
Graefe forceps; 9, Jaeger lid plate; 10, Desmarres retrac-
tor; 11, Bard-Parker knife handle; 12, fine tip marker and 
ruler; 13, Serrefine-Dienffenbach (bull dog clamps); 14, 
Frazier suction tip; 15 and 16, radiofrequency cautery 
monopolar and bipolar tips, 17, single and double skin 
hooks
G. Sundar and F. P. Manjandavida
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 Benign Lesions
In general, benign lesions that are asymptom-
atic and insignificant cosmetically may be 
observed. When the clinical diagnosis is uncer-
tain, early incisional or excisional biopsy are 
reasonable options. Most symptomatic benign 
lesions may be excised safely and easily, with 
precautions taken to avoid damage to vital ocu-
lar and adnexal structures, e.g., canthal ten-
dons, lacrimal puncta and canaliculi, lacrimal 
sac, ocular surface, etc. Whenever possible a 
complete excision is recommended (Figs.  3.2, 
3.3, 3.4, 3.5, 3.6, 3.7, 3.8 and 3.9, Tables 3.1 
and 3.2, Video 3.1).
• Cystic lesions should be excised as to 
 minimize inflammations and recurrences.
• Epidermal lesions are generally excised or ful-
gurated at the dermo-epidermal junction 
avoiding scarring, notching and need for 
wound repair (Video 3.2). Healing occurs by 
reepithelization of the raw area.
• Dermal lesions and dermal adnexal lesions will 
require skin excision in addition to complete 
removal of the lesion (Fig. 3.10a, b). The only 
exception is a compound or dermal nevus of the 
eyelid margin, when a shave excision is per-
formed avoiding notching of the eyelid margins.
• Subcutaneous lesions are accessed through 
skin incisions along the relaxed tension line 
when possible or through preexisting eyelid 
creases.
Most eyelid surgeries are clean surgeries, 
and only topical cleansing of the eyelid with 




Fig. 3.2 (a) Seborrheic keratosis. (b) Fibroepithelial polyp. (c) Verruca vulgaris. (d) Acrochordon (skin tag)
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 Premalignant Lesions
It is essential for the clinician to recognize poten-
tial premalignant lesions. Although these are 
more common in the Caucasian population, they 
may present in all ethnic groups and various skin 
types and pigmentation. In general, there should 
be a low threshold for performing a biopsy of 
suspicious lesions. At risk patients (e.g., actinic 
keratosis  – squamous cell carcinoma, lentigo 
maligna  – melanoma, xeroderma pigmentosa 
(Fig. 3.11) – basal cell carcinoma, squamous cell 
carcinoma, melanoma) should also be advised 
against ultraviolet light/sun exposure. Clinically 
evident change in size, thickness, color and 





Fig. 3.3 (a) Chalazion with pyogenic granuloma. (b) Hidrocystoma Trichoepithelioma. (c) Complete excision. (d) 
Pilomatrixoma. (e) Excised specimen of pilomatrixoma
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mation, which may need surgical intervention 
(Figs. 3.11 and 3.12, Table 3.3).
 Malignant Eyelid Tumors
In general, malignant lesions of the eyelids and 
periocular region are far less common than benign 
lesions [9]. While basal cell carcinomas are the 
most common in all ethnic groups, occurring 
primarily in sun-exposed areas, the prevalence 
of squamous cell carcinomas [10] and sebaceous 
gland adenocarcinomas are different between the 
Caucasian and the Asian populations. In eyelid 
malignancies other than basal cell carcinoma, 
regional lymph nodes, and systemic screening is 
mandated clinically and preferably by imaging 
as well. The decision to perform wide excision 
biopsy with clear margins, regional lymph node/
sentinel node biopsy (sebaceous gland adenocar-
cinoma, melanoma, Merkel cell carcinoma, etc.), 
cryotherapy of the edges, and ocular surface 
map biopsy (Sebaceous gland adenocarcinoma) 
depends on the nature of the primary malignancy. 
Some salient differences and some examples are 
shown in Table 3.4 (Figs. 3.13, 3.14, 3.15, 3.16, 
3.17, 3.18, 3.19, 3.20, 3.21, 3.22 and 3.23).
 Basal Cell Carcinoma (BCC)
Basal cell carcinomas are the most common 
malignant neoplasms of the eyelids and the face, 
globally. While most are sporadic and related 
to sun exposure especially in Caucasians of the 
lower Fitzpatrick skin types, they are seen in 
all ethnic and geographical regions with minor 
variations. Early lesions, typically nodular, are 
either ignored or misdiagnosed unless lesions are 
routinely sent for histopathological examination. 
In pigmented races, a pigmented form of BCC 
is often mistaken for a melanoma (Fig.  3.24). 
While the common type is a nodular or nodulo- 
ulcerative type, rare forms include the morphea-
form, infiltrative BCC (Fig.  3.25) or even the 
multicentric or superficial basal cell carcinoma. 
The latter are often diagnosed late and managed 
poorly as obtaining clear margins are difficult 
with local excision.
When localized, small and early, a simple 
excision with margin of 2–3  mm with frozen 
section control will suffice with primary recon-
struction. Lid margin lesions will require a 
full thickness block resection (and not wedge 
resection) ideally under frozen section control 
with primary reconstruction [11]. Principles of 
wound healing and reconstruction include the 
laissez- faire technique, use of adjacent (eye-




Fig. 3.4 (a) Eyelid margin pigmented nevus. (b) 
Peripunctal nevus. (c) Kissing nevus
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Large lid margin defects may require complex 
reconstruction using either composite graft-flap 
techniques or lid sharing procedures and are dis-
cussed in detail in the following chapter. Large 
extensive and inoperable lesions away from 
the globes may be amenable to external beam 
radiation [12]. While it may obtain tumor con-
trol, tissue destruction is not often addressed by 
this modality of treatment. In the recent years, 
extensive and invasive basal cell carcinomas 
have been shown to be responsive to targeted 
therapy with hedgehog pathway inhibitors and, 
may be considered for extensive, recurrent and 
the rare metastatic lesions [13].
 Squamous Cell Carcinoma (SCC)
Less frequent, but more challenging to diag-
nose and manage are SCC of the eyelid and 
adnexa. They are typically more common 
among the light pigmented races and those 
with predisposing conditions like actinic kera-





Fig. 3.5 (a) Giant hairy nevus. (b) Excised lesion of giant hairy nevus. (c) Post-excision with eyebrow preservation. 
(d) Post-reconstruction with suprapubic skin graft and laser treatment for eyebrow
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cal presentations are easily suspected, atypical 
presentations often result in late diagnosis and 
thus delay in management with a poorer prog-
nosis [10]. Principles of management include 
wide excision with 3–4 mm margins under 
frozen section control, followed by recon-
struction or Moh’s micrographic surgery if 
available. Extensive lesions, deeper invasion, 
positive margins and inoperable lesions may 
a
b
Fig. 3.6 (a) Epidermal cyst. (b) Dissected epidermal cyst
a b
Fig. 3.7 (a) Eyelid xanthelasma. (b) Xanthelasma post-excision
a
b
Fig. 3.8 (a) Neurofibroma. (b) Excised neurofibroma 
(templet method)





Fig. 3.9 (a) Partially involuted infantile hemangioma. (b) Excised partially involuted infantile hemangioma. (c) 
Postoperative image
Table 3.1 Spectrum of anesthetic techniques for various lesions of the eyelid and ocular adnexa
Type of anesthesia Principle Typical indication Technique
None Brief, momentary, simple 
procedure
Acrochordons (skin tags), 
pedunculated verruca
–










epinephrine, with or 
without bupivacaine)
Nerve blocks Larger eyelid lesions, 
planned reconstruction
Frontal nerve block, 
infraorbital nerve block, 
infraorbital fan block etc.
Regional blocks
Fan blocks
General anesthesia Extensive resections/
reconstruction, regional lymph 
node dissection, distal donor 




lymph node dissection, 
etc.
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Table 3.2 Principles of management: benign eyelid lesions
Type of lesion Principles of management
Epidermal lesions
Seborrheic keratosis (Fig. 3.2a) Observation, electrodessication, cautery with curettage
Pseudoepitheliomatous hyperplasia
Fibroepithelial polyp (Fig. 3.2b) Simple excision
Verruca vulgaris (Fig. 3.2c) Excision with no touch technique
Acrochordons or skin tags (Fig. 3.2d) Snip excision (Video 3.1)
Benign adnexal tumors
Hordeolum internum Systemic antibiotics, warm compresses
Hordeolum externum Lash epilation, pus expression
Chalazion: without or with pyogenic granuloma, 
chalazion externum (Fig. 3.3a)
Incision, curettage, subconjunctival steroid injection, 
pyogenic granuloma excision
Sebaceous adenoma Excision
Eccrine sweat gland origin
Eccrine hidrocystoma Marsupialization, complete excision
Syringoma Chemical peel, surface treatment
Pleomorphic adenoma Excision
Apocrine sweat gland origin
Apocrine hidrocystoma Marsupialization, complete excision
Hair follicle origin
Trichoepithelioma (Fig. 3.3b) Complete excision (Fig. 3.3c)
Trichofolliculoma Excision
Tricholemmoma Excision
Pilomatrixoma (Fig. 3.3d) Excision (Fig. 3.3e)
Benign melanocytic lesions
Lid margin involving-
Single margin involving (Fig. 3.4a) Shave excision
Peripunctal nevi (Fig. 3.4b) Limited excision with punctal preservation
Kissing nevi (Fig. 3.4c) Observation, excision with preservation of lid margin
Non-lid margin involving nevi
Simple nevi Observation, excision with skin grafting, pigment laser 
treatmentsHairy nevi
Giant nevi (Fig. 3.5a–d)






Cysts (Fig. 3.6a): Epidermal cyst, implantation cysts, 
inclusion cysts, dermal adnexal cysts
Excision with intact cyst (Fig. 3.6b)
Xanthogranuloma Excision
Xanthelasmata (Fig. 3.7a) Excision (Fig. 3.7b) with primary wound closure
Neurofibromas (Fig. 3.8a) Excision (template technique) (Fig. 3.8b)
Capillary hemangioma (Fig. 3.9a–c) Observation, systemic beta blockers, systemic/
intralesional steroids, excision
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be candidates for radiation therapy. Epidermal 
growth factor receptor (EGFR) inhibitors have 
shown promising results recently [13].
 Sebaceous Gland Carcinoma (SGC)
These are far more common among Asians, 
being increasingly recognized compared to the 
past when they were either misdiagnosed as 
 squamous cell carcinomas or even chronic bleph-
aroconjunctivitis [14, 15]. Most commonly aris-
ing from the meibomian glands situated in the 
posterior lamellae, they may even arise from the 
Zeis glands and caruncle. Seen most commonly 
in the upper eyelid, involving the tarsal meibo-
mian glands, they are notorious for pagetoid 
spread with skip lesions rendering frozen sec-
tions less reliable and frequently involve the ocu-
lar surface. Late presentations may also present 
with anterior orbital extension, regional (preau-




Fig. 3.10 (a) Dermal adnexal cyst. (b) Excised dermal 
adnexal cyst
Fig. 3.11 Xeroderma pigmentosa
Fig. 3.12 Keratoacanthoma
Table 3.3 Principles of management: premalignant/in 
situ malignant eyelid lesions
Type of lesion Principles of management
Actinic keratosis Observation with serial 
follow-up, biopsy of 
suspicious lesions
Lentigo maligna Observation with serial 







Close observation and 
biopsy of suspicious lesions
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Principles of management include preopera-
tive systemic evaluation to rule out regional and 
systemic spread followed by wide excision with 
margin clearance of at least 4  mm [17] (Video 
3.3). Frozen section control is challenging in the 
presence of conjunctival intraepithelial (paget-
oid) spread. A few examples of eyelid sebaceous 
gland carcinoma excision and reconstruction are 
shown in Videos 3.4, 3.5, 3.6 and 3.7.
In the presence of clinically suspicious 
intraepithelial spread with conjunctival hyper-
emia (tarsal and/or bulbar) and lid margin thick-
ening, a conjunctival map biopsy is indicated to 
ensure ocular surface is free of the tumor and 
guide further management if indicated [18]. The 
location of the map biopsy varies according to 
the clinical presentation. These include forniceal 
conjunctival (upper and lower), bulbar conjunc-
tival (upper and lower), perilimbal conjunctival 
(four quadrants) and the caruncle. Invasion of the 
orbit is often considered an indication for orbital 
exenteration.
Recent evidence suggests a possible ben-
efit of systemic “chemoreduction” minimizing 
the need for mutilating exenteration with early 
orbital invasion [19]. With obvious cervical node 
involvement, a modified radical lymph node dis-
section is often indicated. A recent trend toward 
sentinel lymph node biopsy (SNLB) is prac-
ticed in some centers around the world. SNLB is 
indicated in tumors that are clinically measured 
>10  mm in size. Despite a better understand-
ing, greater awareness and improved techniques, 
locoregional recurrences and distant metastases 
are not uncommon resulting in higher mortality 
compared to the above neoplasms.
Table 3.4 Principles of management: malignant eyelid lesions
Type of lesion Principles of management
Basal cell carcinoma (Figs. 3.13a–c, 
3.14a, b and 3.15a–d)
Wide excision with 2–4 mm margin, frozen section control, primary 
reconstruction
Moh’s micrographic excision with delayed primary reconstruction.
External beam radiation (inoperable lesions)
Hedgehog pathway inhibitors (for inoperable, non-radiatable BCCs)
Squamous cell carcinoma (Fig. 3.16) Wide excision 3–4 mm margins, frozen section control, primary 
reconstruction
Moh’s micrographic excision with delayed primary reconstruction
Radiotherapy
Exenteration (extensive eyelid lesion with orbital invasion)
Imiquimod therapy (superficial, extensive, recurrent SCC)
Epidermal growth factor receptor inhibitors
Sebaceous gland adenocarcinoma 
(Figs. 3.17a–c and 3.18a–e)
Wide excision with wide margins (4 mm), under frozen section control 
(less reliable), cryotherapy of edges, conjunctival map biopsy, primary 
reconstruction. Sentinel lymph node biopsy in lesions >10 mm in size, 
regional lymph node dissection (spread, PET-CT positive)
Chemoreduction with local excision
Orbital exenteration
Mucinous carcinoma (Fig. 3.19a–d) Excision with wide margins, frozen section control, primary reconstruction
Merkel cell carcinoma (Fig. 3.20a, b) Wide excision with 4 mm margins under frozen section
Moh’s micrographic excision
Sentinel lymph node biopsy
Regional lymph node dissection, adjuvant chemotherapy, radiotherapy
Melanoma (Fig. 3.21a, b) Wide excision (10 mm if possible), primary reconstruction, sentinel lymph 
node biopsy, orbital exenteration, palliative therapy
Lymphoma (Fig. 3.22) Radiation and chemotherapy
Metastasis (Fig. 3.23) External beam radiotherapy, targeted therapy where applicable
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 Eyelid Melanoma
Melanomas of the eyelid are rare and may be 
either a nodular melanoma or superficial spreading 
melanoma (arising from a lentigo maligna), and 
can be primary or secondary. They are commonly 
associated with a poorer prognosis as recurrence 
rates are high, and the presence of regional or sys-




Fig. 3.13 (a) BCC at medial canthus. (b) BCC at medial 




Fig. 3.14 (a) BCC at medial canthus. (b) Basal cell car-
cinoma medial canthus repaired with paramedian fore-
head flap. Note the reconstruction of lacrimal system
G. Sundar and F. P. Manjandavida
27
In keeping with melanoma elsewhere, whenever 
possible a wide excision with at least 5–10  mm 
margin may be indicated, making reconstruction 
challenging [20]. Video 3.7 demonstrates manage-
ment of lower eyelid melanoma. Histopathological 
features of lymphatic or vascular invasion, lesions 
≥1 mm thick, >1 mitotic figure/high power field 
and/or ulceration and Breslow grading of more 
than 1000 microns are common indications for 
sentinel node biopsy and regional lymph node dis-
section. There is no role for cryotherapy with mel-
anomas of the eyelid. When the systemic spread is 
present, the prognosis for life is usually guarded. 
The recent introduction of targeted therapy with 
BRAF inhibitors and MEK inhibitors in conjunc-
tival melanoma is yet to be validated in eyelid 
melanomas.
 Merkel Cell Carcinoma
These rare but aggressive neoplasms also com-
monly involve the upper eyelids and are often 
diagnosed as recurrent chalazia. Because of their 




Fig. 3.15 (a) Basal cell carcinoma left cheek. (b) Basal cell carcinoma left cheek with markings for reconstruction. (c) 
Basal cell carcinoma left cheek post-reconstruction. (d) Postoperative image
Fig. 3.16 Squamous cell carcinoma at medial canthus
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quently spread regionally and even systemically, 
even at initial presentation resulting in early 
mortality. Localized lesions, after initial inci-
sional biopsy, should undergo wide excision and 
reconstruction with sentinel node biopsy where 
possible. Radiotherapy and immuno-chemother-
apy play an important role with regional and 
systemic spread, despite their guarded prognosis 
[21–23].
 Postoperative Care
As in most surgeries, postoperative care is 
important to avoid complications such as infec-
tion, bleeding, and to maintain wound integ-
rity especially with extensive reconstructions. 
Therefore, immediate postoperative wound care 
plays a major role.
• Local cleaning with 5–10% povidone-iodine 
solution and topical antibiotic ointment is rec-
ommended 2–3 times per day starting the day 
after the surgery to prevent infection until 
3 weeks.
• To avoid bleeding, the patient is advised to 
refrain from strenuous physical activities and 
avoid drugs that may prolong bleeding. 
Traditional medicines including gingko, gar-
lic,  ginseng, and even high doses of Vitamin E 
can alleviate bleeding tendencies.
• Postoperative swelling can be minimized with 
immediate use of ice packs that mostly sub-
sides within 3 days postoperative.
 Follow-Up
Despite meticulous surgical approach, recur-
rence may occur in eyelid tumors, be it benign or 
malignant. Unlike the benign variants, malignant 
eyelid tumors warrant strict follow up to detect 
early recurrence and metastasis. It includes post-
operative follow-up at 1  week, 3  weeks, and 
6 weeks. For the first year 3 monthly follow-up is 
recommended for lethal eyelid malignancies, fol-





Fig. 3.17 (a) Sebaceous gland carcinoma Right upper 
eyelid. (b) Post-resection Sebaceous glands carcinoma. 
(c) 3-month postoperative follow-up image
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In summary, lesions of the eyelid may be 
benign (inflammatory, developmental or true neo-
plasms) or malignant. A high degree of clinical 
suspicion, incisional or excisional biopsy when 
suspected, regional and systemic assessment 
when indicated followed by tailored approaches 
to reconstruction and management are essential 
to deliver the most optimal outcome. Long-term 
follow-up is warranted in detecting early recur-






Fig. 3.18 (a) Sebaceous gland carcinoma lower eyelid. (b) Post-resection. (c) Posterior lamellar reconstruction with 
hard palate mucosal graft. (d) Cheek rotation flap. (e) Post-reconstruction





Fig. 3.19 (a) Mucinous carcinoma right lower eyelid. (b) Intraoperative marking with 4 mm margin. (c) Intraoperative 
specimen. (d) Late postoperative view
a b
Fig. 3.20 (a) Merkel cell carcinoma. (b) PET-CT Merkel cell carcinoma with regional lymph node involvement
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Fig. 3.21 Melanoma eyelid and medial canthus
Fig. 3.22 Lymphoma involving eyelid
Fig. 3.23 Recurrent sebaceous gland carcinoma with 
loco-regional & systemic spread
Fig. 3.24 Pigmented basal cell carcinoma referred as 
melanoma
Fig. 3.25 Infiltrative basal cell carcinoma
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Principles and Techniques of Eyelid 
Reconstruction
Francesco Bernardini and Brent Skippen
 Principles of Periocular 
Reconstruction
The end goal of eyelid reconstruction is both 
functional and aesthetic restoration of the eye-
lid and periocular area while minimizing sur-
gical morbidity. Attention to reconstruction of 
the bilamellar eyelid structure is essential [1]. 
Reconstructive surgical planning is determined 
by several factors including the nature of the 
defect, the health and age of the patient, the avail-
ability and integrity of surrounding tissues, and 
the surgeon’s experience and preferences.
A preoperative consultation is mandatory to 
determine possible sites from which flaps and 
grafts may be obtained to minimize surgical 
 morbidity [1].
In general, the following principles help achieve 
successful eyelid and periorbital reconstruction [2]:
 1. If both anterior and posterior eyelid lamellae 
are to be reconstructed, only one can consist 
of a graft, the other must be composed of a 
vascularized flap. Graft on graft reconstruc-
tion has a high failure probability because of 
lack of vascular supply.
 2. Aim to provide adequate canthal fixation to sup-
port the reconstructed eyelid/globe apposition.
 3. Provide sufficient horizontal and vertical eye-
lid dimensions for maximal function, i.e., 
avoid vertical tension on the lower eyelid.
 4. Perform any appropriate direct closure of the 
defect prior to sizing a graft.
 5. Match tissue characteristics as best as possible 
for grafts and flaps.
 6. Balance complexity of technique(s) with 
improvement(s) in outcome.
 7. Eyelid closure adequate to avoid exposure 
sequelae.
 8. Optimal eyelid symmetry and cosmesis (tissue 
of appropriate color, texture, and thickness).
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Box 4.1 General Principles
• Recognize full-thickness vs. anterior 
lamella defects
• Anterior lamella defects:
 – Always prefer primary closure with 
or without undermining
 – Flaps over grafts
 – Grafts possibly from eyelid skin 
when available
 – Full-thickness skin grafts (FTSGs) to 
the eyelids and canthus require 
Electronic supplementary material The online version 
of this chapter (https://doi.org/10.1007/978-3-030-18757-
6_4) contains supplementary material, which is available 
to authorized users.
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 Reconstruction of Eyelid Defects
The type of surgery depends upon extent of tissue 
removed.
 Preferred Anesthesia
For most surgeries the anesthesia used is the 
same:
 – Local anesthesia with propofol sedation
 – 27G–30G needle, 1% ropivacaine or 0.5% 
bupivacaine with 1:100,000 adrenaline
Basic instruments and necessary equipment 
are shown in Fig. 4.1.
 Anterior Lamella Defects
Partial thickness anterior lamellar defects can 
be left to heal by secondary intention if small 
[3]. Larger defects may warrant direct closure 
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Fig. 4.1 Basic instruments and necessary equipment. A, 
iris (straight, sharp-tipped) scissors; B, Stevens (curved, 
blunt-tipped) scissors; C, surgical calipers; D, bulldog 
clamps; E, skin retractors, single and double pronged; F, 
artery forceps, curved; G, Jaeger lid plate; H, small fine- 
tooth tissue forceps; I, small, non-tooth forceps; J, large 
tooth forceps (Adson); K, Vannas spring scissors, curved; 
L, Westcott tenotomy scissors, curved; M, Castroviejo 
needle holder, with catch; N, eyelid speculum
 ideally a thinner than those used on 
other areas of the face. Thankfully, 
the periocular region is well- 
vascularized, with typically excellent 
wound healing.
• Small to medium size full-thickness 
defects of the lower lid can usually be 
repaired by direct closure, adding can-
thotomy and cantholysis or semicircular 
Tenzel flap if necessary.
• Larger defects (>50%) are usually 
repaired in at least two layers (posterior 
and anterior lamella) using flaps or grafts.
• Medial canthal defects are more chal-
lenging to repair to preserve the lacrimal 
system function.
• Lateral canthal defects can also have 
particular challenges.
Note: Some general principles are 
useful to guide the progression in eye-
lid reconstruction, from basic to more 
advance.
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tion of the eyelashes. Options for reconstruc-
tion of partial thickness periocular defects 
include:
 1. Laissez-faire (small): Healing by secondary 
intention or granulation
 2. Topical imiquimod 5% for 1 month
 3. Direct closure
 4. Flap or graft
• Flaps: e.g., transposition, advancement, 
rotation, bilobed, rhomboid, z-plasty, V-Y 
plasty, Y-V plasty
• Grafts: Full-thickness skin graft, split- 
thickness skin graft
 Laissez-Faire
Laissez-faire is also known as healing by sec-
ondary intention or granulation. Fox and Beard 
described their good results following healing 
by secondary intention in six medial canthal 
defects [4]. Mehta reported 11 cases of satis-
factory healing by secondary intention with 
defects involving the lower lid and medial 
canthus [5]. Da Costa and Jones described 
one patient having an excellent outcome fol-
lowing excision of a lateral canthal lesion [6]. 
Da Costa and Jones also showed that the tech-
nique of laissez-faire can be extended to larger 
defects with a good outcome [6]. One patient 
in their series had an excellent functional and 
aesthetic outcome following healing of a large 
upper eyelid defect.
Shankar et al. reported a series of 25 periocu-
lar defects with healing by secondary intention 
[7]. A “good” or “very good” result was obtained 
in 92% of their cases. Only one patient required 
secondary surgery for cicatricial ectropion [7]. A 
patient satisfaction survey in their study showed 
high patient satisfaction with the aesthetic out-
come and postoperative follow-up required for 
healing by laissez-faire.
Indications for a laissez-faire approach to 
periocular skin tumors also include [8]:
 1. Medial canthal lesions, especially after radio-
therapy, where the skin may be unsuitable for 
flaps or free skin grafts.
 2. Patients with primary skin precancerous con-
ditions like xeroderma pigmentosa.
 3. Patients with poor general health, who may 
not be fit for general anesthesia or prolonged 
surgical procedures involving complex skin 
flaps or skin grafting under local anesthesia.
 4. For tumor surveillance where detection of 
tumor recurrences beneath or adjacent to the 
reconstructed area may be delayed.
 5. Simplicity of wound management for patient 
care associated with this technique [7].
 6. Also, in cases of large defects that are closed 
partially with flaps and grafts but not entirely, 
a small part of the defect can be left to heal by 
secondary intention.
 7. Not indicated in patients with poor compli-
ance for follow-up.
 Disadvantages of Laissez-Faire 
Include
 1. Prolonged healing time
 2. Small risk of a secondary surgical 
intervention
 3. Causing lower lid cicatricial ectropion and 
subsequent watery eye
 4. Poor suitability for large upper lid defects 
where there may the risk of exposure keratitis 
during wound healing
 Direct Closure
Direct closure may be useful for both partial and 
full-thickness eyelid defects following tumor 
excision. The immediate postoperative distor-
tion is temporary thanks to spontaneous tissue 
expansion brought about by the steady pres-
sure of the displaced globe against the recon-
structed eyelid [9]. The surgery is often simple 
and the functional and cosmetic results can be 
excellent. In the event of histologically incom-
plete tumor resection, subsequent re-excision 
for additional clearance would not present the 
problems that other reconstructive techniques 
might. Should postoperative wound dehiscence 
occur, the defect may be allowed to granulate 
as in the “laissez- faire” method. Subsequent 
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excision of any notch or delayed reconstruction 
would still be viable options and made easier by 
the decrease in defect size [9].
The factors that make direct closure possible 
are [9]:
 1. Preexisting eyelid and canthal tendon laxity.
 2. Inherent eyelid elasticity.
 3. Straightening of the normal lid curvature (arc 
to chord conversion) by globe displacement.
 4. The “mechanical tissue creep” phenomenon 
talked of in relation to tissue expander use 
under the skin [10].
 5. Mechanical creep is one of the factors that 
makes direct closure under tension possible 
(Fig. 4.2).
Although the operated eyelid may be under con-
siderable tension at the end of surgery, as long as the 
tension is horizontal, it usually relaxes within a mat-
ter of days without running the risk of eyelid malpo-
sition [9]. Generally, by 2 months postoperatively, 
the eyelid has expanded to normal proportions.
 Full-Thickness Skin Graft
Indication for Surgery Skin grafting is a rela-
tively easy procedure that any reconstructive sur-
geon should master before undertaking tumor 
excision. Even though the best functional and aes-
thetic results are achievable with local flaps, there 
are occasions where a skin graft is the best option 
as in cases of elongated oval-shaped central eyelid 
defects (Fig. 4.3). In the eyelid region, skin graft-
ing means full-thickness skin graft (FTSG). 
FTSGs are best when harvested from the upper 
eyelid skin when available; other potential donor 
areas include the preauricular or postauricular 
areas, inner brachial, and supraclavicular areas. 
When harvesting FTSGs from areas other than the 
upper eyelid, there are some disadvantages include 
the potential for color/thickness mismatch; risk of 
potential complications such as graft contracture, 
scar hypertrophy, and more rarely graft failure. 
Figure 4.3c demonstrates the use of a bolster asso-
ciated with Frost sutures to improve graft survival 
and overall better graft uptake. It is always a good 




Fig. 4.2 (a–f) Direct closure of a lower lid-cheek junction defect





Fig. 4.3 (a–e) Upper lid full-thickness skin graft for closure of lower lid-cheek junction defect
 Standard Surgical Technique
 – A template is used to measure the size of the 
defect and match to the area being harvested.
 – The FTSG is harvested, taking care not to 
button- hole the tissue.
 – The FTSG is then thinned posteriorly, using 
Westcott scissors to remove subcutaneous 
tissue.
 – The thinned graft is then secured to the defect, 
first using 3–4 cardinal sutures of 6-0 Vicryl.
 – The rest of the graft is sutured into place using 
7-0 Vicryl which can be used in an interrupted 
or continuous fashion.
 – A bolster associated with longer Frost sutures 
to keep it in place may assist graft survival 
(Fig 4.3c).
 – A firm pressure dressing should be used for 
48–72 h whether or not the bolster was used 
(Fig. 4.3).
 Full-Thickness Defects (Anterior 
Lamella and Posterior Lamella)
Full-thickness eyelid defects require reconstruc-
tion of both the anterior and posterior lamellae. 
Both lamellae can’t be grafts since at least one 
of them must have a blood supply. The correct 
options include:
 1. Anterior graft + posterior flap OR
 2. Anterior flap + posterior graft OR
 3. Anterior + posterior flap
 Upper Lid Full-Thickness Defect
The surgeon’s choice depends upon extent of tis-
sue removed and especially upon the horizontal 
extent of the defect (Table 4.1).
Two major factors determining the repair are 
the horizontal extent of the defect and how much 
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tarsal plate remains [3]. Repair of the upper eye-
lids is more important than the lower as it is the 
upper eyelid that is the main protector of the cor-
nea during blinking and eye closure [3]. Once an 
upper eyelid defect can no longer be closed by 
direct suture, tissue must be added back to the 
eyelid, and there have been numerous techniques 
described including full-thickness flaps and grafts 
from the surrounding tissues (including the lower 
eyelid); anterior lamella advancement, sliding, 
and rotational flaps; and combined upper and 
lower lid advancement flaps. Numerous grafts 
have been described including skin, mucous 
membrane, hard palate, nasal mucosa, and auric-
ular cartilage [3].
Depending on the laxity of the eyelid tis-
sues, full-thickness defects of the eyelid margin 
involving up to one-third of the horizontal length 
may be closed with direct closure. Residual ten-
sion can be released with a lateral canthotomy 
or cantholysis [11]. Direct closure of a wound 
affecting one-third to two-thirds of the eyelid 
may be done if there is enough horizontal lax-
ity of the eyelid. If the wound is too tight, then 
a canthotomy and cantholysis should be consid-
ered [3]. If the temporal skin can be mobilized, 
then a semicircular advancement (Tenzel) flap 
technique can be utilized [12]. If the lateral can-
thus has been lost, then a local tarsoconjunctival 
flap may be used along with a periosteal strip [13, 
14]. The anterior lamella can be replaced with a 
full-thickness skin graft or myocutaneous flap. 
If there is enough anterior lamella to support a 
graft, then alternatives may be used to recreate 
the posterior lamella, such as a free tarsal graft 
from the contralateral upper eyelid or hard palate.
When there is insufficient local upper eyelid tis-
sue to reconstruct the full-thickness defect, distal 
flaps must be constructed to provide a blood sup-
ply for any reconstruction. The classic upper eye-
lid reconstruction when more than two-thirds of 
the eyelid is missing is a Cutler-Beard procedure, 
which is a two-stage bridging procedure [11].
 Direct Closure
Indication for Surgery. For smaller defects 
of the upper eyelids, the same principles of 
repair for a lower eyelid apply to the upper. 
The amount of upper eyelid tissue that can be 
excised with direct closure to follow is gener-
ally 8–10 mm (up to 50%), but this depends on 
the age of the patient and the degree of eyelid 
laxity. Assessment includes pulling the edges of 
the defect together to confirm the wound is not 
under too much tension [3].
In selected cases, direct eyelid closure may 
be achieved after considerably larger eyelid mar-
gin resections than conventionally taught. The 
immediate postoperative distortion and reduc-
tion in palpebral aperture (ptosis) is temporary 
thanks to spontaneous tissue expansion brought 
about by the steady pressure of the displaced 
globe against the reconstructed eyelid. The sur-
gery is simple and the functional and cosmetic 
results are excellent [15].
Standard Surgical Technique
 – 7-0 polygalactin (Vicryl) sutures placed in the 
tarsus, gray line to gray line with a vertical 
mattress suture; a slight eversion of the wound 
edges is desirable to avoid the risk of notching 
of the eyelid margin (Fig 4.4b).
Table 4.1 Treatment of full-thickness upper eyelid 
defect
Horizontal defect 





>66% Full thickness lower to upper 
eyelid flap repair, e.g., Cutler–
Beard procedure
  2 stages, divide at 2–6 weeks
  Posterior lamella defect: 
graft—opposite tarso- 
conjunctiva, ear, palate
  Cannot use if other eye has poor 
vision
Periosteal strip
Anterior lamella advancement 
from upper lid + posterior lamella 
graft (2 stage)
“Bucket handle” flap
Sliding upper eyelid 
tarsoconjunctival flap
Mustarde total lid switch
F. Bernardini and B. Skippen
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 – A second 7-0 Vicryl suture is used to approxi-
mate the anterior lash line.
 – Two to three deep tarsal sutures are passed par-
tial thickness through the tarsal plate to take 
the horizontal tension off the eyelid margin—
one close to the eyelid margin and a second 
parallel and 1–2 mm from the first (Fig. 4.4c).
 – Skin sutures are then placed in an interrupted 
or continuous fashion, using 7-0 Vicryl 
(Fig 4.4f).
 Lateral Semicircular Skin Flap or Tenzel 
Flap
Indication for Surgery. The amount of skin flap 
that is rotated into the upper eyelid may be small 
as the main benefit of this procedure is the under-
mining of tissue lateral to the canthus, reducing 
the horizontal tension from direct eyelid advance-
ment. The goal of the rotation flap is to use the 
skin lateral to the canthus to form the lateral eye-
lid and to mobilize the residual eyelid tissues cen-
trally in contact with the eye. In elderly patients 
with more extensive upper eyelid tumors, rather 
than submitting the patient to a more complicated 
procedure, the superior limb of the medial can-
thal tendon can also be released [3].
Standard surgical technique (applicable for 
upper and lower eyelids) (see also surgical details 
for Tenzel flap reconstruction of the lower lid):
 – First assess the eyelid tension to exclude the 
ability to close the defect via direct closure.
 – A semicircular incision is marked out with a 
surgical marking pen starting at the lateral 
canthus, curving inferiorly for approximately 
3 cm and laterally for approximately 2 cm, or 
as much as possible taking care to remain 
within the lateral orbital rim with the semicir-
cular flap dissection or less than 2 cm passed 
the rim to avoid injuring the frontal branch of 
the temporalis nerve (Fig 4.5b).
 – The skin incision is made using a number 15 
Bard Parker blade (Fig 4.5c).
 – The flap is then undermined using blunt- 
tipped Stevens scissors to the depth of the 
mid-dermis (Fig 4.5d).
 – A canthotomy and cantholysis are usually also 
required [16].
 – The lateral canthus is suspended to the lateral 
orbital rim periosteum with a buried 5-0 
Vicryl.
 – The primary defect is closed first by way of 
simple primary closure followed by the repair 
of the semicircular defect. 6-0 Vicryl can be 
used, tarsal plate first and then lash line and 
anterior lamella.
 – The lateral angle is then reformed fixating the 




Fig. 4.4 (a–f) Direct closure of a full-thickness upper eyelid wound 33–50% horizontal length
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 Full-Thickness Lower to Upper Eyelid 
Flap Repair
Indication for Surgery. The Cutler-Beard pro-
cedure uses a full-thickness advancement flap 
from the lower eyelid [13]. The method is only 
useful for vertical defects of the upper eye-
lid. Unfortunately, there is minimal to no tar-
sus added to the new upper lid margin, which 
is where the structural support is required and 
consequently upper lid entropion may result. 
Despite some postoperative problems, the 
Cutler-Beard procedure continues to be used 
by many surgeons and can be used for defects 
of 100% of the horizontal eyelid length [7] 
(Fig. 4.6).
Standard Surgical Technique
 – The lower eyelid margin is left intact with 
inferior full-thickness incision made to 
advance a skin–muscle conjunctiva into the 
upper eyelid underneath this bridge of 
tissue.
 – A three-sided inverted U-shaped incision is 






Fig. 4.5 (a–i) Tenzel semicircular flap repair of an upper eyelid defect
Fig. 4.6 End of stage 1 of Cutler-Beard procedure
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marking pen, beginning 4–5  mm below the 
eyelid margin [16].
 – A silk traction suture is passed through the 
gray line of the lower eyelid, which is then 
everted over a Desmarres retractor.
 – A conjunctival incision is made below the 
tarsus.
 – A conjunctival flap is created and dissected 
inferiorly into the lower fornix and onto the 
globe.
 – A free tarsal graft is harvested from the con-
tralateral upper eyelid and sutured to the tarsal 
remnants and to the upper fornix conjunctiva 
and the lower edge of the levator muscle.
 – The flap is advanced into the upper eyelid 
defect and sutured to the free tarsal graft using 
6-0 Vicryl sutures, taking care to bury the 
knots to avoid corneal irritation.
 – The edges of the graft are sutured edge to edge 
to either tarsal remnants or to local periosteal 
flaps using 5-0 Vicryl sutures [16].
 – An incision is then made horizontally through 
the lower eyelid skin and orbicularis muscle just 
inferior to the tarsus and extended inferiorly to 
create a skin–muscle advancement flap [16].
 – The lower eyelid skin–muscle flap is advanced 
posterior to the bridge of lower lid tarsal and 
eyelid margin tissue to cover the graft and 
sutured to the residual upper eyelid skin using 
6-0 Vicryl sutures [16].
Postoperative Medications and Wound 
Care: Pattern of Follow-Up Visits 
and Evaluation
• Antibiotic ointment applied to wound and in 
the eye (check for allergies), firm double pad.
• Remove pad at home after 48 h and apply anti-
biotic ointment three times a day to wound.
• Follow-up in 1–2 weeks.
• The flap is divided 2–8  weeks after recon-
struction with repair of the lower eyelid donor 
site and repair of the new eyelid margin to pre-
vent entropion [11].
 – Earlier division of the flap at 2 weeks has 
been reported without problem except in 
large defects or when the lower lid skin is 
tight such as in younger patients [17].
 – For patients with a poor vascular supply 
(e.g., post-radiotherapy treatment or 
trauma), a longer interval between pri-
mary surgery and flap division is more 
suitable.
 Periosteal Strip: Adjunct Procedure
Indication for Surgery. A strip of periosteum can 
be reflected from the zygoma nasally to function 
as a lateral canthal tendon and posterior lamella 
of the temporal eyelid. This is a useful adjunct 
procedure for larger upper eyelid defects >66% 
of horizontal eyelid length.
Note: This is an adjunctive procedure to help 
with some eyelid reconstruction but not a stand- 
alone posterior lamella substitute.
Standard Surgical Technique
 – After the lateral orbital rim is exposed with 
blunt dissection, a rectangular periosteal strip 
with an intact base is fashioned with a scalpel 
blade and separated from bone with a Freer 
elevator.
 – The periosteal incisions are slanted 45° down-
ward for upper eyelid reconstructions so that 
the strip follows the contour of the upper eye-
lid after it is reflected superonasally.
 – The strip should be at least 1  cm wide and 
long enough to reach the residual tarsal stump 
with adequate tension.
 – The strip is reflected nasally to position the 
outer periosteum against the globe and sutured 
to the anterior surface of the residual tarsal 
stump with 5-0 polygalactin 910 (Vicryl) 
sutures.
 – The anterior lamella needs to then be recon-
structed by advancing a myocutaneous flap or 
FTSG over the strip.
 – Residual conjunctiva in the fornix is sutured to 
the inferior edge of the strip with 7-0 polyga-
lactin 910 sutures, and the side of the strip fac-
ing the eye is allowed to re-epithelialize.
 Bucket-Handle Flap
Indication for Surgery. This has been described 
as a solution for reconstruction of total or semi-
total full-thickness upper eyelid defects which is 
both relatively simple and utilizes well the poten-
tial vascularity of the transferred tissue [18]. This 
flap is also useful in patients with compromised 
healing abilities [18].
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Standard Surgical Technique [18]
 – A free tarsal graft is harvested from the con-
tralateral upper eyelid and sutured to the rem-
nants of the tarsal plate medially and laterally 
(Fig 4.7d). In case of a shortage of residual 
tarsal plate, a periosteal flap can be formed 
and used to anchor the free tarsal graft.
 – The conjunctiva from the upper fornix is 
advanced and sutured to the upper tarsal bor-
der, as is the levator muscle (Fig 4.7e).
 – A bucket handle bipedicle flap of orbicularis mus-
cle and eyelid skin from just below the brow hair 
is transferred onto the lower edge of the upper 
eyelid defect to cover a free tarsal graft harvested 
from the contralateral upper eyelid (Fig 4.7f).
 – The superior limb of the incision is made 
along the margin of the inferior brow with 
a number 15 Bard Parker blade with a hori-
zontal extension as to adapt to fill the 
defect.
 – The inferior limb of the incision corresponds 
to the upper edge of the eyelid defect.
 – The medial and lateral ends of the flap are 
flared slightly to maximize the blood supply at 
each end of the flap.
 – The flap is raised in the sub-orbicularis plane of 
dissection until it is mobile enough to allow for 
tension-free insertion into the upper eyelid 
defect.
 – A FTSG is then harvested, possibly from the 
contralateral upper eyelid skin, and sutured to 
cover the sub-brow anterior lamella defect 
(Fig. 4.7g, h). Video 4.1- Reconstruction with 




Fig. 4.7 (a–i) Bucket handle flap for left upper eyelid reconstruction
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Postoperative Medications and Wound 
Care: Pattern of Follow-Up Visits 
and Evaluation
 – Double pad, antibiotic ointment to wound and 
in the eye (check first for allergies).
 – Remove pad at home after 48 h and apply anti-
biotic ointment three times a day to wound.
 – Follow-up in 1 week.
 – Usually 2–3  weeks later the pedicles are 
divided and the flap insetting completed [18].
 Sliding Upper Eyelid Tarsoconjunctival 
Flap
Indication for Surgery. In our opinion a bucket 
handle flap or an upper eyelid tarsoconjunctival 
flap (Hughes to the upper eyelid) is always prefer-
able to a Cutler-Beard procedure as it is a single- 
stage procedure with a much better aesthetic 
result and avoids complications of the Cutler-
Beard such as entropion, lower eyelid retraction, 
and scarring [19, 20]. The upper eyelid sliding 
tarsoconjunctival flap is possible when some tar-
sus is preserved after Mohs excision. The resid-
ual tarsal plate slides, still attached to the upper 
conjunctival flap, is displaced inferiorly to repair 
the posterior lamella and is subsequently covered 
with a skin graft.
Potential complications of an upper eye-
lid sliding tarsoconjunctival flap include eyelid 
retraction, eyelid margin abnormality, lack of 
cilia, and abnormal eyelid contour. In compari-
son, direct (primary) closure avoids disrupting 
the eyelid margin contour and eyelash loss, but it 
often leads to residual upper eyelid ptosis.
Standard Surgical Technique
 – A tarsoconjunctival flap is formed similarly to 
what happens for the lower eyelid from the 
upper half of the tarsal plate adjacent to the 
defect; vertical cuts are made continued supe-
riorly into the conjunctiva toward the fornix to 
completely release the tarsoconjunctival flap.
 – The extent of the incisions into the conjunc-
tiva depends on the extent of flap mobilization 
required to close the defect under minimal/
modest tension.
 – The conjunctiva is then released from the leva-
tor aponeurosis and Muller’s muscle [20].
 – The flap is then moved to fill the posterior 
lamellar defect and stored medially and later-
ally to the tarsal remnants.
 – The tarsoconjunctival flap should be over- 
corrected inferiorly by about 1 mm beyond the 
anticipated new eyelid margin to allow for 
shrinkage.
 – A FTSG or an upper eyelid skin–muscle 
advancement flap is used to repair the anterior 
lamella.
 – The new anterior lamella is sutured to tarsus 
along the eyelid margin using 7-0 Vicryl 
sutures, taking care to avoid corneal irritation 
with the suture knots.
 Lower Lid Full Thickness
Knowledge of different reconstructive options 
allows for planning of the surgical repair. Lower 
eyelid defects can be categorized by:
 1. Amount of full-thickness eyelid defect (as 
percent of eyelid margin)
 2. Degree of nonmarginal eyelid involvement
 3. Total size of defect
 4. Canthal involvement
 5. Lacrimal involvement
Depending on the laxity of the eyelid tis-
sues, full-thickness defects of the eyelid margin 
involving up to one-third of the horizontal length 
may be closed with direct closure (Table  4.2). 
Minimal tension can be released with a lateral 
canthotomy or cantholysis [1]. Larger defects 
may require use of the Tenzel or Hughes flaps.
Options for anterior lamellar reconstruction 
include skin grafts and local skin flaps. Skin 
graft sites include upper eyelids, postauricu-
lar, preauricular, supraclavicular, neck, or inner 
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arm. One should consider the type and distribu-
tion of hair in the donor graft [21]. Skin flaps 
include advancement, rotation, and transposi-
tion flaps. Flaps may have a base, direct pedicle, 
tubed or pedicle or be an island flap. Specific 
local eyelid flaps include O-to-T, V-to-Y, and 
rhombic flaps.
Periorbital flaps include transposition and 
rotation cheek flaps (Tenzel, Mustarde, etc.), gla-
bellar flaps, paramedian forehead flaps, and tem-
poral forehead flaps (Fricke). Flaps may need to 
be divided or inset as a second stage procedure 
several weeks after the initial repair, e.g., Hughes 
procedure [21].
Options for posterior lamellar reconstruc-
tion also include grafts or flaps [22, 23]. Flaps 
include tarsoconjunctival flap and can be cen-
tral such as in a Hughes flap or lateral-based; in 
either case there is a pedicle of conjunctiva that 
provides vascular supply to the flap. Grafts may 
include tarsoconjunctival grafts, tarsomarginal 
grafts, hard palate grafts, and auricular cartilage 
grafts.
 Direct Closure: Wedge Excision
Indication for Surgery. An eyelid defect of 25% 
or less may be closed directly, and some authors 
have reported excellent results for defects much 
larger than this, closing the defect under consid-
erable tension [4–6]. In patients with marked eye-
lid laxity or through the use of lateral canthotomy 
with or without cantholysis, a defect even larger 
than 50% of the eyelid may sometimes be able to 
be closed directly.
Standard Surgical Technique
 – Initial wedge excision of the lesion with mar-
gin control
 – Primary closure entails first repair of the tar-
sus with 2× buried 6-0 or 5-0 Vicryl sutures
 – Then a 6-0 Vicryl lash line suture
 – Sometimes a gray line suture (7-0 Vicryl, cut 
knot short to avoid corneal irritation)
 – Finally repair of the anterior lamella with 
interrupted or continuous 6-0 Vicryl sutures 
[16, 23]
 Cantholysis: Adjunct Procedure
Indication for Surgery. The size of the defect 
that can be repaired in the lower eyelid can be 
increased if necessary by the addition of a lateral 
cantholysis. In elderly patients, eyelid defects of 
up to half the horizontal length of the eyelid or 
14  mm can be directly repaired. This is some-
times a useful adjunct to direct closure.
Standard Surgical Technique
 – Canthotomy is made with a size 15 blade or 
Westcott scissors.
 – The lower limb of the lateral canthal tendon is 
released.
 – The eyelid is slit at the gray line for at least 
6 mm.
 – The lower canthal tendon fibers are released, 
but the upper lid tendon fibers must remain 
intact to avoid distortion of the canthus 
postoperatively.
 – A traction (Frost) suture to elevate the lower 
lid for 48–72 h is sometimes useful (Fig. 4.8).
Table 4.2 Treatment of full-thickness lower eyelid defect
Full-thickness defect size Primary techniques Adjunct techniques






Medium (30–40%) Lateral advancement flap Canthal fixation
Canalicular reconstruction
Periosteal flap





Autogenous tarsal graft or hard palate mucosal graft
Medial canthotomy/cantholysis
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 Tenzel Semicircular Flap
See upper eyelid description.
Indication for Surgery. The main indication for 
a Tenzel flap is a larger full-thickness lower eyelid 
defect with up to half of the eyelid length involved; 
however, it may be used for defects up to 70% if the 
lower eyelid retractors and inferior orbital septum are 
identified and severed from their attachments [12].
 Hughes Tarsoconjunctival Flap
Indication for Surgery. The original Hughes pro-
cedure was reported in 193725 since which time 
some modifications have been made [25–29]. A 
modified Hughes tarsoconjunctival flap can be 
used for full-thickness defects of more than half 
the lower eyelid length [16, 25]. This procedure 
can be used for defects involving the entire hori-
zontal length of the lower eyelid. The integrity of 
the upper eyelid margin is retained by leaving the 
lower 4 mm of the upper tarsal plate intact [23].
One-eyed (monocular) patients and children 
in the amblyogenic age, whose vision may be 
affected by the temporary eyelid closure, are bet-
ter served with single stage advancement flaps.
Standard Surgical Technique
 – The defect should be assessed under gentle 
tension.
 – A silk traction suture is passed through the 
gray line of the upper eyelid, which is everted 
over a Desmarres retractor [16].
 – The tarsal conjunctiva incision line is marked 
with a surgical marking pen 4 mm above the 
eyelid margin.
 – A superficial horizontal incision is made along 
the conjunctiva and tarsus 4  mm above the 
eyelid margin using a number 15 Bard Parker 
blade [16].
 – The incision is deepened through the full 
thickness of the tarsus using the number 15 
blade, and the horizontal incision is completed 
with Westcott scissors. Vertical relieving cuts 
are then made at both ends of the tarsal inci-
sion [16].
 – Tarsus and conjunctiva are dissected free from 
Müller’s muscle and the levator aponeurosis 
up to the superior fornix. The tarsoconjuncti-
val flap is advanced into the lower eyelid 
defect to reconstruct the posterior lamella of 
the lower eyelid.
 – The flap tarsus is sutured to the remaining 
lower eyelid tarsus edge with interrupted 6-0 
Vicryl sutures. The lower eyelid conjunctival 
edge is sutured to the inferior border of the 
mobilized tarsus with a continuous or inter-
rupted 6-0 Vicryl suture.
 – A FTSG (preferred by us because it reduces 
the risks of cicatricial ectropion) or advancing 
a myocutaneous flap from the cheek can be 
used to reconstruct the anterior lamella. The 
graft or flap is sutured into place with 6-0 
Vicryl sutures.
a b
Fig. 4.8 (a, b) Inferior cantholysis adjunct to direct closure
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 – The skin edge is sewn to the superior aspect of 
the tarsus using interrupted 7-0 Vicryl sutures.
 – The occasional use of oblique medial and lat-
eral periosteal flaps in conjunction with the 
Hughes flap enables the repair of maximal 
defects of the lower eyelid [28]. Video 4.2- 
Reconstruction with Hughes flap.
Postoperative Medications and Wound 
Care: Pattern of Follow-Up Visits 
and Evaluation
 – Remove pad at home after 48  h, and apply 
antibiotic ointment three times a day to wound.
 – At a second operation, the conjunctival pedi-
cle is cut and the lower eyelid margin 
reconstructed.
 – Although the second operation has typically 
been performed 3–4 weeks after the first oper-
ation [25], the tarsoconjunctival pedicle may 
be safely divided at 2 weeks [29] and even as 
early as 7 days [29].
Second Stage
 – Local anesthesia with propofol sedation.
 – 27G–30G needle, 1% ropivacaine with 
1:100,000 adrenaline, injected into the upper 
and lower eyelids.
 – Next, one blade of a pair of Westcott scissors 
is inserted just above the desired level of the 
new eyelid border, and the flap is cut open16 
(Fig. 4.9).
 – The upper eyelid is then everted, and the resid-
ual flap is excised using Westcott scissors.
 – The anterior and posterior lamellar margin are 
sutured together with 7-0 Vicryl sutures.
 Single-Stage Advancement Flaps 
+/− Free Grafts
Indications for Surgery. Disadvantages of the 
Hughes flap are not insignificant and include 
[30]:
 1. The eye is closed postoperatively for 
1–2 weeks or longer.
 2. A second stage is required.
 3. There is a loss of eyelashes in the area of the 
flap.
 4. The edge of the flap can be persistently 
erythematous.
These disadvantages have prompted the 
search for alternative single-stage procedures. 
Reconstruction of the anterior lamella in full- 
thickness eyelid defects can be accomplished by 
a number of different techniques, each with some 
variations. FTSGs may be utilized if the tarsal 
flap has a vascular supply (Hughes flap) or when 
an orbicularis muscle flap is advanced. A myo-
cutaneous pedicle flap will typically result in a 
better color and thickness match [31]. Free tar-
soconjunctival (TC) flaps associated with myo-
cutaneous advancement flaps are less likely to 
lead to complications of eyelid margin erythema 
and subsequent revision surgery than Hughes 
TC flaps with FTSGs [32]. They are also single 
stage procedures and thus useful for monocular 
patients.
Other single-stage alternative procedures to the 
Hughes flap for reconstruction of large lower eyelid 
defects have recently gained favor and include lat-
eral-based full-thickness advancement flaps [33] and 
a b c
Fig. 4.9 (a–c) Stage 2 of the Hughes procedure
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free tarsoconjunctival graft and myocutaneous trans-
position flap [34]. Perry and Allen described success-
ful single-stage reconstruction of large full-thickness 
defects of the lower eyelid which involve 50–75% 
of the horizontal length of the eyelid [30]. The pro-
cedure employs lateral stabilization of the posterior 
lamella with a periosteal strip, medial transposition 
of the lateral posterior lamella for central and medial 
defects, and a myocutaneous advancement flap to 
stabilize the anterior lamella. For defects ≥66% of 
the lower eyelid, a free tarsal graft is often necessary 
in addition to the periosteal strip to complete poste-
rior lamellar reconstruction [30].
 Standard Surgical Technique: Lateral- 
Based Full-Thickness Advancement 
Flap
Indication
Full-thickness lower eyelid defect greater than 
50% eyelid width with no tarsus remaining; 
minimum 25% full-thickness lateral lower eyelid 
intact for medial advancement [33] (Fig 4.10a).
Technique
 – The horizontal dimension of the lower eyelid 
defect is measured along with the residual lat-
eral full-thickness lower eyelid. Lateral inci-
sional markings are then drawn [33] 
(Fig 4.10b).
 – A full-thickness advancement flap, based lat-
erally, is created. The skin height in the flap is 
made 1–2 mm greater than the skin height in 
the defect [33] (Fig 4.10c).
 – The conjunctiva and retractor–orbital sep-
tum fused complex are incised along the 
inferior border of the tarsal plate and then 
incised vertically, 1  mm or so anterior to 
the lateral fornix recess, cutting down onto 
the periosteum of the lateral orbital rim 
[33].
 – The lateral palpebral raphe tissue at that 




Fig. 4.10 (a–g) Single staged flap. (From Skippen et al. [33], with permission)
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completely mobilized from the orbital rim 
(Fig 4.10d).
 – From the lateral eyelid wound edge, the skin is 
incised laterally, superiorly, and inferiorly in 
parallel with the curve of the eyelid margin. 
The full-thickness eyelid flap is then advanced 
medially to ascertain whether there needs to 
be further mobilization of the lateral skin base 
in a V-Y manner [33].
 – The medial tarsal edge of the full-thickness 
flap is sutured to the medial edge of the 
defect with two 6-0 Vicryl interrupted 
sutures. A continuous 6-0 Vicryl suture is run 
along the inferior conjunctival margin of the 
flap with the knots buried away from the ocu-
lar surface [33].
 – The anterior lamella of the flap is sutured to 
the skin edge of the defect with 6-0 Vicryl 
sutures (Fig 4.10e).
Another means of laterally located large, 
full- thickness repair of large lower eyelid 
defects consists of the creation of a lateral-based 
tarso-conjunctival flap with vascular supply 
coming from the lateral conjunctiva; the tarso- 
conjunctival flap is severed from the donor eyelid 
as if it was a free tarsal graft, except for the lateral 
most part attached to the conjunctiva; the flap can 
be fully mobilized to reach the recipient bed in 
the lower eyelid and anchored into the new posi-
tion; subsequently a FTSG or better a  skin/mus-
cle flap from the same upper eyelid (Fig. 4.11), 
providing the best functional and cosmetic result.
Mustarde’s Cheek Rotation Flap. A large 
lower eyelid defect, also involving the cheek, 
can classically be reconstructed with Mustarde’s 
cheek rotation flap, which utilize the lateral cheek 
and zygomatic skin to cover a posterior lamellar 
graft [16, 23]. Excision of a significant amount 
of normal tissue is required in the cheek area to 
avoid a dog ear deformity and this flap is reserved 
for large lower eyelid defects extending to the 
cheek, rather than isolated lower eyelid defects. 
The flap size needs to be 3–4 times the area of 
the primary defect. It is important to remember 
that this is a rotation flap rather than a simple 
advancement and thus requires a very significant 
degree of undermining.
 Medial Canthus Reconstruction
Reconstruction of the medial canthus after the 
excision of cutaneous malignancy is challenging 
not only from an aesthetic aspect, but also due 
to the complexity of the medial canthal anatomy 
and its importance for vision and eyelid function. 
Furthermore, there is minimal laxity of skin in 
this region, often precluding primary closure of 
defects. In addition to consideration of eyelid 
and medial canthal skin reconstruction, the naso-
lacrimal apparatus requires attention to avoid or 
treat potentially disabling epiphora [35]. Primary 
closure is sometimes possible, depending on the 
excision technique used, i.e., Moh’s, frozen sec-
tion, and delayed paraffin.
For larger anterior defects, or those lacking a 
vascular bed for FTSG survival, various trans-
position or advancement flaps can be employed, 
such as a glabellar forehead flap or paramedian 
f g
Fig. 4.10 (continued)
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forehead flap [2, 36]. When the defect involves 
full-thickness medial eyelid(s) or sacrifice of the 
medial canthal tendon, the remaining eyelid must 
be reapproximated and fixated to periosteum 
or bone [38]. When the medial canthal tendon 
is interrupted or completely lost, the remaining 
eyelid portion of the tendon must be fixated to 
the area of the tendinous origin to ensure proper 
alignment and support of the eyelid(s). If only the 
anterior limb of the tendon is disrupted, it may 
not cause malposition of the medial canthus if the 
posterior limb remains intact [24]. If any tendon 
remains on the anterior or posterior lacrimal crest, 
direct reattachment with polygalactin (Vicryl) or 
polypropylene (Prolene) suture is possible.
 Reconstruction Options
 1. Laissez-faire (small, shallow defects)
 2. Direct closure
 3. Glabellar or bilobed flaps (if poor vascular 
support; need to be thinned)
 4. Paramedian forehead flap [37]
 5. Combination flaps for deeper defects [36]
 6. FTSG (if good vascular support; larger defects)
Some of the problems encountered in recon-
struction in this area include [35]:
 1. A difference in skin color between host tissue 
and skin grafts used for reconstruction
 2. Differing skin textures, for example, thick 
skin from the glabellar region is often a poor 
match for medial canthal skin
 3. Poor eyelid motility and function, which 
requires adequate canthal tendon fixation in 
the appropriate position and at the correct 
tension
 4. Loss of volume in the concavity of the medial 





Fig. 4.11 (a–i) Large lower eyelid defect repair using lateral-based tarso-conjunctival flap
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 5. Limited globe motility, typically reduced 
abduction, which may result from a conjuncti-
val cicatrix
 6. Chronic epiphora, which may result from sec-
ondary corneal exposure, an abnormal lid posi-
tion or damage to the nasolacrimal system
 Laissez-Faire (Spontaneous 
Granulation)
After its initial description by Fox and Beard in 
1964, the laissez-faire method has become well- 
established as a method of medial canthal reconstruc-
tion, with excellent cosmetic results [42]. Excess 
scar formation may occasionally occur, which may 
lead to difficulties in subsequent tumor surveillance, 
but this may be dealt with surgically using standard 
techniques. Scarring may be reduced in defects that 
symmetrically bisect the medial canthal tendon with 
appropriate contouring and alignment along the 
relaxed skin tension lines (RSTL) [35].
 Direct Closure of the Defect
Where possible, direct closure of the edges of 
a defect typically provides excellent cosmetic 
results, however, the use of this technique has tra-
ditionally only been used for small defects due to 
concern about closing defects under tension and 
subsequent unacceptable distortion of the pal-
pebral apertures. However, it has recently been 
shown that even when eyelid defects are closed 
under extreme tension, intraoperative, and post-
operative tissue expansion allows the dimensions 
of the palpebral apertures to return to normal 
after a period of a few months [15].
 Mobilization of Nasal Skin into 
a Medial Canthal Defect
Indication for Surgery. A variety of techniques 
involving flaps have been described, permitting 
mobilization of infraglabellar nasal skin into a 
medial canthal defect, all of which allow defect 
closure within a single aesthetic facial unit [35].
 The Rhomboid Transposition Flap
This provides a simple and versatile method for 
medial canthal reconstruction [38]. Custer also 
described a transnasal flap, similar in construc-
tion to a rhomboid flap but triangular in shape, 
which has been reported to provide excellent 
cosmetic results in 22 patients [39].
Advantages of using a rhomboid flap include:
 – Scar length minimized
 – Tissue excision minimized
 – Easier to work with straight defect sides
 Standard Surgical Technique
 – The defect, which may be an irregular shape, 
is conceptualized as a rhomboid shape, with 
its long-axis perpendicular to the relaxed skin 
tension lines (RSTL).
 – Short diagonal of excised rhomboid on the 
same line with RSTL.
 – A flap adjacent to typically the upper half of the 
defect (greater skin motility superiorly) is mobi-
lized, which is then transposed into the defect.
 – Base of triangle of donor flap perpendicular to 
RSTL.
 – After flap advancement, the greatest tension 
lies in closing the triangular donor site.
 – Undermining of tissues allows closure of the 
secondary defect.
 – Tissue closure with interrupted 6-0 Vicryl 
sutures.
 The Bilobed Flap
This is an alternative versatile option to the rhom-
boid flap and uses two lobes of skin on a shared 
pedicle and is thus a double transposition flap 
[40]. This technique permits movement of more 
skin over longer distance than possible with sin-
gle transposition flap.
Standard Surgical Technique
 – Each lobe of the defect is tethered to a cutane-
ous pedicle.
 – The proximal lobe is transposed into the 
defect, whereas the second lobe is rotated into 
the defect created by the first.
 – The first lobe is designed to be equal to the 
width of the original defect.
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 – The defect arising from the second pedicle can 
usually be closed directly, in a linear fashion.
 – This defect bears the greatest closure tension 
and is best placed in a natural skin crease 
where possible.
 – Tissue closure with interrupted 6-0 Vicryl 
sutures.
 Mobilization of Forehead or Glabellar 
Tissue
Mobilization of tissue as a flap from the fore-
head or glabellar area can be achieved through a 
bilobed flap [40] as described above, or a glabel-
lar flap as described by McCord and Wesley [41]. 
The underlying rich vascular supply of this region 
allows for a very robust flap. Such forehead flaps 
can preserve their vascular pedicle along an axial 
pattern, such as a paramedian forehead flap.
 Mobilization of Upper Eyelid Anterior 
Lamella
Skin and/or orbicularis may be mobilized from 
the upper eyelid using a variety of flap techniques 
[42]. Dermatochalasis may provide a large amount 
of redundant skin that can be mobilized with little 
local morbidity in a cosmetically acceptable man-
ner. Tissue flaps can be advanced through a rotation 
flap, hinged laterally, or more commonly through 
a medially based pedicle, which allows the move-
ment of larger quantities of skin and or muscle; this 
latter technique, when used bilaterally, can also be 
used in the reconstruction of the entire superficial 
upper half of the nose. Thin eyelid skin, however, 
does not always allow adequate volume replace-
ment of the medial canthal hollow [35].
 Mobilization of Cheek, Forehead, 
and Midface Tissue
Upward movement of nasolabial, cheek, and 
midfacial tissue into a medial canthal defect can 
be achieved through rotation and/or transposi-
tion flaps, but is perhaps more simply achieved 
with a subcutaneous island pedicle advancement 
flap [43]. The design of the flap is “V-Y,” with 
the lower part of the defect being closed to form 
the limb of the “Y.” Such flaps provide well- 
vascularized tissue and are easily combined with 
other techniques, such as a forehead or glabellar 
flap, for larger defects. Disadvantages include a 
downward vector of the flap, which may predis-
pose to subsequent medial ectropion [35].
 Paramedian Forehead Flap
Indication for Surgery. For large medial canthal 
defects, a paramedian forehead flap can be use-
ful [37]. The paramedian forehead flap method 
elevates the flap with the supratrochlear vessels 
and nerves, ensuring an abundant blood supply. 
The common paramedian forehead flap utilizes 
the contralateral supratrochlear artery as the ped-
icle and has the merit of not bending the artery 
severely due to its large rotation arc. A parame-
dian forehead flap method utilizing the ipsilateral 
supratrochlear artery has also been described, 
with good results [37].
Disadvantages of the paramedian forehead 
flap include the procedure needing two stages 
and the relatively poor aesthetic outcome com-
pared to other techniques. The pedicle crossing 
the skin of the nose like a tube requires second 
stage flap division, usually after 2–3 weeks [37].
 Combination Flaps
Indication for Surgery. For larger, deeper medial 
canthal defects [36].
Standard Surgical Technique
 – Lacrimal system intubated with Crawford 
tubes during tumor excision
 – Medial canthal angle recreated first with 4-0 
Vicryl onto periosteum of posterior lacrimal 
crest then medial part of the eyelid defect
 – Glabellar rotational flap used for superome-
dial part of the defect
 – Lateral-based upper eyelid advancement flap 
used for lateral part of defect
 – Posterior parts of both flaps fixated to perios-
teum in medial canthus with 5-0 Vicryl sutures
 – Skin incisions closed with 6-0 Prolene and 5-0 
fast absorbing gut sutures (Fig. 4.12)
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 Skin Grafting
Indication for Surgery. Medial canthal defects 
can also be effectively covered by means of skin 
grafting, which can be either a split-thickness 
graft (SSG) or more typically a FTSG [44]. 
Contracture of skin grafts seems to occur more 
frequently as the thickness of the graft decreases, 
which often precludes the use of SSG in this 
region. FTSGs for the medial canthal region are 
typically harvested from the upper eyelid skin, 
preauricular or postauricular areas, inner bra-
chial, and supraclavicular areas [44].
 Lateral Canthus Reconstruction
Reconstruction of the lateral canthus, or can-
thoplasty, is not as well described as that of the 
medial canthus. Reconstruction of the lateral 
canthus is dependent upon the extent of injury 
to the surrounding tissues. The key to adequate 
reconstruction is correct recognition of the extent 
of injury and the correct fabrication of the dam-
aged or missing structures [45]. Options for skin-
only defects differ from options for full-thickness 
defects. The lateral canthal angle needs to be 
reformed. If eyelid laxity is present, then options 
include lateral canthopexy and a lateral tarsal 
strip. Other considerations in this region include 
skin rotation flaps for anterior lamella and perios-
teal flaps for posterior lamella.
Commonly used surgical procedures in this 
region include (done after complete clearance of 
the tumor, with adequate margins):
 – Primary closure
 – Advancement flap, rhomboid flap, rotation 
flap, transposition flap
 – Combination flaps
 – Lateral periosteal flaps can be helpful if lateral 




Fig. 4.12 (a–d) Combination flaps for large, deep right medial canthal defect




For small lesions, primary closure is the best 
method of reconstruction. Closing the defect in 
the direction of relaxed skin tension lines is typi-
cally the best orientation to perform primary clo-
sure. However, in the area of the lateral canthus, 
facial rhytids are described to occur in a crow’s 
feet distribution. These rhytids do not always fol-
low the relaxed skin tension lines and care should 
be taken to orient the scars with regards to the 
crow’s feet orientation [45].
 Rhomboid Flap
Indication for Surgery. Initially described 
by Limberg, the rhomboid flap is useful for 
skin reconstruction at the lateral canthus [46]. 
Advantages of the flap are its ability to mini-
mally distort important adjacent anatomic struc-
tures while providing a similar skin for the defect 
reconstruction.
Standard Surgical Technique
 – Excise the defect as a rhomboid so that its 
120° angle is located at the area of greatest 
skin excess.
 – A line is then drawn out into this skin excess 
from the apex of the 120° angle equal to the 
length of one side of the rhomboid.
 – A 60° cut is then drawn at the end of this line.
 – This line will be parallel and equal in length to 
the side of the rhomboid defect.
 – The flap is then cut and transposed so that the 
apex of the 60° cut is inserted in the 60° angle 
of the rhomboid defect.
 – Undermining of tissues allows closure of the 
secondary defect.
 – Tissue closure with interrupted 6-0 Vicryl 
sutures.
 Fricke Flap
The Fricke flap is an inferiorly based transpo-
sition flap designed in the forehead or tempo-
ral skin area and rotated medially to cover skin 
defects at the lateral canthus [47]. It can also be 
used for large lower eyelid full-thickness defects. 
When the flap is narrow the donor site can be 
closed primarily but care should be taken not to 
move the eyebrow laterally or the hairline ante-
riorly. Larger flaps may require FTSG closure of 
the donor site, which may leave an aesthetically 
unsatisfactory result.
An alternative for primary donor site closure 
is the use of a bipedicle flap instead of the Fricke 
flap transposition. Other forehead flaps with/
without preservation of the vascular pedicle (i.e., 
paramedian forehead, axial pattern flaps, etc.) 
may be useful [45].
 Lateral Canthal Tendon Repair
Reestablishment of the attachment of the lateral 
canthal tendon to the internal aspect of the lateral 
orbit at Whitnall’s tubercle is a surgical goal if 
the continuity of these two structures has been 
disrupted. The vector that has been described for 
representing the lateral canthus is one of a supe-
rior and lateral direction with periosteal fixation 
[48]. If both upper and lower eyelid structures 
are involved laterally, periosteum from both 
the upper and lower lateral orbital rim may be 
required to reconstitute the lateral canthal struc-
ture [49].
 Full-Thickness Defects
Full-thickness loss at the lateral canthus almost 
always involves loss of adjacent structures such 
as the eyelids. Reconstruction of these full- 
thickness defects requires both the reconstruction 
of the lateral canthus and that of the adjacent eye-
lids and tarsal plates [50]. Replacement materials 
for these reconstructive cases may include autog-
enous tarsal flaps or grafts, hard palate mucosa, 
palmaris longus tendon, temporal parietal fascia, 
nasal mucosal tissues, dermal fascia, ear carti-
lage, cadaver sclera, and various animal, cadaver 
or artificial skin, dermis or fascial implants [51, 
52]. Therefore, a combination of the techniques 
described above may be needed to reconstruct 
full-thickness lateral canthal defects (Fig. 4.13).
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 Postoperative Medications 
and Wound Care: Pattern 
of Follow-Up Visits and Evaluation
In general terms, for most eyelid procedures 
where a skin graft is not used, the postoperative 
management is similar.
• Management may be more complicated for 
dark skin patients due to the increased risk of 
hypertophic scars:
 – Antibiotic ointment to wound and in the 
eye (check first for allergies), double pad, 
tape.
 – Remove pad at home the next day and 
apply antibiotic ointment three times daily 
to wound.
 – When skin grafts are used, the pad should 
be left intact for a minimum of 48 h.
 – Follow-up in 1 week.
 Complications of Eyelid 
Reconstruction
 Upper Eyelid
The main complications of upper eyelid repair 
involve either the eyelid margin or the position 
of the eyelid [3].




Complications relating to the upper eyelid 
position includes:
• Entropion







Fig. 4.13 (a–h) Lateral canthal defect repairing lateral-based upper-eyelid transposition flap
F. Bernardini and B. Skippen
55
Finally, unevenness of the posterior lamella 
such as after a posterior lamella or tarsal graft can 
result in reduced corneal lubrication and subse-
quent discomfort.
 Lower Eyelid
Complications of lower eyelid repair can include 
[1]
Blurred vision or ocular irritation, secondary 
to:
• A suture
• Tissue irritation on the ocular surface
• Exposure keratopathy
Decreased orbicularis function with 
lagophthalmos
Swelling can cause mechanical ectropion




The predominant complications in this area 
include [35]:
 – Cicatricial contracture, e.g., eyelid 
malposition
 – Epiphora
 – Web deformities
 Lateral Canthus
Potential complications include [45]:
 – Trichiasis
 – Ocular surface irritation
 – Ectropion
 – Entropion
 Full-Thickness Skin Graft 
Complications
The periocular region is a favorable FTSG recipient 
area by virtue of its high vascularity [53]. The usual 
donor sites for harvesting FTSG for the periocular 
area are upper eyelid, preauricular, postauricular, 
neck, clavicular, supraclavicular, and inner brachial 
area. Different sites yield different graft thickness.
 Complications
Early complications seen in the first 2  weeks 
include [53]:
 – Bleeding with hematoma formation beneath 
the graft
 – Infection
 – Seroma formation
These complications may prevent graft adher-
ence to the underlying wound bed, prolong the 
ischemic phase, compromise the graft’s vascular 
supply, and result in graft failure.
Late complications seen by 3 months are [53]:
 – Cicatricial ectropion
 – Graft hypertrophy and contracture
The long-term complications are mainly cos-
metic or functional and result from color and tex-
ture mismatch, and hyper or hypopigmentation.
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Sentinel lymph node biopsy (SLNB) is a 
method of detecting subclinical (microscopic) 
metastasis in regional lymph node at risk 
of metastasis and can be used to detect early 
metastasis from eyelid and conjunctival malig-
nancies. Sentinel lymph node biopsy has been 
demonstrated to be technically feasible and 
have a reasonable positive yield for various 
eyelid and conjunctival cancers including mel-
anoma, squamous cell carcinoma (SCC), seba-
ceous gland carcinoma (SGCa), and Merkel 
cell carcinoma (MCC); these cancers have var-
ious risks of regional lymph node metastasis 
(Table 5.1) [1–10].
The lymphatic drainage in the head and 
neck is complex and could be variable. 
However, commonly the lateral two-thirds of 
the upper eyelid, the lateral third of the lower 
eyelid, and the lateral half of the conjunctiva 
drain into the parotid (preauricular) lymph 
nodes, and the medial third of the upper eye-
lid, the medial two-thirds of the lower eyelid, 
and the medial half of the conjunctiva drain 
into the submandibular and deeper cervical 
nodes [11]. However, recent studies suggest 
that there is higher than expected preponder-
ance of draining SLNs in the parotid and pre-
auricular region even from the more medially 
located tumors [12].
SLNB is based on the concept of an orderly 
drainage of tumor cells through the lym-
phatic drainage system before dissemination 
in the bloodstream and involvement of other 
organs. The sentinel lymph nodes (SLNs) 
or first draining node(s) for a tumor can be 
identified by injecting tracer molecules into 
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Table 5.1 Rate of regional lymph node metastasis for 
eyelid tumors
Sr 
No Type of tumor
Approximate rate of regional 
lymph node metastasis (%)




2 Squamous cell 
carcinoma
7–24
3 Sebaceous gland 
carcinoma
7–20
4 Merkel cell 
carcinoma
21
Data from references [1–10]
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the tissue surrounding the tumor. Identification 
of SLN status provides the surgeon and the 
patient with valuable prognostic information 
[10]. Early detection and early management of 
micro-metastasis is believed to provide long-
term survival benefits in oncological practices, 
and particularly in the recent era of availabil-
ity of immune checkpoint inhibitors for meta-
static melanoma and metastatic carcinomas 
and improved survival with these drugs, there 
is a more compelling reason to identify early 
metastatic disease in patients with biologically 
aggressive eyelid and conjunctival melanomas 
and carcinomas [13–16].
 Patient Selection Criteria
Published studies and major reviews on SLNB 
in ocular and adnexal tumors have identified 
and described several risk factors for possible 
SLN involvement (Table 5.2) [2, 6, 7, 17–21].
 Technique for Sentinel Lymph Node 
Biopsy [10]
 1. Preoperative lymphoscintigraphy [22]
 (a) Topical anesthetic is applied on the eyelid 
surface.
 (b) 0.3–0.4  mCi of filtered technetium [Tc- 
99  m] sulfur colloid (0.2  ml volume) is 
injected in three to four spots around the eye-
lid lesion intradermally or subconjunctivally 
for conjunctival melanomas by an ophthal-
mic surgeon (precise injection of radioiso-
tope into the area immediately surrounding 
the tumor is important to ensure the correct 
mapping of lymphatic channels).
 (c) Serial scanning is carried out every 
15 min, once the first SLN is detected for 
visualization of all SLN.
 (d) Single-photon emission CT (SPECT-CT) is 
utilized to improve anatomic resolution and 
precise localization of SLN (Fig. 5.1a, b).
 2. Surgical procedure
 (a) Ophthalmic surgeon: On the day of the 
planned primary surgical tumor resection, 
technetium-labeled sulfur colloid [Tc- 99 m] 
is injected as described above in preopera-
tive holding area approximately 90  min 
before the primary tumor resection; in some 
instances, if the preoperative SPECT/CT or 
lymphoscintigraphy took place the day 
before the planned surgery, there may not be 
a need for reinjection of technetium.
 (b) Head and neck or another oncologic surgeon: 
Intraoperatively, a handheld gamma probe is 
used to localize the SLNs (Figs. 5.2 and 5.3). 
They are defined as lymph nodes that have 
radioactivity counts at least twice as high as 
the level of background radioactivity.
 (c) The SLNs are then dissected and excised 
(Fig. 5.4).
 (d) The lymph node basin around the “hot” 
nodes is scanned again to look for any other 
SLNs that have high radioactive uptake. 
This is continued until little or no 
 radioactivity is detectable in the draining 
lymph node basins.
Table 5.2 Risk factors for SLN involvement
Sr 
No Type of tumor









Tumor thickness ≥1 mm and 
increasing Breslow depth
Presence of >1 mitotic figure/
HPF





AJCC (7th edition) stage T2b 
or > size 10 mm in the greatest 
diameter
3 Squamous cell 
carcinoma
Tumors ≥2 cm (20 mm) wide
Locally recurrent
4 Merkel cell 
carcinoma
Increasing diameter of the 
lesion





Data from references [2, 6, 7, 17–21]
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 Histopathologic Evaluation of SLN
 1. SLNs are serially sectioned using “bread- loaf” 
approach in 1–2-mm-thick sections, and the 
pathologist then examines the haematoxylin- 
eosin-stained sections for malignant cells.
 2. If no malignant cells are found, additional 
sections are subjected to thorough immuno-
histochemical analysis.
 3. Recommended immunohistochemical (IHC) 
markers:
a b
Fig. 5.1 Single-photon emission CT (SPECT-CT) image of primary eyelid sebaceous gland carcinoma (a) and of the 
sentinel lymph node (b)
Fig. 5.2 Intraoperative use of handheld gamma probe to 
localize the sentinel lymph node
Fig. 5.3 Intraoperative surface markings after use of 
gamma probe
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 (a) Melanoma—antimelanocytic cocktail with 
HMB-45, anti-MART 1, and anti- tyrosinase 
[23, 24]
 (b) Squamous carcinoma—anticytokeratin 
antibody cocktail with cytokeratin AE-1/
AE-3 [25]
 (c) Merkel cell carcinoma—antibodies to 
Cam5.3, chromogranin, and cytokeratin 20 
[26, 27]
 (d) Sebaceous gland carcinoma—anti- 
adipophilin and anti-perilipin antibodies 
[28–30]
 SLN Positivity and False-Negative 
Results
A review of the published literature on SLNB 
for ocular adnexal tumors shows variable results 
of SLN positivity. Savar et  al. in a relatively 
large series (n = 30) of SLNB in ocular adnexal 
melanoma report positivity rate of 17% [17]. In 
cases with sebaceous gland carcinoma classified 
higher than T2b and >10 mm in greatest diam-
eter (n = 16); SLN positivity rate was 13% [10]. 
Both of these reports were generated from MD 
Anderson Cancer Center where a lot of the early 
feasibility studies for SLN biopsy for ocular 
adnexal cancers took place. A similar rate of 13% 
was also reported for squamous cell carcinoma 
(n  =  8) by French colleagues [31]. Regarding 
Merkel cell carcinoma, studies report a SLN pos-
itivity rate of 27–48% for all anatomic location 
[32–34]. The data on Merkel cell carcinoma of 
eyelid is insufficient to determine the positivity 
rate for SLN and prognosis, but there are defi-
nitely case reports and small case series of eyelid 
Merkel cell carcinoma with positive SLN biopsy 
results [10, 35, 36].
A case with histologically negative SLNs and 
subsequent development of nodal metastasis con-
stitutes a false-negative event. The causes for 
false-negative events are cited as steep learning 
curve for SLNB for ocular adnexal as well as head 
and neck tumors, scarring from multiple prior sur-
geries at tumor site causing changes in lymphatic 
drainage routes, and in the event of in- transit 
metastasis that goes undetected on preoperative 
or intraoperative lymphatic mapping, as well as 
inaccurate detection of microscopic metastasis 
in the draining lymph nodes [10]. Our group at 
MD Anderson Cancer Center has performed SLN 
biopsy for ocular adnexal tumors since 2001; we 
have not encountered any cases of false-negative 
SLN biopsy results for the last 15 years suggesting 
the importance of experience with this technique.
However, barring the false-negative events 
that are rare in experienced hands, a negative 
SLNB result can be reassuring to the patient. 
And identification of microscopic metastasis in 
the draining lymph nodes could mean that the 
patient would benefit from earlier treatments for 
metastatic disease.
 Further Considerations
Though there is a certain risk of metastasis to 
regional lymph nodes associated with different 
conjunctival and eyelid tumors, radical neck dis-
section and/or parotidectomy for all tumors or 
empiric radiation therapy for all does not seem 
to be justified given the relatively low yield, 
radiation- related complications, and lack of 
improvement in survival, as described by several 
published studies. The first Multicenter Selective 
Lymphadenectomy Trial (MSLT) -I confirmed 
the value of early nodal evaluation and treat-
ment. This prospective, international, random-
ized trial showed that the pathologic status of the 
sentinel node or nodes was the most important 
Fig. 5.4 Surgically excised lymph node
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prognostic factor and that patients who under-
went sentinel- node biopsy had fewer recurrences 
of melanoma than patients who underwent wide 
excision and nodal observation. Among patients 
with intermediate- thickness melanomas (defined 
as 1.2–3.5 mm) and nodal metastases, early sur-
gical treatment, guided by sentinel-node biopsy, 
was associated with increased melanoma-specific 
survival (survival until death from melanoma) 
[37–39]. These results provide support for the 
recommendation by several professional orga-
nizations that staging by means of sentinel-node 
biopsy should be performed when appropriate.
However, the subsequent management deci-
sion in patients with sentinel lymph node- 
positive metastasis, in the form of completion of 
lymph node dissection with or without radiation 
therapy or observation and imaging for clinically 
apparent disease before radical surgery, remains 
controversial.
In an effort to shed some light on this con-
troversy, the most recent report by MSLT-II 
involving 1934 cases of cutaneous melanoma 
concludes that immediate completion of lymph 
node dissection in SLN-positive cases increased 
the rate of regional disease control, reduced the 
rate of regional nodal recurrence by nearly 70%, 
and provided prognostic information but did not 
improve melanoma-specific survival [40].
Thus, the subsequent management decision in 
sentinel lymph node metastasis needs to be taken 
at the surgeon’s discretion and detailed discus-
sion regarding disease control and survival for 
individual case with the patient and family.
In summary, SLNB technique is a relatively 
low-risk and minimally invasive procedure. It 
maintains a potential to offer important informa-
tion to patients and surgeons in terms of accurate 
tumor staging and prognosis and potential for 
appropriate patients to receive additional surgery, 
radiation therapy, and/or systemic therapy for 
their microscopically metastatic nodal disease. 
The availability of immune checkpoint inhibi-
tors for patients with metastatic melanoma and 
metastatic squamous carcinomas is an additional 
consideration making detection of early nodal 
metastasis more critical because of the potential 
for earlier treatment with this new class of drugs 
that has revolutionized our expectations for the 
length and quality of life after diagnosis of meta-
static melanoma [13–16].
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Tumors affecting the conjunctiva and cornea 
include benign and malignant neoplasms arising 
from the conjunctival epithelium, conjunctival 
stroma, and structures within the stroma including 
the blood vessels, nerves, fat, and lymphoid tis-
sue. Corneal tumors can arise specifically from the 
corneal epithelium and rarely does the stroma pro-
mote a tumor. Most corneal tumors are secondary 
to extension from an adjacent conjunctival tumor.
The first step in the management of a conjunc-
tival tumor is to take a detailed history regarding 
the onset, previous precursors, rate of growth, and 
presence of symptoms such as pain or irritation. 
The second step is proper evaluation by external 
examination and slit lamp biomicroscopy. Tumor 
color, size, location, extension into the orbit or 
globe, and presence of related features like cysts, 
feeder, and intrinsic vessels, relationship to the 
limbus or fornix, and others should be recorded. 
In many instances, the clinician can differenti-
ate malignant from benign tumors by history and 
examination. Following thorough clinical evalua-
tion, ancillary testing with external photography, 
anterior segment photography, anterior segment 
optical coherence tomography (AS-OCT), ultra-
sound biomicroscopy, and incisional or exci-
sional biopsy are all important in achieving an 
accurate diagnosis. Treatment of conjunctival 
tumors requires a basic understanding of the 
biological behavior and the tumor response to 
currently available therapeutic modalities includ-
ing surgery, chemotherapy, immunotherapy, and 
radiotherapy. In this chapter, some of the com-
mon benign and malignant tumors of the con-
junctiva and their management are presented.
Conjunctival tumors are relatively infrequent 
[1–5]. An epidemiologic review of 125 patients 
with ocular cancers from the Singapore Cancer 
Registry found only 16 (13%) with a conjuncti-
val tumor [3]. In a histopathology review of 2455 
biopsied conjunctival lesions in adults at a ter-
tiary referral center, Grossniklaus et al. identified 
a broad spectrum of lesions including inflamma-
tory, degenerative, and pseudotumors (lesions 
simulating neoplasm) to represent 53% (n = 1292) 
of cases, while true tumors represented 47% 
(n = 1163) [4]. Among the tumors, the most com-
mon included acquired epithelial tumors (26%), 
pigmented tumors (13%), acquired subepithelial 
tumors (6%), and congenital tumors (2%) [4]. By 
contrast, in a clinical study from an ocular oncol-
ogy tertiary referral center, pigmented (melano-
cytic) conjunctival tumors were found to be most 
common [5]. Shields et al. described 1643 con-
junctival lesions, among which 872 (53%) were 
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melanocytic tumors, including nevus, primary 
acquired melanosis, and melanoma [5]. Even in 
the pediatric population, melanocytic tumors are 
the most common tumor in a clinical practice as 
Shields et  al. reviewed 262 children and noted 
the leading tumors included melanocytic (67%), 
choristomatous (10%), vascular (9%), and benign 
epithelial tumors (2%), as well as other miscella-
neous lesions (10%) [6, 7].
Recent mega-data on over 5000 conjuncti-
val tumors confirmed that melanocytic nevus 
was the most common conjunctival tumor 
(1163/5002, 23%) [8]. Other common tumors 
were primary acquired melanosis (623/5002, 
12%), melanoma (612/5002, 12%), and squa-
mous cell carcinoma (440/5002, 9%) [8]. A 
separate analysis of this mega-data on pediatric 
conjunctival tumors in 806 cases disclosed that 
melanocytic (492/806, 61%) followed by chori-
stomatous tumors (65/806, 8%) were the most 
common tumors in this age group [9]. In the 
overall group, comparative analysis of patients 
with primary acquired melanosis versus mela-
noma in 1224 cases found those with melanoma 
more likely showing tarsal location (relative risk 
[RR] = 1.6), thickness >1 mm (RR = 2.8), pres-
ence of intralesional cysts (RR = 2.1), feeder ves-
sels (RR = 2.3), intrinsic vessels (RR = 2.2), and 
hemorrhage (RR = 1.8) [8]. Comparative analy-
sis of patients with conjunctival intraepithelial 
neoplasia versus squamous cell carcinoma in 
715 cases found those with squamous cell car-
cinoma more likely showing greater diffuse 
involvement (p < 0.0001), median basal diame-
ter (p < 0.0001) and thickness (p < 0.0001), loca-
tion >1 mm from the limbus (p = 0.0228), brown 
pigmentation (p = 0.0264), and intrinsic vessels 
(p  =  0.0234) [8]. Similarly, in children, nevus 
versus melanoma revealed melanoma more 
likely with greater tumor thickness (p = 0.037) 
and base (RR = 4.92), presence of tumor hemor-
rhage (RR = 25.3), and absence of intrinsic cysts 
(RR  =  5.06), and lymphoid hyperplasia versus 
lymphoma revealed lymphoma more likely with 
larger mean basal dimension (p = 0.002) and dif-
fuse in location vs nasal (RR = 16.5) [9].
Conjunctival tumors are classified based on 
the type of tissue that they arise from including 
conjunctival epithelium, melanocytes, blood ves-
sels, nerves, adipose tissue, and lymphoid tissue. 
They can also be classified as melanocytic and 
non-melanocytic tumors, or as benign and malig-
nant tumors. In the following paragraphs, we will 
discuss the various conjunctival tumors based 
on major grouping including choristomatous, 
epithelial, melanocytic, vascular, neural, xan-
thomatous, myxomatous, lipomatous, lymphoid, 
leukemic, caruncular, metastatic, and secondary 
tumors (Table 6.1).
 Conjunctival Choristomas
Conjunctival choristoma is a tumor composed of 
tissues not normally present in the conjunctiva. 
A simple choristoma contains only one type of 
tissue, whereas a complex choristoma contains 
more than one type [10]. Choristomas form a 
minority of lesions in adults but are the second 
most common conjunctival tumors found in chil-
dren after melanocytic tumors [5, 6]. Examples 
of choristomas include dermoid, osseous, lacri-
mal gland, respiratory, and complex choristomas. 
Most choristomas remain stable with little poten-
tial for malignant transformation.
 Conjunctival Epithelial Tumors
Conjunctival epithelial tumors encompass a wide 
spectrum of conjunctival and corneal squamous 
cell proliferation including benign squamous 
papilloma, keratoacanthoma, hereditary benign 
intraepithelial dyskeratosis, dacryoadenoma, 
intraepithelial neoplasia, and malignant squa-
mous cell carcinomas (SCC). Papillomas con-
stitute approximately 1% of all lesions and are 
associated with human papillomavirus (HPV) 
in up to 81% of cases [11, 12]. In a large series 
of 5002 conjunctival tumors, there were only 
77 (1.5%) childhood or adult papillomas [8]. 
Despite this small number, papillomas formed 
a majority of the benign conjunctival epithelial 
tumors (77/95, 81%) [8].
Ocular surface squamous neoplasia is an 
umbrella term for premalignant and malignant 
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epithelial tumors on the eye, including conjunc-
tival intraepithelial neoplasia (CIN) and invasive 
SCC.  CIN is squamous neoplasia that extends 
through the entire thickness of the conjunctival 
epithelium but is confined to the epithelium, not 
invading beyond the basement membrane. On 
the other hand, invasive SCC has gross or micro-
scopic invasion into the adjacent tissue.
Invasive conjunctival SCC typically presents 
in the elderly between 60 and 80  years of age. 
Younger patients with conjunctival SCC often 
have underlying disease that promotes a risk like 
immunodeficiency, allowing human papillomavi-
rus (HPV) to proliferate, or xeroderma  pigmentosa, 
with inability to repair DNA alterations. The exact 
pathogenesis of conjunctival SCC is not known 
Table 6.1 Classification of conjunctival tumors
Conjunctival tumors Benign Malignant
Choristomas Dermoid
Dermolipoma
Simple and complex 
choristoma



























Lymphoid and leukemic tumors Benign reactive lymphoid 
hyperplasia
Lymphoid and plasmacytic tumors
Leukemia
Caruncular tumors Papilloma SCC
Nevus Melanoma
Lipoma Sebaceous carcinoma




Metastatic tumors Tumors metastasizing from primary tumors 
located in the breast, lungs, cutaneous 
melanoma, etc.
Secondary tumors Tumors extending from the eyelid, orbit, 
intraocular structures, and paranasal sinuses
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but it most commonly occurs in areas with high 
ultraviolet light B rays exposure [13]. A close asso-
ciation with HPV infection has also been observed 
[13]. Patients with human immunodeficiency virus 
(HIV) and other immunodeficient diseases are 
reported to have recurrent and more aggressive 
tumors [13, 14]. There is also a relationship of con-
junctival SCC with heavy cigarette smoking.
Clinically, conjunctival SCC typically manifests 
in the limbal area as a thin or thick placoid lesion 
with a gelatinous or papillomatous surface, occa-
sionally forming a nodular mass. A clinical vari-
ant of this tumor, called diffuse conjunctival SCC, 
appears flat and gelatinous in a horizontal growth 
pattern with diffuse thickening of the conjunctiva 
and corneal surface. This can be mistaken as chronic 
conjunctivitis, leading to a delay in diagnosis and 
treatment. Invasive SCC is associated with feeder 
vessels, intrinsic vascularity, keratin formation, and 
sometimes surface inflammation. The tumor can 
extend into the sclera and globe or into the orbit 
in neglected cases. Rarely, metastasis to regional 
lymph nodes and distant sites can occur, particularly 
in immune-deficient patients. The mucoepidermoid 
variant of SCC tends to be more aggressive and has 
increased capacity for local invasion [15].
 Conjunctival Melanocytic Tumors
The conjunctival melanocytic tumors include 
nevus, racial melanosis, primary acquired mela-
nosis, and melanoma. Conjunctival nevus is the 
most common tumor in both children and adults 
[5–7, 16]. In a large clinical review of 5002 cases, 
nevus accounted for 45% (n  =  1163/2590) of 
conjunctival melanocytic lesions and for 23% of 
all 5002 conjunctival lesions [8]. Although con-
sidered congenital, it frequently becomes clini-
cally apparent in the first or second decade of 
life, especially if it is gaining pigment. The nevus 
evolves from a junctional to a compound and then 
to a subepithelial nevus with age, as the melano-
cytes migrate from the basal layer of the epithe-
lium into the underlying stroma [17]. It can be 
pigmented or nonpigmented, and multiple clear 
intralesional cysts are commonly seen. Shields 
et  al. described 410 consecutive cases of con-
junctival nevi and found that the most common 
location for a nevus was the bulbar conjunctiva 
(72%), followed by the caruncle (15%), semi-
lunar fold (11%), fornix (1%), tarsus (1%), and 
cornea (1%). Malignant transformation occurs in 
less than 1% [16, 17].
Conjunctival primary acquired melanosis 
(PAM) refers to an acquired conjunctival pig-
mentation that is flat and noncystic, which does 
not resemble either a nevus or complexion- 
associated melanosis (CAM). PAM commonly 
presents in middle age and is usually unilateral. It 
can be focal or diffuse, and sometimes multifocal. 
Rarely, PAM can be nonpigmented. Progression 
to melanoma occurs when PAM demonstrates 
severe atypia, and this represents 13–48% of 
cases [18, 19].
Conjunctival melanoma arises either de novo or 
from a preexisting nevus or PAM. Melanoma aris-
ing from PAM accounts for 74% of cases, while 
those arising from a preexisting nevus and de novo 
account for 7% and 19% of cases, respectively 
[20]. The presentation is generally in middle- aged 
or elderly individuals and it appears as a pig-
mented or fleshy, elevated conjunctival mass with 
a lobulated surface. The most frequent location of 
melanoma is on the bulbar conjunctiva, although 
forniceal or palpebral conjunctiva is occasion-
ally the site of origin [20]. Similar to nevus and 
PAM, conjunctival melanoma can be amelanotic 
and the diagnosis is confirmed on histopathol-
ogy. Conjunctival melanoma is malignant and can 
metastasize to preauricular and submandibular 
lymph nodes, and carry potential for remote hema-
togenous spread to brain, liver, skin, and bone [17].
 Conjunctival Lymphoid Tumors
Conjunctival lymphoma is a clonal prolifera-
tion of lymphoid tissue normally present in the 
conjunctiva. Lymphoid proliferation of the con-
junctiva ranges from benign reactive lymphoid 
hyperplasia (BRLH) to malignant lymphoma. A 
lymphoid tumor occurring in the conjunctiva can 
be an isolated condition or a manifestation of gen-
eralized systemic disease. In the conjunctiva, the 
most commonly occurring lymphoma is B-cell 
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non-Hodgkin lymphoma (NHL). Of the various 
subtypes, the most frequent includes extranodal 
marginal zone lymphoma (ENMZL), follicular 
lymphoma, diffuse large B-cell lymphoma, and 
mantle cell lymphoma [21]. Clinically, a lymphoid 
tumor presents as a diffuse, slightly elevated fleshy 
salmon-colored mass deep to the epithelium, fre-
quently located in the forniceal or bulbar conjunc-
tiva. A review of 117 patients with conjunctival 
lymphoma revealed that 31% eventually devel-
oped systemic lymphoma [22].
 Caruncle Tumors
The caruncle is a composite structure that com-
prises both cutaneous elements such as hair fol-
licles, sebaceous glands, and sweat glands, as also 
conjunctival tissue including accessory lacrimal 
gland tissue. Hence, the caruncle is a site for 
tumors of both skin and conjunctival origin. The 
common tumors of caruncle include papilloma 
(32%), melanocytic nevus (24%), inclusion cyst 
(7%), and oncocytoma (4%) [23]. Papilloma has 
a distinct frond-like vascular appearance arranged 
in hairpin loops. Caruncular nevus or melanoma 
is often pigmented and nodular. Oncocytoma 
originates from the accessory lacrimal gland duc-
tal tissue and appears as a reddish blue solid or 
cystic mass. Sebaceous gland hyperplasia and 
sebaceous adenoma appear as a yellow mass.
Vascular, neural, fibrous, lipomatous, xan-
thomatous, metastatic, and secondary tumors of 
the conjunctiva are rare and together comprise 
approximately 10% of all conjunctival tumors 
[5]. For more information on those tumors, refer-
ence to major articles [1, 4–9] and textbooks [10, 
17, 24–27] is advised.
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A thorough examination with documentation of 
the clinical findings and systematic planning is 
a prerequisite to any surgery. Clinical examina-
tion by penlight and slit-lamp biomicroscopy 
helps determine the extent of the tumor. Careful 
inspection of the entire conjunctiva with lid ever-
sion should be performed. Conjunctival nevus, 
primary acquired melanosis (PAM), or mela-
noma sometimes has amelanotic component 
which should be noted. A large drawing of the 
conjunctival tumor replicating the extent of the 
lesion in the eye is used in all cases in the office 
and at the time of surgery. The drawing should 
include the extent of corneal involvement and the 
surgical plan.
In general, management alternatives include 
surgical excision, topical or injection chemother-
apy or immunotherapy, radiotherapy, chemother-
apy, or targeted medications such as rituximab. 
Tumors that come to surgical excision include 
malignant tumors and some symptomatic benign 
tumors. Complete excisional biopsy using the tra-
ditional “no-touch” technique is advised. The “no 
touch” technique involves tumor removal without 
directly touching the mass and only manipulat-
ing the surrounding normal tissue as well as the 
avoidance of balanced salt solution (BSS) for 
corneal wetting as this also can lead to tumor dis-
semination. So the entire procedure is performed 
under dry circumstances and without touching 
the tumor directly. This is especially important 
for conjunctival melanoma as it can easily seed 
into the subconjunctival space and demonstrate 
recurrence after surgery. Incisional surgery and 
frozen sections are not often used. However, 
there are certain exceptions in which incisional 
biopsy might be considered (Table 7.1).
For papillomas, excisional biopsy and cryo-
therapy using the “no touch” technique with or 
without adjuvant oral cimetidine and/or topi-
cal/injection interferon alfa-2b provides sat-
isfactory tumor control [1]. For conjunctival 
intraepithelial neoplasia (CIN) and invasive 
squamous cell carcinoma (SCC), surgical exci-
sion can be performed especially if there is a 
need to quickly manage the patient, if there are 
dexterity problems in which the patient cannot 
place therapeutic eyedrops, or if there is con-
cern about compliance. In such cases, complete 
surgical excision of SCC using the “no touch” 
technique is employed. However, with CIN and 
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SCC, topical chemotherapy (mitomycin-C and 
5- flurouracil) and topical immunotherapy (topi-
cal or injection interferon alpha-2b) are alterna-
tives to surgical resection for reliable patients, 
dexterous in placing eyedrops, for small tumors 
and for large tumors, especially important for the 
elderly or sickly patient not amenable to surgical 
procedures.
For malignancies that invade into the sclera, 
local plaque radiotherapy is performed to irra-
diate the invasive area and prevent intraocular 
growth. For SCC an apex dose of 4500  cGy is 
given and for melanoma the dose is 6000  cGy. 
Plaque radiotherapy is particularly useful for 
those with multiple recurrences, in an effort to 
avoid orbital exenteration and other mutilating 
surgeries [2, 3].
Exenteration is reserved for advanced cases 
with clinical and radiological evidence of orbital 
invasion. In general, we use the eyelid sparing 
technique in which incision is made just outside 
the eyelash margin so that the posterior lamella is 
dissected up to the orbital rim, sparing the ante-
rior lamella (skin and orbicularis muscle). The 
orbit is dissected and removed.
Special consideration is given to the man-
agement of conjunctival nevus and PAM. 
Conjunctival nevus can be managed by peri-
Table 7.1 Indications for surgery or topical therapy for conjunctival tumors
Conjunctival 
tumor Indication for excisional surgery Indication for other treatments
CIN/SCC Large, well- circumscribed tumor Topical chemotherapy or immunotherapy
  Small tumor
  Large tumor for chemoreduction or 
immunoreduction before surgery
  Diffuse tumor not amenable to surgery
  Positive margins post-excision
Plaque radiotherapy
  Multiple recurrences
  Scleroinvasive tumors
Incisional surgery and possible exenteration
  Tumor invasion into orbit
Nevus Documented growth
Atypical location (fornix, palpebral 
conjunctiva, cornea)
Atypical age at presentation (middle age or 
later)




  Small, typical nevus
PAM Lesion diameter ≥5 mm
Documented progression of the lesion
Thickness of the lesion
Distinct nodule arising within the lesion 
(pigmented or non-pigmented)
Nutrient vessels to the lesion
Involvement of the cornea
Involvement of palpebral conjunctiva
Dysplastic nevus syndrome in the affected 
patient or close relatives
Personal history of cutaneous or uveal 
melanoma
Observation
  Lesion diameter <5 mm
Melanoma All cases except where exenteration is 
necessary
Incisional surgery and possible exenteration
  Orbital extension
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odic observation with photographic docu-
mentation or surgical resection, depending on 
tumor size, symptoms, features, and parental 
concerns [4]. For most children with conjunc-
tival nevus, observation is provided and the 
tumor is surgically removed when the patient 
is older, in the late teenage years. If growth is 
found, excision is advised. Prompt surgery for 
conjunctival nevus is considered in those pre-
senting at atypical sites (fornix, palpebral con-
junctiva, cornea), at an older age, in patients 
with family history of conjunctival or cutane-
ous melanoma, and in large nevus causing cos-
metic blemish [4].
Newly discovered PAM which is flat and 
measures <5  mm in a patient without dysplas-
tic nevus syndrome or cutaneous melanoma can 
be observed [5]. However, if the lesion shows 
growth, multifocality, or asymmetry compared to 
the opposite eye, or measuring ≥5 mm (>2 clock 
hours), surgery is indicated [5]. If PAM dem-
onstrates even minimal nodulatity, melanoma 
is suspected and surgical removal is advised. 
Conjunctival melanoma is a surgical disease and 
all cases require careful removal of the entire 
lesion with negative margins [6].
Each tumor is managed in a slightly differ-
ent way. Conjunctival choristoma is managed 
by superficial shaving or deeper excision with 
lamellar sclerectomy and keratectomy [7]. For 
papillomas, a meticulous “no touch” technique is 
employed and pedunculated tumors are excised 
at the base and additional interferon is considered 
[1]. CIN and SCC require wide excisional biopsy 
with 4 mm margins followed by cryotherapy to the 
resected edges [8]. Nevus is a benign growth and 
excisional biopsy is performed with 2 mm wide 
margins [4]. PAM and melanoma also require a 
4 mm wide margin excisional biopsy and cryo-
therapy to the resected edges [5, 6, 9]. Lymphoid 
tumors are treated by excisional biopsy and cryo-
therapy for smaller tumors, and incisional biopsy 
followed by chemotherapy and radiotherapy for 
larger tumors [10, 11]. Caruncular tumors are 
always managed by complete surgical excision 
with an appropriate margin on the conjunctival 
edge [12, 13].
 Surgical Techniques
Conjunctival tumor excision can be performed 
under local anesthesia. This is achieved by 5 mL 
of retrobulbar injection of a combination of 2% 
bupivacaine and 0.75% of mepivacaine with 
hyaluronidase into the retrobulbar space. The 
injection is given using a 1.25  inch 27G needle 
attached to a 5  mL syringe. A well-performed 
retrobulbar block eliminates pain sensation, pre-
vents ocular motility, and does not produce any 
conjunctival chemosis. We specifically avoid 
subconjunctival anesthesia as this balloons the 
conjunctiva and blurs tumor margins. It is impor-
tant to prevent chemosis to help identify the ana-
tomical landmarks and tumor margins during the 
surgery. An eyelid speculum is applied and topi-
cal anesthesia used for the cornea. The surgery is 
always done under an operating microscope.
Surgical steps for benign and malignant tumors 
are similar, except for the need for wider surgical 
margins for malignant tumors, and a thin scleral 
base. Wide excision of the lesion (4  mm surgi-
cal margin) is the standard care of treatment for 
malignant conjunctival tumors including invasive 
SCC (Fig.  7.1a–i and Video 7.1) and malignant 
melanoma (Fig. 7.2a–l and Video 7.2). In contrast, 
a 1–2 mm surgical margin is adequate for conjunc-
tival nevus (Fig. 7.3a–i and Video 7.3) and PAM 
(Fig. 7.4a–h and Video 7.4). The corneal compo-
nent is identified and the site is gently patted – dry 
with a single movement without rubbing and with 
a dry cellulose sponge. Absolute alcohol (ethyl 
alcohol-ETOH) is applied directly to the affected 
cornea using a wexcel sponge for 10–20 s and then 
a second dry sponge absorbs the alcohol to pre-
vent damage [14, 15]. This is done to devitalize the 
corneal tumor cells. The corneal tumor is removed 
off the cornea by gently scrolling the epithelium 
from center to limbus using a #57 Beaver scalpel 
and this is termed as alcohol keratoepitheliectomy. 
The plane of dissection is kept anterior to the 
Bowman’s membrane so as to not cause corneal 
scarring. The scrolled tissue is left at the limbus 
in a dry fashion. Next, a 4 mm wide surgical mar-
gin around the conjunctival component is marked 
using a bipolar cautery. Minimum manipulation is 
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advised to prevent  dispersion of the tumor cells. 
The peri-tumoral limbal conjunctiva is lifted using 
forceps, and a small incision placed in the con-
junctiva at one end of the marked surgical mar-
gin using a blunt- tipped conjunctival scissors. A 
similar incision is placed at the other end of the 
marked margin. The conjunctiva is incised along 
the entire length of the surgical margin, allowing 
adequate normal tissue surrounding the tumor. 
Only normal conjunctiva is handled and the tumor 
is never touched. The tumor is then undermined 
from the tissues below with the help of the scis-
sors. Similar undermining of the Tenon’s fascia is 
undertaken by gentle spreading of the scissors. In 
tumors where dissection is close to the insertion of 
the rectus muscles, the muscles may be hooked to 
avoid damage to the muscle fibers. Hemostasis is 
achieved with the use of bipolar cautery.
The scleral component of the tumor is removed 
using a clean #57 Beaver scalpel and a few under-
lying scleral fibers (5% thickness) are dissected 
with the mass to provide tumor-free basal margin 
[14, 15]. This is termed partial scleroconjuncti-




Fig. 7.1 Excision surgery for conjunctival squamous cell 
carcinoma. (a) Conjunctival squamous cell carcinoma of 
the left eye with prominent feeder and intrinsic vessels. 
(b) Corneal component of the tumor is identified and 
dried with a dry cellulose sponge, followed by application 
of absolute alcohol using a cotton-tipped applicator for 
1 min. (c) Corneal tumor is excised off the cornea by gen-
tly scrolling away the epithelium using a #57 Beaver scal-
pel, with the plane of dissection maintained anterior to the 
Bowman’s membrane. (d) Prominent feeder vessels are 
identified and cauterized to minimize bleeding. (e) The 
conjunctiva is incised with a 4-mm-wide surgical margin 
using a blunt-tipped conjunctival scissors. (f) At the lim-
bus, limbectomy is done parallel to the limbus by sliding 
the blade back and forth, thus completely excising the 
tumor with a thin scleral base. (g) Double freeze-thaw 
cryotherapy is done to the resected edges of the conjunc-
tiva by lifting the conjunctiva with forceps and freezing 
the underside of the conjunctiva to prevent accidental 
freezing of the sclera or the ciliary body. (h) Conjunctival 
closure is done using a 7-0 absorbable suture. (i) Minimal 
conjunctival scarring with no recurrence at 6  months 
follow-up
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flat blade parallel to the limbus with the motion of 
the blade from the cornea toward the sclera, thus 
completely excising the tumor with a thin scleral 
base. Through all these steps of the surgery, use of 
BSS on the ocular surface is avoided, and this is 
the dry-technique of tumor excision. The tumor is 
labeled indicating all the margins on a cardboard 
bed, preserved in 10% formalin, and sent for histo-
pathology ensuring the correct patient identity on 
the pathology form.
For further steps of the surgery, a fresh set 
of instruments is used to prevent any possible 
tumor seeding from the previous instruments. 
Episcleral hemostasis is achieved with bipolar 
cautery. Absolute alcohol is then applied over the 
bare sclera using a wexcel sponge to devitalize 
any remaining tumor cell on the scleral surface 
then with a #57 beaver blade the episcleral debris 
is swept onto a wexcel sponge.
Double freeze-thaw cryotherapy is done to the 
resected conjunctiva edges. This is done by lift-
ing the conjunctiva with Bishop-Harmon forceps 
and freezing the underside of the conjunctiva to 
prevent accidental freezing of the sclera or the 
ciliary body. A dense ice ball formation for 10 s 
is allowed before slow thawing is done. There is 
no BSS used for defrosting. The probe is shifted 
to an adjacent spot such that two adjacent frozen 
spots overlap slightly to prevent any untreated 
area. The entire margin is frozen in a freeze- 
defrost, freeze-defrost fashion (double freeze- 
thaw). Conjunctival closure is done in two layers 
with Tenon’s fascia deep and conjunctiva superfi-
cial or with a superficial graft as described below.
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Fig. 7.2 Excision surgery for conjunctival melanoma. (a) 
Conjunctival melanoma of the right eye with dark pig-
mentation and prominent feeder vessels. (b) A 4-mm-
wide surgical margin is delineated around the tumor using 
bipolar cautery, and the corneal component of the tumor is 
identified and dried with a dry cellulose sponge, followed 
by application of absolute alcohol using a cotton-tipped 
applicator for 1 min. (c) The limbal conjunctiva is lifted 
using a forceps, and a small incision placed in the con-
junctiva at one end of the marked surgical margin using a 
blunt-tipped conjunctival scissors. (d) The conjunctiva is 
incised along the marked margin. (e) Corneal tumor is 
excised off the cornea by gently scrolling away the epithe-
lium using a #57 Beaver scalpel, with the plane of dissec-
tion maintained anterior to the Bowman’s membrane. 
(f) At the limbus, limbectomy is done parallel to the lim-
bus by sliding the blade back and forth, thus completely 
excising the tumor with a thin scleral base. (g) The excised 
tumor is placed on a cardboard and placed in 10% forma-
lin for histopathology. (h) Double freeze-thaw cryother-
apy is done to the resected edges of the conjunctiva by 
lifting the conjunctiva with forceps and freezing the 
underside of the conjunctiva to prevent accidental freez-
ing of the sclera or the ciliary body. (i) Conjunctival relax-
ation is achieved by excising the intermuscular septum. (j) 
Conjunctival closure is done using a 7-0 absorbable 
suture. (k) Application of tissue glue on the ocular surface 
for patient comfort and better wound healing. (l) Minimal 
conjunctival and corneal scarring with no recurrence at 
9 months follow-up
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Caruncular tumors can also be excised in a 
similar fashion. Medial rectus muscle hooking 
is necessary in larger tumors. However, unlike 
at other sites, it is not possible to obtain a 4 mm 
margin around the tumor of the caruncle.
Post-operative care involves patching of 
the eye for 2 days with cycloplegic drops and 
antibiotic- steroid ointment. Use of the oint-
ment twice daily for 3 weeks is advised. Patient 
is generally seen in a month after the surgery 
by which time the pathology report is avail-
able and the patient can be counseled regard-
ing the final histopathologic diagnosis. In 
invasive SCC, if the surgical margins are posi-
tive, topical immunotherapy (preferred over 
topical chemotherapy) is advised for 3 months. 
Radiotherapy in the form of surface plaque 
brachytherapy is gaining popularity for recur-
rent tumors and for tumors with deeper scleral 
invasion [2, 3]. For conjunctival melanoma, 
if the margins are positive, repeat surgery for 
clear margins is done. The patient can then be 
followed-up every 3  months for 1  year, every 
6 months for 3 years, and yearly thereafter. The 





Fig. 7.3 Excision surgery for conjunctival nevus. (a) 
Conjunctival nevus of the right eye with melanotic and 
amelanotic components. (b) Corneal tumor is identified 
and dried with a dry cellulose sponge, followed by appli-
cation of absolute alcohol using a cotton-tipped applicator 
for 1 min. (c) Corneal tumor is excised off the cornea by 
gently scrolling away the epithelium using a #57 Beaver 
scalpel, with the plane of dissection maintained anterior to 
the Bowman’s membrane. (d) The conjunctiva is incised 
with a 2 mm wide surgical margin using a blunt-tipped 
conjunctival scissors. (e) At the limbus, limbectomy is 
done parallel to the limbus by sliding the blade back and 
forth, thus completely excising the tumor with a thin 
scleral base. (f) Double freeze-thaw cryotherapy is done 
to the resected edges of the conjunctiva by lifting the con-
junctiva with forceps and freezing the underside of the 
conjunctiva to prevent accidental freezing of the sclera or 
the ciliary body. (g) Conjunctival relaxation is achieved 
by excising the intermuscular septum. (h) Conjunctival 
closure is done using a 7-0 absorbable suture. (i) Minimal 
conjunctival scarring with no recurrence at 5  months 
follow-up
R. Rao and C. L. Shields
81
 Ocular Surface Reconstruction
Conjunctival reconstruction is done by conjunc-
tival advancement, rotational, and flap or with 
the use of amniotic membrane grafts (AMGs). 
Advancement flap involves sliding of the con-
junctiva to cover the bare sclera. This is done by 
creating a peritomy at the limbus for 4–5 mm so 
that the conjunctiva can be mobilized over the 
defect. The conjunctiva is then closed with 7-0 
Vicryl sutures in a running or an interrupted fash-
ion in 2 layers (Tenon’s fascia and conjunctiva). 
For larger conjunctival defects which cannot be 
closed by an advancement flap, a rotational flap 
or an AMG can be placed over the bare sclera. 
The rotational flap is derived generally from the 
superotemporal fornix and rotated into the defect. 
The AMG can be freeze-dried or frozen type and 
is anchored on the surface with the use of tis-
sue glue alone, or by cardinal suturing it to the 
conjunctiva with 7-0 absorbable sutures. AMG 
is a source of stem cells and provides a surface 
over which conjunctivalization can take place 
[16, 17]. A recently popularized method for stem 
cell harvest is excision of a 2  ×  2  mm area of 
the superior limbal tissue and cutting it into 8–10 
pieces [18, 19]. These small limbal transplants 
are placed on the AMG, and fixed with tissue 
glue [18, 19]. This is known as the simple limbal 
epithelial transplantation (SLET).
 Conjunctival Map Biopsy
Conjunctival map biopsies are performed for exten-
sive conjunctival tumors or those that have invaded 
from adjacent structures, like sebaceous carcinoma. 
Sebaceous carcinoma has a tendency to exhibit dif-
fuse involvement in the conjunctiva, known as the 
pagetoid spread (intraepithelial involvement). Small 
map biopsies are useful to determine the extent of 
the disease and to plan definitive treatment. The 
surgery is performed under local anesthesia using 
retrobulbar block as described above.
Routinely, 10–14 biopsies are taken depending 
on the suspected area of conjunctival involvement 
[20]. To gain good surgical access to the deeper 
fornix, the lids can be everted over a Desmarre’s 
retractor or a simple Q-tip. The map biopsies must 
include both surface epithelium and tarsal tissue 
(or the stroma in the bulbar conjunctiva). Each 
biopsy is approximately 2 mm in basal diameter 
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Fig. 7.4 Excision surgery for conjunctival primary 
acquired melanosis. (a) Conjunctival primary acquired 
melanosis of the left eye. (b) Corneal component of the 
tumor is identified and dried with a dry cellulose sponge, 
followed by application of absolute alcohol using a 
cotton- tipped applicator for 1 min. (c) Corneal tumor is 
excised off the cornea by gently scrolling away the epithe-
lium using a #57 Beaver scalpel, with the plane of dissec-
tion maintained anterior to the Bowman’s membrane. (d) 
The conjunctiva is incised with a 2-mm-wide surgical 
margin using a blunt-tipped conjunctival scissors. (e) 
Double freeze-thaw cryotherapy is done to the resected 
edges of the conjunctiva by lifting the conjunctiva with 
forceps and freezing the underside of the conjunctiva to 
prevent accidental freezing of the sclera or the ciliary 
body. (f) Conjunctival relaxation is achieved by excising 
the intermuscular septum. (g) Conjunctival closure is 
done using a 7-0 absorbable suture. (h) Minimal conjunc-
tival scarring with no recurrence at 4-month follow-up
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[21, 22]. The areas of map biopsies includes supe-
rior tarsus (n = 2), inferior tarsus (n = 2), and all 
four quadrants on the bulbar conjunctiva (n = 4 or 
more) [21, 22]. If possible, central tarsus biopsy 
is avoided to prevent scarring that could lead to 
corneal erosion. If clinically limbal or corneal 
involvement is suspected, then limbal conjuncti-
val biopsies (n = 4) are taken at superior, medial, 
inferior, and temporal limbus. Each of the speci-
mens is carefully labeled and numbered on a large 
diagram for histopathologic study. The small map 
biopsy specimens should be submitted for perma-
nent sections rather than frozen sections.
Once the permanent histopathologic results 
are obtained, then the definitive surgery can be 
undertaken after 3  weeks. The need for repeat 
map biopsies in a patient depends on the clinical 
findings during follow-up. Double freeze-thaw 
cryotherapy is done to most of the bulbar and 
palpebral conjunctiva to provide further assur-
ance that microscopic intraepithelial involvement 
by the tumor is adequately treated [20].
In conclusion, a variety of benign and conjunc-
tival tumors are seen in children and adults. A basic 
understanding of the biological behavior of the 
tumor is pertinent in planning its management. Not 
all conjunctival tumors require surgery. However, 
when a surgery is planned, the application of a 
protocol-based surgical technique can achieve a 
high cure rate. In addition, the use of adjunctive 
treatment including topical and locally injectable 
chemotherapy and immunotherapy, and surface 
application of plaque radiotherapy have rendered 
most conjunctival tumors eminently curable.
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Intraocular tumours may be classified accord-
ing to a wide range of variables, including their 
malignant potential, incidence, age of presenta-
tion, anatomical location within the eye, tissue 
from which the tumour arises, relation to sys-
temic disease, and primary site of origin (i.e. a 
primary ocular tumour versus secondary deposit 
from a distant cancer).
Patients with intraocular tumours may pres-
ent with acute vision-related symptoms, such as 
reduced visual acuity, visual field defects, flash-
ing lights or floaters; however they can be asymp-
tomatic, depending on the size and location of the 
tumour. A significant number of asymptomatic 
patients harbouring an intraocular tumour are 
diagnosed on routine eye examinations or as part 
of screening surveys for other diseases such as 
diabetic retinopathy.
The main benign and malignant intraocular 
tumours that will be discussed in this chapter 
are retinoblastoma, choroidal naevus, choroi-
dal melanoma, choroidal osteoma, choroidal 
haemangioma, retinal capillary haemangioma, 
vasoproliferative tumour, sclerochoroidal calcifi-
cation and intraocular lymphoma.
 Retinoblastoma
Retinoblastoma is the most common intraocular 
malignancy of childhood, with a constant inci-
dence worldwide of 1  in 15,000 to 1  in 20,000 
live births [1]. In the majority of cases the tumour 
is initiated by a mutation in the RB1 gene and 
mutations in both RB1 alleles are a prerequisite 
for developing the cancer [2]. In heritable reti-
noblastoma, which in most cases affects both 
eyes, mutation in one RB1 allele is constitutional, 
whereas a somatic mutation in the second allele 
initiates tumour growth in the sensory retinal 
cells. In non-heritable RB1-related retinoblas-
toma, both mutations are somatic, giving rise to 
unilateral, unifocal disease in the vast majority of 
cases. Retinoblastoma patients with the heritable 
form are also prone to developing additional non-
ocular tumours [3] and are at risk of developing 
trilateral retinoblastoma [4].
Median age of diagnosis of unilateral retino-
blastoma is 24 months and of bilateral retinoblas-
toma is 10 months [5]. A white pupillary reflex, 
also termed leucocoria (Fig.  8.1), is the most 
common presenting clinical sign, both in devel-
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oping and developed countries [6–8]. Additional 
signs are strabismus, and less frequently, red 
eye, inflammation and additional non-specific 
signs [8]. Untreated, retinoblastoma will spread 
outside the globe, via the central nervous sys-
tem, and haematogenously, inevitably leading to 
death. In developing countries, in which there is 
a lack of educational strategies and infrastructure 
is poor, retinoblastoma patients’ survival rate is 
estimated to be 40% or less [1, 9]. In developed 
countries, while these were the rates in the early 
twentieth century, nowadays 5-year survival is 
estimated to be >95% [10].
Treatment strategies for retinoblastoma have 
evolved significantly throughout the years. 
Traditionally, retinoblastoma was treated by 
enucleation of the eye, a treatment modality still 
in use today in cases of advanced intraocular 
disease.
In the mid-twentieth century, external beam 
radiotherapy (EBRT) was developed and was 
found to be an effective conservative treat-
ment modality for retinoblastoma. It soon 
replaced enucleation as the mainstay of treat-
ment for most retinoblastoma cases [11, 12]. 
Unfortunately, after nearly half a century of 
extensive use of EBRT for retinoblastoma, it was 
recognized that radiation significantly increases 
the risk of developing a secondary cancer in sur-
vivors of hereditary retinoblastoma [13, 14]. As 
a result, radiotherapy was widely abandoned, 
replaced by chemotherapy as the primary treat-
ment for intraocular retinoblastoma, and to date, 
is reserved only as a last resort, when all other 
modalities have failed. Radiotherapy also forms 
a part of the protocol for treatment of Orbital 
RB. The use of systemic chemotherapy as a pri-
mary treatment modality for intraocular disease 
was initiated in the 1990s using potent chemo-
therapeutic agents, namely vincristine, etopo-
side and carboplatin (VEC). It was first given in 
combination with EBRT, resulting in 70% eyes 
salvaged [15], and following with additional 
focal therapy, used as an alternative to EBRT, 
and resulted with high eye salvage rate [16–18]. 
Soon after it was first introduced, the VEC regi-
men became the standard protocol for retino-
blastoma in most centers.
In order to better predict outcomes of reti-
noblastoma patients treated with chemotherapy, 
the International Intraocular Retinoblastoma 
Classification (IIRC) was introduced in early 
2000’s [19]. Eyes manifesting the tumour were 
classified into five groups from A to E (Fig. 8.2) 
according to size, presence and extent of tumour 
seeds (vitreous or sub-retinal), and development 
of secondary complications (e.g. neovascular 
glaucoma).
In an attempt to avoid potential systemic 
complications of systemically delivered chemo-
therapy, new methods of delivery arose, namely, 
intra-arterial and intravitreal chemotherapy. The 
former method of delivery developed in Japan 
[20] and refined in the USA [21] is used in some 
centres as the primary modality for retinoblas-
toma, and the latter developed in Sweden [22, 23] 
and extensively used in Japan and Switzerland is 
used as adjuvant or salvage therapy [24, 25].
 Choroidal Naevus
The commonest fundus tumour in adults is a 
benign choroidal naevus (Fig. 8.3), arising from 
melanocytes of the choroidal stroma, often dis-
covered as an incidental finding and is rarely 
symptomatic. It is a flat or minimally elevated 
pigmented lesion, but infrequently can be a pale 
colour (amelanotic). Overlying changes such 
as drusen or retinal pigment epithelial changes 
imply chronicity. Approximately 5% of the white 
population has a choroidal naevus and the risk of 
Fig. 8.1 Leucocoria, or white pupillary reflex
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malignant transformation is low (approximately 
1:8000) [26].
A choroidal naevus does not usually war-
rant treatment, however leakage of fluid into the 
subretinal space, presence of visual symptoms, 
secretion of orange-pigmented lipofuscin and/
or growth, raise the suspicion for malignant 
transformation into choroidal malignant mela-
noma and need for intervention. Occasionally a 
naevus will cause symptoms without malignant 






Fig. 8.2 Retinoblastoma tumour grouping according to 
the International Intraocular Retinoblastoma Classification. 
Group A: Tumour confined to the retina, >3  mm away 
from the macula (a); Group B: tumour confined to the ret-
ina, at the macular region (b); Group C: local seeding 
(arrow) (c); Group D: diffuse vitreous seeding (d); and 
Group E: iris neovascularization of the iris and a large 
tumour seen behind the crystalline lens (e)
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Patients diagnosed from photographic diabetic 
retinopathy screening with a choroidal naevus 
should be referred to an ophthalmologist, retinal 
specialist or even an ocular oncologist depending 
on the level of suspicion for a complete evalua-
tion. In future this may be changed into a virtual 
assessment process [28], but for now, the gold 
standard remains clinical examination, photo-
graphic and ultrasonographic documentation.
 Uveal Melanoma
Uveal melanoma is the most common primary 
intraocular malignancy in adults, occurring in 
approximately 6 individuals per million popula-
tion annually [29]. Of these, 5% originate from the 
iris, 10% from the ciliary body, and the majority, 
85%, are choroidal (Fig.  8.4). Uveal melanoma 
mainly affects light-skinned individuals, though it 
can occur less frequently in dark- skinned. There is 
a slight male preponderance. It is considered to be 
a sporadic event, although associated with dysplas-
tic naevus syndrome and ocular melanocytosis.
An undiagnosed or untreated choroidal mela-
noma will eventually not only threaten vision, 
but also the integrity of the globe and even risk 
life. Early detection of a choroidal melanoma is 
of paramount importance, as tumour size directly 
correlates with chances of metastatic spread [30].
Common symptoms related to choroidal mel-
anoma include blurred vision, floaters and pho-
topsia. However, patients can be asymptomatic, 
and the lesion picked up on a routine eye check. 
Compared to choroidal naevus a choroidal mela-
noma is an active cancer that grows in size (albeit 
slowly) and leaks subretinal fluid, and therefore 
more commonly causes visual symptoms.
Examination reveals a dome-shaped or ‘collar 
stud’ mass, located in the choroid, usually pig-
mented, but can occasionally be partly or entirely 
non-pigmented (amelanotic). Retinal detachment 
and lipofuscin orange pigment deposition are 
common features. Less frequently, they can cause 
severe glaucoma, cataract, and even extra-ocular 
extension into the orbit. Such tumours generally 
carry a worse prognosis.
Historically, uveal melanoma was treated by 
primary enucleation. However with advances in 
radiation delivery, most centers now use radio-
therapy by proton beam or plaque brachytherapy 
if tumour size allows, with high local tumour 
control rates and more than 90% eyes salvaged 
[31]. In spite of treatment, vision is often compro-
mised or lost due to radiation damage to the retina 
and optic nerve. Additional modalities, used less 
frequently, include surgical resection, by means 
of transscleral local resection or endoresection. 
Deciding on which treatment modality should be 
employed depends on multiple factors, including 
tumour size, visual acuity of the affected eye and 
contralateral eye, age and general health of the 
patient, and the presence of metastases.
Uveal melanoma metastasizes via hae-
matogenous spread primarily to the liver, and 
is believed to occur early in the course of the 
disease, despite successful treatment of the eye 
[32]. In a retrospective analysis by Shields et al. 
of more than 8000 patients, 33% and 25% of 
ciliary body and choroidal melanoma patients, 
respectively, were diagnosed with metastatic 
spread at 10  years [30]. Iris melanoma had a 
more favourable prognosis. Size of the primary 
tumour at time of detection was important in 
determining the chances for secondary spread: 
at 10 years,  metastasis were diagnosed in 12% 
of small melanoma (elevation ≤3.0 mm), 26% of 
medium melanoma (elevation 3.1–8.0 mm) and 
49% of large melanoma (elevation >8.0  mm). 
Metastatic spread at the time of presentation 
with the intraocular tumour is unusual, but sys-
Fig. 8.3 A left eye choroidal naevus
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temic screening is advised for detection of liver 
involvement, even years after treatment of the 
primary intraocular tumour. Despite the improve-
ments in treatment of the primary tumour, a cor-
responding decrease in metastatic death has not 
been documented and stands overall at a 5 year 
survival of 20–30% and a 10 year survival esti-
mate of 50% [33, 34]. To date, metastatic uveal 
melanoma is a major challenge for physicians 
to treat although many new targeted immune 
modulatory treatments are now available such as 
PD1 inhibitors and MEK inhibitors in addition 
to targeted hepatic chemotherapy.
 Ocular Metastasis
Secondary deposits from distant malignancies 
occur in the eye; particularly in the choroid 
due to its vascular nature [35]. The common-
est primary cancers to metastasize to the eye 
are lung cancer in males and breast cancer in 
females. In approximately 2/3 of cases the pri-
mary site of the cancer is already known, but 
in the other 1/3 will prompt examination and 
imaging of the rest of the body. If no primary 
cancer is found, then biopsy of the eye tumour 
may be required. Choroidal metastases present 
as yellow creamy subretinal deposits that grow 
rapidly (Fig.  8.5). They tend to leak fluid in 
large amounts, as compared to primary ocular 
malignancies.
Treatment involves controlling the primary 
tumour site, but also local treatment to the eye 
with EBRT, visudyne photodynamic therapy 
(PDT) or plaque radiotherapy to try to preserve 
as much vision as possible. Patients with poor 
systemic status usually warrant observation 
only and systemically treatment-naïve patients 
that were newly diagnosed might benefit from 
systemic therapy (e.g. chemotherapy) to have a 




Fig. 8.4 Uveal melanoma in the iris (a), ciliary body with iris root erosion (b) and choroid (c)
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 Choroidal Osteoma
Choroidal osteoma (Fig.  8.6) is a benign intra-
ocular tumour composed of mature bone that 
typically replaces the full thickness of the cho-
roid, and hence is a choristoma (abnormal tis-
sue growth not indigenous to that anatomical 
location). The tumour classically manifests as 
an orange-yellow plaque deep to the retina in 
the juxtapapillary or macular region. It typically 
occurs as a unilateral condition found in healthy 
young females in the second or third decades of 
life. Patients with a choroidal osteoma may be 
asymptomatic. When symptoms are present they 
include mild to severe visual blurring, metamor-
phopsia, and visual field defects corresponding to 
the location of the tumour. Clinical complications 
of a choroidal osteoma include enlargement of its 
basal diameter, leakage of subretinal fluid and 
development of subretinal neovascularization 
with or without haemorrhage [36]. Management 
options include observation, when no complica-
tions occur, or the use of intravitreal anti-VEGF 
or laser for treatment of neovascular membrane 
and subretinal fluid.
 Choroidal Haemangioma
Choroidal haemangiomas are benign, vascular 
hamartomas, classified as circumscribed or dif-
fuse. The circumscribed form (Fig.  8.7) occurs 
sporadically, while the diffuse one is related to 
Sturge-Weber syndrome, a rare non-hereditary 
neuro-oculo-cutaneous syndrome presenting at 
childhood [37].
Circumscribed choroidal haemangiomas 
commonly occur between the second and fourth 
decades of life, are usually asymptomatic, but 
may be associated with visual symptoms, includ-
ing decreased vision, metamorphopsia, float-
ers and photopsia. On clinical examination, 
circumscribed choroidal haemangiomas appear as 
orange-coloured masses with indistinct borders. 
Ultrasonography usually demonstrates a dome 
shaped choroidal lesion with high internal echo-
genicity. Leakage of fluid into the subretinal space 
overlying the choroidal lesion is a common mani-
festation, and depending on location, might result 
with visual loss. Management options for circum-
scribed choroidal haemangiomas include monitor-
ing asymptomatic cases, use of oral beta blockers, 
laser photocoagulation, and visudyne PDT and 
for resistant or large tumours – EBRT or brachy-
therapy. Resolution of SRF is achieved in most 
cases; however visual prognosis depends mainly 
on tumour location (i.e. involvement of macula).
 Retinal Capillary Haemangioma
Retinal capillary haemangioma (RCH) is a 
benign retinal vascular tumour (Fig.  8.8). RCH 
may occur sporadically or in association with von 
Hippel Lindau (VHL) disease, a genetic disorder, 
Fig. 8.5 A right eye pale choroidal metastasis (arrows)
Fig. 8.6 A left eye choroidal osteoma in the macular 
region
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which may involve the adrenal glands, kidneys, 
cardiovascular system, spine and central nervous 
system [38].
The mean age of diagnosis of RCH in VHL 
patients is 25  years old. Common symptoms 
include vision deterioration and photopsia, but 
some patients may be asymptomatic and diag-
nosed indecently in a routine eye examinations 
or as part of screening test for families with 
VHL. On clinical examination and more evident 
on fluorescein angiography, a prominent feed-
ing vessel and a draining vein are commonly 
seen entering and exiting the tumour. Most 
RCH are located in the temporal periphery and 
cause intra- and subretinal leakage. Treatment 
options include observation for small tumours, 
laser photocoagulation of the tumour and/or 
feeding artery, cryotherapy, visudyne PDT and 
plaque radiotherapy. In advanced cases, com-
plicated with retinal detachment, vitreoretinal 
surgery is a valid option. Regular screening of 
the body is also recommended.
a b
c d
Fig. 8.7 A left eye choroidal haemangioma (a), with overlying sub- and intra-retinal fluid, as shown on OCT (b). After 
treatment with photodynamic therapy, the lesion formed into a scar (c) and fluid resolved (d)
Fig. 8.8 A right eye retinal capillary haemangioma with 
feeding and draining vessels
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 Vasoproliferative Tumour
Similar to RCH, a vasoproliferative tumour 
(VPT) is a benign vascular retinal lesion, present 
at the third–fourth decades of life. VPTs appear 
as isolated lesions (Fig.  8.9), but may develop 
secondary to a pre-existing ocular disorder, in 
which case multiple lesions are commonly found 
[39]. VPTs are usually present in the peripheral 
retina and show significant leakage of fluid. They 
can be distinguished from RCHs by the absence 
of large dilated feeder and drainage vessels that 
commonly occur with RCHs. Macular pucker is 
a common feature, causing visual deterioration. 
Treatment options used for RCH are also used for 
VPT, and decisions as to the best management 
step depend on tumour size, location, related 
clinical complications (e.g. exudation, epireti-
nal membrane) and association to other ocular 
disorders.
 Sclerochoroidal Calcification
Sclerochoroidal calcification is a rare benign 
condition that classically manifests as multiple 
discrete yellow lesions, often discovered as an 
incidental finding in asymptomatic older white 
individuals (Fig.  8.10). This condition may 
be idiopathic, secondary to hypercalcemia, or 
syndrome- associated [40]. The clinical appear-
ance is typical and recognizable by indirect oph-
thalmoscopy as an elevated mass with overlying 
retinal pigment epithelial atrophy. Diagnostic 
evaluation using ultrasonography can confirm 
the presence of intrinsic calcification. The lesions 
are commonly bilateral and located in the supe-
rotemporal quadrant along the arcades, and are 
frequently multiple, features that help differenti-
ating them from choroidal osteoma.
Patients diagnosed with sclerochoroidal cal-
cifications require no ocular intervention unless 
vision loss occurs from the development of a 
choroidal neovascular membrane. They should 
undergo systemic workup to screen for abnor-
malities in calcium and phosphate metabolism.
 Primary Intraocular Lymphoma
Primary intraocular vitreoretinal lymphoma, or 
PIOL (Fig.  8.11), is an intraocular malignancy 
that is a subset of primary central system lym-
phoma (PCNSL). Approximately one-third of 
PIOL patients will have concurrent PCNSL at 
presentation, and up to 90% will develop PCNSL 
within 1–2  years [41]. PIOL is bilateral in up 
to 85% of cases, although initially it may seem 
unilateral. Posterior segment findings of PIOL 
include the presence of vitreous cells in the 
majority of cases. Another sign is the develop-
ment of creamy lesions with orange–yellow 
infiltrates that are deep to the retina. Imaging 
studies, including fluorescein angiography, 
OCT and ultrasonography, and tissue (vitreous/
retina/choroid) biopsy are usually required for 
Fig. 8.9 A right eye vasoproliferative tumour with sur-
rounding exudation
Fig. 8.10 Typical appearance of a left eye sclerochoroi-
dal calcifications located along the superotemporal arcade
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diagnosis. Treatment of PIOL includes systemic 
chemotherapy and eyes and brain radiotherapy. 
Intravitreal chemotherapy with methotrexate 
and/or rituximab is used to control the ocular dis-
ease. Mortality rate in PIOL patients may be as 
high as 80% at 3 years.
 Conclusion
There are many different types of intraocular 
tumours. Pattern recognition with suitable ancil-
lary testing can assist in the diagnosis and sub-
sequent management of the majority of tumour 
types.
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Localised Therapy and Biopsies 
of Intraocular Tumors
Dan S. Gombos
The majority of intraocular neoplasms are ame-
nable to a variety of treatment options depend-
ing on the underlying pathology and location 
within the globe. Increasingly the role of diag-
nostic and prognostic biopsies has become an 
integral part of the management of these lesions. 
Enucleation and radiation therapy are important 
treatment modalities that are discussed elsewhere 
in this textbook. This chapter will review focal 
modalities including cryotherapy and laser treat-
ment as well as incisional and excisional biopsy 
techniques.
 Cryotherapy
There are many tumors amenable to cryother-
apy including retinoblastoma, retinal capillary 
hemangioblastoma, and vasoproliferative tumors 
of the retina [1, 2]. Generally, anterior tumors 
less than 3  mm in height are preferred for this 
approach. Multiple applications may be neces-
sary to ensure complete tumor regression. The 
technique can be performed on an outpatient 
basis with a local block or alternatively under 
general anesthesia for children. Using indirect 
ophthalmoscopy and scleral depression the tumor 
is visualized and cryotherapy is administered 
trans-scleraly. The surgeon visualizes the uptake 
of ice through the entire extent of the tumor fol-
lowed by thawing. Generally, 2–3 freeze-thaw 
cycles are administered per session depending on 
the thickness of the tumor. Care is also taken not 
to freeze the overlying vitreous. Complications 
can include serous and rhegmatogenous retinal 
detachment, vitreous hemorrhage and periocu-
lar edema. It is recommended not to administer 
cryotherapy to retinoblastoma foci associated 
with significant calcification due to the risk of 
retinal tear [3].
There are various cryotherapy models that are 
available, some with greater length and curva-
ture. While the technique is best suited for ante-
rior tumors, following a conjunctival cut down, 
access and administration to posterior segment 
lesions is possible.
 Laser Therapy
Laser therapy plays a significant role in the 
treatment of various tumors managed by ocu-
lar oncologists. It can be administered as a pri-
mary or adjuvant modality and is used for both 
malignant and benign neoplasms including 
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uveal  melanoma, choroidal metastasis, retino-
blastoma, circumscribed choroidal hemangi-
oma, and retinal capillary hemangiomas. There 
are different types of lasers each with distinct 
indications. These include traditional photoco-
agulation, thermotherapy, and photodynamic 
therapy.
 Thermotherapy
Thermotherapy is generally used to manage 
uveal tumors as well as retinoblastoma. Small 
lesions can be lasered as a primary modality. 
Alternatively, it can be administered in an adju-
vant setting after primary radiation or chemother-
apy [4–6]. The laser is painful and requires either 
retrobulbar or (for pediatric patients) general 
anesthetic. The technique utilizes an 810 nm laser 
administered via slit lamp or indirect attachment. 
Principles of therapy include continuous large 
spot application directly to the tumor. The clini-
cian begins at a low energy setting and gradually 
increases power at small intervals until a gray 
uptake is appreciated. A dense white appearance 
and application directly to retinal vessels should 
be avoided. Concomitant administration of indo-
cyanine green (ICG) can be used for amelanotic 
lesions such as retinoblastoma and select cho-
roidal metastases [7]. Complications to therapy 
include retinal and vitreous hemorrhage, vascu-
lar occlusion, serous and rhegmatogenous retinal 
detachment. It is preferred to avoid direct laser 
over areas with calcification for retinoblastoma 
foci. In general, this technique requires multiple 
applications until an acceptable endpoint with 
flattening of the tumor is achieved.
 Photocoagulation
Photocoagulation administers therapy at higher 
temperatures than thermotherapy. It is commonly 
used for retinal tumors including capillary hem-
angiomas and in select cases as an adjuvant for 
retinoblastoma. Historically it was used to man-
age small uveal melanomas however, this has 
largely been abandoned. Laser can be adminis-
tered with various wavelengths. A common one 
is 532 nm. For retinal capillary hemangioblasto-
mas, topical anesthesia is administered and laser 
applied via slit lamp or indirect attachment. Spots 
are applied circumferentially avoiding draining 
vessels. Subsequently, laser is administered to 
the surface of the lesion. Settings employ a low 
power, long interval approach. Multiple sessions 
may be necessary to achieve complete regression 
[8, 9]. Complications include hemorrhage, vascu-
lar occlusion, retinal exudation, and detachment. 
Treating retinoblastoma lesions with this modal-
ity requires care to avoid retinal perforation, 
tear, and rupture of the tumor leading to seed-
ing. Clinicians should avoid direct application 
to areas of calcification and maintain low power 
settings with a gray endpoint.
 Photodynamic Therapy
Photodynamic therapy was initially introduced 
for the management of macular degeneration. 
It includes the intravenous infusion of a pho-
tosensitizing agent, vertoporfin, followed by 
laser administration. Subsequent studies dem-
onstrated efficacy in the management of cir-
cumscribed choroidal hemangiomas [10, 11]. 
Recent reports have expanded its indication 
to include choroidal metastatic tumors [12]. 
Treatment involves topical anesthesia and 
administration of the photosensitizing agent 
intravenously. Similar to macular degeneration 
treatment is applied with a large spot over the 
entire neoplasm. If the lesion is too large to 
be encompassed with one spot, multiple spots 
can be applied with minimal overlap. Full flu-
ence (50 J/cm2 600 mW/cm2 689 nm light over 
83  seconds) as well as half fluence (25  J/cm2 
600 mW/cm2 689 nm light over 83 seconds) has 
been described. One or two sessions are effec-
tive in inducing tumor regression. Following 
laser, patients should be instructed to avoid 




Historically many clinicians deferred intraocu-
lar biopsy for concern of extraocular extension. 
The last two decades has seen a significant shift 
toward increased use of this technique. Biopsies 
may be excisional with the intent of tumor resec-
tion or incisional with the desire of tumor sam-
pling. Incisional biopsies can be performed for 
diagnostic or prognostic purposes. Except under 
unique circumstances, the biopsy of an eye 
thought to be harboring retinoblastoma is contra-
indicated. The techniques differ for tumors in the 
anterior versus posterior segment.
 Posterior Segment Incisional Biopsy
Indications of incisional biopsy are for histo-
pathologic diagnosis or prognostic testing for 
diseases such as uveal melanoma. Posterior 
segment lesions can be approached with either 
an ab interno or ab externo approach. External 
approaches are preferred for tumors anterior to 
the equator. Internal approaches work best for 
those located more posteriorly.
 An Interno
Internal approaches involve sampling the eye 
from the pars plana through the vitreous into 
the retina and underlying choroid. This can be 
achieved with a use of an indirect ophthalmo-
scope and a 25- or 27-gauge needle [13, 14]. The 
patient is placed under general anesthesia and a 
conjunctival peritomy is performed. The mus-
cles are isolated in standard fashion and indirect 
ophthalmoscopy is used to visualize the tumor. 
The biopsy is obtained from the same quadrant 
were the tumor is located. The needle is inserted 
between 3 and 4 mm posterior to the limbus and 
is visualized through its introduction into the eye 
toward the center of the tumor. The sample is 
aspirated under direct visualization and the nee-
dle removed through the pars plana. Cryotherapy 
can be administered at the biopsy site to lower the 
risk of extraocular extension. The same approach 
can be used with a traditional three-port vitrec-
tomy. Some surgeons prefer a two-port approach 
(excluding the infusion line) using a small gauge 
vitrector. It should be noted that biopsies requir-
ing histopathologic assessment often require 
more tissue than those for prognostic testing 
alone. Complications include vitreous hemor-
rhage and retinal detachment (Video 9.1).
 Ab Externo
For tumors anterior to the equator, an external 
approach is sometimes preferred and allows for 
larger volume tissue sampling. Following a perit-
omy and isolation of the extraocular muscles, 
the tumor is identified with a combination of 
transillumination and indirect ophthalmoscopy. 
The biopsy is directed toward thickest portion of 
the tumor. A 90% thickness scleral flap measur-
ing approximately 4 × 4 mm is constructed and 
hinged over the center of the neoplasm. Toward 
the base of the flap, the remaining fibers of the 
sclera are pierced with a blade, removing a uveal 
sample approximately one by one millimeters in 
size. Judicious application of cautery and use of 
systemic hypotension are helpful in minimizing 
bleeding. The wound is closed with nylon or silk 
suture. If lymphoma the tissue should be placed 
in liquid media (RPMI).
 Vitrectomy
Primary intraocular lymphoma often presents 
as a vitritis. Vitrectomy is critical in obtaining 
accurate diagnosis. In these cases, a three-port 
vitrectomy is used with a low rate of cutting on 
the vitrector. As much vitreous debris as possi-
ble should be removed. An initial undiluted core 
sample is sent to the pathologist as well as the 
cassette. The pathologist should be informed in 
advance of the possible diagnosis of intraocular 
lymphoma so that the specimen can be properly 
analyzed with ThinPrep and flow cytometry [15].
 Biopsy of Anterior Segment Tumors
Similar to the posterior segment, the anterior seg-
ment can be biopsied via an internal or external 
approach. For fine-needle aspirations, a 27-gauge 
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or smaller-gauge needle is inserted through the 
limbus under direct microscopic visualization 
into the tumor. The surgeon or assistant performs 
the aspiration. Following removal of the needle, 
the anterior chamber may need to be reinflated 
with BSS.  Post biopsy hyphema can occur and 
is often self-limited. Alternatively, an external 
approach can be used in which a keratome is 
inserted slightly behind the limbus in the quad-
rant of the tumor allowing the iris to present at 
the wound. Using forceps and iris scissors a small 
piece of tumor is excised and the iris positioned 
back into the anterior chamber. The wound is 
then closed with interrupted nylon suture in tra-
ditional fashion.
 Excisional Biopsy of Intraocular 
Neoplasm
Posterior scleral-uvectomy was once a common 
technique within the field of ocular oncology. Its 
use has diminished significantly in part due to its 
technical difficulties and numerous complica-
tions. It is more common for this approach to be 
used for smaller irido-ciliary neoplasms.
The patient is placed under general anesthe-
sia preferably under hypotensive conditions. 
Following a peritomy and isolation of the extra-
ocular muscles, the margins of the tumor are 
demarcated with an adjacent circumferential 
2–3 mm margin. A nearly full-thickness scleral 
flap is constructed hinged toward the fornix. 
Cautery is applied to the peripheral edges and the 
tumor is then incised with a knife and circum-
ferentially excised with scissors. As the tumor is 
expressed, it is gently separated from the retina. 
The sclera is then reapproximated with inter-
rupted nylon suture and the eye reinflated with 
BSS. Some surgeons combine this approach with 
a posterior vitrectomy. Following excision adju-
vant radiotherapy in the form of a plaque may 
be necessary. Common complications include 
hypotony, retinal detachment, and vitreous hem-
orrhage. Incomplete excision and expulsive hem-
orrhage are also possible [16, 17].
 Excisional Biopsy of Iris Tumors
The complete excision of an iris tumor is simi-
lar to the approach used for extracapsular cata-
ract surgery. The patient is given general or local 
(retrobulbar) anesthesia. An incision is made into 
the anterior chamber in the same quadrant as the 
neoplasm. Corneal scleral scissors are used to 
extend the wound 1–2 mm beyond the margins of 
the tumor. Using iris forceps and scissors a wedge 
of the iris is excised and the lesion removed from 
the anterior segment. Care is made to avoid exten-
sion into the ciliary body region. Localized hem-
orrhage can occur. The wound is reapproximated 
with interrupted nylon suture and the anterior 
chamber inflated with BSS. Due to the associated 
defect of the iris, some surgeons suture the edges 
of the lesion with a nonabsorbable (prolene) suture 
to reconstruct the pupil. Adjuvant radiotherapy 
may be necessary if the margins are positive on 
histopathology. Complications include hyphema, 
incomplete excision, photophobia and polyopia.
 Conclusion
Focal therapies such as laser and cryotherapy are 
important treatment options in the management 
of many intraocular neoplasms such as retinoblas-
toma and uveal melanoma. Similarly, excisional 
and incisional biopsy techniques have become 
increasingly important, as the role of prognostic 
testing for uveal melanoma has become standard 
of care. It is imperative that the ocular oncolo-
gist understand the advantages and complications 
of each technique to provide an individualized 
approach for tumor management.
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Tumors
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 Incidence of Orbital Tumors
 Primary Tumors of Orbit
Although the incidence of different orbital tumors 
varies considerably among large series, it is plau-
sible to group the orbital space-occupying lesions 
as 60% benign and 40% malignant pathologies 
in adults.
The frequency of malignancy is about 20% 
among young patients within the age range of 
1–18 years. The incidence of malignant tumors 
upsurges with aging chiefly because of the higher 
prevalence of lymphomas and metastatic tumors 
[1–9].
Another approach to classification is to divide 
the orbital tumors as cystic or partially cystic, ver-
sus solid lesions; in adults this ratio is about 30% 
and 70% respectively. The percentage of cystic 
lesions is higher in younger age groups primarily 
because of the common occurrence of dermoid 
and other congenital hamartomas (vascular and 
others) and rarely as a result of cystic degenera-
tion within some solid tumors such as meningi-
oma and schwannoma in children [10–11].
The most common diagnoses in all age groups 
are vascular hamartomatous lesions [infantile 
hemangioma, cavernous malformations, and 
venolymphatic malformations] representing 
approximately 15–20% of all orbital masses. 
Lymphoproliferative lesions and lacrimal fossa 
masses represent between 10% and 15%, while 
non-specific orbital inflammatory lesions, optic 
nerve tumors [glioma and meningioma], and sec-
ondary masses from regional tumors all represent 
between 5% and 10%. Metastatic tumors from a 
systemic primary disease may represent approxi-
mately 5% of orbital disease. Mesenchymal 
lesions such as schwannoma, rhabdomyosarcoma, 
osteogenic tumors, etc. are encountered much less 
frequently, usually below 2–3% in large series.
The most frequently encountered primary 
orbital tumors in adults are lymphoproliferative 
lesions and cavernous malformations. In children, 
the most common orbital tumors tend to be cystic 
and benign including dermoid cysts and vascular 
lesions [infantile hemangioma, venolymphatic 
malformations]. Less common malignancies 
include rhabdomyosarcoma, histiocytic tumors, 
Burkitt’s lymphoma, neuroblastoma, Ewing sar-
coma, Wilms tumor, and leukemia [12–13].
 Metastatic Tumors of Orbit
The prevalence of metastatic neoplasms to orbit 
has increased in recent decades, due to increased 
numbers of cancer patients in general, viral 
 epidemics, higher levels of UV and chemical 
exposures. Further, improved treatments have 
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led to an upsurge in the median survival of these 
patients, which may increase the risk of devel-
oping metastatic lesions throughout the body, 
including the orbit. An improved level of aware-
ness for orbital metastases has increased detec-
tion of these lesions across all disciplines of 
medicine.
Recent cumulative data indicates that the most 
commonly affected regions of the orbit with met-
astatic tumors are lateral (40%), superior (30%), 
medial (20%), and inferior (10%) quadrants [14]. 
Another report claims that the anterior orbit, 
adjacent to lymphatic rich conjunctiva and eye-
lids, is most commonly involved with metastatic 
tumors [15].
Some malignancies show distinct tissue selec-
tivity in metastatic disease, for instance, prostate 
cancer tends toward bone, breast to orbital fat, 
and carcinoid tumor to muscle. These tendencies 
can aid in diagnostic planning.
In about 25% of the cases, there may be no 
history of systemic cancer at the time of orbital 
tumor presentation. Similar to primary tumors 
of the orbit, most common presenting signs and 
symptoms include rapidly developing proptosis 
and associated eyelid and conjunctiva anoma-
lies, pain, diplopia, and rarely isolated optic neu-
ropathy and enophthalmos. Because of the rapid 
growth of the malignant neoplasm, the motil-
ity disturbance may be out of proportion to the 
degree of proptosis. Enophthalmos is rare and 
typically seen in sclerotic carcinomas or after 
radiation therapy of a preceding orbital mass. 
Isolated metastases to the eyelid and periocular 
skin and eyelids are rare [16–17].
Most commonly encountered secondary and 
metastatic tumors in adult orbit are squamous cell 
carcinoma (SCC) of paranasal sinuses, menin-
giomas from CNS and breast, lung and prostate 
cancers respectively [14].
 General Considerations in Orbital 
Tumor Patient
During the patient assessment process, it is vital 
to establish a good rapport with the patient and 
the family, which will fortify their trust with the 
surgeon. It is further critical that the patient’s 
problem be discussed in detail at every step of 
management as cancer is usually a serious issue 
with high morbidity and mortality. If possible, 
the images of MRI or CT revealing a space- 
occupying mass in the orbit should be shared with 
the patient and the family; the obvious difference 
between the tumor containing orbit and the nor-
mal one is usually very informative and convinc-
ing for the patient. Furthermore, the reasons for 
surgery, the expected benefits, and especially 
potential complications should be discussed in an 
open manner. If the case is inoperable, alternative 
management plans should be debated. It is most 
important that the patient and the family, not the 
surgeon, decide whether to proceed with surgery. 
It should be carefully explained that the orbital 
problem may be part of a systemic disease and 
that better understanding of the orbital pathology 
may eventually help to arrive at an effective sys-
temic treatment.
 Clinical Evaluation of Orbital Tumor 
Patient
The evaluation of the orbit begins with a thor-
ough history and physical examination. Detailed 
systemic and ocular inquiries offer many use-
ful clues. The family history should specify any 
cancer, craniofacial abnormalities, and other 
systemic familial diseases such as neurofibro-
matosis. A history of previous hospitalizations, 
head and neck injuries, and surgeries should be 
investigated. A list of the patient’s medications 
and allergies should be obtained and a tendency 
toward bleeding should specifically be elicited. 
Anticoagulants and chemicals which may affect 
bleeding should be noted and appropriately 
addressed by cessation at an appropriate interval 
prior to surgery or managed in conjunction with 
an internist/hematologist.
Special emphasis on the duration and speed of 
progression of the symptoms should be heard in 
the patient’s own words. Symptoms such as dis-
placement of the eye(s), pain, tenderness, diplo-
pia, pulsation, change in the degree of proptosis 
with position or Valsalva maneuver, and distur-




A complete ophthalmic examination including 
assessment of visual acuity, visual field, extraocu-
lar motility, anterior and posterior segments, sen-
sory capacity and cranial is essential. Periorbital/
orbital changes such as proptosis, abnormal eye-
lid configuration, skin lesions, edema, chemosis, 
and the appearance of conjunctival vessels should 
be carefully evaluated and photographs should 
be obtained if possible. Apposition and motility 
abnormalities of the eyelids and the status of lac-
rimal drainage system (LDS) are additional key 
points to be checked during the examination.
Diminished or changing visual acuity, color 
vision, abnormal visual fields, and pupillary abnor-
malities are important to note. Motility dysfunc-
tion and diplopia should be carefully assessed and 
quantified if possible by Hess screen and/or alter-
nating prism cover test throughout the course of ill-
ness. Intraocular pressure should be elevated. Slit 
lamp examination can discern chemosis, congested 
tortuous vessels. Dilated indirect ophthalmoscopy 
may reveal optic disc edema or pallor, retinal 
detachment, choroidal folds, scleral indentation, 





Fig. 10.1 Checking the 
position of the globes with 
Hertel’s exophthalmometer 
(a, b); “Worm’s eye view” 
examination of proptosis of 
the left eye secondary to a 
large space occupying 
lesion in the orbit; (c) 
Axial CT image showing 
left eye proptosis (d)
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Bilateral or unilateral displacement of the eye 
(proptosis) is an important clinical manifestation 
of orbital space-occupying lesions. In addition to 
axial proptosis, one should note the displacement 
of the eye in planes other than the antero- posterior 
direction, vertical and lateral globe dystopia should 
be documented. The degree of displacement, com-
pared to the fellow eye is generally quantified in 
millimeters with exophthalmometry (typically 
with Hertel Exophthalmometer) (Fig.  10.1). If 
an exophthalmometer is not available, the rela-
tive protrusion can be observed by simply stand-
ing behind a seated patient and gazing downward 
from the forehead to assess the displacement of 
one globe compared to the other. Alternatively, 
this can be noted by having the patient elevate the 
head and looking from below the nose or “worm’s-
eye” view. The displacement (proptosis) of the eye 
is estimated based on the distance (in millimeters) 
in an anterior-posterior plane between the anterior 
surface of the cornea and the anterior margin malar 
eminence. This distance normally varies from 16.5 
to 21.5 mm in Caucasian men and 15.5–20 mm in 
Caucasian women. In African American adults, 
the measurements are increased by approximately 
2 mm in both sexes (Fig. 10.2) [22–24].
External examination for orbital pathology 
must include the changes of the eyelids, conjunc-
tiva, and periorbital skin and the underlying soft tis-
sues. Regional lymph nodes should be examined. 
Edema, discoloration, and tenderness of these tis-
sues may provide information regarding the orbital 
process. Edema of the eyelids without erythema 
or other inflammatory signs may be associated 
with vascular and neurogenic tumors, presumably 
secondary to long-standing venous stasis. Edema 
with inflammatory signs such as hyperemia and/
or tenderness is commonly associated with thyroid 
eye disease (particularly if in association with eye-
lid retraction) and orbital inflammatory syndromes 
(infectious and non- infectious, specific and non-
specific). Ecchymosis should not be confused 
with hyperemia (Fig.  10.3). The former is often 
seen in metastatic neuroblastoma but may also be 
encountered with amyloidosis, plasmacytoma, and 
leukemic infiltrates. A typical feature of ecchymo-
sis, secondary to neuroblastoma, is its changing 
appearance from day to day [25].
Xanthelasmas on the periorbital skin should also 
be noted, since they may be a part of orbital xantho-
granuloma or systemic disease (Fig. 10.4) [26–27].
Lesions palpable in the anterior orbit can be 
evaluated for mobility and the solid versus cystic 
a
b
Fig. 10.2 (a, b) Normal anatomy of orbits in white and 
black women in CT. (From Karcioglu [8], with 
permission)
Fig. 10.3 Bilateral ecchymosis in a patient with meta-
static neuroblastoma. (From Karcioglu [8], with 
permission)
Fig. 10.4 Bilateral upper lid xanthelasmas in the patient. 
(From Karcioglu [8], with permission)
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nature of the mass and its relationship to orbital 
bones and to other underlying tissues. Some ante-
rior cystic masses can be transilluminated over 
the skin (Fig. 10.5).
Retropulsion is the degree of posterior freedom 
of movement of the globe which can be tested 
by the examiner’s hand, pushing over patient’s 
closed lids without creating too much discomfort. 
Tactile examination is also helpful to reveal pul-
sations of the globe secondary to arteriovenous 
communications and occasionally crepitations 
in an emphysematous orbit. Auscultation of the 
orbit may rarely detect a bruit, secondary to A-V 
malformations or carotid- cavernous fistula but it 
is of vital importance to recognize this sign clini-
cally. Attention should also be paid to regional 
lymph nodes for enlargement and tenderness. 
Certain types of clinical laboratory tests may also 
be helpful throughout the diagnosis and manage-
ment of the tumor patient (Table 10.1).
 Imaging in Orbital Tumor Patient
Whereas many pathologic processes intrinsic to 
the globe may be easily evaluated under direct 
visualization, radiological imaging is of greater 
value in the evaluation of orbital and intracranial 
processes. In current practice, imaging including 
CT and MRI is the gold standard for diagnosis 
and management [28–31] (Tables 10.2, 10.3, 
10.4, 10.5, 10.6 and 10.7).
CT and MRI, independently or together, provide 
a wealth of information on orbital lesions. Each has 
a
b
Fig. 10.5 (a, b) Transillumination of cystic basal cell 
carcinoma in inferior orbit displacing the globe superi-
orly. (From Karcioglu [8], with permission)
Table 10.1 Laboratory tests for orbital tumor patient
Tests to screen for cancer or precancerous conditions
Tumor marker tests measure the presence, levels, or 
activity of specific proteins or genes in tissue and 
blood that may be signs of cancer
Tests for cancer gene mutations
For example, searching for BRCA1 and BRCA2 
mutations that play a role in the development of 
breast, ovarian, and other cancers
Tests to screen for immune status of the patient
Tests for antibody deficiency: IgG, IgA and IgM levels 
in blood
Tests for evaluation of cellular (T-cell) immunity
Tests for evaluation of neutrophil function
Tests for evaluation of complement: hemolytic 
complement assay or CH50
Tests to determine HIV/AIDS, HPV, EB and other 
virus positivity when indicated
Pre-operative and post-operative tests to assure a safe 
surgical course
Complete blood count (CBC) and clotting studies 
including prothrombin time (PT), activated partial 
thromboplastin time (aPTT), and thrombin time (TT), 
to assess blood clotting function of the patient
Tests to diagnose cancer at the time of biopsy
Frozen-section, histopathology, 
immunohistochemistry, Immunophenotyping
Flow-cytometry, DNA sequencing and antibody/gene 
microarray, PCR, quantitative PCR
Tests to make a management plan
Confirmation of tumor type and staging for chemo and 
radiation treatments
Tests to determine the dissemination of cancer; 
sentinel node biopsy; LP cytology; BM biopsy
Tumor marker tests to measure the presence, levels, or 
activity of specific proteins or genes in tissue and 
blood that may indicate the presence of cancer. A 
tumor that shows greater than normal level of a certain 
tumor marker may respond to treatment with a drug 
targeting that specific marker
Tests to monitor the patient during treatment and look 
for adverse effects of the treatment
Urinalysis; CBC; blood chemistry; tests detect 
metabolites, electrolytes, fats, and proteins, and 
enzymes including blood urea nitrogen (BUN) and 
creatinine and many others
Tests to determine whether the tumor is responding to 
treatment and tests to monitor recurrence
Clinical Laboratory tests can be useful for orbital tumor 
patient for numerous purposes. Although many of these 
tests are only available in major medical and research cen-
ters, the spectrum of laboratory capabilities is important 
to appreciate
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Table 10.2 Imaging protocols for CT and MRI
Routine imaging protocol for orbit and brain CT
The standard orbital CT protocol calls for the acquisition of 0.625 mm axial source images which are then 
reconstructed as overlapping 1.25 mm slices and also converted into soft tissue and bone algorithms. Additionally, 
overlapping 1.5 mm sagittal and coronal reformatted images are routinely generated
Routine imaging protocol for orbit and brain MRI
Generally speaking, T1-weighted images provide the best overall anatomic detail. Several tissues demonstrate high 
T1 signal: fat, subacute blood, and often melanin. Tissues with high fluid content (such as edema) demonstrate high 
T2 intensity. Fat-suppressed sequences are typically performed in the orbit to allow for differentiation of 
hyperintense structures from the underlying normal fat, for instance, in contrast- enhanced sequences. Diffusion 
weighted images (DWI) and the apparent diffusion coefficient (ADC) help to evaluate ischemic tissues and cellular 
tumors like lymphomas, which can be bright on DWI and dark on ADC. Today MRI is most commonly performed 
with 1.5 T units using either head or surface coils
MRA and MRV
Magnetic resonance angiography and venography may be added to conventional MRI protocols when differential 
diagnosis includes cavernous carotid fistula, arterial dissection, vascular malformations or other vascular anomalies
Data from ICRP statement on tissue reactions. International Committee on Radiological Protection [33]; Belden and 
Zinreich [34]; Sepahdari et al. [35] and Lee et al. [36]
Table 10.3 Advantages and disadvantages of CT and MRI
Advantages Disadvantages
CT Low cost Ionizing radiation
Availability and fast scanning time Contrast reaction
Good detail of bone anatomy Beam-hardening and other artifacts
MRI Superior detail of anatomy Incompatible with a number of metallic implantable 
medical devices and foreign bodies
No ionizing radiation Motion and other artifacts
High cost, longer scanning times
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hyperintense
++++ with fat 
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Table 10.4 (continued)
a role. CT has advantages in the examination of 
bony or other high-density lesions. Positron emis-
sion tomography (PET) CT is useful for the detec-
tion of suspicious lesions throughout the body, in 
the context of a potentially metastatic orbital tumor.
MRI is advantageous for delineating soft 
tissue processes, in that different sequences 
can highlight differences in cellular content of 
lesions and the local surrounding tissues. Special 
sequences such as diffusion-weighted MRI, MRI 
arteriography, and MRI venography can also be 
particularly helpful for specific suspected diag-
noses. Time-resolved sequences such as TRICKS 
or TWIST can also be useful for vascular lesions.
Ultrasonography (US) which can be done 
quickly in the clinic at a low cost is uniquely 
suitable to reveal dynamic changes such as com-
pressibility and internal reflectivity, as well as 
the cystic nature of lesions. Doppler imaging 
can provide information regarding vascular flow 
characteristics within a lesion. This modality 
is typically applicable primarily for anteriorly 
located lesions. The information US provides can 
also be additive to other types of imaging [32].
The most irreplaceable benefit of orbital 
imaging is not only to provide insight into the 
differential diagnosis of the tumor but also 
to reveal the exact localization of the pathol-
ogy in the orbit. This anatomical precision 
allows the ophthalmologist to appropriately 
plan for potential surgery, whether incisional 
or excisional. Such improvements in preop-
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Table 10.6 MRI features of lacrimal fossa lesions (appearance and signal with respect to vitreous)
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Homogenous Homogenous Homogenous 
(small)
Scalloping of orbital bone
Hypo-/isointense Iso-/hyperintense Heterogenous 
(large)
+++





Hyperintense Hypointense Bony destruction with Ca 
++ on CT
4 Dacryoadenitis Homogenous Homogenous Homogenous On CT hypo/iso to muscle
Hypo-/isointense Iso-/hyperintense Variable, not very 
helpful
5 Dacryops Homogenous Homogenous Minimal, 
homogenous
Cyst with fluid density on 
contrast enhanced CTIso-/hyperintense Hypo-/isointense
a Gd-DTPA, gadolinium-diethylenetriaminepentaacetic acid
Table 10.7 MRI features of cystic orbital lesions (appearance and signal with respect to vitreous)
Orbital lesions T1-weighted image T2-weighted image
Enhancement with 
Gd-DTPAa Comments
1 Dermoid cyst Heterogenous Heterogenous Homogenous Perilesional 
inflammation if 
ruptured; bone 
remodeling on CT 
occasionally
Hypointense Hypo-/hyperintense +++




colobomatous cystIso-/hyperintense Iso-/hypointense Heterogenous 
(large)
+++
3 Hydatid cyst Homogenous Homogenous Homo-/
heterogenous
Multiple cysts, may be 
calcifiedIsointense Isointense
4 Mucocele Homo-/heterogenous Homo-/heterogenous Homogenous High protein content; 




5 Lymphangioma Heterogenous Heterogenous Minimal, 
homogenous




Heterogenous Heterogenous Heterogenous Fat suppression
Hyperintense Hyperintense Central hyper, 
rim hypointense
Remains high signal
a Gd-DTPA, gadolinium-diethylenetriaminepentaacetic acid
erative data availability have led to less inva-
sive approaches such as anterior orbitotomies 
through conjunctival and skin incisions, rather 
than wider lateral approaches where the loca-
tion is less well understood preoperatively 
[33–36].
 Summary
As in any medical diagnostic process, the data 
obtained in the assessment is assembled into a 
plan for the patient. The history will guide the 
examination, and the findings will in turn guide 
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the selection of ancillary procedures and often 
imaging. Often the differential diagnosis at this 
point can be narrow, and reasonably so. Based 
on the requirements of differentiating these diag-
nostic possibilities and their respective treatment 
modalities, a management plan is selected. It is 
often the case in orbital disease that a tissue sam-
ple would be required, and the critical decision 
will be related to whether this tissue sample is 
obtained in fine needle aspirate, open incisional 
biopsy, excisional biopsy, or en bloc resection. 
This decision will be based on the characteristics 
of the lesion, the considerations for diagnosis and 
treatment beyond, as well as the wishes of the 
patient and the capabilities of the treating team.
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Surgical Techniques for Orbital 
Tumors
Zeynel A. Karcioglu
 Anesthesia in Orbital Tumor Patient
Many mid and deep orbital surgeries in adults and 
virtually all procedures in children are performed 
under general anesthesia; however, anterior orbit 
explorations and/or simple biopsies in adults can 
be performed with local anesthesia and intrave-
nous sedation [1].
The administration of regional anesthetics, 
even when general anesthesia is used, containing 
epinephrine about 5–15 min prior to incision into 
the soft tissues of the surgical field contributes 
to vasoconstriction significantly. If nasal or sinus 
involvement is anticipated during the orbital 
exploration, it may be helpful to use a vasocon-
strictive nasal spray and pack the nose with half- 
inch gauze-strip, soaked in Neosynephrine or 
another vasoconstrictive agent [2].
All local anesthetic solutions are prepared 
as weak hydrochloride salts to extend their 
shelf lives and to stabilize added vasoconstric-
tors. However, this weak acid assembly delays 
their onset of action and makes them painful 
on injection. Lidocaine (1% or 2%) is the most 
widely used local anesthetic and produces the 
least amount of pain on injection. Anesthetics 
commonly utilized can be generally ordered on 
a scale from least to most painful for injection: 
lidocaine 1%, procaine 2%, bupivacaine 0.5%, 
and etidocaine 1%. Pain during injection varies 
with pH of solution, osmolality, lipid solubility, 
temperature, the speed of injection, size of nee-
dle, as well as other environmental and emotional 
patient-related factors [3, 4].
Addition of epinephrine (1:100,000, 1:200,000, 
1:400,000) for vasoconstriction decreases the 
absorption rate, prolongs the action, but increases 
the pain of local anesthetics at injection. At the 
incision site, lidocaine with epinephrine is usually 
injected subcutaneously into deeper soft tissues. 
The use of a long-acting local anesthetic, adminis-
tration of an IV steroid to minimize inflammation 
and utilization of a nonsteroidal anti-inflamma-
tory drug on a regular basis will minimize the 
need for postoperative opioids, and this works 
well in ASA I and II patients.
The effect of local anesthetics begins approxi-
mately 5 and 4  min after injection without and 
with epinephrine respectively. The duration 
of the effect ranges from 1 to 2  h. The maxi-
mum recommended dose is 4.4  mg/kg without 
epinephrine and 7.0  mg/kg with epinephrine. 
Lidocaine, like all other local anesthetics, may 
lead to systemic toxicity with increased BP and 
heart rate, arrhythmias, dysrhythmias, and CNS 
signs and symptoms of drowsiness, seizures, and 
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headaches. In patients who use nonselective beta 
blocker (Β1, Β2), the administration of a vaso-
constrictor will act solely at the a1 site, producing 
vasoconstriction. Epinephrine may not be used 
with patients who are on tricyclic antidepressants 
or MAO inhibitors. On the other hand, patients 
who are on the newer SSRIs such as Prozac may 
be given epinephrine.
Small doses of local anesthetics injected into 
the orbit and periorbital tissues may rarely pro-
duce serious adverse reactions similar to systemic 
toxicity such as confusion, convulsions, respira-
tory arrest, and cardiovascular changes. These 
reactions may be due to unintended intra- arterial 
injection of the local anesthetic with retrograde 
flow to the cerebral circulation. Patients receiving 
these blocks should be under constant observa-
tion. Resuscitative equipment and personnel for 
treating adverse reactions should be immediately 
available [5, 6].
 General Surgical Principles 
in Orbital Tumor Patient
The details of the lesions in individual compart-
ments of the orbit should be ascertained together 
with the below listed general concepts of orbital 
surgery. The anatomic distributions of tumors in 
orbital compartments are not perfectly defined; 
however some lesions do have a tendency toward 
one region or another. These include, in the upper-
outer quadrant (lacrimal gland fossa), dermoid 
cyst, lacrimal gland tumors, and lymphoma; in the 
upper-inner quadrant (lacrimal gland fossa), der-
moid cyst, lacrimal gland tumors, and lymphoma; 
in the upper-inner quadrant, commonly mucocele; 
in the inferior orbit, basal cell carcinoma medi-
ally, and inflammatory or squamous lesions from 
perinasal sinuses centrally; in the lateral and pos-
terior orbit, commonly cavernous malformations 
and nonspecific inflammatory disease; and, in the 
posterior and apical orbit, meningioma, cavernous 
malformations, Schwannoma, and inflammatory 
lesions (Tables 11.1 and 11.2). Understanding these 
tendencies may assist in planning the approach, as 
well as in preparing for the gross appearance of the 
lesion and the tactile characteristics of the capsule 
and/or internal contents of the mass.
The best position for orbital surgery is reverse 
Trendelenburg, which reduces arterial flow to the 
orbit and promoted venous return to the heart. 
The head should be positioned according to the 
planned orbitotomy. It is best to prep both sides 
allowing intra-operative comparison to oppo-
site orbit for assessment of symmetry. If tissue 
harvesting from other sites (thigh, retro auricu-
lar area, fellow eyelid, etc.) will be performed, 
graft sites should also be prepared and covered 
with sterile towels. If the use of a microscope or 
endoscope is planned, the OR team and anesthe-
siologist should be notified beforehand. Refer to 
Fig. 11.1 for an example of hand-held instrument 
tray for common orbital surgeries.
 Incisions
Skin incisions of the eyelids and the periorbital 
area should ideally follow the relaxed skin ten-
sion lines (RSTLs) and are best placed in natural 
creases or other hidden locations such as the con-
junctival fornix or the eyelid caruncle (Fig. 11.2) 
[7]. Prior to injection with local anesthetics, the 
incision line should be marked with a surgical 
pen. The skin incisions can be made with a Bard- 
Parker 15-C or a 3  mm, 30° sharp, disposable 
blade (e.g., Super Blade®). Ideally, the incision 
should cut only the skin, not the underlying sub-
cutaneous tissues, as dissection can carry forward 
in a stepwise, layer-by-layer manner. In general, 
the skin incisions are made perpendicular to the 
skin surface; however, if an eyebrow incision is 
needed, the incision may be made at a 45° angle 
following the angulation of the hair follicles in a 
beveled manner to allow for hair growth through 
the incision after healing.
The lazy-S incision, starting in the mid-eye-
lid crease is particularly useful to gain access 
to superior and lateral orbital space. Other sur-
geons convincingly claim that the transconjunc-
tival inferior approach provides quicker surgical 
access to the intraconal zone with a low incidence 
of complications and a better aesthetic outcome 
than lateral orbitotomy. (Personal communica-
tion with Dr. Santosh Hanovar, ISOO Meeting 
2019). Conjunctival incisions allow direct admis-
sion to the primarily inferior compartments of the 
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Table 11.1 Space-occupying lesions of the orbit in anatomical compartments
Location of commonly 
encountered lesions Proptosis Associated findings Surgical approach
Benign lacrimal fossa lesions 
(pleomorphic adenoma, cysts 
such as dermoid)
Inferior/nasal Choroidal folds; 
disproportionally preserved 
EOM to lesion size
Lacrimal gland fossa 
exposure through 
lid-crease or brow 
incision
Malignant lacrimal fossa 
lesions (adenocarcinoma, 
adenoid cystic carcinoma)
Inferior/nasal Pain; sensory deficit; poor 
motility; lymphadenopathy
Same approach may need 
to expand superiorly or 
laterally depending on 
the extent of tumor
Superior/inferior medial 
lesions (cysts such as dermoid, 
mucocele, LDS tumors, SCC 
from ethmoid cells)
Inferior/temporal Usually w/o choroidal 
folds; associated trauma, 
sinusitis, pain; horizontal 





Anterior lesions (lymphoma, 
cysts like dermoid, epithelial)
Mild proptosis away 
from the site of lesion
Lid/conjunctival 
involvement
Anterior orbit exposure 
according to the location 
of lesion
Benign muscle cone lesions 
(cavernous malformation, 
schwannoma)
Axial Posterior choroidal folds; 
vein congestion; early disk 
edema; optic nerve 
dysfunction
Lateral orbitotomy
Extraconal and intraconal 
lesions (vascular hamartomas; 
rhabdomyosarcoma)
Massive without rule Lid/conjunctival 
involvement; optic nerve 
dysfunction w or w/o disc 
edema; amblyopia
Lateral orbitotomy 
modified according to the 
location and size of 
lesion







Abnormal motility in all 
gazes; ON dysfunction, 
lymph nodes
Location oriented 
approach; core needle 
biopsy or FNAB or 
FACT
Inferior lesions (SCC from 
maxillary sinus, inflammatory 
lesions)
Superior/axial Pain and/or sensory deficit 
in lower periorbital area; 
motility dysfunction
Inferior trans- 
conjunctival or subciliary 
skin approach w or w/o 
lateral crus incision 
(“swinging lid”)
Posterior orbit, apical lesions 
(meningioma, glioma, 
paraganglioma)
Minimal axial, late 
proptosis
Optic nerve dysfunction; 
mild axial proptosis
Lateral orbitotomy; deep 
transorbital approach
Entire orbit such as solid/
cystic teratoma
Massive proptosis Distortion of orbital 
anatomy; axial 
displacement of globe with 
marked chemosis
Usually requires 
exenteration; globe may 
be saved in rare cases




























Tolosa hunt HLA B27 related Behçet’s disease Psoriatic
Allergic 
Aspergillosis
Diffuse IgG4-related Kimura’s disease Scleroderma
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orbit with minimal external scaring. The addition 
of a lateral inferior cantholysis, converting to a 
swinging eyelid incision, can enhance access to 
the lateral orbit and midface. Any quadrant of the 
orbit can be approached through a segmental con-
junctival peritomy overlying the area. The intra-
conal space may easily be approached through 
perilimbal incisions through the sub-Tenon’s 
space. For the extraconal space one should use 
forniceal incisions, which are particularly useful 
medially and inferiorly [8].
The medial conjunctival approach (through 
the caruncle) allows ample access to the eth-
moid/medial wall area of the orbit. Furthermore, 
the caruncular incision provides excellent access 
to the medial and posterior orbit [9, 10]. These 
conjunctival incisions can be combined to allow 
for an extended orbital exposure of the floor and 
medial wall.
The most commonly used medial and superior 
medial skin incisions include modifications of 
the Lynch approach and the sub-brow incision. 
Although the classic Lynch incision can leave 
visible scarring, it may be quite advantageous 
in some cases to provide access to the lacrimal 
drainage system (LDS), the ethmoid sinuses, and 
the nasal cavity.
Fig. 11.1 A typical tray containing commonly used hand-held instruments for orbital tumor surgery. Rarely utilized instru-
ments such as rongeurs, Kerrison punch, mallet, chisel, and gouge are not included. Larger surgical apparatus like recipro-
cating saw, rotary drill, Bovie and bipolar cauterizes, cryo instruments and tips, and dermatomes are not depicted as well
Fig. 11.2 Skin and conjunctival incisions for orbit surgery. 
The dotted white circle roughly corresponds to the bony 
margin of the orbit. Black: sub-brow incision in continuity 
with lynch incision; orange: lid. Crease incision; purple: 
caruncular incision; red: lateral canthal incision; Blue: sub-
ciliary incision; green: lateral crus incision (“swinging”), 
“Lid incision”; turquoise: lower lid incision; yellow: peril-
imbal incision; Pink: lazy-s incision within the lid crease of 
upper lid. (From Karcioglu [29], with permission)
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Superior and superior lateral fornix incisions 
are not ordinarily used, to avoid traumatizing the 
palpebral portion of the lacrimal gland and the 
ductules.
Innovative techniques to enhance the surgi-
cal exposure of the posterior orbit and apex have 
been proposed by many plastic and craniofacial 
surgeons and neurosurgeons [11, 12]. However, 
most of these approaches require elaborate pro-
cedures and experienced surgical teams and 
should not be attempted in ordinary ophthalmic 
surgery settings.
Bone incisions (osteotomies) may offer cer-
tain advantages but again these techniques are 
rarely needed to be utilized for orbital biopsy 
and only in experienced hands. In orbital tumor 
surgery, the bone is removed for two main rea-
sons: first, the removal of the marginal bone to 
provide a wider surgical field, such as in lateral 
orbitotomy. Secondly, the bone may need to be 
removed to control a malignancy advancing into 
the bone, such as adenoid cystic carcinoma of the 
lacrimal gland.
 Surgical Field
During orbital exploration, magnification and 
lighting are very important. A great majority of 
cases can be done under 3- to 5-power surgi-
cal loupes. A headlight combined with surgical 
loupes provides the best illumination.
 Exposure for Exploration
The orbit is a small anatomical chamber crowded 
with vital tissues that are suspended within a sep-
tal network that compartmentalizes the orbital 
structures and orbital fat. It may be quite inhos-
pitable to the surgeon particularly when the addi-
tional volume is added to this tight space by a 
tumor and secondary edema.
From whatever direction, the orbital 
exploration commits the surgeon to a deep, 
three- dimensional field with poor visibility. 
Furthermore, changes in the anatomic relation-
ships between structures because of the orbit’s 
conal shape add to the difficulty of the pursuit of 
the tumor. Therefore, adequate exposure of the 
surgical field is of utmost importance. The opti-
mization of the exposure begins with the proper 
selection of initial incision and is maintained 
with precise positioning of the surgical retractors 
and placement of traction sutures. Continuous 
maneuvering employed during orbital explora-
tion to gain ideal exposure often takes more time 
than the actual biopsy or removal of the tumor.
Proper placement of the patient’s head, posi-
tioning of the surgeon and assistants, as well as 
optimum lighting and magnification are the key 
elements of success in orbital surgery. Patience 
is an important virtue in orbital dissection, to 
maintain a bloodless surgical field and adequate 
exposure of the pathology and the surrounding 
structures. Because of unanticipated shifting 
of the orbital fat, the surgeon should be famil-
iar with continuous interruptions of the visibil-
ity. The fat can be retracted from the field and 
often the use of small neurosurgical patties keeps 
the retracted fat under control; however, the fat 
moves like water and small variations in posi-
tion are translated into great perturbations in 
visualization. All surgical maneuvers should be 
done with minimum trauma, typically with blunt 
rather than sharp dissection.
Most of the retraction requirements through-
out the procedure are accomplished with the use 
of hand-held retractors. A wide range of retrac-
tors, including Desmarres, Semm, Ragnell, and 
malleable ribbon retractors (3/8–1 in. width), are 
used. In addition, rakes (Peck or Follet), muscle 
hooks (Graf or Jameson), and skin hooks (Joseph 
or Freer) function well for different levels of tis-
sue retraction (Fig. 11.1).
Another method of improving the surgical 
visibility is to utilize sutures to pull tissues away 
from the field. One common application is to use 
4–0 silk for eyelid retraction. It is also advisable to 
pass a marking suture under the extraocular mus-
cles (EOM) to ensure that they can be identified 
during the later stages of the procedure. In partic-
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ular, medial and inferior recti muscles should be 
anchored with sutures during orbital explorations 
of corresponding sites. Traction sutures may also 
be applied to the stumps of  disinserted EOMs. A 
good example is the capture of the stump of the 
medial rectus during medial orbitotomy through 
the conjunctival approach. It is best to run a 5-0 
Vicryl or Mersilene suture at the stump of the 
medial rectus muscle and cuff both ends of the 
suture with silicone tubing to avoid corneal and 
conjunctival damage during retraction of the 
globe (Fig. 11.3) (also see Videos 11.1 and 11.2).
Sutures may also be used to retract bone. For 
example, the zygomatic arch is attached to the 
temporalis fascia/muscle can be hinged laterally 
and posteriorly by traction sutures passed through 
pre-drilled holes in the bone. With this approach, 
the closure is quicker and the arch fits in its origi-
nal position well, healing better and faster.
At all times, the orbital surgeon should main-
tain a mental correlation between the imaging of 
the lesion and its actual position within the orbit 
and should approach the lesion through appropri-
ate planes of tissue. The importance of the defi-
nition of the plane of entry is aptly emphasized 
by Rootman, Stewart, and Goldberg: “Instead of 
entering directly into the pathologically involved 
tissue planes, the surgeon should begin the dis-
section in the more easily distracted and pliable 
normal tissues adjacent to the lesion” [13].
This approach allows the distinct advantage of 
comparing the normal tissues and the abnormal 
areas in order to permit the ready identification 
of the pathology.
 Hemostasis
In case of bleeding the first thing to do is to deter-
mine if the hemorrhage experienced in the surgi-
cal field is due to a damaged blood vessel or to 
generalized oozing of blood. This can usually be 
accomplished by alternating suction and gentle 
pressure over a neurosurgical patty. Usually, a 
negligible amount of time allows vasoconstric-
tion and subsequent clotting to occur in most 
cases of small unnamed vessels.
If brisk bleeding is experienced, the culprit 
blood vessel should be identified, isolated, and 
cauterized with an insulated bipolar cautery. If 
the bleeding is due to generalized oozing, it is 
beneficial to apply thrombin-soaked Gelfoam™ 
or surgical cottonoids. Neurosurgical cotton pad-
dies are preferable because they are easier to 
identify and remove once the oozing has stopped. 
Powdered Avitene® can also be packed into the 
surgical field or delivered by syringe in cases with 
persistent oozing; Avitene® should be irrigated 
gently at the end of the procedure (Fig. 11.4).
As mentioned earlier, hemostasis should be 
initiated by hypotensive anesthesia, as well as 
by injection of epinephrine-containing local 
Fig. 11.3 Silicone tubing cuffed over traction suture to 
protect underlying cornea and conjunctiva during the 
course of medial orbitotomy. (From Karcioglu [29], with 
permission)
Fig. 11.4 Application of Avitene® to control oozing 




anesthetics. Intraoperative bleeding can be con-
trolled with bipolar or unipolar coagulators; 
the fine- needle tip (Colorado tip®) is preferred. 
Furthermore, vascular ties, clips, and chemi-
cal adjuncts can be used to maintain hemostasis 
(Table 11.3).
 Orbital Biopsy
Orbital biopsy is a very important procedure, 
and in fact more than half of tumor-related sur-
geries are performed just to obtain an adequate 
tissue sample for diagnosis and management. 
Different biopsy techniques, including FNAB, 
core biopsy, and excisional biopsy, are utilized 
depending on the need of the patient [14]. Many 
papers have been written on biopsy procedures, 
tissue processing techniques, and benefits of 
special studies. The reader is referred to these 
references for detailed information. One impera-
tive requisite for the surgeon is to contact the 
pathologist prior to surgery and inquire about 
specific processing requirements and the capa-
bilities of the laboratory.
 Tissue Removal/Ablation
In all quadrants of the orbit, once the sufficient 
exposure of well-delineated masses (and cysts) 
is accomplished the lesion is stabilized with for-
ceps, cryoprobe, and/or sutures to be removed. 
This allows the surgeon to apply gentle traction 
while dissecting the surrounding tissue attach-
ments to the lesion (Fig. 11.5).
The lesions of the anterior orbit are sur-
gically approached directly over the lesion. 
About 80% of the mid and posterior orbital 
pathologies can be easily accessed surgically 
with time-honored techniques of lateral and 
conjunctival medial (caruncular) orbitotomies 
(Table  11.1 and Videos 11.1 and 11.2). Only 
the rare tumors in unusual locations in the orbit 
require special surgical methods including 
combined craniotomies which are not covered 
in this chapter.
Although the classical lateral orbitotomy 
approach with retraction or removal of the zygo-
matic arch is useful in many cases, benign orbital 
tumors of the intraconal space may be removed 
effectively through medial transconjunctival and 
superomedial lid crease incisions even with local 
anesthesia. According to some surgeons, this 
approach has a number of advantages over the 
lateral orbitotomy, including ease of dissection, 
incision-to nerve distance, and angle of approach 
to the optic nerve [1, 15, 16].
Table 11.3 Hemostasis in orbital surgery
Pre-surgical
Reverse Trendelenburg position on the operating table
Hypotensive general anesthesia
Application or injection of chemical vasoconstrictors 
(epinephrine, cocaine, etc.)
Surgical
Application of strip gauze and/or neurosurgical 
paddies soaked with chemical vasoconstrictors and/or 
coagulators (Avitene®)
Thrombin-soaked gelatin sponge (Gelfoam®)
Oxidized regenerated cellulose (Surgicel®)
Bone wax for oozing in osteotomies
Cautery application (bipolar, unipolar, fine-tipped 
disposable)
Pressure by hand or hand-held instruments
Post-surgical
Gentle extubation at the end of the procedure without 
“bucking”
Application of pressure bandage over the orbit with 
head bandage with gauze
Immediate application of crushed ice on orbit in OR in 
plastic bag or surgical glove
Application of ice for 24–48 h after surgery
Fig. 11.5 Cryoprobe attached to tumor, is being used as 
a handle during extraction of tumor. (From Karcioglu 
[29], with permission)
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Unlike well-encapsulated tumors, infiltrating 
lesions cannot be removed totally but can only 
be removed in a piecemeal fashion for diagnos-
tic or debulking purposes. Partial removals can 
be accomplished by isolating areas of the tumor 
and excising sections that are not infiltrating vital 
structures.
Well encapsulated lesions can often be 
removed completely. Most small and medium 
size cysts are best dissected with an intact cap-
sule, although it may be advisable in very large 
cysts to deflate the cystic structure for removal. In 
certain space-occupying lesions of the orbit, such 
as pleomorphic adenoma of the lacrimal gland, 
hemangiopericytoma, and echinoccocal cysts, it 
would be compulsory to remove the lesion within 
its capsule to avoid seeding into the surgical field.
Innovative surgical techniques for the manage-
ment of orbital mass lesions have been expanding in 
the literature. Such methods include direct emboli-
zation techniques via the superior ophthalmic vein 
for cavernous sinus-dural fistulas, image-guided 
orbital surgery, endoscopic orbitotomy, and percu-
taneous sclerotherapy [17–22]. These techniques 
can be extremely useful in specific situations, and 
however may require specific material and techni-
cal capacities that can be institution dependent.
 Complications of Orbit Surgery
 Intraoperative Complications
The most serious complication during surgery is 
the unintentional laceration of a vital structure 
such as a peripheral nerve, muscle, blood vessel, 
the optic nerve, or the globe. Although this kind 
of injury is rare, the damage should be repaired 
before the procedure is continued. Scleral lacera-
tions are exceedingly rare and should be treated 
as an open globe repair. Optic nerve damage may 
not appear immediately and can be related to vas-
cular occlusion or vasospasm. Vascular lacera-
tions are difficult if not impossible to restore with 
an end-to-end anastomosis because of the small 
size of the orbital blood vessels and the difficulty 
in locating the severed ends. If a major peripheral 
nerve is cut accidentally, it is ideal to anastomose 
the nerve under high magnification (preferably 
with the microscope) with 9-0 nylon suture from 
perineurium to perineurium after the cut ends of 
the nerve have been aligned. If anastomosis is 
not possible, the nerve edges should be approxi-
mated to facilitate healing. Tissue glue is another 
option if available. If an extraocular muscle is cut 
or damaged inadvertently, it should be approxi-
mated and sutured with a 6-0 Vicryl suture.
Lacerations to the nasolacrimal drainage sys-
tem may also lead to postoperative problems. 
Here as well every attempt should be made to 
repair the laceration, and canalicular silicone 
stent should be placed in a position to maintain 
the patency of the LDS. If the damage is limited 
at the canaliculus level, both ends of the cut cana-
liculus should be aligned and repaired with fine 
sutures under the operating microscope. If the 
damage is serious, at the lacrimal sac or nasolac-
rimal duct level, and judged to be irreparable, a 
DCR may be the choice of treatment at the end of 
the orbital exploration or at a later date.
If dural laceration is suspected during sur-
gery, it should be identified to rule out CSF leak. 
Although small lacerations can be repaired with 
direct suturing, the visualization is usually not 
good enough to allow this procedure. The best way 
to repair the dural rents is to apply free grafts from 
temporalis fascia or muscle, which can be applied 
with or without tissue adhesives. For small leaks, 
orbital fat may be sufficient to plug the leak. If 
the CSF leak cannot be controlled, neurosurgical 
consultation should be sought intraoperatively. A 
lumbar puncture may be of some help to reduce 
the CSF pressure and thereby allow the surgeon 
to control the leak better [23].
Intraoperative hemorrhage due to vascu-
lar laceration or generalized oozing is the most 
challenging part of orbital surgery, as it inter-
feres with direct visualization. Therefore, intra-
operative bleeding during orbit surgery should 
be addressed methodically until hemostasis is 
regained. The first objective is the identification 
of the bleeding source. Alternating suction and 
pressure by hand may accomplish this. If any 
obvious bleeding from blood vessels is detected, 
these can be cauterized or tied off. If no direct 
source can be seen, generalized pressure with 
epinephrine-soaked gauze or thrombin-soaked 
Gelfoam can be applied with gentle pressure. 
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Bleeding from the bone may be controlled with 
unipolar cautery. If this is not successful, bone 
wax may be applied. Excess bone wax should be 
carefully removed as it can lead to postoperative 
foreign body reaction [24].
 Postoperative Complications
 Emergent Postoperative Complications
One of the most serious complications in orbital 
surgery is a unilateral or (rarely bilateral) orbital 
hemorrhage leading to compartment syndrome 
and visual loss. The orbit is a small, non- expansile 
space, and an expanding hematoma can create a 
compartment syndrome, which is a potentially 
vision-threatening condition. The use of orbital 
drains is somewhat controversial, and their effect 
in preventing orbital compartment syndrome is 
not well established (Fig. 11.6).
Generous application of ice and elevation of 
the head of the bed during the first 24–48 h of the 
postoperative period may reduce the likelihood 
of orbital bleeding and can assist with swell-
ing. However, postoperative hemorrhage may 
occur even in patients treated in this way, who 
do not have risk factors such as hypertension or 
hypocoagulability.
Physician’s orders should be clearly written 
to alert the nursing staff to recognize symptoms 
of acute postoperative hemorrhage, including 
loss of vision, pain, and rapidly increasing pro-
ptosis. Small postoperative hematomas that pro-
duce some proptosis and chemosis but no pain or 
afferent pupillary defect can be observed under 
conservative treatment. If a large postoperative 
hematoma is suspected, the eye should be exam-
ined immediately by checking the visual acuity, 
intraocular pressure, and pupillary light reflex. If 
the patient complains of visual loss in the pres-
ence of rapidly developing painful proptosis, 
one should check the intraocular pressure, which 
correlates with orbital pressure in the acute set-
ting [25]. Even when the imaging studies do not 
reveal obvious nerve compression but the clini-
cal symptoms suggest an acute increase in intra-
orbital pressure, the patient should be managed 
urgently.
Acute increase in orbital pressure is an emer-
gency. In case of suspicion of a postoperative 
bleed in a patient with a drain in place, adjust-
ment and/or irrigation of the drain should be tried 
before surgical intervention. If the high pressure 
persists, it should be relieved surgically. Opening 
the surgical wound may be effective as an egress 
point for the hemorrhage. However, the simplest 
and the most effective way of relieving the orbital 
pressure is by performing a lateral canthotomy 
and cantholysis [26]. This should be performed 
without delay based on clinical findings [27].
Catholysis splits the lateral canthal tendon 
in parallel and allows for access to the supe-
rior and inferior crus of the tendon, it does not 
relieve pressure in itself. In cantholysis pro-
cedure, the orbital volume expansion is best 
accomplished with the lysis of the inferior 
crus of the lateral canthal tendon. This should 
include generous portions of the inferior reti-
naculum, essentially 90° of the orbital rim. If 
the pressure is not relieved, the superior crus 
can be cut in the same fashion. When the can-
thotomy is done, the lids may not cover the cor-
nea which should be protected with ointment, 
collagen shield, bandage contact lens, or light 
patching. If the increased orbital pressure can-
not be relieved, the patient should be taken back 
to the operating room so that the wound can be 
opened to evacuate the blood. If active bleed-
ing is observed, hemostasis should be accom-
plished and new drains should be placed before 
re-closure. The addition of mannitol and acet-
azolamide can be considered to lower the intra-
ocular pressure as well.
Fig. 11.6 Hemovac™ drain in position one day after sur-
gery. (From Karcioglu [29], with permission)
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 Non-emergent Postoperative 
Complications
Excessive traction or blind dissection of the 
orbital tissues may damage the nerves, causing 
postoperative sensory and motor complications. 
In one study, the greatest incidence of complica-
tions was recorded in lateral orbitotomies (35%). 
Complications of lateral orbitotomy included 
extraocular motility problems, particularly 
abduction deficit (17.5%), and loss of pupillary 
reflex (10%). The majority of complications were 
associated with the lateral surgical approach to 
excise an intraconal mass and tumor type did not 
appear to be a factor. Ptosis may also be a prob-
lem following lateral and superior orbitotomy, 
typically resolving in weeks to months. However, 
damage to the superior division of the III CN 
and injury in the orbital apex can also produce 
long- term ptosis [28]. Anterior orbitotomy, not 
surprisingly, had much lower incidence of com-
plications in only 3% of surgeries reported.
Dissection in the lateral orbit may injure the 
ciliary ganglion, particularly after removal of 
intraconal lesions, and the patient may develop 
dilated, nonreactive pupil postoperatively. This 
may take up to 6  months to resolve, or can be 
permanent. In superior medial orbitotomy, if 
the trochlea is injured, the patient may develop 
acquired Brown’s syndrome postoperatively. 
This usually resolves spontaneously. In superior 
lateral orbitotomy, the lacrimal gland or its con-
necting ductules may be damaged, potentially 
resulting in dry eye. This is usually a permanent 
problem and should be managed with artificial 
tears, ointments, and punctal plugs.
Another long-term complication in any surgi-
cal procedure is scar formation, which in general 
can be minimized with strict attention to precise 
surgical technique. The surgical approach for 
orbital tumor biopsies is usually well planned 
and accomplished with relatively small skin inci-
sions. Therefore, scars are seen less often after 
orbital tumor surgery than following treatment 
for other orbital problems, such as trauma and 
inflammation.
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Enucleation and exenteration for the manage-
ment of intraocular and orbital malignancies, 
respectively, was the standard treatment of care 
before the advent of radiotherapy and chemo-
therapy. Over the past few decades, enhanced 
knowledge on the biology of the tumors, 
advances in the histopathologic and cytological 
techniques, use of various diagnostic modali-
ties for an early and a more precise diagnosis, 
implementation of protocol-based management, 
and use of multimodal treatment including che-
motherapy, radiotherapy, immunotherapy, and 
conservative surgeries, have greatly contributed 
to the reduction in the need for enucleation and 
exenteration. This paradigm shift toward less 
radical treatment has brought about a refine-
ment in the absolute indications for enucleation 
and exenteration.
 Overview and Indications 
of Enucleation
Enucleation is defined as the removal of the eye-
ball while preserving the rest of the orbital tissues, 
including the extraocular muscles. Following 
enucleation, the aim is to achieve a good cos-
mesis by placing a prosthesis which matches 
the contralateral eye. A well-planned surgical 
technique with adequate volume replacement 
provides gratifying static and dynamic cosme-
sis. The characteristics of an ideal anophthalmic 
socket include a centrally placed well-covered 
implant of adequate volume, a socket lined with 
healthy conjunctiva, deep fornices to help retain 
the prosthesis, normal eyelid position with sym-
metric lid crease, and good implant motility 
which is transmitted to the overlying prosthesis.
In oncology practice, enucleation is routinely 
performed for the management of malignant 
intraocular tumors with an aim for complete 
tumor control [1–12]. To achieve this end, it 
sometimes entails the removal of an additional 
and adequate length of the optic nerve, excision 
of any adherent conjunctiva and tenon’s fascia to 
the underlying tumor, or sacrificing a part of the 
orbital tissue, and this is termed as extended enu-
cleation. Over the past few decades, advances in 
chemotherapy and radiotherapy have led to eye- 
salvaging treatment options for intraocular 
tumors, and the indications for enucleation have 
thus become specific [9, 10, 13–15].
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Enucleation continues to play a major role in 
the management of retinoblastoma and uveal 
melanoma (Table  12.1). In retinoblastoma, 
indications for primary enucleation include 
advanced unilateral retinoblastoma without sal-
vageable vision (group E of international clas-
sification of retinoblastoma [ICRB]), unilateral 
retinoblastoma with diffuse anterior chamber 
involvement, unilateral retinoblastoma with 
total vitreous hemorrhage, unilateral retino-
blastoma with accompanying neovascular glau-
coma, and retinoblastoma with a phthisical eye 
[1–3]. Secondary enucleation is performed for 
recurrent retinal tumor not controlled with cur-
rent treatment modalities, vitreous seeds or 
subretinal seeds with suboptimal response to 
chemotherapy and/or radiotherapy, eyes with 
opaque media (total hyphema or dense vitreous 
hemorrhage) after an initial failed response to 
chemotherapy and/or radiotherapy, and as a 
part of the treatment protocol in orbital retino-
blastoma [2–4].
Enucleation for ciliochoroidal melanoma as a 
primary treatment is indicated in very large 
tumors (>18  mm in diameter and >10  mm in 
thickness) which are not amenable to plaque 
radiotherapy (Table 12.1) [5, 6]. Choroidal mela-
nomas with optic nerve invasion are also an indi-
cation for enucleation [7]. Enucleation may be 
necessary in recurrent posterior melanoma, 
which has not responded favorably to radiation 
treatment [5, 6]. Extraocular extension of mela-
noma also warrants enucleation, although there 
has been a recent trend to manage such cases by 
plaque brachytherapy where the size of the extra-
ocular extension is less than 3  mm [8, 9]. 
Ciliochoroidal melanomas presenting with dense 
vitreous hemorrhage, or as a painful blind eye 
due to extensive necrosis or secondary glaucoma, 
are other indications for enucleation [5, 6].
Enucleation in iris melanoma is generally 
reserved for tumors which have progressed to a 
size where surgery or radiotherapy is not feasible 
(Table 12.1) [10, 11]. These include eyes where 
Table 12.1 Indications for enucleation
Tumor Primary Secondary
Retinoblastoma Advanced unilateral retinoblastoma 
without salvageable vision




Unilateral retinoblastoma with 
accompanying neovascular 
glaucoma
Retinoblastoma with a phthisical eye
Recurrent retinal tumor, vitreous seeds or subretinal 
seeds with suboptimal response to chemotherapy and/
or radiotherapy
Eyes with opaque media (total hyphema or dense 
vitreous hemorrhage) after an initial failed response to 
chemotherapy and/or radiotherapy




Very large tumors (>18 mm in 
diameter and >10 mm in thickness)
Optic nerve invasion
Extraocular extension of melanoma 
more than 3 mm in size
Dense vitreous hemorrhage
Painful blind eye secondary to 
extensive necrosis or secondary 
glaucoma
Recurrent posterior melanoma, which has not 
responded favorably to radiation
Iris melanoma Tumor involving all iris quadrants
Eyes with uncontrolled secondary 
glaucoma with angle seeding
Eye with large extrascleral extension
Recurrent iris melanoma, which has not responded 
favorably to radiation
Others Large medulloepithelioma
Intraocular extension of conjunctival 
squamous cell carcinoma
Blind painful eyes harboring large 
benign or malignant intraocular 
tumors
Recurrent tumors, which has not responded favorably 
to other conservative treatment
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the tumor involves all iris quadrants, eyes with 
uncontrolled secondary glaucoma with angle 
seeding, or in the presence of extrascleral exten-
sion [10, 11]. In a long-term analysis of 144 
patients with iris melanoma treated by plaque 
radiotherapy, Shields et al. noted that glaucoma 
was present at the initial visit in 40% of cases, 
and by Kaplan-Meier estimate at 7 years, enucle-
ation was necessary in 12% [11].
Enucleation is sometimes necessary in other 
conditions including medulloepithelioma, intraoc-
ular extension of conjunctival squamous cell carci-
noma, and blind painful eyes harboring large 
benign or malignant intraocular tumors (Table 12.1) 
[7, 12]. In a two-institutional study of 41 eyes with 
medulloepithelioma, 26 eyes (63%) required enu-
cleation, and it was mainly indicated in larger 
tumors (n = 21), and in smaller tumors that failed to 
respond to conservative treatment (n = 5) [12].
 Overview and Indications 
of Exenteration
Orbital exenteration is the surgical removal 
of the orbital contents, including the eyeball. 
Exenteration is performed as a life-saving mea-
sure for primary or secondary orbital malignan-
cies where conservative treatment has failed or is 
not feasible. Exenteration maybe sub-total, total, 
extended, or radical exenteration depending on 
the amount of orbital contents excised. Subtotal 
exenteration entails removal of only the anterior 
orbital tissue. In total exenteration, the orbital 
contents are removed in their entirety. In extended 
exenteration, removal of orbital bones is also per-
formed. In radical exenteration, adjacent struc-
tures like the paranasal sinuses are also sacrificed.
Exenteration is generally considered to be a 
radical procedure that should be performed only 
when there is a valid indication (Table 12.2) [16–
20]. It is indicated in advanced primary orbital 
malignancies, eyelid tumors with orbital exten-
sion, conjunctival tumors with orbital extension, 
and intraocular tumors with orbital extension. 
Rarely, it may even be indicated in advanced 
benign tumors like neurofibromatosis or arterio-
venous malformation with orbital deformity [19].
 Preoperative Evaluation
Preoperative evaluation of a patient with an 
ocular tumor includes documentation of symp-
toms, vision, pressure, slit lamp findings, and 
fundus findings. Additionally, transillumina-
tion test is performed for a suspected ciliary 
body tumor. The extent and nature of the tumor 
is assessed with the help of fundus images, 
ultrasound, fluorescein angiography (FA), 
and ocular coherence tomography (OCT). 
Examination of a child with a suspected intra-
ocular tumor is always done under anesthesia, 
with complete evaluation including external 
photographs, RetCam images, and ultrasound 
performed in the same sitting. A large fundus 
diagram of the tumor replicating its extent in 
the eye with the measurements listed is used at 
the time of surgery.
For orbital tumors, careful inspection and 
palpation is necessary including evaluation of 
ocular motility, globe and lid position. 
Examination of the regional lymph nodes and 
other possible relevant details must be done. 
Radiological images of the orbit to study the 
tumor extent are obtained which must be avail-
able at the time of surgery. Malignancies with 
the potential for systemic spread must undergo 
a complete metastatic workup. In tumors which 
require adjunctive treatment with chemother-
apy, radiotherapy or immunotherapy, a collab-
orative team consisting of medical and radiation 
oncology is essential. An incisional biopsy for 
the histopathologic diagnosis of the malignancy 
is recommended before proceeding with 
exenteration.
Table 12.2 Indications for exenteration
Advanced primary or recurrent orbital malignancies
Advanced primary or recurrent eyelid tumors with 
orbital extension
Advanced primary or recurrent conjunctival tumors 
with orbital extension
Advanced primary or recurrent intraocular tumors 
with orbital extension




 Technique of Enucleation (Video 12.1)
It is pertinent that fundus examination be done 
by the operating surgeon at the time of surgery 
to identify and mark the correct eye. Enucleation 
can be performed under general anesthesia 
or local anesthesia with intravenous sedation. 
Even for cases done under general anesthesia, 
it is advised that retrobulbar injection of 2% 
lignocaine in combination with 1:100,000 epi-
nephrine, mixed with 75% bupivacaine (1:1), be 
administered (8–10 mL).
After the patient is prepared and draped, a 
wire speculum is placed to exclude the eyelashes 
from the field. A lateral canthotomy is performed 
when additional space is required, as in an eye 
with retinoblastoma where the globe maybe 
enlarged [2, 21]. A 360° peritomy is performed 
using a blunt tipped Westcott scissors, cutting as 
close to the limbus as possible to preserve the 
conjunctiva (Fig.  12.1a). The underlying poste-
rior tenon’s fascia is undermined in all four quad-
rants between the recti muscles in a spreading 
action using a blunt tipped tenotomy scissors. 
The medial rectus muscle is hooked using a mus-
cle hook and freed from the surrounding inter-
muscular septa by blunt dissection. The muscle is 
then identified, hooked and double-tagged, first 
with 6-0 silk suture 2 mm from the insertion and 
then with 6-0 vicryl suture 4 mm from the inser-
tion (Fig. 12.1b, c) [2, 21]. 6-0 silk sutures serve 
as traction sutures while 6-0 vicryl sutures would 
later be used to suture the muscles through the 
implant or the conjunctiva (described later). The 
muscle is then transected between the two 
sutures. This is followed by similar tagging and 
transection of inferior rectus, lateral rectus, and 




Fig. 12.1 Technique of enucleation in a 5-year-old male 
with right eye advanced retinoblastoma. (a) A 360° perit-
omy is performed using a blunt-tipped Westcott scissors, 
cutting as close to the limbus as possible. After undermin-
ing the posterior tenon’s fascia, each rectus is double 
tagged, (b) first with 6-0 silk suture 2 mm from the inser-
tion and then with (c) 6-0 vicryl suture 4 mm from the 
insertion. After transecting the muscles, (d) the eyeball is 
prolapsed between the blades of the speculum, and the 
optic nerve divided just a little anterior to the superior 
orbital fissure. (e) The transected optic nerve length is 
measured in all cases of retinoblastoma before the eyeball 
is submitted for histopathology. (f) Hemostasis is achieved 
and (g) the orbital implant placed within the posterior 
tenon’s fascia, closing it with interrupted 6-0 vicryl suture. 
(h) Each rectus is sutured to the conjunctiva in its respec-
tive fornix by passing the tagged 6-0 vicryl suture through 
the conjunctiva. (i) Anterior tenon’s closure is done with 
interrupted 6-0 vicryl suture and (j) conjunctival closure 
with a continuous key-suturing pattern. (k) An appropriate- 
sized conformer is placed in the socket and (l) a temporary 
median tarsorrhaphy performed with 6-0 vicryl suture
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oblique muscles are transected and allowed to 
retract posteriorly. Each of the sutures is clamped 
with a bulldog clip.
A conjunctival relaxing incision is made for 
easy manipulation in large globes [21]. The eye-
ball is then prolapsed between the blades of the 
speculum (Fig.  12.1d). With a forward traction 
on the eyeball using the four silk sutures, a gently 
curved blunt-tipped tenotomy scissors is passed 
along the lateral wall and the optic nerve is 
strummed along its length. With one bold cut, the 
optic nerve is transected at the desired length. In 
retinoblastoma, the transection is performed just 
a little anterior to the superior orbital fissure, to 
gain a good length of the nerve (15–20 mm) and 
at the same time avoiding injury to the superior 
orbital fissure contents [2]. Adequate hemostasis 
is achieved using firm pressure for 5–10 min. The 
enucleated globe is inspected thoroughly for any 
scleral thinning, perforation, extraocular tumor 
extension, and dilated vessels. The transected 
optic nerve length is measured (Fig. 12.1e), and 
the eyeball is then sent for histopathologic exam-
ination in 10% formalin.
An implant of adequate size and the surgeon’s 
preferred material is placed posterior to posterior 
tenon’s fascia (intraconal fat space). Posterior 
tenon’s fascia is closed with interrupted 6-0 vic-
ryl sutures (Fig.  12.1f, g). The recti are then 
attached to the implant using the 6-0 vicryl 
sutures by passing the needles through posterior 
tenons including the implant wrapping material 
as anteriorly as possible. Alternately, the muscles 
can be sutured to the conjunctiva in their respec-
tive fornices by passing the needle through the 
conjunctiva (Fig. 12.1h). These are the myocon-
junctival sutures and the technique is known as 
the myoconjunctival technique [21]. The advan-
tage of this technique is that it allows the use of a 
non-integrable orbital implant (silicone or 
PMMA sphere) which offers a safe and cost- 
effective alternative, with prosthesis motility 
comparable to biointegrable implants while mini-
mizing the complications of implant extrusion 
and migration [21].
Following this, anterior tenon’s is closed with 
interrupted 6-0 vicryl sutures (Fig.  12.1i). 
Conjunctival closure is done in a continuous key- 
suturing pattern with 6-0 vicryl suture (Fig. 12.1j). 
An appropriate sized conformer is placed in the 
socket (Fig. 12.1k) and a temporary median tar-
sorrhaphy performed with 6-0 vicryl suture 
(Fig. 12.1l). The suture tarsorrhaphy is removed 
after 1  week, and a customized prosthesis can 
then be placed in the socket after 6 weeks [21].
 Choice of Implant
Currently available implants can be categorized 
as:
 1. Non-integrable: Implants that do not integrate 
with either the prosthesis or the orbital tissues. 
Examples for this include PMMA spheres, 
silicone spheres, and titanium spheres.
 2. Semi-integrable: Implants that integrate with 
either the prosthesis or the orbital tissues. 
Allen’s implant is an example for a semi- 
integrable implant.
 3. Fully integrable: Implants that integrate with 
both the prosthesis and the orbital tissues. 
Cutler’s implant is an example for a fully inte-
grable implant.
 4. Biointegrable: Implants that induce fibrovas-
cularization within their substance and thus 
get integrated, for example, hydroxyapatite 
spheres.
 5. Biogenic: Implants that are of biological ori-
gin, for example, dermis fat graft.
Non-integrated spherical implants by the con-
ventional technique have a higher chance of 
migration, and also of poor implant and prosthesis 
motility. But when used in conjunction with the 
myoconjunctival technique, as described above, 
excellent static and dynamic cosmesis can be 
obtained [21]. Allen’s implant and Cutler’s 
implants are complicated by a high incidence of 
infection and extrusion [22]. Traditionally, dermis 
fat grafts are used in long-standing anophthalmic 
sockets with volume loss and surface loss [22].
Hydroxyapatite implants represent a new gen-
eration of integrated spheres that allow fibrovas-
cular growth, which theoretically reduces the 
chances of migration, infection, and extrusion 
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[23–25]. Also, these biointegrated implants with 
pegging achieve satisfactory excellent motility 
[23–25]. Porous polyethylene offers a good alter-
native to hydroxyapatite implants, as they cause 
less irritation to the conjunctiva owing to their 
smoother surface [22]. Porous implants, although 
in wide use, are known to cause certain complica-
tions. These include conjunctival irritation, dis-
charge, pyogenic granuloma formation, implant 
exposure, scarring, implant infection, and persis-
tent discomfort [22–25]. These implants are also 
not suitable in immunocompromised individuals, 
diabetics, or in those who have had or require 
periorbital radiation therapy [22]. The choice of 
implant used is left to the surgeon’s discretion.
 Technique of Exenteration (Video 12.2)
Exenteration can be performed by either an 
eyelid- sacrificing or eyelid-sparing technique. 
With the eyelid-sacrificing method, the orbital 
cavity has to be lined by temporalis muscle, fore-
head flaps or grafts. Some surgeons advocate 
spontaneous granulation, and this offers com-
parable cosmetic results. However, healing by 
granulation takes longer and requires intensive 
postoperative care.
To circumvent this problem, an eyelid-sparing 
technique maybe used when possible. This 
method, popularized by Coston and Small, is a 
modification of the total exenteration technique 
which spares parts of both the eyelids, with trans-
verse blepharorrhaphy to cover the orbit, thus 
ensuring better cosmesis and early rehabilitation 
[17]. In addition, sparing of the orbicularis mus-
cle provides an excellent vascular supply to the 
skin flap, enabling early wound healing [17, 20].
Assistance from an otorhinolayrngologist or a 
neurosurgeon may be necessary in patients with 
extensive maxillary sinus involvement or roof 
erosion by the orbital tumor. The correct eye is 
identified and marked. Exenteration is always 
performed under general anesthesia. After the 
patient has been prepped and draped, the incision 
marking is placed 2  mm behind the lash line, 
joining them at the medial and lateral commis-
sures (Fig. 12.2a) [17]. Three double-armed trac-
tion sutures with 4-0 silk are placed through the 
upper and lower tarsi to provide traction on the 
orbital contents. The incision is then made with a 
radiofrequency probe along the skin marking 
(Fig. 12.2b). Dissection is carried in the preseptal 
plane which decreases the likelihood of perforat-
ing the orbital septum, which is especially impor-
tant in tumors present in the anterior orbit 
(Fig.  12.2c) [17]. Also, it leaves the orbicularis 
muscle intact, which provides a source for vascu-
lar supply to the skin flap.
Dissection is done till the orbital rim is 
reached, and the periosteum just outside the arcus 
marginalis is incised all around (Fig.  12.2d). 
Periosteal elevators are used to dissect the perios-
teum off the bony orbit, beginning at the incised 
margin along the orbital rim and continuing all 
the way back to the orbital apex (Fig.  12.2e). 
Most of the periosteum is loosely adherent to the 
underlying bone, with tight adhesions seen at cer-
tain anatomic locations, including the bony 
sutures and orbital fissures, as also in areas where 
the tumor has spread to the periosteum. At these 
points, gentle dissection is done to prevent any 
rip in the periosteum. Along the superior rim, dis-
section is gently carried around the supraorbital 
notch. The supraorbital and supratrochlear neuro-
vascular bundle are identified and cauterized. 
Subperiosteal dissection is then carried from 
anterior to posterior lacrimal crest and beyond. 
Dissection is performed carefully along the 
medial wall, so as to not fracture the thin lamina 
papyracea. After negotiating the frontozygomatic 
suture with gentle dissection, zygomaticofacial 
and zygomaticotemporal neurovascular bundles 
are identified and cauterized. Dissection should 
be performed carefully along the orbital floor, so 
as to not fracture the thin bone and create a com-
munication with the maxillary sinus. The sac is 
approached by dissecting medial to it and divid-
ing the common canaliculus and orbicularis 
attachments. It is dissected from the lacrimal sac 
fossa and divided from the nasolacrimal duct 
with cautery. The exposed nasolacrimal duct is 
obliterated by cautery to reduce the risk of post-
operative fistula formation (Fig. 12.2f).
Further deeper along the medial wall, anterior 
and posterior ethmoidal vessels are identified and 
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cauterized (Fig.  12.2g). In the inferotemporal 
orbit, the inferior orbital fissure is encountered 
and penetrating vessels divided with cautery. 
Next, the infraorbital nerve is identified and cau-
terized. Ensure that the periosteum has been dis-
sected to the apex, by passing a lid speculum all 
around in the orbit. A pair of curved enucleation 
scissors is then introduced into the posterior 
orbit. The optic nerve, superior orbital fissure 
contents, and posterior orbital tissues are divided 
(Fig.  12.2h). Hemostasis can be obtained with 
ice-cold wet gauze, pressure, and/or cautery. If 
necessary, additional hemostasis is achieved with 
surgicel or bone wax. The socket is carefully 
inspected for any residual tumor. The adequacy 
of resection may be judged with the aid of frozen- 
section control. The resection of additional 
orbital apical tissue may be done as deemed nec-
essary. The eyelid flaps are reapproximated in 
two layers, with orbicularis closed using 4-0 vic-
ryl, and the skin using 6-0 silk suture (Fig. 12.2i) 
[17]. Aspiration of the orbital cavity is done at the 
end of the procedure using a 10 cc syringe which 
yields some amount of blood and serum, and pro-
vides a concave lid flap. The wound is then 
patched using an antibiotic ointment.
Following surgery, aspiration of the socket 
for any blood or serum is done every day using 
a 10 cc syringe till a dry aspiration is obtained. 
The socket usually heals quickly over the course 
of 3–6 weeks and is ready for a prosthesis at the 
end of 6–8 weeks. Eyelid-sparing orbital exen-
teration enables early wound healing and cos-
metic rehabilitation thus minimizing patient 
morbidity.
For lid-sacrificing exenteration, the incision 
marking is placed along the orbital rim. 




Fig. 12.2 Eyelid-sparing orbital exenteration technique 
in a 49-year-old male with the left orbital extension of 
conjunctival squamous cell carcinoma. (a) An incision 
marking is placed 2 mm behind the lash line in both the 
upper and lower eyelids, joining them at the medial and 
lateral commissures. (b) The incision is made with a 
radiofrequency probe along the skin marking. (c) 
Dissection is carried in the preseptal plane till the orbital 
rim is reached. (d) The periosteum just outside the arcus 
marginalis is incised all around. (e) A periosteal elevator 
is used to dissect the periosteum off the bony orbit, begin-
ning at the incised margin along the orbital rim and con-
tinuing all the way back to the orbital apex. (f) After 
dividing the nasolacrimal duct, the exposed duct is oblit-
erated by cautery. (g) Along the deeper medial wall, ante-
rior and posterior ethmoidal vessels are identified and 
cauterized. (h) The orbital tissue is held in forward trac-
tion while dividing the posterior structures. (i) After ade-
quate hemostasis, the eyelid flaps are reapproximated in 
two layers, with the orbicularis closure using 4-0 vicryl 
and skin closure using 6-0 silk suture
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The periosteum just outside the arcus marginalis 
is incised, and the rest of the steps are similar as 
above. After excision of the orbital contents, the 
orbital cavity is left open to granulate in which 
case epithelialization generally occurs over 
3–4  months, or reconstruction using split skin 
lining or skin flaps is done.
Following enucleation and orbital exentera-
tion, the challenge lies in providing a good 
cosmesis. Once complete healing of the wound 
has occurred, a customized ocular prosthesis in 
an enucleated socket can be placed in 6 weeks. 
A good surgical technique is essential to pro-
vide a concave, smooth, and stable skin cover, 
over which an orbital prosthesis can be placed 
[17, 20].
In conclusion, enucleation and exenteration in 
ocular oncology are mainly performed in 
advanced malignant tumors. These procedures 
can be life-saving and are used as a part of multi-
modal treatment in achieving complete local 
remission. The cosmetic disfigurement caused by 
these radical procedures must be rehabilitated by 
a well-matched prosthesis.
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Loss of an eye is an immense psychological setback 
for any patient. Providing an appropriate implant 
with a well fitted mobile prosthesis can go a long 
way to alleviate this pain. Orbital implants are 
medical prosthetics used to replace the lost orbital 
volume as well as maintain it and allow some 
amount of realistic movement of a prosthetic eye 
following enucleation (or evisceration). In 1884 
implants were first described by Mules, and ever 
since then different implant materials, designs and 
shapes have been tried [1]. An orbital implant may 
be autologous or alloplastic, integrated, or semi- or 
non- integrated [2]. The shapes of the implants are 
usually spherical and range from 12 to 24 mm in 
diameter. The wrapping materials act as buffer to 
shield the conjunctiva as well as act as a conducive 
niche for the attachment of the extraocular muscles.
Wrapping materials may be either organic (autol-
ogous and heterologous) or alloplastic. Advantages 
and disadvantages of wrapping an implant and 
choice of wrapping material are still matter of debate 
among the surgeons [3]. While human donor sclera is 
commonly used as a readily available cost-effective 
wrapping material, it entails some potential risk of 
disease transmission. Specially processed and mar-
keted allografts like human donor pericardium, fascia 
lata, sclera, bovine pericardium, and acellular dermis 
have been implemented as safe alternatives with vari-
able success rate. These materials increase the cost of 
surgery. Autologous materials like temporalis fascia, 
rectus abdominus sheath, fascia lata, etc. have also 
been tried as wrapping materials. However use of 
these autologus tissues needs a second donor opera-
tive site resulting in prolonged operation time and 
increased morbidity. Synthetic wrapping materials 
(e.g., undyed polyglactin 910 mesh) are gaining pop-
ularity due to eliminated risk of disease transmission, 
no need of second surgical site, simple technique, 
and relatively inexpensive nature.
Enucleation especially in retinoblastoma 
patients undergoing adjuvant radio or chemo-
therapy has a higher risk of long-term complica-
tion [4]. Enucleation at a young age enhances the 
perils of volume deficiency both in terms of bone 
and soft tissue [5, 6]. Hence, careful selection of 
implant material and meticulous surgical tech-
nique is a necessity for these patients.
Various types of implants like gold, silver, glass, 
silicone, cartilage, bone, fat, cork, titanium mesh, 
acrylics, rubber, catgut, peat, agar, silicon, hydroxy-
apatite, and polyethylene have been described. At 
present most popular integrated implants are the 
hydroxyapatite and polyethylene and the non-inte-
grated being the acrylic and silicon.
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Natural coralline hydroxyapatite material is used 
as the hydroxyapatite (HA) ocular implant. It 
contains approximately 500 μm diameter pores 
structurally that simulate the haversian system of 
human bone. The microstructure of this implant 
allows fibrovascular ingrowth of host tissues in 
the anophthalmic socket [7]. Once the implant is 
well vascularized and integrated, it can be drilled 
and fitted with a motility peg implant. This motil-
ity peg is then coupled to the ocular prosthesis to 
enhance prosthesis motility and cosmesis.
The hydroxyapatite implant is usually 
wrapped in donor sclera or fascia. The socket 
is measured using sterile trial spheres. Usually 
an 18–22 mm implant is appropriate. Wrapping 
the implant adds approximately 1–1.5 mm to the 
overall diameter.
The scleral shell is cut to the appropriate size 
and shape to enclose the implant securely with the 
corneal window placed posteriorly. Multiple inter-
rupted 6-0 Vicryl sutures are used for securely clos-
ing the sclera; 2–4  mm rectangular windows are 
cut through the sclera within 8–10 mm from the 
anterior most apex of the implant. Multiple holes 
are then drilled manually into the implant using 
a 20-gauge needle to promote further fibrovascu-
lar ingrowth at the site of each window and at the 
site of the posterior corneal window [8]. The four 
recti muscles are sutured and fixed to the anterior 
lip of the corresponding scleral windows. Anterior 
Tenon’s fascia is sutured with multiple interrupted 
6-0 Vicryl sutures. The conjunctiva can be closed 
with continuous 6-0 plain suture. Some authors 
report a relatively high exposure rate with hydroxy-
apatite compared with alloplastic sphere implants 
emphasizing the need for a meticulous closure in 
layers as well as placement of the implant posterior 
to the posterior tenon deep in the socket [9–12].
 Polyethylene (Medpor®) Implant
Polyethylene is a high-density straight-chain 
hydrocarbon material, formed by polymerization 
of ethylene molecules. It is nontoxic, nonaller-
genic, and biocompatible. Medpor (Porex Surgical 
Inc., Georgia, USA) is a lightweight, polyporous 
form (150–400 μm) of polyethylene. This mate-
rial enables fibrovascular proliferation of orbital 
tissue allowing biointegration of the implant with 
the host’s body, thus reduces the risk of migration, 
exposure and extrusion. Unlike hydroxyapatite, it 
is much resilient, allowing muscles to be sutured 
directly to it without wrapping. Many studies 
have reported favorable surgical outcomes after 
Medpor orbital implantation [13–15].
A range of implant diameters of 14–22 mm are 
available. A set of resterilizable sizer is available 
for measuring the appropriate implant diameter.
The classic Medpor has a rough surface with 
some tendency to cause erosion of overlying 
Tenon’s capsule and conjunctiva. To compen-
sate for this, other types of Medpor have been 
designed. Medpor-SST is a further refinement 
with a smooth, porous anterior surface, which 
helps minimize late-implant exposure, and the 
preplaced suture tunnels allow for easy anchoring 
of the rectus muscles. Medpor-MCOI is cone- 
shaped, to provide extra volume in the orbit with 
a similar diameter implant. They have proved to 
be more effective in patients with phthisis bulbi 
or microphthalmos.
 Bio-ceramic Implant
Bioceramic orbital implant is made of the porous, 
nonbrittle biomaterial alumina (Al2O3). It has 
uniform interconnected pores of approximately 
500 μm in size. Unlike hydroxyapatite, it is manu-
factured with no disruption to marine ecosystems.
Advantages of bio-ceramic implants include:
• Easy to manufacture, structurally strong, and 
free of contaminants.
• Porous, strong, and resilient composition
• Rapid fibrovascular ingrowth
• No risk of disease transmission
• Lightweight and easy manuverability during 
surgery
• Easy suturing of extra ocular muscles to implant
• Effortlessly hand-drilled
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• Noninflammatory, nonallergenic
• Improved motility of the artificial eye
• After implantation, a biofilm develops over 
the implant that acts as a barrier and helps in 
prevention of rejection.
 Self-Inflating Tissue Expanders
Self-inflating tissue expanders are hydrogel 
implants which follow principle of osmotic gradi-
ent leading to volume enhancement. After implan-
tation, absorbs body fluid and grow consistently 
to a predefined volume. The swelling capacity of 
the implant is between 7- and 12-fold, depending 
on the product type. These implants are indicated 
in the treatment of clinical anophthalmia, post 
enucleation socket syndrome, and congenital 
microphthalmia. Their advantages are as follows:
• Procedure is safe, quick, and minimally invasive
• High biocompatibility
• Lesser postoperative complications
• Optimized swelling
• Various shapes available for various indications
Being a relatively new technique, long-term 
safety of the material as an orbital implant has yet 
to be established, but early results are promising.
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Radiation therapy is an indispensable tool used 
by eye cancer specialists around the world [1, 2]. 
However, ophthalmic radiation therapy can be 
expensive and typically requires collaboration 
between an ophthalmic oncologist, radiation 
oncologist, and a medical physicist. This chap-
ter provides an overview of a basic ophthalmic 
radiation therapy program as well as indications 
for irradiation of common ocular malignancies.
Ionizing radiation has been used to destroy 
cancers of the eyelids, conjunctiva, iris, ret-
ina, choroid, optic nerve, and orbit [3–5]. The 
most common applications are brachytherapy 
(implanted and surface applicators), external 
beam radiation therapy (EBRT), and rarely 
interstitial orbital brachytherapy techniques. 
Most of these approaches have a surgical 
component.
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Herein, we describe technical aspects required 
to start a radiation therapy program. These 
include specific imaging protocols for treat-
ment planning of the various lesion types, spe-
cifically tumor- imaging or simpler nonimaging 
methods, quality assurance for the radiation 
sources encompassing the implanted brachy-
therapy device, and sterilization methods and 
radiation surveys of the operating theater and 
patient before/after implantation and explanta-
tion. Once the agreed-upon workflow is estab-
lished and formalized in writing, it must be 
approved by the appropriate local radiation 
control agencies. All participants in each pro-
cess should have reached a consensus as how 
to proceed. Any new staff should be trained, 
and there should also be annual retraining for 
all participants. It is helpful to have test condi-
tions to evaluate staff comfort and proficiency 
with the multitude of tasks comprising ocular 
brachytherapy. An open environment will aid 
the long-term objective of having a safe and 
successful ocular brachytherapy program.
 Costs
To be successful, all programs should perform 
a financial analysis before starting any proce-
dures and then reviewed at least annually to 
ensure that prior assumptions were accurate 
and to capture looked-over items. In doing this 
financial analysis, a proposed workflow should 
be defined and include the following compo-
nents: initial patient consultation, image acqui-
sition, treatment planning, source ordering, 
quality assurance measures, treatment device 
sterilization, device implantation, radiation sur-
veys, patient discharge (if applicable), device 
explant, post-explant wound care, device 
cleaning, and source disposal (if applicable). 
Estimates for each component cannot be given 
herein as every center will have unique circum-
stances that should be carefully assessed in the 
financial analysis. However, it is known that 
brachytherapy is both a cost-effective and clini-
cally successful means of treating numerous 
ocular diseases. With consistent high- quality 
care and reproducible treatments for a given 
prescription, there should be a simple means 
for billing code entry by the staff performing 
the procedures or their designates.
In general, a brachytherapy program 
is typically less expensive to start than 
EBRT. Brachytherapy requires the purchase of 
implantable materials. For example, ruthenium-
 106 (106Ru) applicators are solid brachyther-
apy sources, which are relatively inexpensive 
because they can be reused for multiple tem-
porary implants over their longer half-life 
(372 days). In contrast, low-energy eye plaques 
[e.g., palladium- 103(103Pd), iodine-125 (125I)] 
are relatively more expensive because radioac-
tive seeds must be purchased, inserted in plaque 
shells, and calculated to the prescribed dose. 125I 
and 103Pd seeds exhibit half-lives of 59.4 and 
17  days, respectively [2]. Therefore, they can 
be reused but only after reassessment of their 
current strength. It is important to note that 
seeded plaques are more versatile compared 
to solid sources. Seeded plaques are capable 
of treating larger tumors, can be customized 
to load the seeds eccentrically to try to spare 
normal tissues from radiation exposure, seeds 
can be mixed to modulate intraocular radia-
tion distribution and require smaller margins 
(2–3 mm) [1, 6–8]. Thus, low-energy seeds can 
be affixed into custom-designed plaques to treat 
tumors of the iris, ciliary body, optic disc and 
conjunctiva more pre-cisely than a solid source 
plaque. Though most western centers use one 
plaque for each patient, high volume centers 
have decreased the cost per patient by reusing 
low-energy seeds and seed carriers.
In contrast, EBRT (e.g., photon, electron, 
proton) carries the highest startup cost [9]. In 
addition to the large capital cost of the linear or 
particle radiation accelerator, EBRT typically 
requires large, expensive facilities and radiation- 
shielded rooms. Although brachytherapy and 
proton EBRT provide comparable tumor control 
rates, brachytherapy produces the most confor-
mal radiation dose distributions (within the eye) 
with less long-term radiation toxicity, particu-
larly to anterior ocular and adnexal structures 
[6, 10–12].
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 Personnel
 The Team: Medical Physicist, Radiation 
Oncologist, and Ophthalmic Oncologist
Radiation therapy personnel are required. The 
medical physicist (MP) and radiation oncologist 
(RO) are typically responsible for collaborating 
on radiation source selection, dose calculation 
(dose rate, implant duration, and target volume) 
[1, 2]. The MP usually constructs radioactive 
sources prior to implantation and/or administering 
EBRT.  However, it is the ophthalmic oncologist 
(OO) who selects the patients and monitors for 
radiation side-effects. Therefore, the OO should 
become familiar with both MP and RO aspects 
of therapy [1]. For the purpose of this chapter, the 
OO’s primary role is to make or confirm the diag-
nosis, biopsy tumors (when necessary), and surgi-
cally insert radioactive devices. In some countries, 
the OO can obtain licensing for the selection and 
prescription of radioactive plaques. Similarly, the 
RO may assume the role of MP.
 Indications for Surgery
 Available Evidence-Based Guidelines
 Uveal Melanoma
Commonly treated with eye and vision-sparing 
surgical “plaque” irradiation [13]. In 2014, con-
sensus guidelines were published by an interna-
tional multicenter Ophthalmic Oncology Task 
Force (OOTF) that included 47 radiation oncolo-
gists, medical physicists, and ophthalmic oncolo-
gists from 10 countries. From this work, there 
was level 1 consensus that all centers:
 1. Adopt the use of the American Joint 
Committee on Cancer (AJCC) or Union for 
International Cancer Control (UICC) staging 
systems to facilitate communication.
 2. Brachytherapy procedures are performed at 
specialized medical centers with expertise.
 3. These centers were defined as having a 
subspecialty- trained ophthalmic surgeon, a 
radiation oncologist, and a medical physicist 
who are all familiar with the AAPM TG-129 
report [2].
 Uveal Melanoma Case Selection
 1. A clinical diagnosis of uveal melanoma is 
adequate (biopsy is not needed).
 2. Small melanomas can be treated at the eye 
cancer specialist’s discretion.
 3. AJCC-UICC T1, T2, T3, and T4a-d uveal 
melanoma patients can be treated after coun-
seling about likely vision, eye retention, and 
local control outcomes.
 4. Patients with peripapillary, sub-, and perifo-
veal melanoma and those with exudative reti-
nal detachments should be counseled about 
poorer resultant vision and local control 
outcomes.
 5. Tumors with T4e extraocular extension, diam-
eters that exceed the limits of brachytherapy, 
blind painful eyes, or no light perception 
vision are not suitable.
ABS  =  American Brachytherapy Society; 
AJCC = American Joint Committee on Cancer, 
UICC = Union International for Cancer Control; 
106Ru and 90Sr plaques are less accommodating 
for nodular extra-scleral extension. (Reprinted by 
permission of Brachytherapy [1].)
 Retinoblastoma Case Selection
The most common reasons to use plaque radia-
tion for retinoblastoma is for eye and vision 
salvage after systemic, regional, or intraocular 
chemotherapy [1, 14]. An example: residual or 
relapsed RB that failed local control with chemo-
reduction and large enough not to be controlled 
by focal laser and/or cryotherapy. Prospects for 
sight-threatening complications should be dis-
cussed with the family as part of the consent pro-
cess, through retinoblastoma typically requires 
a lower tumor apex dose than uveal melanoma. 
Further, the ABS groups achieved Level 2 con-
sensus that the most common indication for 
plaque treatment of retinoblastoma is when the 
tumor is anterior to the equator in unilaterally 
affected children [1]. Exceptions include when 
there is evidence of anterior chamber tumor. 
The ABS-OOTF recommended that children at 
risk for extraocular RB undergo systemic stag-
ing [1]. Episcleral brachytherapy can be used to 
treat unilateral unifocal tumor or as an adjunct to 
treat chemoresistant tumors, post-chemotherapy 
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residue showing signs of recurrence, and too large 
to treat with laser or cryotherapy. However, note 
chemotherapy treated eyes appear more likely 
to develop intraocular radiation vasculopathy. 
Lastly, specialized orbital applicators have been 
devised to irradiate orbital RB recurrence [1].
 Orbital Brachytherapy Case Selection
There are three general indications for orbital 
brachytherapy implants: extrascleral extension 
of uveal melanoma, orbital invastion of adnexal 
tumors and recurrent retinoblastoma [15, 16]. 
Extrascleral extension of intraocular cancers 
presents unique challenges. Small amounts of 
uveal melanoma extrascleral extension are often 
treated with local plaque therapy with or with-
out subsequent scleral patch grafting. However, 
in cases where the eye has been removed and 
residual tumor (microscopic disease) is sus-
pected, postoperative radiation therapy has been 
employed to sterilize any remaining orbital can-
cer. EBRT (≈40–50 Gy) with 6 MV photons has 
been prescribed [4]. However, such treatment 
typically results in entry dose- associated eye 
lash and brow loss, dry socket, a sunken orbit, 
or orbital bone dysgenesis (in children) [4]. 
There exist alternative high-dose-rate interstitial 
brachytherapy methods to temporarily implant 
the radiation within the orbit. These techniques 
increase the dose within the targeted orbit while 
decreasing the dose to the eye lids and brow [15]. 
More cosmetically acceptable, this technique has 
been reported to yield equivalent local control 
and improved cosmesis [4, 15, 16].
 Intraocular Tumors
 Uveal Melanoma
Uveal melanoma is the most primary common 
ocular tumor treated with implant radiation therapy 
in the developed world [17]. Methods of radiation 
plaque construction and dosimetry were reviewed 
by the American Association of Physicists in 
Medicine (AAPM) Task Group 129  in 2012 [2]. 
Similarly, open-access consensus clinical treat-
ment guidelines were published in 2013 by the 
American Brachytherapy Society (ABS) [1]. 
Both of these guidelines offered the most widely 
accepted, evidence-based consensus from teams 
of eye cancer specialists. Invaluable for a new cen-
ter, this information includes methods of dosim-
etry, quality assurance, and case selection [1, 2]. 
Though both apply to uveal melanoma, aspects 
also are relevant for selected intraocular retino-
blastomas, as well as other intraocular tumors.
 Vascular Tumors of the Retina 
and Choroid
Peripapillary or large retinal angiomas can be 
treated with brachytherapy. Circumscribed or 
diffuse choroidal hemangiomas smaller than 
the largest available episcleral brachytherapy 
implant can also be treated. However, when com-
pared to brachytherapy, low-dose (16–24  Gy), 
photon- based external beam radiation therapy of 
choroidal hemangiomas will typically offer rela-
tive-sparing vision-critical intraocular structures 
[4, 18, 19, 31].
 Uveal Metastasis
While most choroidal metastases are treated with 
nonsurgical EBRT, indications for plaque radia-
tion therapy include radiation resistant tumors 
(e.g., renal cell, adenoid cystic carcinoma), when 
prior ocular radiation does not permit treatment 
of subsequent metastasis and when a patient 
refuses EBRT [4].
 Ocular Adnexal Tumors
 Conjunctival Tumors (Melanoma, 
Squamous Carcinoma)
Conjunctival tumors (melanoma, squamous carci-
noma) can be treated with radiation. Melanomas are 
more commonly treated with these methods in that 
squamous carcinomas are more amenable to sur-
gery with adjuvant cryotherapy and more recently 
topical chemotherapy [20]. Specialized plaques 
have been used to treat the ocular surface malig-
nancies in select centers using a variety of radio-
nuclides. Though the use of 106Ru and 125I plaques 
has been reported, by far the least expensive (but 
not widely available) method is strontium- 90 (90Sr) 
brachytherapy due to its 28.9-year half-life.
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 Orbital Tumors (Melanoma, 
Retinoblastoma)
Orbital Tumors (melanoma, retinoblastoma) can 
also receive curative and/or adjuvant ophthalmic 
brachytherapy [4]. Albeit rare, most commonly 
reported are treatments of residual tumors after 
enucleation of the eye. In addition, orbital adenoid 
cystic and basal cell carcinomas have been treated 
with orbital radiation implants. By far the most 
common use of orbital radiation therapy (EBRT) 
is for lymphoma (not covered in this chapter).
 Presurgical Preparations
 Ocular Imaging
Intraocular tumor imaging is used to determine 
whether or not the patient is eligible for brachy-
therapy treatment and then to dictate how the 
treatment should proceed [1]. Tumor dimensions 
are determined by clinical examination, photo-
graphic imaging, and ultrasonographic measure-
ments. Typically performed with ultrasound (US) 
in A-scan or B-scan modes eye cancer specialists 
determine the largest basal dimension and fur-
thest apical height of intraocular tumors. Other 
preimplant imaging modalities include optical 
coherence tomography and fundus autofluores-
cence imaging which offer more information 
about tumor extent (within tissues).
Small iris tumors are best localized and mea-
sured by slit lamp and gonioscopic photography 
as well as high-frequency ultrasound imaging. 
The clinically measured size and extent should 
be mapped in the chart. In addition, the tumour 
can be measured with calipers. Immidiately prior 
to surgery, the tumour borders should be drawn 
on the cornea and sclera with a marking pen. 
Transillumination may be used to help define the 
posterior extent of anterior segment tumours that 
allow production of an episcleral shadow. The 
surgeon should place the transilluminator in the 
quadrant opposite that of the tumor (or through the 
pupil if better) to produce a tumor shadow to be 
marked with a marking pen. Transillumination is 
often difficult in individuals with pigmented fundi 
and with tumors obscured by the ciliary body band. 
In such situations and posteriorly placed tumors, 
the anterior and lateral margins of the tumor may 
be localized on to the scleral surface using indi-
rect ophthalmoscopy with scleral depression. Such 
localization techniques are equivalent to those 
used for scleral buckling surgery [1].
 Treatment Planning
Tumor measurements and distances to critical 
intraocular structure drive the resultant radiation 
treatment plan. Depending on the center, treat-
ment planning can range from a simple calcula-
tion of the time to deliver the prescribed radiation 
dosage to a desired depth, to the sophisticated 
fusion of multiple radiographic imaging modali-
ties used to measure the lesion, its location and 
distances to critical intraocular structures. Such 
computer-based radiographic imaging can be 
helpful for calculation of 3D dose distributions 
and the biologic effective dose.
As time marches forward, there have been 
significant advances in ocular brachytherapy 
treatment planning. The COMS approach 
derived dose to points based on characterizing 
125I brachytherapy seeds as point sources on a 
template diagram in a liquid water environment 
without concern for high-Z materials such as the 
treatment device or bony anatomy [21]. More 
recently, image-guided (CT/MRI) brachytherapy 
treatment planning has permitted more accurate 
approximations of volumetric dose informa-
tion throughout the lesion and adjacent healthy 
structures. At this time, there exists no widely 
accepted radiographic image guided method or 
application for intraocular tumors [1].
To our knowledge, there is only one treatment 
planning system (TPS) created for eye plaque 
brachytherapy [22]. Many centers employ 
generic brachytherapy systems altered to per-
form for ocular use. Commissioning of any treat-
ment planning system will include checks on the 
linearity of dose with prescription, tests of expo-
nential decay based on the radionuclide half-life, 
spot checks of the reference dose distribution 
for a given source or brachytherapy treatment 
device with that replicated by the TPS, checks 
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of volumetric calculations for accurate structure 
assessments, checks of dose-volume calculations 
for depiction of accurate 3D volumetric informa-
tion, and many other basic features as prevalent 
in brachytherapy TPSs. Further, modern systems 
may include the ability to depict source collima-
tion or dose differences between tissue and water 
[23].
 Device Preparation
Most centers purchase solid or assemble seeded 
treatment devices. Therefore, each center must 
have a protocol to validate their treatment devices 
to match what is expected and characterized 
within the brachytherapy TPS.  Commissioning 
the device will include comparisons of the 
manufacturer- reported dimensions and composi-
tions to hands-on measurements and also those 
used in the TPS.
COMS-type plaques and other multicompo-
nent treatment devices consist of a combination 
of several components that must be compatible. 
Sometimes the components (such as the glue 
necessary to hold the device together) are not 
explicitly approved by local governmental or 
regulatory agencies for medical purposes such 
as sterilization and implantation. To be proac-
tive for regulatory audits, the center will need to 
document the suitability of all components and 
their intended use in their ocular brachytherapy 
program.
Some brachytherapy devices such as 
106Ru/106Rh episcleral plaque have a built-in 
radiation source and are intended to be used 
on multiple patients. Other devices may have a 
nonradioactive plaque into which low-energy 
photon- emitting brachytherapy seeds (i.e., 103Pd, 
125I, or 131Cs) are loaded. These seeds may be 
reused depending on the source half-life, rate of 
patient accrual, and variety of prescriptions. In 
both cases, care must be taken to inspect (pre-
ceding first use and subsequent reuse) to ensure 
radioactive capsule integrity. Evaluation (math-
ematical or physical) of source strength is gen-
erally made prior to each use. Measurements of 
source strength require a re-entrant well-type air 
ionization chamber and seed holder with calibra-
tion for a given source model that is traceable 
to a primary standards calibration laboratory. In 
the United States of America, this is achieved 
through calibrating the chamber and seed holder 
at one of three Accredited Dosimetry Calibration 
Laboratories, which are traceable to the National 
Institute of Standards and Technology (NIST) 
[24]. Centers located elsewhere should follow 
local regulations. While not technically chal-
lenging, sterilization of the ocular brachytherapy 
device requires diverse attributes and coordina-
tion across multiple disciplines (Video 14.1).
Multicomponent devices will have differ-
ing or unspecified sterilization procedures with 
a limited number of permissible sterilization 
cycles (pertinent for devices to be used on multi-
ple patients). Given the sensitive nature of some 
components such as glue or a seed holder, care 
must be taken to establish a sterilization program 
that accommodates limitations of all compo-
nents yet provides timely and effective steriliza-
tion [1, 2].
Whichever approaches are taken, it is recom-
mended that a patient database be established 
from the inception of an ocular brachytherapy 
program to capture information on various 
patient specific aspects of the procedure. This 
database can include imaging datasets and treat-
ment planning information in addition to sim-
ple fields like implant/explant dates and times; 
names of participating staff; lesion height and 
basal dimensions; prescription dose, extent, and 
radionuclide; and dose-volume information for 
adjacent healthy structures. These data may be 
stored within the electronic health record system 
for later query.
 Therapy Techniques
 Orbital Brachytherapy for Residual 
Orbital Melanoma
We recommend that this procedure be performed 
4–6  weeks after enucleation or other subtotal 
excisional surgery to allow wound healing [15]. 
When used for orbital extrascleral melanoma 
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extension, the temporary prosthesis or con-
former is removed and the patient placed under 
general anesthesia. The eyelids and conjuncti-
val surfaces are prepared with povidone-iodine 
antiseptic (Table 14.1). The orbit is inspected for 
the condition of the conjunctival wound and the 
position of the orbital implant. A marking pen 
is used to define evenly spaced (1 cm) sites for 
catheter placement. The sites should be located 
just within the bony rim of the orbital bone by 
palpation. Care is taken to avoid critical struc-
tures (e.g., lacrimal drainage system, superior 
and inferior orbital nerves, and anterior ethmoid 
artery). Using the marks as a guide, transcuta-
neous #11 blade incisions should be performed 
(sequentially) as to create 3-mm wide orbitotomy 
sites. The aforementioned brachytherapy cath-
eters were marked with ink to indicate when they 
are <4.5cm deep into the orbit. A brachytherapy 
button is placed onto the catheter to aid cutane-
ous fixation.
Then, a bimanual catheter implantation tech-
nique is used to guide the trochar toward the 
orbital apex. While the catheter enters the orbit, 
the surgeon uses on finger to palpate the catheter 
tip as it traverses through the orbital soft tissues. 
Once in place, with the catheter tip at the orbital 
apex, a cutaneous 4-0 suture is placed though the 
brachytherapy button to anchor it in place. Then, 
the catheters trocar is withdrawn. This series of 
steps is repeated with each catheter until there 
are 8–10 evenly spaced catheters in place. Then 
medical grade glue is placed to affix the trocars 
to the brachytherapy buttons and allowed to dry 
(Video 14.2).
Prior to being discharged to the recovery room, 
the catheters are trimmed to 5 cm in length and 
covered with a protective gauze dressing. Upon 
recovery from anesthesia, the orbit is imaged by 
computed tomography for treatment planning by 
the medical physicist.
 Orbital Brachytherapy for Extrascleral 
Uveal Melanoma
High-dose-rate (HDR) brachytherapy is per-
formed in a shielded room using a remote after 
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loader that houses an 192Ir source. Under mild 
sedation and with pain medication, the orbital 
catheters are attached to the mechanical remote 
after-loader which sends the source down the 
catheters into the orbit for the prescribed dwell 
time, and are then retracted. Nine to ten treatment 
fractions are typically delivered (BID) over 5 con-
secutive days. At the end of treatment, 3–5 cm3 
of lidocaine is placed into the orbit 15 min prior 
to extraction of the catheters. Once removed, the 
3 mm cutaneous wounds are treated with topical 
antibiotic ointment and the ocular prosthesis is 
replaced.
 Orbital Brachy-Boost Technique
In an effort to treat microscopic residual 
radiation- resistant tumor (e.g., adenoid cystic 
carcinoma, hemangiopericytoma, invasive car-
cinomas) HDR radiation can be applied to the 
tumor bed [4]. While the surgery is similar to 
the aforementioned technique (for treatment of 
melanomatous orbit extension), a lower brachy-
therapy dose is employed in addition to a sub-
sequent overlay of EBRT. The result intensifies 
treatment of the tumor bed with relative spar-
ing of the rest of the orbit. This eye and vision 
sparing HDR orbital brachytherapy technique is 
typically employed as an alternative to orbital 
exenteration.
 Anesthesia for Radioactive Plaque 
Surgery
General anesthesia is preferred. This is because 
introduction of 3–5 cm3 of orbital fluid can limit 
the surgeons view and increase the difficulty of 
plaque placement. However, these procedures 
can be performed with local assisted surgery if 
needed, particularly for iris, ciliary body and 
anterior uveal tumors.
In that episcleral brachytherapy can be per-
formed under peribulbar or retrobulbar anes-
thesia, we recommend using a mixture of 2% 
xylocaine and 0.5% bupivacaine. Caution to 
be taken to avoid inadvertent globe perforation 
which can increase the risk of orbital tumor 
dissemination. Vitreoretinal management of 
 complications of globe perforation is both com-
plicated and controversial.
 Surgical Steps for Radioactive Plaque 
Surgery
The chart should be reviewed immediately prior 
to implantation surgery. Eye lid skin and peri-
orbital area is sterilized with 10% povidone 
iodine solution with application of 5% povidone 
iodine eye drops in the conjunctival cul de sac. 
Then the patient should be draped with only the 
operative eye exposed for surgery. Then a sec-
ondary examination (ophthalmoscopy or ultra-
sound imaging) should be performed to confirm 
the presence of the tumor and condition of the 
eye. An eyelid speculum is placed. Then a lim-
bal conjunctival periotomy is followed by open-
ing of the intermuscular septa (Tenon’s fascia) 
in all four quadrants. This is performed using a 
curved tenotomy scissors which is placed with 
closed blades in the episcleral space between the 
muscles. The scissors are opened in the orbit and 
withdrawn with open blades thereby lysing the 
intermuscular septa.
 Anterior Plaques
Melanomas of the anterior uvea, ciliary body, 
and iris are commonly treated with plaque radia-
tion [1, 17] (Video 14.3). Such treatment offers 
a method to cure the patient without intraocular 
surgery and often preserves the iris and its func-
tion. However, epicorneal plaque position can be 
painful and cause corneal erosions. This is why 
centers place a thin layer of donor tissue (e.g., 
amniotic membrane) as a buffer between the 
plaque and the cornea [25, 26]. In addition, inser-
tion is complicated by “backward” plaque place-
ment where the plaque eyelets are rotated onto 
the sclera as to avoid eyelet corneal suturing (see 
youtube.com/watch?v=B8IxecQCGOQ).
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 Circumpapillary Plaques
While the intraocular optic disc diameter is typi-
cally 1.8  mm, behind the eye the optic nerve is 
encased within the optic nerve sheath (ONS). The 
retrobulbar optic nerve sheath diameter is typically 
5–6 mm, which means that a plaque placed against 
the ONS can only reach to 1.5 mm from the optic 
disc [3, 27–29]. The ONS presents a significant 
obstruction to normal radioactive plaque place-
ment, defined by the ABS as covering the tumor 
plus a 2–3 mm margin. In order for a plaque to 
overcome the ONS diameter, 8-mm wide (vari-
able depth) slots have been cut from COMS-
type plaques. In that the seeds are the radioactive 
sources, the space within the slot can be filled with 
radiation. However, this requires more complex 
medical physics planning that guides placement of 
seeds within the plaque [27]. Due to their sharp 
penumbra and the 8-mm slot distance, complete 
tumor coverage or “normal plaque placement” 
cannot be achieved with solid 106Ru plaques.
 Radioactive Plaque Placement
Most uveal melanomas are located in the poste-
rior choroid. Herein we include a movie showing 
plaque insertion for a posterior choroidal mela-
noma (Video 14.4). However, melanomas can 
occur beneath a variety of extraocular muscles 
as well as near the optic nerve. Any muscles that 
might interfere with plaque placement or displace 
the plaque during treatment should be temporar-
ily relocated to a location that will not disturb the 
plaque. This typically requires standard disinser-
tion on locking sutures. They will be returned 
to their original insertions at the time of plaque 
removal. Permanent diplopia is uncommon [30].
Transillumination of the eye (transocular or 
transpupillary) will allow the surgeon to view 
the tumors shadow. The edges of the shadow 
are marked as well as the 2–3 mm surrounding 
free margin with tissue dye on the sclera. Scleral 
depression, diathermy marking, and/or focal light 
transillumination may be required for patients 
with darkly pigmented choroid.
A dummy plaque is placed on the sclera 
overlying the tumor and is anchored to the 
sclera using sutures passed through the eye-
let of the plaque. Temporary knots are used 
to secure the dummy plaque. Intraoperative 
ultrasound (with the probe wrapped in a sterile 
sleeve) should be performed to ensure accurate 
localization of the plaque. Once ensured, the 
dummy plaque is removed and the radioactive 
plaque is secured in place using the aforemen-
tioned sutures.
In some centers, the radioactive plaque is 
used instead of a dummy plaque, thus avoiding 
one step. This change increases irradiation of 
the surgeon, eliminates possible differences in 
dummy- active plaque suture-related placement, 
allows for ultrasonographic verification of the 
actual radioactive device and decreases surgical 
time. After plaque placement, the conjunctiva 
is closed with absorbable sutures. Peribulbar 
infusion and topical antibiotic and steroid are 
placed. The eye is covered with a soft pad and 
a lead shield. Removal of the plaque can also 
be performed under local or general anesthesia. 
When the plaque has been placed to treat con-
junctival lesions, it can be removed under topical 
anesthesia.
 The Russian Experience 
with Strontium-90
 Case Selection
Сonjunctival melanoma, squamous carcinoma, 
and lymphomas may be treated. Brachytherapy of 
biopsy proven tumors with the exception of uveal 
melanoma. Tumor thickness should not exceed 
3–4 mm. Maximum diameter is practically irrel-
evant, because the irradiation can be performed 
in several fields. Margins extend 3–4 mm beyond 
the visible tumor (on every side). In cases of 
thicker conjunctival tumors, surgical removal is 
performed prior to brachytherapy.
Contraindications:
 1. Full lid-thickness infiltration.
 2. Intraocular and orbital extension.
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Methods:
 1. Brachytherapy performed in a reclining chair.
 2. Local anesthesia.
 3. Head fixation.
 4. Strontium-90 plaque (Resotech) is applied to 
the targeted zone, using a rod (plaque holder) 
fixed to a headlamp retainer.
 5. Single dose applied over 10–30 min.
Dose (cumulative dose at depth):
 1. For melanoma, 200  Gy; carcinoma, 120–
150 Gy; lymphoma, 90–110 Gy.
 2. Single dose in a depth, 10–15 Gy.
Strontium-90 for uveal melanoma:
 1. Tumor thickness up to 3.5 mm.
 2. Dose to the apex 200–230 Gy.
Strontium-90 for retinoblastoma:
 1. Tumor thickness up to 3.5 mm.
 2. Dose to the apex, 120–150 Gy.
 Postsurgical Procedures
The patient is treated with topical steroid antibi-
otic eye drops on a tapering schedule for 4 weeks 
and is examined periodically depending on the 
type of tumor and plaque treatment.
 Radiation Surveys and Regulations
After each case (insertion and removal), the 
patient’s eye and operating room are assessed 
to ensure that emitted radiation falls within the 
prescribed and acceptable range. Precautions 
and safety measures are detailed to the patient 
and attenders. Please consult your governmen-
tal regulatory authority governing the use of 
radiation. Each locality typically prescribes 
the practices related to patient handling after 
brachytherapy. For instance, in India patients 
are hospitalized for the duration of treatment. In 
New York City, using 125I and 103Pd, they are sent 
home or to a hotel until plaque removal.
Governing regulatory agencies for most cen-
ters require radiation surveys to ensure a radio-
logically safe environment for the staff, patient, 
and general public. You should consult your gov-
ernment regulatory agency to determine require 
radiation safety procedure. The practice of radia-
tion surveys should follow the radiation source(s) 
towards documenting the environment before 
and after their introduction.
Specifically, this may include receipt of the 
sources from the manufacturer with wipe tests 
and radiation survey of the shipping package; 
wipe tests and radiation survey of the brachy-
therapy source(s) upon opening the shipping 
package; radiation survey of the assembled 
brachytherapy treatment device preceding 
sterilization; radiation survey of the operating 
theater and the patient preceding implant; radi-
ation survey of the operating theater, patient, 
and sterilization container following implant; 
radiation survey of the operating theater, 
patient, and sterilization container preceding 
explant; and radiation survey of the operating 
theater, patient, and sterilization container fol-
lowing explant. Expected and maximum per-
missible exposure rates should be included in 
a standardized form. Survey instrumentation 
should be calibrated for the radiation quality 
and expected exposure rates.
 Summary
The authors of this chapter recognize the sig-
nificant challenges that face any center starting 
a new ophthalmic radiation therapy program. 
However, those who are willing to orga-
nize this effort will likely see generations of 
patients benefitting from sight and life-saving 
treatment.
This chapter was created to serve as a starting 
point for ophthalmologists, radiation oncologists, 
and medical physicists around the world. Herein, 
we pledge to share our knowledge in support to 
your efforts.
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The partnership between an ophthalmologist 
and an ophthalmic pathologist is critical to 
ensure that the final histopathology report is 
accurate and intelligible and contains as much 
relevant information to ensure safe patient 
management. At all stages of this process, 
clear verbal and written communication is 
key; every link in the chain must be robust to 
ensure the patient comes to no harm. To quote 
Professor Christopher Fletcher, Director of 
Surgical Pathology at Harvard Medical School, 
‘the reality is that the histology report is the 
principal determinant of diagnosis, likely clini-
cal course and therapy in any patient found to 
have a mass….’ [1].
Ocular pathology specimens travel through 
three phases: pre-analytical (pre-surgery com-
munication, surgery, request form, specimen 
handling prior to fixation, fixation and trans-
portation), analytical (processing of specimen, 
stains, ancillary investigations and histologi-
cal interpretation by pathologist) and post-
analytical (histopathology report, post-report 
discussion at multidisciplinary meeting, sup-
plementary reporting).
This chapter will cover the following topics:
• Pre-analytical phase
 – Pre-surgical planning.
 – The ophthalmic pathology request form.
 – Handling specimens in theatre before 
fixing.
 – Fixation.
 – Transportation of specimens to the histopa-
thology laboratory.
• Post-analytical phase
 – Basic histopathology terminology and 
understanding the histopathology report.
 – The use of ancillary investigations in oph-
thalmic pathology.
 – Ocular tumour prognostic factors.
As this chapter is meant to be a practical guide 
for clinicians, it will not cover the analytical aspects 
of how the specimen is grossed/cut up, its process-
ing or staining in the ocular pathology laboratory. 
Many texts are available that cover these steps in 
detail and interested readers should consult these.
 Pre-analytical Phase
 Discussion of Cases Prior to Surgery
Some cases (complex margins), specimens 
requiring frozen sections or those requiring spe-
cial requirements (e.g. certain fixatives), are best 
discussed in advance with the ocular pathology 
laboratory. This will ensure the pathology 
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 laboratory can meet the needs of the surgical 
procedure and ensure adequate handling without 
compromising the specimen.
 How to Complete the Ophthalmic 
Pathology Request Form [2]
A pathology request form is a referral letter and 
a primary source of communication between 
the ophthalmologist and pathologist. It is also 
a medico- legal document. For all specimens 
submitted to the laboratory, a fully completed 
request form should accompany each case. 
Request forms are designed to provide:
• Unique identification of the patient.
• A destination for the report and any charging 
information.
• The laboratory with the clinician contact 
details if discussion of the case is required.
• Date and time of specimen collection/removal 
and investigations required (e.g. histology/
cytology).
• Type of specimen and anatomical site of ori-
gin. This is especially important for multiple 
map biopsies taken from the conjunctiva to 
establish the extent of ocular surface squa-
mous, sebaceous and melanocytic malignan-
cies. It is critical that the request form include 
a diagram indicating the precise origin of each 
biopsy.
• Clinical information so that the pathologist 
may handle the specimen appropriately and 
interpret microscopic findings in the proper 
context.
• An awareness of any health and safety issues 
with a given specimen.
• Complete information must be supplied on the 
request form. Each specimen container, no 
matter how small, should also be labelled with 
the appropriate patient identification data 
(minimum of three identifiers, e.g. first and 
last name, date of birth/age and gender and 
preferably patient’s hospital no).
• The information must be consistent with the 
request form, to prevent errors in specimen 
and patient identification.
See Fig. 15.1a–e showing examples of well- 
filled out and suboptimally filled out pathology 
request forms.
 Specimen Handling in Operation 
Theatre Prior to Fixation
 Multiple Specimens from a Surgical 
Procedure
As a general principle, specimens from different 
locations should be placed in separate fixation 
pots. If multiple pieces of tissue from different 
sites are placed in the same fixation pot and one 
of the pieces of tissue turns out to be malignant, 
it is impossible to ascertain where the tissue has 
been sampled from.
 Orientation of Specimens
Orientation of specimens is required, to ensure 
the pathologist can report the margins of exci-
sion accurately. This is best done by plac-
ing sutures at particular margins and then 
specifying the sutured margin on the pathol-
ogy request form in writing or as a diagram 
(Fig. 15.2a).
 Conjunctival Mapping Biopsies
Conjunctival biopsies comprise thin strips of 
epithelium and stroma and are prone to curling 
if placed straight into fixative. They should be 
attached to sponge or card before placing into 
the fixative, so that they arrive in the ocular 
pathology laboratory in a flattened state. The 
latter facilitates orientation during embedding 
H. S. Mudhar
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Fig. 15.1 (a–c) These are examples of well-filled out 
pathology request forms that detail all the relevant infor-
mation. (c) The surgeon has drawn a very useful diagram, 
to indicate the orientation of the specimen. (d, e) 
Suboptimally filled out pathology request forms that 
merely state the procedure carried out with no indication 






and greatly facilitates the histological assess-
ment for the presence or absence of invasion 
by tumour. If multiple mapping biopsies are 
performed, the pathology request form must 
state the precise location of the biopsies. 
Figure  15.2b shows a very helpful diagram 
drawn by the surgeon that shows the extent 
of this patient’s conjunctival lesion (shaded 
areas) and the precise location of the mapping 
biopsies.
 Sampling Fresh Tissue Prior 
to Fixation
Some tumours require to be sampled fresh for 
special genetic/ molecular investigations (diag-
nostic and prognostic testing) or for research.
• In the case of an enucleation, sample the 
optic nerve first and place in a separate pot 






contaminating the optic nerve resection 
margin.
• The globe is transilluminated and using a 
scalpel, a sclera-choroidal flap is created 
beneath the tumour, leaving the scleral-
choroidal flap hinged along one side. Fresh 
tumour is harvested with scissors and 
forceps.
• Fresh tumour is placed in an appropriate 
medium and vessel.
• Some use a corneal trephine to cut a window 
into the sclera and choroid.
• After harvesting fresh tumour, the specimen is 
fixed.
• An alternative strategy is to submit the intact 
specimen unfixed to the ocular pathology 
 laboratory, where the above steps can be car-
ried out.
 Fixation of Ocular Pathology 
Specimens
 Routine Surgical Specimens
Standard 10% phosphate-buffered formalin in 
a leak-proof container is the fixation of choice 
(Table 15.1) [3–5]. This will allow routine hae-
matoxylin and eosin staining (H&E), other spe-
cial tinctorial stains and immunohistochemistry. 
In addition, numerous molecular studies for 
diagnosis and prognosis can be performed on 
formalin- fixed tissue (Fig. 15.3a).
• If certain molecular biological diagnostic 
techniques or research is to be done on unfixed 
tumour samples, the clinician or assistant 
must remove fresh tumour from the specimen 
prior to fixing in formalin.
• The formalin should ideally be 10x the vol-
ume of the specimen to allow timely penetra-
tion of the tissues at room temperature. To 
ensure this, an adequate sized plastic container 
is required. Most well-stocked pathology labs 
have a variety of sizes of plastic container to 
facilitate this. Many containers come pre- 
filled with formalin (Fig. 15.3a).
• Specimens should be placed into the container 
that has been pre-filled with formalin. If for-
malin is poured into a dry container that has 
the specimen in it, there is a chance that the 
specimen will be ejected by the formalin and 
will end up on the bench or floor.
• Specimen containers must then be sealed 
tightly with the lids to avoid spillage of haz-
ardous formalin.
• Smaller containers are then usually placed in a 
plastic bag which also accommodates a side 















Fig. 15.2 (a) shows an eyelid skin ellipse excision orien-
tated by the surgeon using two sets of sutures. 
(b) A conjunctival mapping biopsy diagram sketched by 
the surgeon in theatre. The hash shading denotes the dis-
tribution of the lesion and the letters denote the locations 
of the biopsies that correspond to the formalin pots into 
which the biopsies have been placed/fixed
15 Ocular Pathology
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Table 15.1 Various surgical specimen types and fixations used
Type of specimen Type of fixative
Eyelid tumour incisional biopsy 10% buffered formalin
Eyelid tumour excision 10% buffered formalin
Conjunctival tumour biopsy 10% buffered formalin
Conjunctival tumour excision 10% buffered formalin
Intraocular solid tissue biopsy (not FNA) 10% buffered formalin
Localised resection of intraocular tumour 10% buffered formalin
Tumour enucleation 10% buffered formalin—remember to sample any fresh 
tumour prior to fixation if indicated
Tumour exenteration 10% buffered formalin—remember to sample any fresh 
tumour prior to fixation if indicated
Orbital tumour biopsy 10% buffered formalin
Orbital tumour excision 10% buffered formalin—remember to sample any fresh 
tumour prior to fixation if indicated
Lacrimal drainage system/sac biopsy or excision 10% buffered formalin
Aqueous tap for cytology Equal volume of CytoLyt or similar methanol-based 
fixative
Aqueous tap for flow cytometry RPMI
Vitreous tap or pars plana vitrectomy specimen for 
cytology
Equal volume of CytoLyt or similar methanol-based fixative
Vitreous tap or pars plana vitrectomy specimen for 
flow cytometry
RPMI
FNA intraocular of solid tumour (e.g. retinal, 
subretinal uveal tumour and orbital)
CytoLyt or similar methanol-based fixative
a b
Fig. 15.3 (a) shows a globe specimen (containing a 
uveal melanoma) in a standard plastic pot, containing 
10% buffered formalin for fixing the specimen. (b) This is 
a universal tune that contains green, methanol-based cyto-
fixative for intraocular tumour aspiration cytology. The 
colour of the fluid varies according to the manufacturer. 
(c) The arrows point to black specs of an aspirated mela-
notic tumour, fixed in cytofixative in a universal tube. (d) 
This is a vitrectomy cassette containing vitreous washings 
from a patient with suspected intraocular lymphoma, 
fixed in green cytofixative of a volume equal to the vol-
ume of the vitreous washings. (e) This shows an impres-
sion cytology plastic ring, fixing in 10% buffered formalin. 
(f) A small plastic tube containing buffered glutaralde-




your institutional standard operation protocols 
for additional packaging.
• The appropriate institutional health and safety 
protocols must be followed when handling 
formalin.
 Which Specimens Should Not Be Fixed?
• Tissue destined for frozen sections (to assess 
margins of excision for eyelid, adnexal and 
orbital tumours).
• Tissue for research or tissue banking.
• Some tumours requiring prognostic informa-
tion (e.g. sarcomas, paediatric small round 
blue cells tumours, retinoblastoma) may 
require special studies on fresh tissue.
• Biopsies destined for flow cytometry (e.g. vit-
reous and fine-needle aspiration specimens for 
assessment of lymphoma). In this situation, 
many practitioners send the cell sample in 
Roswell Park Medical Institution medium 
(RPMI) to enhance the survival of the cells.
• Some labs still do Oil Red O staining for sus-
pected cases of sebaceous carcinoma. 
However, this is being superseded by haema-







 Fixation of Cytology Specimens
• Fine-needle aspiration specimens (FNA) are 
preferably fixed in CytoLyt or Shandon cyto-
fixative (or equivalents) which are methanol- 
based mild fixatives (Table  15.1). They 
preserve the cyto-morphology well and permit 
good-quality DNA to be extracted for molecu-
lar diagnostic tests. CytoLyt preserved speci-
mens can be used to make thin-prep slides as 
well. FNA samples are usually squirted into 
pre-filled universal tubes that contain the fixa-
tive. The syringe used in the collection of the 
sample may be submitted with the fluid inside. 
Needles must be removed and the syringe 
capped. If the specimen is to be fixed, an equal 
volume of cytology fixative may be drawn up 
into the same syringe, capped and then agi-
tated gently to mix the sample with the fixa-
tive (Fig. 15.3b, c).
• Vitrectomy specimens: It is preferable to 
receive a pars plana vitrectomy specimen in a 
vitreous cassette or bag. If samples are 
required for microbiology, virology, PCR, 
etc., please remove these from the cassette/
bag before fixation, although, ideally, these 
should have been sent from the initial core vit-
reous tap. Vitrectomy samples need to be pre-
served/fixed in an equal or excess volume of 
RPMI or cytology fixative. It is important to 
seal the bag or cassette to prevent leaks in 
transit (Fig. 15.3d).
• Impression cytology plastic rings can be 
dropped into a small pot of formalin for fixa-
tion (Fig. 15.3e).
 Fixation of Specimens Requiring 
Transmission Electron Microscopy
• Buffered 2.5–3% glutaraldehyde is used to 
fix fresh specimens for transmission electron 
microscopy. This would be done for cases 
that are intended for research or in which the 
original interpretation of an initial tumour 
biopsy was equivocal and clarification is 
sought from ultrastructure. It is best to place 
only part of the fresh tissue into buffered glu-
taraldehyde, as whilst it is an excellent fixa-
tive for ultrastructure, it adversely affects 
antigen retrieval for immunohistochemistry 
and extraction of DNA for molecular studies 
(Fig. 15.3f).
 Transporting Specimens 
to the Pathology Laboratory
 High Risk/Danger of Infection 
Specimens
• It is the ophthalmologist’s responsibility to 
indicate on the request form and the specimen 
pot if the patient is known or suspected to be a 
‘High Risk/Danger of Infection’ category 
(e.g. HIV, TB, hepatitis B, hepatitis C), to 
facilitate appropriate handling in the 
laboratory.
• It is the ophthalmologist’s responsibility to 
ensure that all specimens are submitted to the 
laboratory in suitable and approved 
containers.
• Approved specimen containers have leak- 
proof lids and the appropriate hazard warning 
signs for the fixative, e.g. formalin.
• Specimen containers should be closed securely 
and placed inside a sealed specimen bag.
• Specimens received leaking or damaged are a 
danger to all those who come into contact with 
them, including theatre staff, porters and labo-
ratory staff and can also compromise the 
diagnosis.
 Mailed or Couriered Specimens
• Specimens mailed or couriered should be 
packaged in approved containers in accor-
dance with the requirements of the delivery 
service. To confirm receipt of specimen(s) 
in the department, it is good practice that a 
‘confirmation of receipt fax-back’ form, 
providing the senders’ confidential fax num-




 Understanding the Ophthalmic 
Histopathology Report
The ophthalmic histopathology report contains 
a lot of specialised pathology terminology that 
can seem rather bewildering. To understand his-
topathologic terminology related to tumours, it 
is best to return to basics. Table 15.2 outlines the 
tissue of origin and their related tumours that 
are commonly encountered [6] (Fig. 15.4a–j).
Knowledge of this basic table does go a 
long way to understanding the various tumours 
encountered in ocular oncology practice and 
their behaviour and prognosis. It also allows for 
a conversation with your local pathologist, who 
is often equally keen to learn specialised oph-
thalmology terminology to enhance the quality 
and clarity of the professional interaction.
 Examples of Histopathology Reports 
with Explanations of Specialised 
Terminology
Set out below are examples of ophthalmic his-
topathology reports that may be encountered in 
a busy ocular oncology practice with specialised 
terms defined and figures provided for clarity [6].
 Eyelid Tumour Histopathology 
Report Example
This full thickness wedge excision contains 
an invasive neoplasm. It is arising from the 
Meibomian gland and is composed of pleo-
morphic cells, with vacuolated cytoplasm, 
indenting the nuclei. Numerous mitotic fig-
ures are present. The individual tumour cells 
exhibit hyperchromatic chromatin and nucleoli 
are prominent. Foci of intraepithelial paget-
oid spread are seen over the invasive tumour, 
involving the tarsal conjunctival epithelium and 
the epidermis of the skin. The invasive tumour 
shows focal comedo-like necrosis and shows 
vascular and perineural invasion.
Immunohistochemistry shows that the inva-
sive tumour is positive for adipophilin, EMA and 
shows nuclear androgen receptor positivity.
The features are those of an invasive seba-
ceous carcinoma, derived from the meibomian 
gland. The excision of the invasive component 
is complete (nearest margin is 3 mm). However, 
the pagetoid spread contaminates the tarsal con-
junctival margin and is therefore incompletely 
excised.
Sebaceous neoplasms can be associated with 
the Muir-Torre syndrome. Is there a history of 
internal malignancies in this patient or is there a 
family history of malignancies?
Table 15.2 Tissues of origin and related tumours
Tissue of origin Benign In situ Invasive malignancy
Squamous Epithelium Squamous cell papilloma In situ squamous 
carcinoma




Sebaceous adenoma In situ sebaceous 
carcinoma
Invasive sebaceous carcinoma
Melanocytes Nevus In situ melanoma Invasive malignant melanoma
Blood cells Reactive lymphoid 
hyperplasia
Lymphoma or leukaemia





Fig. 15.4 (a) Haematoxylin & eosin (H&E)-stained his-
tology image of a typical viral squamous papilloma of the 
conjunctiva. Note the typical cauliflower-like appearance 
caused by the fibrovascular cores covered in thickened 
epithelium. (b) H&E-stained section showing conjuncti-
val in situ squamous carcinoma. The epithelium is thicker 
than usual and packed full of atypical nuclei, with no 
maturation at all. (c) H&E section showing conjunctival 
invasive squamous cell carcinoma with keratin formation. 
The latter is the orange material in the centre of the irregu-
lar invasive islands of tumour. (d) H&E of a cystic con-
junctival nevus. The asterisk is the cystic space and the 
arrow points to the bland, monotonous nevus cells. (e) 
H&E of conjunctival in situ melanoma. The arrow points 
to the melanoma cells confined to the epithelium. (f) H&E 
of invasive conjunctival melanoma. The asterisk indicates 
an invasive nodule of melanoma in the substantia propria. 
(g) H&E of reactive lymphoid hyperplasia. The thicker 
arrow shows the paler germinal centre lymphocytes of the 
well-organised nodular lymphoid tissue. The thinner 
arrow indicates the darker staining mantle lymphocytes, 
surrounding the germinal centre lymphocytes. (h) H&E of 
a conjunctival extranodal marginal zone lymphoma. Note 
the sheet-like population of monotonous lymphoid cells. 
(i) H&E of an alveolar variant rhabdomyosarcoma of the 
orbit. (j) H&E of a higher power of Fig.  15i showing 
small round blue cells with occasional larger pink (eosin-
ophilic cells) present. (k) H&E of a squamous cell carci-
noma of the conjunctiva that illustrates nuclear size, shape 
and colour variation-called pleomorphism and is a feature 
of malignant cells. (l) H&E of the same tumour in plate K 
showing a typical tumour mitotic figure (arrow). (m) 
H&E showing cytoplasmic vacuolation (clear spaces) of 
sebaceous tumour cells (arrow). (n) H&E of a sebaceous 
carcinoma with the arrow pointing to a hyperchromatic 
nucleus (darker in shade compared to other nuclei in 
image). (o) H&E of a sebaceous carcinoma showing 
intraepithelial ‘Pagetoid’ spread (arrows). (p) H&E of a 
retinoblastoma. The asterisk indicates pink irregular 
necrotic tumour. (q) H&E of an adenoid cystic carcinoma 
of the orbit showing tumour around a nerve (arrow). This is 
perineural invasion. (r) Melanoma cells (stained red) are 
within the lumen of a lymphatic channel (stained brown). 
This is intra-lymphatic spread of tumour. (s) H&E of con-
junctival squamous dysplasia (mid- to right aspect of 
image). The latter epithelium is thicker compared to the 
epithelium on the left which is much thinner. (t) H&E of a 
spindle-rich uveal melanoma. (u) H&E of an epithelioid 
rich uveal melanoma. The cells are much rounder and 
larger compared to the spindle cells in plate T.  This is 
because they possess larger nuclei and more cytoplasm. (v) 
This is a Periodic Acid Schiff’s (PAS) stain of a uveal mela-
noma showing rounded clones of tumour cells surrounded 
by pink/purple basement membrane boundaries, so-called 
loops. (w) This is a fluorescence in situ hybridisation 
(FISH) image showing different chromogenic-labelled 
DNA probes (green, red, blue, yellow) hybridising with 
various gene loci. (x) This is an orbital lymphoma stained 
with a B-cell marker antibody called CD20, by the tech-
nique of immunohistochemistry. The positive cells stain 
brown (different coloured chromogens can be employed 
such as red, brown, blue, etc.). Note how it is the cell mem-
branes that stain, imparting a chicken-wire appearance. (y) 
This is an orbital lymphoma stained with Ki67 antibody by 
immunohistochemistry. The antibody stains the nuclei 
brown. The proliferation fraction of the tumour can be esti-
mated by counting the number of stained nuclei out of 100 
cells. (za) This trace shows a typical polyclonal population 
of B-cells when assessed for B-cell IgH rearrangement by 
PCR. Note the spread of varying sized peaks in a Gaussian 
dumbbell curve configuration. The histology showed a 
reactive lymphocytic population in the vitreous with a final 
diagnosis of chronic vitritis. (zb) This trace shows a typical 
monoclonal population of B-cells when assessed for B-cell 
IgH rearrangement by PCR. The final diagnosis was vit-



















Invasive Malignant tumours invade through base-
ment membranes into the surrounding tissue and 
can metastasise by invading into blood vessels and 
lymphatics.
Neoplasm Literally means ‘new growth’ 
(derived from Greek).
Pleomorphic Variation is size and shape of the 
nucleus and cytoplasm of the individual tumour 
cells. This is a feature of malignant cells that have 
lost their normal constraining signals (Fig. 15.4k).
Mitotic Figures Prophase, metaphase, anaphase, 
telophase and cytokinesis are the five phases of 
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Mitotic figures are seen in normal and repairing tis-
sues. An example of a normal tissue containing 
mitotic figures is the proliferative phase of endome-
trial glands and stroma. When injured tissue is 
regenerating, it is common to see many mitotic fig-
ures, e.g. regenerating epithelium in skin after 
trauma. Benign and malignant tumours contain 
mitotic figures. Malignant tumours tend to have 
more mitotic figures than benign tumours. Of the 
malignant tumours, poorly differentiated tumours 
tend to have higher mitotic figure counts compared 
to better differentiated tumours. In malignant 
tumours, the mitotic figures can have an abnormal 
morphology that is not seen in benign, normal or 
regenerating tissues. These include tripolar or mul-
tipolar forms (Fig. 15.4l).
Vacuolated A bubbly appearance to the cyto-
plasm due to the presence of various substances. 
In this case, it is lipid as the diagnosis is seba-
ceous carcinoma. It could be mucin (mucin 
forming carcinomas) or glycogen (e.g. renal cell 
carcinoma). The products made by tumour cells 
can be very helpful for classification 
(Fig. 15.4m).
Hyperchromatic Chromatin Simply means 
dark staining DNA in the nucleus. This is a fea-
ture of malignant cells (Fig. 15.4n).
Intraepithelial Within the confines of the 
epithelium.
Pagetoid Horizontal and vertical spread of 
malignant tumour cells as individuals or groups 
within epithelium. Named after Sir James Paget, 
an English surgeon and pathologist who described 
Paget’s disease that shows this pattern of spread. 
Tumours that show this pattern of spread include 
malignant melanoma and sebaceous carcinoma 
(Fig. 15.4o).
Comedo Literally means like a ‘zit’. Malignant 
tumour cells forming sheets are hypoxic in the 
middle and undergo necrosis. The appearance is 
that of a necrotic centre surrounded by a viable 
rim of malignant tumour cells. If the tissue is 
squeezed gently during handling, the necrotic 
tumour centre oozes out of the cut surface like 
zits being squeezed.
Necrosis Cell death with loss of cell contents to 
the exterior. Malignant tumours that outstrip their 
blood supply often become necrotic (Fig. 15.4p).
Vascular and Perineural Invasion Malignant 
tumours can invade into vessels and metastasise 
to distant locations. They also follow the paths of 
least resistance and spread along natural tissue 
scaffolds such as nerves (Fig. 15.4q, r).
Immunohistochemistry A common ancillary 
technique employed in histopathology to detect 
signature proteins using antibodies in various 
disease processes. In malignant tumours, it can 
help to type the tumour (e.g. carcinoma, lym-
phoma, melanoma, sarcoma) and can also reveal 
vital prognostic and therapeutic information.
Carcinoma A malignant epithelial neoplasm.
 Further Comments
The last comment in the report relates to the sur-
gical margins. In this case, the contamination of 
the conjunctival margin may necessitate mapping 
biopsies to ascertain the extent of the pagetoid 
spread that would inform subsequent therapy 
choices.
 Conjunctival Tumour Histopathology 
Report Example
The bulbar conjunctiva contains a focus of in situ 
squamous carcinoma, arising in a background 
of various degrees of dysplasia. No invasion is 
identified in the planes examined. The surgical 
margins are clear. The background stromal tissue 
shows solar elastosis.
 Terminology Explained
Dysplasia Derived from Greek meaning ‘disor-
dered growth’. Dysplasia is a term that is applied 
to epithelium. Histologically, the individual epi-
thelial cells show pleomorphism (defined above), 
can have hyperchromatic nuclei and have a disor-
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ganised distribution within the epithelium. 
Mitotic figures may be seen. Pathologists can 
grade epithelial dysplasia according to how much 
of the epithelial thickness is occupied by the dys-
plastic cells. For example, common classifica-
tions of epithelial dysplasia are mild, moderate 
and severe or low-grade and high-grade. When 
the full thickness of the epithelium is consumed 
by dysplastic cells and the basement membrane 
has not been breached, it is called carcinoma in 
situ and is said to be pre-invasive. Invasion is not 
present. Therapeutic intervention at this stage of 
the disease is potentially curative (Fig. 15.4s).
 Intraocular Tumour Histopathology 
Report Example
This enucleation contains a malignant melanoma 
of uveal type. It is located in the ciliary body and 
choroid and has a diffuse component. It is com-
posed of spindle and epithelioid cells and has up 
to 15 mitotic figures per 10 hpf. Closed loops and 
networks matrix patterns are seen. Focal tumour 
necrosis is present. The tumour does not breach 
Bruch’s membrane. There is no scleral invasion. 
The vortex veins are tumour-free. FISH analysis 
on the tumour has shown monosomy 3 and a gain 
of iso-chromosome 8q in 90% of the cells.
Summary: A pathological stage pT3b uveal 
melanoma of the ciliary body and choroid. The 
presence of monosomy 3 and iso-chromosome 
8q indicates a poor prognosis.
 Terminology Explained
Spindle and Epithelioid Cells This refers to the 
shape of the cells found in uveal melanoma, 
referred to as the Callender classification. This is 
of prognostic significance; more epithelioid cells 
carry a worse prognosis [7] (Fig. 15.4t, u).
Per 10hpf This is a mitotic count performed in 
10 ‘high-power fields’ (each with an area of 
0.152 mm2 and usually corresponding to a ×40 
lens on a high-quality light microscope).
Closed Loops and Networks’ Matrix 
Patterns This refers to the presence of specific 
basement membrane patterns stained with a peri-
odic acid-Schiff (PAS) stain, present around 
expanding nests of melanoma cells. These matrix 
patterns are related to a poorer prognosis in uveal 
melanoma [8] (Fig. 15.4v).
FISH: Fluorescence In Situ Hybridisation 
FISH has been used in this case to gain genetic 
data on the status of chromosomes 3 and 8 in this 
uveal melanoma. Uveal melanoma genetics data 
is a powerful predictor of prognosis [9–13] 
(Fig. 15.4w).
Pathological Stage pT3b This refers to the 
TNM pathological classification of the stage of 
the uveal melanoma [14].
 Further Comments
Ophthalmic pathologists will use the TNM14 or 
AJCC [15] cancer staging manuals to include all 
of the relevant tumour prognostic information 
required for prognosis and treatment planning for 
uveal melanoma.
Also note how the report has combined histo-
pathological and genetic data. This is increasingly 
common and is called integrated reporting, in the 
context of individualised oncology practice.
 Orbital Tumour Histopathology 
Report Example
This orbital fat biopsy contains numerous reactive 
lymphoid aggregates. On this background, there 
is a larger expansile nodule composed of small 
lymphocytes, with a monocytoid appearance, 
associated with cells exhibiting lymphoplasma-
cytic differentiation. These monocytoid cells are 
positive for B-cell markers using immunohisto-
chemistry (CD20 and CD79a positive) and are 
negative for CD5, CD10, Cd23 and Cyclin D1. 
The Ki67 fraction is 5%. PCR for IgH rearrange-
ment shows clonal peaks in FR1, FR2 and FR3 
confirming an unequivocal clonal population of 
B lymphocytes.
The appearances are those of an indolent 
B-cell lymphoma, sub-classification: extrano-
dal marginal zone lymphoma of MALT type 
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(MALToma-WHO classification). This patient 
requires referral to your haemato-oncology ser-
vice for further management.
 Terminology Explained
Reactive Lymphoid Aggregates These are non- 
lymphomatous collections of lymphocytes com-
prising a germinal centre of larger lymphocytes 
undergoing apoptosis surrounded by a mantle of 
smaller lymphocytes. They indicate chronic anti-
genic stimulation and contain polyclonal groups 
of B lymphocytes.
Monocytoid Appearance It is common for a 
pathologist to describe the appearance of certain 
tumour cells with peculiar adjectives. Monocytoid 
means a lymphocyte nucleus within a clear cyto-
plasm, resembling a fried egg.
B-cell Markers This refers usually to immuno-
histochemistry markers for staining B-cells. 
Common markers include CD20 and CD79a. It is 
vitally important that any lymphoma should be 
differentiated into B or T cell type for diagnostic, 
prognostic and treatment purposes (Fig. 15.4x).
The Ki67 Fraction This refers to the % of cells 
that express Ki67. This protein is expressed in 
cells in all non-G0 phases of the cell cycle. It 
gives an indication of how fast tumour cells are 
proliferating. A higher Ki67 fraction tends to pre-
dict aggressive tumour behaviour (Fig. 15.4y).
PCR for IgH Rearrangement PCR, polymerase 
chain reaction. IgH-heavy chain of the immunoglob-
ulin molecule. This is a common molecular diagnos-
tic test performed in cases of suspected lymphoma.
Clonal Population of B Lymphocytes This 
means a population of B-cells all expressing the 
same heavy chain of immunoglobulin. 
Monoclonality usually means lymphoma but not 
always. Reactive lymphoid populations can con-
tain monoclonal lymphocyte populations. The 
pathologist will always interpret the results of 
ancillary diagnostic/supportive molecular tests in 
the  context of the clinical and histopathological 
findings (Fig. 15.4za, zb).
 Further Comments
Lymphoma diagnosis often requires histopatho-
logical, immunohistochemical and molecular 
diagnostic tests to secure a firm diagnosis. An 
ophthalmic pathologist will often discuss the case 
with a specialist lymphoma pathologist and the 
case reviewed at the local multidisciplinary team 
meeting to plan further investigations (e.g. stag-
ing) and treatment. Again, note how the report 
contains integrated items of histopathological 
and molecular data and a suggestion for referral 
to an appropriate clinical team.
 Common Ancillary Investigations 
Used in Ophthalmic Histopathology
Ancillary investigations are used to assist in mak-
ing a diagnosis and to give prognostic informa-
tion. The results of ancillary tests must always be 
interpreted alongside the light microscopic histo-
logical features in order to avoid an over or under 
diagnosis.
 Immunohistochemistry
This is the application of antibodies to antigens 
in formalin-fixed, paraffin-embedded sections, 
visualised with various coloured chromogens. 
The antibodies are directed toward certain pro-
teins that are expressed by specific cell types. 
Tumour cells express specific proteins allowing 
the tumour type to be established, which other-
wise may be difficult on light microscopic exami-
nation alone.
 Diagnostic Application
Example 1 Figure 15.5a shows a biopsy of the 
conjunctiva. The morphology shows atypical cells 
occupying the full thickness of the epithelium. The 
morphological differential diagnosis includes in 
situ melanoma, in situ squamous carcinoma and in 
situ sebaceous carcinoma. These are tumours with 
varying behaviour, prognosis and treatments so the 
diagnosis must be refined. Application of a small 
panel of antibodies allows discrimination. In this 








Fig. 15.5 (a) H&E of a conjunctival biopsy showing 
amelanotic atypical cells occupying the full thickness of 
the epithelium. (b) Melan A immunohistochemistry shows 
positivity in the atypical intraepithelial cells (brown sig-
nal), indicating in situ melanoma. (c) H&E showing a dif-
fuse sheet of round lymphoid cells. (d) The lymphoid cells 
in Fig. (c) are positive for CD20. (e) The lymphoid cells in 
panel c are positive for nuclear Cyclin D1, indicating a 
diagnosis of Mantle cell lymphoma. (f) BAP 1 immunohis-
tochemistry on a uveal melanoma showing nuclear positiv-
ity. (g) BAP 1 immunohistochemistry on another uveal 
melanoma showing a lack of nuclear staining. (e, courtesy 
of Dr. Karen Sisley, Senior Lecturer, Department of 
Oncology, Sheffield University, Sheffield, UK)
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(Fig.  15.5b) and negative for cytokeratin and 
androgen receptor. Melan A is a protein specific to 
melanoma cells. Cytokeratins are expressed by 
epithelial malignancies (in situ squamous and 
sebaceous carcinoma), and androgen receptor is 
expressed strongly by in situ sebaceous carci-
noma. The final diagnosis is in situ melanoma.
Example 2 This orbital biopsy shows a lympho-
cytic infiltrate that histologically is a lymphoma 
(Fig. 15.5c). However, every lymphoma must be 
precisely sub-typed as each lymphoma has a spe-
cific morphology, immunohistochemical pheno-
type, molecular signature, prognosis and treatment 
(WHO classification). Application of a panel of 
lymphoid markers shows that this lymphoma is of 
B-cell phenotype (positive for CD20, Fig. 15.5d) 
and furthermore is positive for Cyclin D1 
(Fig. 15.5e) which indicates the precise diagnosis 
of mantle cell lymphoma [16].
 Prognostic Application
Figure 15.5f shows a uveal melanoma that shows 
nuclear positivity for BAP1. Figure 15.5g shows 
nuclear BAP-1 absence in another uveal mela-
noma, an indication that the tumour is of prob-
able monosomy 3 genotype, associated with a 
poor prognosis [17].
 Polymerase Chain Reaction (PCR)
 Diagnostic Application
Sometimes, it is difficult to ascertain on light 
microscopy whether a lymphoid infiltrate is 
reactive or neoplastic. Formalin-fixed, paraffin- 
embedded extracted DNA can be tested for 
lymphocyte clonality, to establish whether a 
population of lymphoid cells are polyclonal 






























Fig. 15.6 (a) This trace shows a single, sharp peak indi-
cating a monoclonal population of B-cells when assessed 
for B-cell IgH rearrangement by PCR. (b) MLPA study of 
uveal melanoma showing ‘piano key’ score. The arrow 
points to an area of loss of one copy of chromosome 3 
(monosomy 3). (c) FISH study of an orbital alveolar rhab-
domyosarcoma showing separate green and red hybridisa-
tion dots within the nucleus. This indicates rearrangement 
of the FOXO1 gene on chromosome 13q14. (d) FISH 
study showing three uveal melanoma nuclei. The red dot 
indicates one copy of chromosome 3 (monosomy 3), and 
the extra blue dot in the nucleus on the right indicates a 
gain of chromosome 8q. (e) Array CGH result from a 
uveal melanoma. Chromosome deletions in red are on the 
left of the and gains in blue on the right of the chromo-
somes. This study shows a loss of chromosome 3 (left 
arrow) and a loss of 8p and gain of 8q (right arrow). Other 
changes include deletion of chromosome 1 and gains of 
chromosome 20 and 21. (f) SNP array data from a uveal 
melanoma showing loss of one copy of chromosome 3 
(left arrow) and loss of 8p and gain of 8q (right arrow). 
(Courtesy of: b, Professor Sarah E Coupland-Professor of 
Ophthalmic Pathology, Liverpool University, Liverpool 
UK; c, Dr Duncan Baker, Cytogeneticist, Sheffield 
Children’s Hospital, Sheffield UK; d, Dr Karen Sisley, 
Senior Lecturer, Department of Oncology, Sheffield 
University, Sheffield UK; f, Dr Natasha van Poppelen and 
Dr Rob Verdijk, Department of Pathology, Erasmus 
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The states of chromosomes 1, 3, 6 and 8 allow 
uveal melanoma to be stratified into good and 
bad prognostic categories. A technique called 
MLPA (multi-ligation-dependent probe ampli-
fication), which is a variation of PCR, can be 




This technique is used in some centres to ascer-
tain whether a neoplastic population of B or T 
cells are present in vitreous or aqueous biopsies, 
in limited material. It is a powerful technique 
for the diagnosis of lymphoma [19]. Multiple 
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antibodies directed to various lymphoid cell pro-
teins, including kappa and lambda light chains, 
are applied as a cocktail to an unfixed suspension 
of lymphoid cells.
 Fluorescence In Situ Hybridisation 
(FISH)
This technique uses fluorescent-tagged DNA or 
RNA probes to detect the presence or absence 
of a specific chromosome or the identification of 
two genes involved in a translocation. It can be 
used on cytology and paraffin-embedded tissue.
 Diagnostic Application
Many sarcomas have distinctive, diagnostic 
recurrent genetic translocations. The example in 
Fig.  15.6c shows a FISH analysis of an orbital 
alveolar rhabdomyosarcoma with the diagnostic 
1:13 translocation, which is also important as a 
prognostic marker in this tumour [20].
 Prognostic Application
Uveal melanoma can have its chromosome 3 and 
8 status tested by FISH [10, 12, 13] (Fig. 15.6d).
 Chromosomal Microarray Analysis 
(aCGH and SNP)
Techniques such as array comparative genomic 
hybridisation (aCGH)[21] and single nucleotide 
polymorphism (SNP) chromosomal arrays [22] 
are powerful tools to detect genome-wide copy 
number changes in chromosomes. Furthermore, 
SNP arrays can detect copy-neutral changes and 
loss of heterozygosity. These techniques can be 
applied to fresh and paraffin-embedded tumour 
tissue successfully.
 Diagnostic Applications
Can be used to help differentiate benign nevus 
from melanoma of the skin.
 Prognostic Application
Can be used in uveal melanoma prognostic chro-
mosomal analysis (Fig. 15.6e, f).
 Tumour Prognostic Factors
Histopathology reports contain critical bits 
of information that will reflect the biological 
behaviour of the tumour; hence, its prognosis 
will trigger specific clinical management. What 
follows are brief descriptions of prognostic fac-
tors for some ocular tumours impacting on clini-
cal management.
Every prognostic factor for every ocular 
tumour cannot be reproduced here. The relevant 
chapters in the TNM classification of Malignant 
Tumours (8th edition -UICC) [14] and the AJCC 
Cancer Staging Manual (8th edition) [15] have 
comprehensive lists of prognostic factors for 
all major ophthalmic tumours. Additionally, the 
tumour- reporting guidelines/datasets from the 
College of American Pathologists [23, 24] and 
the Royal College of Pathologists UK [25, 26] 
are a very comprehensive guide to macroscopic 
and microscopic prognostic factors for ocular 
tumours. Tumour prognostic factors from a path-
ological perspective can be macroscopic, micro-
scopic and molecular/genetic.
 Examples of Tumour Prognostic 
Factors Encountered in Ophthalmic 
Histopathology Reports
 Eyelid Basal Cell Carcinoma [14, 15, 27]
The growth pattern of basal cell carcinoma 
will be mentioned in a report. Infiltrating and/
or sclerosing/morphoea and/or micronodular 
growth patterns are high-risk growth patterns. 
These growth patterns correlate with a signifi-
cantly increased risk for local recurrence and 
very occasionally metastasis, hence high risk. 
The clearance of the tumour in ‘mm’ from spe-
cific margins will be mentioned in the report. 
Contaminated margins will trigger further treat-
ment to ensure clearance.
 Conjunctival Melanoma [14, 15]
For conjunctival melanoma, the site and depth 
of invasion determine the ‘pT’ staging of these 
tumours. Tumours of the palpebral, forniceal and 
caruncular conjunctiva are higher risk compared 
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to bulbar conjunctival tumours. The higher risk 
relates to recurrence and metastatic rates. The 
deeper the invasive component, the higher the pT 
stage.
 Retinoblastoma [14, 15, 23, 24]
The presence of ‘high-risk’ histopathological fac-
tors on a histopathology report of a retinoblas-
toma enucleation includes ‘massive choroidal 
invasion’, ‘extra-scleral tumour extension’, ‘optic 
nerve invasion’ and ‘anterior chamber exten-
sion’. These features will lead to post-enucleation 
chemotherapy.
 Uveal Melanoma [14, 15, 25, 26]
Iris melanomas have a much better prognosis 
that ciliary body and choroidal located tumours. 
Ciliary body and choroidal uveal melanomas 
with monosomy 3 and iso-chromosome 8q gain 
will have a poor prognosis, compared to tumours 
with balanced genetics.
 Orbital Alveolar Rhabdomyosarcoma
Histology reports will make the distinction 
between the different subtypes of orbital rhab-
domyosarcoma as they have different prognoses. 
An alveolar growth pattern which shows a 1:13 
or 2:13 translocation [28] has is more aggressive 
and of higher risk for recurrence and metastasis 
compared to the embryonal variant.
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 Appendices
 Appendix A: American Joint 
Committee on Cancer (AJCC) 8th 
Edition Cancer Staging
From Amin MB, Edge SB, Greene FL, et al., eds. 
AJCC Cancer Staging Manual. 8th ed. New York: 
Springer; 2017. Used with permission of the 
American College of Surgeons, Chicago, Illinois. 
The original and primary source for this infor-
mation is the AJCC Cancer Staging Manual, 




TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor <10 mm in greatest dimension
  T1a Tumor does not invade the tarsal plate or 
eyelid margin
  T1b Tumor invades the tarsal plate or eyelid 
margin
  T1c Tumor involves full thickness of eyelid
T2 Tumor >10 mm but <20 mm in greatest 
dimension
  T2a Tumor does not invade the tarsal plate or 
eyelid margin
  T2b Tumor invades the tarsal plate or eyelid 
margin
  T2c Tumor involves full thickness of eyelid
T3 Tumor >20 mm but <30 mm in greatest 
dimensions
  T3a Tumor does not invade the tarsal plate or 
eyelid margin
  T3b Tumor invades the tarsal plate or eyelid margin
  T3c Tumor involves full thickness of eyelid
T4 Any eyelid tumor that invades adjacent 
ocular, orbital, or facial structures
  T4a Tumor invades ocular or intra-orbital 
structures
  T4b Tumor invades (or erodes through) the bony 
walls of the orbit or extends to the paranasal 
sinuses or invades the lacrimal sac/ 
nasolacrimal duct or brain
Regional lymph node (N)
NX Regional lymph nodes cannot be assessed
N0 No evidence of lymph node involvement
N1 Metastasis in a single ipsilateral lymph node, 
<3 cm in greatest dimension
  N1a Metastasis in a single ipsilateral lymph node 
based on clinical evaluation or imaging 
findings
  N1b Metastasis in a single ipsilateral lymph node 
based on lymph node biopsy
N2 Metastasis in a single ipsilateral lymph node, 
>3 cm in greatest dimension, or in bilateral 
or contralateral lymph nodes
  N2a Metastasis documented based on clinical 
evaluation or imaging findings
  N2b Metastasis documented based on 
microscopic findings on lymph node biopsy
Distant metastasis (M)




TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
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T1 Tumor (<5 mm in greatest dimension) 
invades through the conjunctival basement 
membrane without invasion of adjacent 
structures
T2 Tumor (>5 mm in greatest dimension) 
invades through the conjunctival basement 
membrane without invasion of adjacent 
structures
T3 Tumor invades the adjacent structures 
(excluding the orbit)
T4 Tumor invades the orbit with or without 
further extension
  T4a Tumor invades orbital soft tissue without 
bone invasion
  T4b Tumor invades bone
  T4c Tumor invades adjacent paranasal sinuses
  T4d Tumor invades brain
Regional lymph node (N)
NX Regional lymph nodes cannot be assessed
N0 No evidence of lymph node involvement
N1 Regional lymph node metastasis
Distant metastasis (M)





TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor of the bulbar conjunctiva
  T1a <1 quadrant
  T1b >1 to <2 quadrant
  T1c >2 to <3 quadrant
  T1d >3 quadrants
T2 Tumor of nonbulbar (forniceal, palpebral, 
tarsal) conjunctiva, the tumor involving the 
caruncle
  T2a Noncaruncular, and <1 quadrant of nonbulbar 
conjunctiva involved
  T2b Noncaruncular, and >1 quadrant of nonbulbar 
conjunctiva involved
  T2c Caruncular, and <1 quadrant of the nonbulbar 
conjunctiva involved
  T2d Caruncular, and >1 quadrant of the nonbulbar 
conjunctiva involved
T3 Tumor of any size with local invasion
  T3a Globe
  T3b Eyelid
  T3c Orbit
  T3d Nasolacrimal duct and/or lacrimal sac and/or 
paranasal sinuses
T4 Tumor of any size with invasion of central 
nervous system
Pathological tumor (pT)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Melanoma confined to the conjunctival 
epithelium
T1 Tumor of the bulbar conjunctiva
  T1a Tumor of the bulbar conjunctiva with 
invasion of the substantia propria, not more 
than 2.0 mm in thickness
  T1b Tumor of the bulbar conjunctiva with 
invasion of the substantia propria, more than 
2.0 mm in thickness
T2 Tumor of the nonbulbar (forniceal, palpebral, 
tarsal) conjunctiva, and tumor involving the 
caruncle
  T2a Tumor of the nonbulbar conjunctiva with 
invasion of the substantia propria, not more 
than 2.0 mm in thickness
  T2b Tumor of the nonbulbar conjunctiva with 
invasion of the substantia propria, more than 
2.0 mm in thickness
T3 Tumor of any size with local invasion
  T3a Globe
  T3b Eyelid
  T3c Orbit
  T3d Nasolacrimal duct and/or lacrimal sac and/or 
paranasal sinuses
T4 Tumor of any size with invasion of paranasal 
sinuses and/or central nervous system
Regional lymph node (N)
NX Regional lymph nodes cannot be assessed
N0 No evidence of lymph node involvement
N1 Regional lymph node metastasis
Distant metastasis (M)





cTX Unknown evidence of intraocular tumor
cT0 No evidence of intraocular tumor
cT1 Intraretinal tumor(s) with subretinal fluid 
<5 mm from base of any tumor
  cT1a Tumors ≤3 mm in size and > 1.5 mm away 
from the optic disc and fovea
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  cT1b Tumors >3 mm in size and < 1.5 mm away 
from the optic disc and fovea
cT2 Intraretinal tumor(s) with retinal 
detachment, subretinal seeding/vitreous 
seeding
  cT2a Subretinal fluid >5 mm from the base of 
any tumor
  cT2b Tumors with vitreous seeding and/or 
subretinal seeding
cT3 Advanced intraocular tumor(s)
  cT3a Phthisis or pre-phthisis bulbi
  cT3b Tumor invasion of choroid, pars plana, 
ciliary body, lens, zonules, iris, or anterior 
chamber
  cT3c Raised intraocular pressure with 
neovascularization and/or buphthalmos
  cT3d Hyphema and/or massive vitreous 
hemorrhage
  cT3e Aseptic orbital cellulitis
cT4 Extraocular tumor(s) involving orbit, 
including optic nerve
  cT4a Radiological evidence of retrobulbar optic 
nerve involvement or thickening of optic 
nerve or involvement of orbital tissues
  cT4b Extraocular tumor clinically evident with 
proptosis and /or an orbital mass
Regional lymph node (cN)
cNX Regional lymph nodes cannot be assessed
cN0 No regional lymph node involvement
cN1 Evidence of preauricular, submandibular, 
and cervical lymph node involvement
Distant metastasis (M)
cM0 No signs or symptoms of intracranial or 
distant metastasis
cM1 Distant metastasis without microscopic 
confirmation
  cM1a Tumor(s) involving any distant site (e.g., 
bone marrow, liver) on clinical or 
radiological tests
  cM1b Tumor involving the CNS on radiological 
imaging (not including trilateral 
retinoblastoma)
pM1 Distant metastasis with microscopic 
confirmation
  pM1a Pathological evidence of tumor at any 
distant site (e.g., bone marrow, liver, or 
other)
  pM1b Pathological evidence of tumor in the 
cerebrospinal fluid or CNS parenchyma
Heritable trait (H)
HX Unknown or insufficient evidence of RB1 
gene constitutional mutation
H0 Normal RB1 alleles in blood tested with 
demonstrated high-sensitivity assays
H1 Bilateral retinoblastoma, retinoblastoma 
with an intracranial primitive 
neuroectodermal tumor (i.e., trilateral 
retinoblastoma), family history of 
retinoblastoma, or molecular definition of 
constitutional RB1 gene mutation
Pathological classification
Primary tumor (pT)
pTX Unknown evidence of intraocular tumor
pT0 No evidence of intraocular tumor
pT1 Intraocular tumor(s) without any local 
invasion, focal choroidal invasion, or pre- 
or intralaminar involvement of the optic 
nerve head
pT2 Intraocular tumor(s) with local invasion
  pT2a Concomitant focal choroidal invasion and 
pre- or intralaminar involvement of the 
optic nerve head
  pT2b Tumor invasion of stroma of iris and/or 
trabecular meshwork and/or Schlemm’s 
canal
pT3 Intraocular tumor(s) with significant local 
invasion
  pT3a Massive choroidal invasion (>3 mm in 
largest diameter, or multiple foci of focal 
choroidal involvement totaling >3 mm, or 
any full-thickness choroidal involvement)
  pT3b Retrolaminar invasion of the optic nerve 
head, not involving the transected end of 
the optic nerve
  pT3c Any partial-thickness involvement of the 
sclera within the inner two-thirds
  pT3d Full-thickness invasion into the outer third 
of the sclera and/or invasion into or around 
emissary channels
pT4 Evidence of extraocular tumor: tumor at the 
transected end of the optic nerve, tumor in 
the meningeal spaces around the optic 
nerve, full-thickness invasion of the sclera 
with invasion of the episclera, adjacent 
adipose tissue, extraocular muscle, bone, 
conjunctiva, or eyelids
Regional lymph node (pN)
pNX Regional lymph node involvement cannot 
be assessed
pN0 No lymph node involvement
pN1 Regional lymph node involvement
Distant metastasis (M)
cM0 No signs or symptoms of intracranial or 
distant metastasis
cM1 Distant metastasis without microscopic 
confirmation
  cM1a Tumor(s) involving any distant site (e.g., 




  cM1b Tumor involving the CNS on radiological 
imaging (not including trilateral 
retinoblastoma)
pM1 Distant metastasis with histopathologic 
confirmation
  pM1a Histopathologic confirmation of tumor at 
any distant site (e.g., bone marrow, liver, or 
others)
  pM1b Histopathologic confirmation of tumor in 




T1 Tumor limited to the iris
  T1a Tumor limited to the iris, not more than 3 
clock hours in size
  T1b Tumor limited to the iris, more than 3 clock 
hours in size
  T1c Tumor limited to the iris with secondary 
glaucoma
T2 Tumor confluent with or extending into 
ciliary body, choroid, or both
  T2a Tumor confluent with or extending into 
ciliary body, without secondary glaucoma
  T2b Tumor confluent with or extending into 
ciliary body and choroid, without secondary 
glaucoma
  T2c Tumor confluent with or extending into 
ciliary body, choroid, or both with secondary 
glaucoma
T3 Tumor confluent with or extending into the 
ciliary
Body, choroid, or both, with scleral 
extension
T4 Tumor with extrascleral extension
  T4a Tumor with extrascleral extension <5 mm in 
largest diameter
  T4b Tumor with extrascleral extension >5 mm in 
largest diameter
Choroidal and ciliary body melanomas
T1 Tumor size category 1
  T1a Tumor size category 1 without ciliary body 
involvement and extraocular extension
  T1b Tumor size category 1 with ciliary body 
involvement
  T1c Tumor size category 1 without ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
  T1d Tumor size category 1 with ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
T2 Tumor size category 2
  T2a Tumor size category 2 without ciliary body 
involvement and extraocular extension
  T2b Tumor size category 2 with ciliary body 
involvement
  T2c Tumor size category 2 without ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
  T2d Tumor size category 2 with ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
T3 Tumor size category 3
  T3a Tumor size category 3 without ciliary body 
involvement and extraocular extension
  T3b Tumor size category 3 with ciliary body 
involvement
  T3c Tumor size category 3 without ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
  T3d Tumor size category 3 with ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
T4 Tumor size category 4
  T4a Tumor size category 4 without ciliary body 
involvement and extraocular extension
  T4b Tumor size category 4 with ciliary body 
involvement
  T4c Tumor size category 4 without ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
  T4d Tumor size category 4 with ciliary body 
involvement but with extraocular extension 
<5 mm in largest diameter
  T4e Any tumor size category with extraocular 
extension >5 mm in largest diameter
Regional lymph node (N)
N1 Regional lymph node metastases or discrete 
tumor deposits in the orbit
  N1a Metastases in one or more regional lymph 
node (s)
  N1b No regional lymph nodes are positive, but 
there are discrete tumor deposits in the orbit 
that are not contiguous to the eye
Distant metastasis (M)
M0 No distant metastasis by clinical 
classification
M1 Distant metastasis
  M1a Largest diameter of the largest metastasis 
<3.0 cm
  M1b Largest diameter of the largest metastasis 
3.1–8.0 cm






TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor <2 cm in greatest dimension
T2 Tumor >2 cm in greatest diameter without 
invasion of bony walls or globe
T3 Tumor of any size with invasion of bony walls
T4 Tumor of any size with invasion of globe or 
periorbital structures, including eyelid, 
conjunctiva, temporal fossa, nasal cavity, 
paranasal sinuses, and/or central nervous system
Regional lymph node (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
 Ocular Adnexal Lymphoma
Primary tumor (T)
TX Lymphoma extent not specified
T0 No evidence of lymphoma
T1 Lymphoma involving the conjunctiva alone 
without eyelid or orbital involvement
T2 Lymphoma with orbital involvement with or 
without conjunctival involvement
T3 Lymphoma with pre-septal eyelid 
involvement with or without orbital 
involvement and with or without 
conjunctival involvement
T4 Orbital adnexal lymphoma and extraorbital 
lymphoma extending beyond the orbit to 
adjacent structures, such as bone, 
maxillofacial sinuses, and brain
Regional lymph node (N)
NX Involvement of lymph nodes not assessed
N0 No evidence of regional lymph node 
involvement
N1 Involvement of lymph node region or 
regions draining the ocular adnexal 
structures and superior to the mediastinum 
(preauricular, parotid, submandibular, and 
cervical nodes)
  N1a Involvement of a single lymph node region 
superior to mediastinum
  N1b Involvement of two or more lymph node 
regions superior to mediastinum
N2 Involvement of lymph node regions of the 
mediastinum
N3 Diffuse or disseminated involvement of 
peripheral and central lymph node regions
Distant metastasis (M)
M0 No evidence of involvement of other 
extranodal sites
  M1a Noncontiguous involvement of tissues or 
organs external to the ocular adnexa (e.g., 
parotid glands, submandibular gland, lung, 
liver, spleen, kidney, breast)
  M1b Lymphomatous involvement of the bone 
marrow
  M1c Both M1a and M1b involvement
 Lacrimal Gland Carcinoma
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor <2 cm in greatest dimension with or 
without extraglandular extension into the 
orbital soft tissue
  T1a No periosteal or bone involvement
  T1b Periosteal involvement only
  T1c Periosteal and bone involvement
T2 Tumor >2 cm and <4 cm in greatest diameter
  T2a No periosteal or bone involvement
  T2b Periosteal involvement only
  T2c Periosteal and bone involvement
£ 3.0
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T3 Tumor >4 cm in greatest dimension
  T3a No periosteal or bone involvement
  T3b Periosteal involvement only
  T3c Periosteal and bone involvement
T4 Involvement of adjacent structures, including 
sinuses, temporal fossa, pterygoid fossa, 
superior orbital fissure, cavernous sinus, or 
brain
  T4a Tumor <2 cm in greatest dimension
  T4b Tumor >2 cm and <4 cm in greatest 
dimension
  T4c Tumor >4 cm in greatest dimension
Regional lymph node (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis








Includes pTNM requirements from the 8th Edition, 
AJCC Staging Manual
Reproduced by permission of the College of 
American Pathologists (CAP) © 2019. The CAP 
periodically revises the CAP Cancer Protocols, 
and the current versions may be retrieved from 
www.cap.org/cancerprotocols. The CAP does 
not permit reproduction of any substantial por-
tion of these protocols without its written autho-
rization. The CAP hereby authorizes use of 
these protocols by physicians and other health-
care providers in reporting on surgical speci-
mens, in teaching, and in carrying out medical 
research for nonprofit purposes. This authoriza-
tion does not extend to reproduction or other use 
of any substantial portion of these protocols for 
commercial purposes without the written con-
sent of the CAP.
For accreditation purposes, this protocol 
should be used for the following procedures 
and tumor types:
Procedure Description





Hans E. Grossniklaus, MD, MBA1; Paul T. Finger, 
MD; J. William Harbour, MD; Tero Kivëla, MD
With guidance from the CAP Cancer and CAP 
Pathology Electronic Reporting Committees.
 Accreditation Requirements
This protocol can be utilized for a variety of pro-
cedures and tumor types for clinical care pur-
poses. For accreditation purposes, only the 
definitive primary cancer resection specimen is 
required to have the core and conditional data 
elements reported in a synoptic format.
• Core data elements are required in reports to 
adequately describe appropriate malignancies. 
For accreditation purposes, essential data ele-
ments must be reported in all instances, even 
if the response is “not applicable” or “cannot 
be determined.”
• Conditional data elements are only required 
to be reported if applicable as delineated in the 
protocol. For instance, the total number of 
lymph nodes examined must be reported, but 
only if nodes are present in the specimen.
• Optional data elements are identified with “+” 
and although not required for CAP accredita-
tion purposes, may be considered for report-
ing as determined by local practice standards.
The use of this protocol is not required for 
recurrent tumors or for metastatic tumors that are 




resected at a different time than the primary tumor. 
Use of this protocol is also not required for pathol-
ogy reviews performed at the second institution 
(i.e., secondary consultation, second opinion, or 
review of outside case at the second institution).
 Synoptic Reporting
All core and conditionally required data elements 
outlined in the surgical case summary from this 
cancer protocol must be displayed in synoptic 
report format. Synoptic format is defined as:
• Data element: followed by its answer 
(response), outline format without the paired 
“Data element: Response” format is not con-
sidered synoptic.
• The data element must be represented in the 
report as it is listed in the case summary. The 
response for any data element may be modified 
from those listed in the case summary, includ-
ing “Cannot be determined” if appropriate.
• Each diagnostic parameter pair (Data element: 
Response) is listed on a separate line or in a 
tabular format to achieve visual separation. 
The following exceptions are allowed to be 
listed on one line:
 – Anatomic site or specimen, laterality, and 
procedure
 – Pathologic Stage Classification (pTNM) 
elements
 – Negative margins, as long as all negative 
margins are specifically enumerated where 
applicable
• The synoptic portion of the report can appear 
in the diagnosis section of the pathology 
report, at the end of the report or in a separate 
section, but all data element: Responses must 
be listed together in one location.
Organizations and pathologists may choose to 
list the required elements in any order, use addi-
tional methods in order to enhance or achieve 
visual separation, or add optional items within 
the synoptic report. The report may have required 
elements in a summary format elsewhere in the 
report in addition to but not as replacement for 
the synoptic report, i.e., all required elements 
must be in the synoptic portion of the report in 
the format defined above.
CAP Laboratory Accreditation Program Protocol 
Required Use Date: March 2018a
aBeginning January 1, 2018, the 8th edition AJCC 
Staging Manual should be used for reporting pTNM.
 CAP Retinoblastoma Protocol 
Summary of Changes
The following data elements were modified:




• Tumor Involvement of Other Ocular Structures
• Histologic Grade
• Additional Pathologic Findings
The following data element was added:
• Cytologic Features Suggesting MYCN 
Amplification
 Surgical Pathology Cancer Case 
Summary
Protocol posting date: June 2017
Retinoblastoma
Select a single response unless otherwise 
indicated.
Procedure (Notes A, B, and C)
___ Enucleation
Length of optic nerve (millimeters): ___ mm
___ Partial exenteration
___ Complete exenteration









Tumor Site (Macroscopic Examination/
Transillumination) (Select All that Apply) 
(Notes D and E)
___ Cannot be determined
___ Superotemporal quadrant of globe
___ Superonasal quadrant of globe
___ Inferotemporal quadrant of globe
___ Inferonasal quadrant of globe
___ Anterior chamber
___ Between ____ and ____ o’clock
___ Other (specify): _______________________
Tumor Size After Sectioning (Note F)
___ Cannot be determined
Greatest basal diameter (millimeters): ____ mm
+ Base at cut edge (millimeters): ____ mm
Greatest thickness (millimeters): ____ mm
+ Thickness at cut edge (millimeters): ____ mm
Tumor Site After Sectioning (Notes G 
and H)





+ Distance from anterior edge of tumor to limbus 
at cut edge (millimeters): ____ mm
+ Distance of posterior margin of tumor base from 
edge of optic disc (millimeters): ____ mm
Tumor Involvement of Other Ocular 
Structures (Select all that Apply) (Note I)










___ Subretinal pigment epithelial space
___ Optic nerve head
___ Choroid, minimal (solid tumor nest less than 
3  mm in maximum diameter [width or 
thickness])
___ Choroid, massive (solid tumor nest 3 mm or 





___ Other (specify): ______________________
__________________
Growth Pattern (Note J)






Extent of Optic Nerve Invasion
___ Cannot be determined
___ None
___ Anterior to lamina cribrosa
___ At lamina cribrosa
___ Posterior to lamina cribrosa but not to end of 
nerve
___ To cut end of optic nerve
Histologic Grade
___ G1: Tumor with areas of retinocytoma (fleu-
rettes or neuronal differentiation)
___ G2: Tumor with many rosettes (Flexner- 
Wintersteiner or Homer Wright)
___ G3: Tumor with occasional rosettes (Flexner- 
Wintersteiner or Homer Wright)
___ G4: Tumor with poorly differentiated cells 
without rosettes and/or with extensive areas 
(more than half of tumor) of anaplasia
___ GX: Grade cannot be assessed
+ Anaplasia Grade (Note K)
Note: Grade based on the highest level of ana-
plasia in the tumor, with at least 30% of the tumor 




+ ___ Cannot be determined
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+ Cytologic Features Suggesting MYCN 
Amplification (Note K)
Note: Unilateral retinoblastoma with a loose cel-




Margins (Select All that Apply)
___ Cannot be assessed
___ No tumor at margins
___ Tumor present at surgical margin of optic 
nerve
___ Extrascleral extension (for enucleation 
specimens)
___ Other margin(s) involved (specify): 
________________________
Regional Lymph Nodes
___ No lymph nodes submitted or found
Lymph Node Examination (Required Only if 
Lymph Nodes Are Present in the Specimen)
Number of Lymph Nodes Involved: _____
___ Number cannot be determined (explain): 
____________________
Number of Lymph Nodes Examined: _____
___ Number cannot be determined (explain): 
____________________
Pathologic Stage Classification (pTNM, 
AJCC 8th Edition) (Note M)
Note: Reporting of pT, pN, and (when appli-
cable) pM categories is based on information 
available to the pathologist at the time the 
report is issued. Only the applicable T, N, or 
M category is required for reporting; their 
definitions need not be included in the report. 
The categories (with modifiers when appli-
cable) can be listed on one line or more than 
one line.
TNM Descriptors (Required Only if 
Applicable) (Select All That Apply)




___ pTX: Unknown evidence of intraocular 
tumor
___ pT0: No evidence of intraocular tumor
___ pT1: Intraocular tumor(s) without any local 
invasion, focal choroidal invasion, or pre- or 
intralaminar involvement of the optic nerve 
head
___ pT2: Intraocular tumor(s) with local 
invasion
___ pT2a: Concomitant focal choroidal invasion 
and pre- or intralaminar involvement of the 
optic nerve head
___ pT2b: Tumor invasion of stroma of iris and/
or trabecular meshwork and/or Schlemm’s 
canal
___ pT3: Intraocular tumor(s) with significant 
local invasion
___ pT3a: Massive choroidal invasion (>3 mm 
in largest diameter, or multiple foci of 
focal choroidal involvement totaling 
>3  mm, or any full-thickness choroidal 
involvement)
___ pT3b: Retrolaminar invasion of the optic 
nerve head, not involving the transected end of 
the optic nerve
___ pT3c: Any partial-thickness involvement of 
the sclera within the inner two-thirds
___ pT3d: Full-thickness invasion into the outer 
third of the sclera and/or invasion into or 
around emissary channels
___ pT4: Evidence of extraocular tumor: tumor 
at the transected end of the optic nerve, tumor 
in the meningeal spaces around the optic 
nerve, full-thickness invasion of the sclera 
with invasion of the episclera, adjacent adi-




Regional Lymph Nodes (pN)
___ pNX: Regional lymph nodes cannot be 
assessed
___ pN0: No regional lymph node involvement
___ pN1: Regional lymph node involvement
Distant Metastasis (pM) (Required Only if 
Confirmed Pathologically in This Case)
___ pM1: Distant metastasis with histopatho-
logic confirmation
___ pM1a: Histopathologic confirmation of 
tumor at any distant site (e.g., bone marrow, 
liver, or others)
___ pM1b: Histopathologic confirmation of 
tumor in the cerebrospinal fluid or CNS 
parenchyma
Specify site(s), if known: ________________
_________________
+ Additional Pathologic Findings (Select 
All that Apply)
+ ___ None identified
+ ___ Calcifications
+ ___ Mitotic rate: Number of mitoses per 40 
fields determined by using a 40x objective 
with a field area of 0.152 mm2 (specify): ____
+ ___ Apoptosis
+ ___ Necrosis
+ ___ Basophilic vascular deposits
+ ___ Inflammatory cells
+ ___ Hemorrhage (specify site): ____________
___________________________
+ ___ Retinal detachment
+ ___ Neovascularization (specify site): 
________________________




Cytologic and biopsy specimens are rarely 
obtained from eyes with suspected retinoblastoma 
owing to the potential risk of tumor seeding. An 
anterior chamber paracentesis may be performed, 
if indicated by clinical findings, and is not associ-
ated with risk of tumor  seeding [1, 2].
 B. Fixation
The minimum recommended fixation time for 
whole globes with intraocular tumors is 48 hours. 
The globe should be fixed in an adequate volume 
of fixative with a 10:1 ratio of fixative volume to 
specimen volume recommended. Incisions or 
windows in the globe are not necessary for ade-
quate penetration of fixative and are not recom-
mended. Injection of fixative into the globe is also 
not recommended.
 C. Additional Studies
Genetic studies may be requested on neoplas-
tic tissue and should be harvested prior to fixation 
[3]. Identification of RB1 mutations and other 
genetic studies in tumor tissue are difficult with 
formalin-fixed tissue.
The surgical margin of the optic nerve should be 
obtained prior to opening the globe (Note E). Once 
tissue is harvested for genetic studies, the globe can 
be fixed prior to completing macroscopic examina-
tion. The appropriate materials/medium required 
by the laboratory performing genetic testing should 
be obtained prior to the procedure.
 D. Processing With Tumor Sampling
To collect the tumor specimen, the optic 
nerve should be removed before opening the 
globe to prevent the optic nerve from acciden-
tally becoming contaminated with artifactual 
clumps of tumor cells (so-called “floaters”). The 
surgeon should first ink the surgical margin of 
the optic nerve, then cut the optic nerve stump 
off from the sclera with a sharp razor about 
2 mm behind the globe. The optic nerve stump, 
which should be kept separate from the globe, 
should be placed into a jar of 10% buffered 
formaldehyde. Then, a sample of tumor should 
be obtained by opening a small sclero-choroidal 
window adjacent to the tumor near the equator 
with a 6- to 8-mm corneal trephine. Once the 
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opening into the vitreous chamber is estab-
lished, tumor tissue should be gently removed 
with forceps and scissors. It is best to leave a 
hinge on one side of the scleral flap so that it can 
be closed with one or two suture(s) following 
the removal of tumor sample. This is done in an 
attempt to maintain the overall spherical archi-
tecture of the specimen during fixation. The 
globe should be placed in the second jar of for-
malin (separate from the optic nerve stump) and 
be allowed to fix for at least 24 to 48 hours.
 E. Orientation of Globe
The orientation of a globe may be determined 
by identifying extraocular muscle insertions, 
optic nerve, and other landmarks as illustrated 






















Fig. B.1 Anatomic landmarks of the posterior aspect of 
the globe (right eye). The position of the inferior oblique 
muscle relative to the optic nerve is most helpful in orient-
ing the globe. The inferior oblique muscle insertion is 
located temporal (lateral) to the optic nerve on the sclera, 
and its fibers travel inferonasally from its insertion. The 
long posterior ciliary artery is often seen as a blue-gray 
line in the sclera on either side of the optic nerve and 




generally used in place of lateral and medial 
with reference to ocular anatomy.
F. Processing Without Tumor Sampling
If there is no need for fresh tissue sampling, 
the enucleated globe should simply be fixed in 
10% buffered formaldehyde for at least 24 and 
preferably 48  hours. When the fixed globe is 
examined by the pathologist, if the optic nerve 
was not previously amputated in the operative 
room, that should be performed first as described 
above. The surgical margin of the nerve stump 
should be embedded face down in paraffin for 
sectioning (i.e., thereby obtaining cross sections 
of the nerve, starting at the surgical margin). 
Then, the eye itself is sectioned. First, a section 
should be made that extends from pupil through 
the optic nerve (the “P-O” section), which con-
tains the center of the optic nerve with all the 
optic nerve structures (optic nerve head, lamina 
cribrosa, and postlaminar optic nerve). 
Preferably this plane should bisect the largest 
dimension of the tumor, previously identified by 
 transillumination and during clinical examina-
tion. When possible, the plane should avoid the 
scleral opening if one was made for fresh tumor 
sampling. This section is critical for evaluation 
of the optic nerve for tumor invasion. The P-O 
section and minor calottes are then embedded in 
paraffin. The embedded P-O calotte is then sec-
tioned every 100–150 microns (each section 
being about 5 microns thick), for a total of about 
10–20 sections. Additional sections should also 
be made anterior-posteriorly in a bread-loaf 
fashion through the minor callotes. These seg-
ments should be submitted in one cassette per 
calotte on edge to evaluate the choroid for inva-
sion. Three levels of this block are usually suf-
ficient for examination. In total, four cassettes 
are submitted: the optic nerve stump, the P-O 
section, and the two minor calottes (unless one 
or both of these have no visible tumor).
 G. Sectioning the Globe
The globe is generally sectioned in the hori-
zontal or vertical plane, with care to include the 
pupil and optic nerve in the cassette to be submit-
ted for microscopic examination. If the mass can-
not be included with horizontal or vertical 
sectioning, the globe is sectioned obliquely to 
include tumor, pupil, and optic nerve (Fig. B.2). 
The surgical margin of the optic nerve should be 
sectioned and submitted prior to sectioning the 
globe to ensure that intraocular malignant cells 
do not contaminate this important surgical mar-
gin [3]. Retinoblastoma is an extremely friable 
tumor.
Each calotte should also be sampled. The 
calottes should be bread-loafed and submitted in 
a cassette on edge for processing as shown in Fig. 
B.3.
 H. Sections Submitted for Microscopic 
Examination
Multiple sections should be examined, with 
special attention to sections containing optic 
nerve and tumor. The nerve should be sectioned 
along the various levels to determine tumor 
extension.
 I. Rules for Classification
Choroidal invasion: The presence and the 
extent (focal versus massive) of choroidal inva-
sion by tumor should be stated. Differentiation 
should be made between true choroidal invasion 
and artifactual invasion due to seeding of fresh 
tumor cells during post-enucleation retrieval of 
tumor tissue and/or gross sectioning.
Artifactual invasion is identified when there 
are groups of tumor cells present in the open 
spaces among intraocular structures, extraocular 
tissues, and/or subarachnoid space.
True invasion is defined as one or more solid 
nests of tumor cells that fills or replaces the cho-
roid and has pushing borders. Note: Invasion of 
the subretinal pigment epithelium (RPE) space, 
where tumor cells are present under the RPE (but 
not beyond Bruch’s membrane into the choroid), 
is not choroidal invasion.
Focal choroidal invasion is defined as a solid 
nest of tumor that measures less than 3  mm in 
maximum diameter (width or thickness).
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Massive choroidal invasion is defined as a 
solid tumor nest 3  mm or more in maximum 
diameter (width or thickness) in contact with the 
underlying sclera.
 J. Growth Pattern
Endophytic growth pattern indicates growth 
from the inner retinal surface into the vitreous 
cavity. Exophytic tumors grow primarily from 
the outer surface of the retina into the subretinal 
space toward the choroid. Mixed growth pattern 
exhibits features of both endophytic and exo-
phytic growths. Diffuse infiltrating tumors grow 
laterally within the retina without significant 
thickening.
 K. Histologic Features
Histopathologic features of retinoblastoma 
include small round cells staining blue on 
hematoxylin- eosin. Flexner-Wintersteiner rosettes 
(typical for retinoblastoma) and Homer Wright 
rosettes (characteristic of neuroectodermal tumors) 
both occur. Tumors with many Flexner-






Fig. B.2 The most 
common methods of 
sectioning a globe. After 
transillumination, the 
tumor base is marked, if 
possible, and included in 
the pupil-optic (p-o) nerve 
section and submitted for 
processing. If tumor is 
found in either of the 
calottes, these may also be 
submitted for sectioning. 
The meridian in which the 
globe was sectioned should 
be included in the gross 
description of the 
pathology report. It is not 
uncommon to induce an 
artifactitious retinal 
detachment while 
sectioning the globe. This 
can be minimized by 
gentle handling and by 
avoiding a sawing motion 




differentiated. Some tumors show photoreceptor-
like differentiation (fleurettes) or neuronal differ-
entiation without mitoses or apoptosis, which is 
evidence of an underlying premalignant lesion: 
retinocytoma [6, 7]. It is not uncommon to find a 
retinocytomatous area at the base of the tumor [8]. 
Retinocytomatous areas are more resistant to che-
motherapy and, occasionally, only the retinocyto-
matous part may remain viable, surrounded by 
calcifications and debris from the regressed retino-
blastoma that it spawned. Tumors that show no 
fleurettes or rosettes are graded as poorly differen-
tiated. The nuclei of poorly differentiated tumors 
may show anaplasia [9]. Rarely, unilateral retino-
blastoma tumors show a loose cellular pattern with 
round nuclei and prominent multiple nucleoli 
indicative of MYCN amplification and normal RB1 
alleles [10]. Retinoblastoma undergoes pathogno-
monic dystrophic calcification. Small tumors ini-
tially are limited by the retinal boundaries (Bruch’s 
membrane and the inner limiting membrane). As 
the tumor grows, it spreads into the adjacent vitre-
ous, subretinal space, underlying choroid, optic 
nerve, or anterior segment (iris, trabecular mesh-
work, or Schlemm’s canal).
 L. Histologic Features of Additional 
Prognostic Significance
Histologic features with prognostic signifi-
cance for survival include the following: inva-
sion of optic nerve, particularly if tumor is 
present at the surgical margin (most important 
feature); invasion of sclera; invasion of choroid; 
tumor size; basophilic staining of tumor vessels; 
seeding of vitreous; degree of differentiation; 
involvement of anterior segment; and growth 
pattern [11–17]. This list should not be confused 
with the Reese-Ellsworth classification, which is 
intended as a predictor for visual outcome, not 
survival [18].
 M. Pathologic Stage Classification
The American Joint Committee on Cancer 
(AJCC) and the International Union Against 
Cancer (UICC) TNM staging system for retino-
blastoma is shown below [19].
By AJCC/UICC convention, the designation 
“T” refers to a primary tumor that has not been 
previously treated. The symbol “p” refers to the 
Fig. B.3 Calotte sampling. (From Grossniklaus HE [5] with kind permission of Springer Science+Business Media)
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pathologic classification of the TNM, as opposed 
to the clinical classification, and is based on 
gross and microscopic examination. pT entails a 
resection of the primary tumor or biopsy ade-
quate to evaluate the highest pT category, pN 
entails removal of nodes adequate to validate 
lymph node metastasis, and pM implies micro-
scopic examination of distant lesions. It is not 
uncommon to receive an eye of histopathologic 
examination that has been enucleated after 
failed conservative treatment such as chemore-
duction or intra-arterial chemosurgery com-
bined with focal treatments and radiotherapy. In 
such cases, the symbol “y” referring to a treated 
tumor and/or the symbol “r” referring to a recur-
rent tumor may be added. Clinical classification 
(cTNM) is usually carried out by the referring 
physician before treatment during initial evalua-
tion of the patient or when pathologic classifica-
tion is not possible.
Pathologic staging is usually performed after 
surgical resection of the primary tumor. 
Pathologic staging depends on pathologic docu-
mentation of the anatomic extent of disease, 
whether or not the primary tumor has been com-
pletely removed. If a biopsied tumor is not 
resected for any reason (e.g., when technically 
unfeasible) and if the highest T and N categories 
or the M1 category of the tumor can be confirmed 
microscopically, the criteria for pathologic clas-
sification and staging have been satisfied without 
total removal of the primary cancer.
TNM Descriptors
For identification of special cases of TNM or 
pTNM classifications, the “m” suffix and “y,” “r,” 
and “a” prefixes are used. Although they do not 
affect the stage grouping, they indicate cases 
needing separate analysis.
The “m” suffix indicates the presence of mul-
tiple primary tumors in a single site and is 
recorded in parentheses: pT(m)NM.
The “y” prefix indicates those cases in which 
classification is performed during or following 
initial multimodality therapy (i.e., neoadjuvant 
chemotherapy, radiation therapy, or both che-
motherapy and radiation therapy). The cTNM 
or pTNM category is identified by a “y” prefix. 
The ycTNM or ypTNM categorizes the extent 
of tumor actually present at the time of that 
examination. The “y” categorization is not an 
estimate of tumor prior to multimodality ther-
apy (i.e., before initiation of neoadjuvant 
therapy).
The “r” prefix indicates a recurrent tumor 
when staged after a documented disease-free 
interval, and is identified by the “r” prefix: rTNM.
The “a” prefix designates the stage deter-
mined at autopsy: aTNM.
Additional Descriptors
Residual Tumor (R)
Tumor remaining in a patient after therapy with 
curative intent (e.g., surgical resection for cure) is 
categorized by a system known as R classifica-
tion, as shown below.
RX Presence of residual tumor cannot be assessed
R0 No residual tumor
R1 Microscopic residual tumor
R2 Macroscopic residual tumor
For the surgeon, the R classification may be 
useful to indicate the known or assumed status of 
the completeness of a surgical excision. For the 
pathologist, the R classification is relevant to the 
status of the margins of a surgical resection spec-
imen. That is, tumor involving the resection mar-
gin on pathologic examination may be assumed 
to correspond to residual tumor in the patient and 
may be classified as macroscopic or microscopic 




LVI indicates whether microscopic lymph- 
vascular invasion is identified in the pathology 
report. LVI includes lymphatic invasion, vascular 
invasion, or lymph-vascular invasion. By AJCC/
UICC convention, LVI does not affect the T 
 category indicating local extent of tumor unless 






TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
cT1 Intraretinal tumor(s) with subretinal fluid 
≤5 mm from the base of any tumor
cT1a Tumors ≤3 mm and further than 1.5 mm from 
disc and fovea
cT1b Tumors >3 mm or closer than 1.5 mm from 
disc or fovea
cT2 Intraocular tumor(s) with retinal detachment, 
vitreous seeding, or subretinal seeding
cT2a Subretinal fluid >5 mm from the base of any 
tumor
cT2b Vitreous seeding and/or subretinal seeding
cT3 Advanced intraocular tumor(s)
cT3a Phthisis or pre-phthisis bulbi
cT3b Tumor invasion of choroid, pars plana, ciliary 
body, lens, zonules, iris, or anterior chamber
cT3c Raised intraocular pressure with 
neovascularization and/or buphthalmos
cT3d Hyphema and/or massive vitreous hemorrhage
cT3e Aseptic orbital cellulitis
cT4 Extraocular tumor(s) involving orbit, including 
optic nerve
cT4a Radiologic evidence of retrobulbar optic nerve 
involvement or thickening of optic nerve or 
involvement of orbital tissues
cT4b Extraocular tumor clinically evident with 
proptosis and/or an orbital mass
Regional lymph nodes (N)
cNX Regional lymph nodes cannot be assessed
cN0 No regional lymph node involvement




cM1 Distant metastasis without microscopic 
confirmation
cM1a Tumor(s) involving any distant site (e.g., bone 
marrow, liver) on clinical or radiologic tests
cM1b Tumor involving the CNS on radiologic 
imaging (not including trilateral 
retinoblastoma)
Definition of heritable trait (H)
HX Unknown or insufficient evidence of a 
constitutional RB1 gene mutation
H0 Normal RB1 alleles in blood tested with 
demonstrated high-sensitivity assays
H1 Bilateral retinoblastoma, any retinoblastoma 
with an intracranial primitive neuroectodermal 
tumor (i.e., trilateral retinoblastoma), patient 
with family history of retinoblastoma, or 
molecular definition of a constitutional RB1 
gene mutation















cN0 cM0 Any I
cT4a cN0 cM0 Any II
cT4b cN0 cM0 Any III
Any cN1 cM0 Any III



















pN0 cM0 Any I
pT4 pN0 cM0 Any II
Any pN1 cM0 Any III
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Includes pTNM requirements from the 8th Edition, 
AJCC Staging Manual
Reproduced by permission of the College of 
American Pathologists (CAP) © 2019. The 
CAP periodically revises the CAP Cancer 
Protocols and the current versions may be 
retrieved from www.cap.org/cancerprotocols. 
The CAP does not permit reproduction of any 
substantial portion of these protocols without 
its written authorization. The CAP hereby 
authorizes use of these protocols by physicians 
and other healthcare providers in reporting on 
surgical specimens, in teaching, and in carry-
ing out medical research for nonprofit pur-
poses. This authorization does not extend to 
reproduction or other use of any substantial 
portion of these protocols for commercial pur-
poses without the written consent of the CAP.
For accreditation purposes, this protocol 
should be used for the following procedures 
and tumor types:
Procedure Description
Resection Includes local resection, enucleation, 




The following tumor types should not be 
reported using this protocol:
Tumor type
Cutaneous melanoma (consider skin melanoma 
protocol)
 Authors
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With guidance from the CAP Cancer and CAP 
Pathology Electronic Reporting Committees.
 Accreditation Requirements
This protocol can be utilized for a variety of pro-
cedures and tumor types for clinical care pur-
poses. For accreditation purposes, only the 
definitive primary cancer resection specimen is 
required to have the core and conditional data 
elements reported in a synoptic format.
• Core data elements are required in reports to 
adequately describe appropriate malignancies. 
For accreditation purposes, essential data ele-
ments must be reported in all instances, even 
if the response is “not applicable” or “cannot 
be determined.”
• Conditional data elements are only required 
to be reported if applicable as delineated in 
the protocol. For instance, the total number 
of lymph nodes examined must be reported, 
but only if nodes are present in the 
specimen.
• Optional data elements are identified with “+” 
and although not required for CAP accredita-
tion purposes, may be considered for report-
ing as determined by local practice standards.




The use of this protocol is not required for recur-
rent tumors or for metastatic tumors that are resected 
at a different time than the primary tumor. Use of 
this protocol is also not required for pathology 
reviews performed at the second institution (i.e., 
secondary consultation, second opinion, or review 
of outside case at the second institution).
 Synoptic Reporting
All core and conditionally required data elements 
outlined in the surgical case summary from this 
cancer protocol must be displayed in synoptic 
report format. Synoptic format is defined as:
• Data element: followed by its answer 
(response), outline format without the paired 
“Data element: Response” format is not con-
sidered synoptic.
• The data element must be represented in the 
report as it is listed in the case summary. The 
response for any data element may be modi-
fied from those listed in the case summary, 
including “Cannot be determined” if 
appropriate.
• Each diagnostic parameter pair (Data element: 
Response) is listed on a separate line or in a 
tabular format to achieve visual separation. 
The following exceptions are allowed to be 
listed on one line:
 – Anatomic site or specimen, laterality, and 
procedure
 – Pathologic Stage Classification (pTNM) 
elements
 – Negative margins, as long as all negative 
margins are specifically enumerated where 
applicable
• The synoptic portion of the report can appear 
in the diagnosis section of the pathology 
report, at the end of the report or in a separate 
section, but all data element: Responses must 
be listed together in one location.
Organizations and pathologists may choose to 
list the required elements in any order, use addi-
tional methods in order to enhance or achieve 
visual separation, or add optional items within 
the synoptic report. The report may have required 
elements in a summary format elsewhere in the 
report in addition to but not as replacement for 
the synoptic report, i.e., all required elements 
must be in the synoptic portion of the report in 
the format defined above.
CAP Laboratory Accreditation Program Protocol 
Required Use Date: March 2018a
aBeginning January 1, 2018, the 8th edition AJCC 
Staging Manual should be used for reporting pTNM.
 CAP Uveal Melanoma Protocol 
Summary of Changes
The following data elements were modified:




• Tumor Involvement of Other Ocular Structures
• Microscopic Tumor Extension
• Additional Pathologic Findings
 Surgical Pathology Cancer Case 
Summary
Protocol posting date: June 2017
Uveal Melanoma
















Tumor Site (Macroscopic Examination/
Transillumination) (Select All that Apply) 
(Note B)
___ Cannot be determined
___ Superotemporal quadrant of globe
___ Superonasal quadrant of globe
___ Inferotemporal quadrant of globe
___ Inferonasal quadrant of globe
___ Anterior chamber
___ Between ____ and ____ o’clock
___ Other (specify): ______________________
________________
Tumor Size After Sectioning (Note C)
___ Cannot be determined
Greatest basal diameter (millimeters): ____ mm
+ Base at cut edge (millimeters): ____ mm
Greatest thickness (millimeters): ____ mm
+ Thickness at cut edge (millimeters): ____ mm
Tumor Site After Sectioning (Note D)





+ Distance from anterior edge of tumor to limbus 
at cut edge (millimeters): ___ mm
+ Distance of posterior margin of tumor base 
from edge of optic disc (millimeters): ___ mm
Tumor Involvement of Other Ocular 
Structures (Select All that Apply)
___ Sclera
___ Vortex vein(s)







___ Extrascleral extension (anterior)





___ Other (specify): ______________________
________________
___ Cannot be assessed
Growth Pattern




___ Diffuse (ciliary body ring)
___ Diffuse (flat)
Histologic Type (Note E)
___ Spindle cell melanoma (>90% spindle 
cells)
___ Mixed cell melanoma (>10% epithelioid 
cells and < 90% spindle cells)




+ ___ Anterior margin between ciliary body and 
iris
+ ___ Anterior margin between equator and cili-
ary body
+ ___ Anterior margin between disc and 
equator
+ ___ Posterior margin between ciliary body and 
iris
+ ___ Posterior margin between equator and cili-
ary body
+ ___ Posterior margin between disc and 
equator
+ ___ Cannot be determined




___ Extrascleral (≤5 mm largest diameter)
___ Extrascleral (>5 mm largest diameter)




___ Cannot be assessed
___ No melanoma at margins
___ Extrascleral extension (for enucleation 
specimens)
___ Other margin(s) involved (specify): 
____________________________
Regional Lymph Nodes
___ No lymph nodes submitted or found
Lymph Node Examination (Required Only if 
Lymph Nodes Are Present in the Specimen)
Number of Lymph Nodes Involved: _____
___ Number cannot be determined (explain): 
____________________
Number of Lymph Nodes Examined: _____
___ Number cannot be determined (explain): 
____________________
Pathologic Stage Classification (pTNM, 
AJCC 8th Edition) (Note F)
Note: Reporting of pT, pN, and (when applicable) 
pM categories is based on information available 
to the pathologist at the time the report is issued. 
Only the applicable T, N, or M category is 
required for reporting; their definitions need not 
be included in the report. The categories (with 
modifiers when applicable) can be listed on one 
line or more than one line.
TNM Descriptors (Required Only if 
Applicable) (Select All That Apply)





___ pTX: Primary tumor cannot be assessed
___ pT0: No evidence of primary tumor
___ pT1: Tumor limited to the iris
___ pT1a: Tumor limited to the iris not more than 
3 clock hours in size
___ pT1b: Tumor limited to the iris more than 3 
clock hours in size
___ pT1c: Tumor limited to the iris with second-
ary glaucoma
___ pT2: Tumor confluent with or extending into 
the ciliary body, choroid, or both
___ pT2a: Tumor confluent with or extending 
into the ciliary body, without secondary 
glaucoma
___ pT2b: Tumor confluent with or extending 
into the ciliary body and choroid, without sec-
ondary glaucoma
___ pT2c: Tumor confluent with or extending 
into the ciliary body, choroid, or both, with 
secondary glaucoma
___ pT3: Tumor confluent with or extending into 
the ciliary body, choroid, or both, with scleral 
extension
___ pT4: Tumor with extrascleral extension
___ pT4a: Tumor with extrascleral extension 
≤5 mm in largest diameter
___ pT4b: Tumor with extrascleral extension 
>5 mm in largest diameter
Note: Iris melanomas originate from, and are 
predominantly located in, this region of the uvea. 
If less than half the tumor volume is located 
within the iris, the tumor may have originated in 
the ciliary body, and consideration should be 
given to classifying it accordingly.
Ciliary Body and Choroid
___ pTX: Primary tumor cannot be assessed
___ pT0: No evidence of primary tumor
___ pT1: Tumor size category 1
___ pT1a: Tumor size category 1 without ciliary 
body involvement and extraocular extension
___ pT1b: Tumor size category 1 with ciliary 
body involvement
___ pT1c: Tumor size category 1 without ciliary 
body involvement but with extraocular exten-
sion ≤5 mm in largest diameter
___ pT1d: Tumor size category 1 with ciliary 
body involvement and extraocular extension 
≤5 mm in largest diameter
___ pT2: Tumor size category 2
___ pT2a: Tumor size category 2 without cili-




___ pT2b: Tumor size category 2 with ciliary 
body involvement
___ pT2c: Tumor size category 2 without ciliary 
body involvement but with extraocular exten-
sion ≤5 mm in largest diameter
___ pT2d: Tumor size category 2 with ciliary 
body involvement and extraocular extension 
≤5 mm in largest diameter
___ pT3: Tumor size category 3
___ pT3a: Tumor size category 3 without ciliary 
body involvement and extraocular extension
___ pT3b: Tumor size category 3 with ciliary 
body involvement
___ pT3c: Tumor size category 3 without ciliary 
body involvement but with extraocular exten-
sion ≤5 mm in largest diameter
___ pT3d: Tumor size category 3 with ciliary 
body involvement and extraocular extension 
≤5 mm in largest diameter
___ pT4: Tumor size category 4
___ pT4a: Tumor size category 4 without ciliary 
body involvement and extraocular extension
___ pT4b: Tumor size category 4 with ciliary 
body involvement
___ pT4c: Tumor size category 4 without ciliary 
body involvement but with extraocular exten-
sion ≤5 mm in largest diameter
___ pT4d: Tumor size category 4 with ciliary 
body involvement and extraocular extension 
≤5 mm in largest diameter
___ pT4e: Any tumor size category with extra-
ocular extension >5 mm in largest diameter
Notes:
 1. Primary ciliary body and choroidal melano-
mas are classified according to the four tumor 
size categories defined in Fig. C.1.
 2. In clinical practice, the largest tumor basal 
diameter may be estimated in optic disc diam-
eters (DD; average: 1 DD  =  1.5  mm), and 
tumor thickness may be estimated in diopters 
(average: 2.5 diopters  =  1  mm). 
Ultrasonography and fundus photography 
are used to provide more accurate 
measurements.
 3. When histopathologic measurements are 
recorded after fixation, tumor diameter and 
thickness may be underestimated because of 
tissue shrinkage.
Regional Lymph Nodes (pN)
___ pNX: Regional lymph nodes cannot be 
assessed
___ pN0: No regional lymph node metastasis
___ pN1: Regional lymph node metastasis or dis-
crete tumor deposits in the orbit
___ pN1a: Metastasis in one or more regional 
lymph node(s)
___ pN1b: No regional lymph nodes are posi-
tive, but there are discrete tumor deposits in 
the orbit that are not contiguous to the eye 
(choroidal and ciliary body).
Distant Metastasis (pM) (Required Only if 
Confirmed Pathologically in This Case)
___ pM1: Distant metastasis
___ pM1a: Largest diameter of the largest metas-
tasis ≤3 cm
___ pM1b: Largest diameter of the largest metas-
tasis 3.1–8.0 cm
___ pM1c: Largest diameter of the largest metas-
tasis ≥8.1 cm
£ 3.0








3.1–6.0 6.1–9.0 9.1–12.0 12.1–15.0 15.1–18.0 >18.0
1 1 1 1 2 2 4
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Fig. C.1 Tumor size 




Specify sites(s), if known: _______________
__________________
+ Additional Pathologic Findings (Select 
All that Apply) (Note G)
+ ___ None identified
+ ___ Mitotic rate (number of mitoses per 40 
fields determined by using a 40X objective 
with a field area of 0.152  mm2) (specify): 
_____
+ ___ Extravascular matrix pattern (extracellular 
closed loops and networks, the latter defined 
as at least three back-to-back closed loops, are 
associated with death from metastatic 
disease)
+ ___ Vascular invasion (tumor vessels or other 
vessels)
+ ___ Degree of pigmentation
+ ___ Inflammatory cells/tumor infiltrating lym-
phocytes and macrophages
+ ___ Drusen
+ ___ Retinal detachment
+ ___ Invasion of Bruch’s membrane
+ ___ Nevus
+ ___ Hemorrhage (specify site): 
____________________________
+ ___ Neovascularization
+ ___ Other (specify): 
____________________________
+ Comment(s)
Note: Chromosome 3 and 8 loss or gain, immu-
nohistochemical staining for the presence or 
absence of BAP1 protein immunoreactivity, and/




The minimum recommended fixation time for 
whole globes with intraocular tumors is 48 hours. 
The globe should be fixed in an adequate volume of 
fixative, with a 10:1 ratio of fixative volume to spec-
imen volume recommended. Incisions or windows 
in the globe are not necessary for adequate penetra-
tion of fixative and are not recommended. Injection 
of fixative into the globe is also not recommended.
 B. Orientation
The orientation of a globe may be deter-
mined by identification of extraocular muscle 
insertions, the optic nerve, and other landmarks, 
as illustrated in Fig. C.2. The terms temporal 
and nasal are generally used in place of lateral 
and medial with reference to ocular anatomy.
 C. Tumor Size
Tumor size has prognostic significance. Many 
studies of choroidal and ciliary body melanoma 
have defined small tumors as being less than 10 mm 
in greatest diameter [4]. More recently, an ongoing 
study started in 1986, the Collaborative Ocular 
Melanoma Study [20, 21], defined the following 
size classification based on clinical measurements.
Small 
tumorsa




Greater than or equal to 2.5 mm, less than 
or equal to 10 mm in height, and less than 
or equal to 16 mm in basal diameter
Large 
tumors
Greater than 10 mm in height or
Greater than 2 mm in height and greater 
than 16 mm in basal diameter or
Greater than 8 mm in height with optic 
nerve involvement
aSmall tumors have a more favorable prognosis 
[22, 23]
Since then, the AJCC TNM system defined 
empirically four tumor sizes (Fig. C.1)—small 
(T1), medium (T2), large (T3), and very large 
(T4)—that differ significantly in survival prog-
nosis [24, 25]. This size classification was 
externally validated and is now recommended.
 D. Sectioning the Globe
The globe is generally sectioned in the hori-
zontal or vertical plane, with care to include the 
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pupil and optic nerve in the section to be sub-
mitted for microscopic examination. If the mass 
cannot be included with horizontal or vertical 
sectioning, the globe is sectioned obliquely to 
include the tumor, pupil, and optic nerve, as 
illustrated in Fig. C.3. Alternative methods of 
sectioning have been described [24].
 E. Histologic Type
The modified Callender classification shown 
below is used for determining cell type but has 
prognostic significance only for tumors of the 
choroid and ciliary body, not those of the iris, 






















Fig. C.2 Anatomic landmarks of the posterior aspect of 
the globe (right eye). The position of the inferior oblique 
muscle relative to the optic nerve is most helpful in orient-
ing the globe. The inferior oblique muscle insertion is 
located temporal (lateral) to the optic nerve on the sclera, 
and its fibers travel inferonasally from its insertion. The 
long posterior ciliary artery is often seen as a blue-gray 
line in the sclera on either side of the optic nerve and 




invade the chamber angle [4, 26–29]. The 
American Joint Committee on Cancer (AJCC) 
defined the histopathologic types3 as follows [28]:
• Spindle cell melanoma (>90% spindle cells)
• Mixed cell melanoma (>10% epithelioid cells 
and <90% spindle cells)
• Epithelioid cell melanoma (>90% epithelioid 
cells)
3 Spindle cell melanomas have the most favorable progno-




GX Grade cannot be assessed
G1 Spindle cell melanoma (>90% spindle cells)
G2 Mixed cell melanoma (>10% epithelioid cells 
and < 90% spindle cells)
G3 Epithelioid cell melanoma (>90% epithelioid cells)
Note: Because of the lack of universal agreement regarding 
which proportion of epithelioid cells classifies a tumor as 
mixed or epithelioid, some ophthalmic pathologists cur-
rently combine grades 2 and 3 (nonspindle, i.e., epithelioid 
cells detected) and contrast them with grade 1 (spindle, i.e., 
no epithelioid cells detected) or even tumors that have no 






Fig. C.3 The most 
common methods of 
sectioning a globe. After 
transillumination, the 
tumor base is marked, if 
possible, and included in 
the pupil-optic (p-o) nerve 
section and submitted for 
processing. If tumor is 
found in either of the 
calottes, these may also be 
submitted for sectioning. 
The meridian in which the 
globe was sectioned should 
be included in the gross 
description of the 
pathology report. It is not 
uncommon to induce an 
artifactitious retinal 
detachment while 
sectioning the globe. This 
can be minimized by 
gentle handling and by 
avoiding a sawing motion 




 F. Pathologic Stage Classification
The American Joint Committee on Cancer 
(AJCC) and the International Union Against 
Cancer (UICC) TNM staging systems for uveal 
melanoma of the iris, ciliary body, and choroid 
are shown below [19].
By AJCC/UICC convention, the designation 
“T” refers to a primary tumor that has not been 
previously treated. The symbol “p” refers to 
the pathologic classification of the TNM, as 
opposed to the clinical classification, and is 
based on gross and microscopic examination. 
pT entails a resection of the primary tumor or 
biopsy adequate to evaluate the highest pT cat-
egory, pN entails removal of nodes adequate to 
validate lymph node metastasis, and pM 
implies microscopic examination of distant 
lesions. Clinical classification (cTNM) is usu-
ally carried out by the referring physician 
before treatment during initial evaluation of 
the patient or when pathologic classification is 
not possible.
Pathologic staging is usually performed 
after surgical resection of the primary tumor. 
Pathologic staging depends on pathologic doc-
umentation of the anatomic extent of disease, 
whether or not the primary tumor has been 
completely removed. If a biopsied tumor is not 
resected for any reason (e.g., when technically 
unfeasible) and if the highest T and N catego-
ries or the M1 category of the tumor can be 
confirmed microscopically, the criteria for 
pathologic classification and staging have been 
satisfied without total removal of the primary 
cancer.
TNM Descriptors
For identification of special cases of TNM or 
pTNM classifications, the “m” suffix and “y,” “r,” 
and “a” prefixes are used. Although they do not 
affect the stage grouping, they indicate cases 
needing separate analysis.
The “m” suffix indicates the presence of mul-
tiple primary tumors in a single site and is 
recorded in parentheses: pT(m)NM.
The “y” prefix indicates those cases in which 
classification is performed during or following 
initial multimodality therapy (i.e., neoadjuvant 
chemotherapy, radiation therapy, or both chemo-
therapy and radiation therapy). The cTNM or 
pTNM category is identified by a “y” prefix. The 
ycTNM or ypTNM categorizes the extent of 
tumor actually present at the time of that exami-
nation. The “y” categorization is not an estimate 
of tumor prior to multimodality therapy (i.e., 
before initiation of neoadjuvant therapy).
The “r” prefix indicates a recurrent tumor 
when staged after a documented disease-free 
interval, and is identified by the “r” prefix: rTNM.
The “a” prefix designates the stage deter-
mined at autopsy: aTNM.
Additional Descriptors
Residual Tumor (R)
Tumor remaining in a patient after therapy with 
curative intent (e.g., surgical resection for cure) is 
categorized by a system known as R classifica-
tion, as shown below.
RX Presence of residual tumor cannot be assessed
R0 No residual tumor
R1 Microscopic residual tumor
R2 Macroscopic residual tumor
For the surgeon, the R classification may be use-
ful to indicate the known or assumed status of the 
completeness of a surgical excision. For the 
pathologist, the R classification is relevant to the 
status of the margins of a surgical resection spec-
imen. That is, tumor involving the resection mar-
gin on pathologic examination may be assumed 
to correspond to residual tumor in the patient and 
may be classified as macroscopic or microscopic 
according to the findings at the specimen 
margin(s).
T Category Considerations
Iris melanomas originate from, and are predomi-
nantly located in, this region of the uvea. If less 
than half of the tumor volume is located within 
the iris, the tumor may have originated in the 
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ciliary body, and consideration should be given 
to classifying it accordingly.
Ciliary Body and Choroid
Primary ciliary body and choroidal melanomas 
are classified according to the four tumor size 
categories in Fig. C.1 [19]:
In clinical practice, the largest tumor basal 
diameter may be estimated in optic disc diameters 
(dd, average: 1 dd = 1.5 mm). Tumor thickness 
may be estimated in diopters (average: 2.5 diop-
ters = 1 mm). However, techniques such as ultra-
sonography and fundus photography are used to 
provide more accurate measurements. Ciliary 
body involvement can be evaluated by the slit 
lamp, ophthalmoscopy, gonioscopy, and transil-
lumination. However, high-frequency ultrasonog-
raphy (ultrasound biomicroscopy) is used for 
more accurate assessment. Extension through the 
sclera is evaluated visually before and during sur-
gery, and with ultrasonography, computed tomog-
raphy, or magnetic resonance imaging.
When histopathologic measurements are 
recorded after fixation, tumor diameter and thick-
ness may be underestimated because of tissue 
shrinkage.
Lymph-Vascular Invasion (LVI)
LVI indicates whether microscopic lymph-vascu-
lar invasion is identified in the pathology report. 
LVI includes lymphatic invasion, vascular inva-
sion, or lymph-vascular invasion. By AJCC/
UICC convention, LVI does not affect the T cat-
egory indicating local extent of tumor unless spe-
cifically included in the definition of a T category. 
It should be noted that regional lymph node 
involvement is rare in uveal melanoma, but 
metastasis to the liver and direct extension into 
the orbit are more common [19].
Stage Grouping
Stage I T1a N0 M0
Stage IIA T1b-d N0 M0
T2a N0 M0
Stage IIB T2b N0 M0
T3a N0 M0
Stage IIIA T2c-d N0 M0
T3b-c N0 M0
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direct closure, 35, 36
full-thickness skin graft, 36–38, 55
laissez-faire approach, 35
partial thickness periocular defects, 35
Anterior plaque, 154
Array comparative genomic hybridisation (aCGH), 180
B
Basal cell carcinoma (BCC), 3, 15, 16
left cheek, 23
markings for reconstruction, 23
post reconstruction, 23
at medial canthus, 22
paramedian forehead flap, repaired with, 22
regional flap, repaired with, 22
B-cell markers, 175, 176
Benign epithelial proliferations, 3
Bilateral ecchymosis, 110
Bilateral upper lid xanthelasmas, 110
Bilobed flap, 50–51





excisional biopsy technique, 29
incisional biopsy technique, 29, 30
preoperative considerations, 29
punch biopsy technique, 29, 30
shave biopsy technique, 29–31
snip biopsy, 31
Blind painful eyes, 133
B lymphocytes, 176
Bone incisions (osteotomies), 121
Bucket-handle flap, 42, 43
C
Cantholysis, adjunct procedure, 44–45
Caruncle tumors, 73, 80
Chalazion with pyogenic granuloma, 14
Choristomatous tumors, 70
Choroidal haemangiomas, 92, 93
Choroidal naevus, 88, 90
Choroidal osteoma, 92
Chromosomal microarray analysis, 180
Ciliochoroidal melanoma, 132
Circumpapillary plaques, 155
Circumscribed choroidal haemangiomas, 92
Classical lateral orbitotmy approach, 123
Complexion-associated melanosis (CAM), 72




conjunctival choristoma, 70, 77
conjunctival intraepithelial neoplasia vs. squamous 
cell carcinoma, 70











no touch technique, 75






Conjunctival choristoma, 70, 77
Conjunctival epithelial tumors, 70–72
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Conjunctival intraepithelial neoplasia (CIN), 71
Conjunctival lymphoma, 72, 73
Conjunctival map biopsies, 11, 81, 82
Conjunctival melanocytic tumors, 72
Conjunctival melanoma, 72, 180
Conjunctival nevus, 72, 76
Conjunctival squamous cell carcinoma, 133
Conjunctival tumor histopathology report, 174, 175
Conjunctival tumors, 71, 150
Corneal tumors, 69




Cystic basal cell carcinoma, 111
D
Dermal adnexal cyst, 20
Diffuse conjunctival SCC, 72
Direct closure, 36
Dissected epidermal cyst, 17





blind painful eyes, 133
choice of implants, 135
ciliochoroidal melanoma, 132
conjunctival squamous cell carcinoma, 133
definition, 131
ideal anophthalmic socket, 131
indications, 132
intraocular and orbital malignancies, 131
iris melanoma, 132




recurrent posterior melanoma, 132
retinoblastoma and uveal melanoma, 131
surgical technique, 134, 135
Epidermal cyst, 17
Epidermal growth factor receptor (EGFR) inhibitors, 20
Episcleral brachytherapy, 149
Episcleral hemostasis, 79
Excised dermal adnexal cyst, 20
Excised neurofibroma (templet method), 17




conjunctival primary acquired melanosis, 81
conjunctival squamous cell carcinoma, 78
Exenteration
choice of implant, 135
indications, 133





Extrascleral uveal melanoma, 153–154
Eyebrow, laser treatment, 16
Eyelid basal cell carcinoma, 180
Eyelid defects
anterior lamella defects
direct closure, 35, 36
full-thickness skin graft, 36–38, 55
laissez-faire approach, 35
partial thickness periocular defects, 35
full-thickness
bucket-handle flap, 42, 43
direct closure, 39
full-thickness lower to upper eyelid flap repair, 
40–41
lateral semicircular skin flap/tenzel flap, 39, 40
periosteal strip, adjunct procedure, 41
sliding upper eyelid tarsoconjunctival flap, 43
standard surgical technique, 39
upper lid full-thickness defect, 38–39
lower eyelid defects
cantholysis, adjunct procedure, 44–45
complications, 55
direct closure–wedge excision, 44
Hughes tarsoconjunctival flap, 45–46
lateral-based full-thickness advancement flap, 
47–49
Mustarde’s cheek rotation flap, 48
periorbital flaps, 44
single-stage advancement flaps +/- free grafts, 
46–47
skin flaps, 44
tenzel semicircular flap, 45
treatment, 44
preferred anesthesia, 34
Eyelid margin pigmented nevus, 15
Eyelid reconstruction
complications, 55




full-thickness grafts, 53, 54










forehead or glabellar tissue, 51
laissez-faire (spontaneous granulation), 50
nasolabial, cheek, and midfacial tissue, 51
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paramedian forehead flap, 51
reconstruction options, 49–50
rhomboid transposition flap, 50
skin grafting, 52
upper eyelid anterior lamella, 51
periocular area, 33–34






excisional biopsy technique, 29
incisional biopsy technique, 29, 30
preoperative considerations, 29
punch biopsy technique, 29, 30
shave biopsy technique, 29–31
snip biopsy, 31






basal cell carcinomas, 15, 16
benign lesions, 13, 19
follow-up, 24, 25
instruments, 12
malignant lesions, 15, 21
melanomas, 22, 23
merkel cell carcinoma, 23, 24
postoperative care, 24
premalignant lesions, 14, 20
SCC, 16
sebaceous gland carcinoma, 20–21
extensive basal cell carcinoma, 7















vascular and perineural invasion, 174
malignant melanoma, 3, 4, 8
no touch technique, 12
oncological principles, 11
postoperative care, 31
sebaceous gland carcinoma, 7









bucket-handle flap, 42, 43
direct closure, 39
full-thickness lower to upper eyelid flap repair, 40–41
lateral semicircular skin flap/tenzel flap, 39, 40
periosteal strip - adjunct procedure, 41
sliding upper eyelid tarsoconjunctival flap, 43
standard surgical technique, 39
upper lid full-thickness defect, 38–39
Full-thickness skin graft (FTSG), 36
G
Giant hairy nevus, 16
H
Handheld gamma probe, 61
Hemostasis, 78, 122–123
High-dose-rate (HDR) brachytherapy, 153
Hughes tarsoconjunctival flap, 45–46
Hydroxyapatite (HA) ocular implant, 135, 142
I
IgH rearrangement, 176
Immune checkpoint inhibitors, 63
Incisional biopsy technique, 29, 30
Infiltrative basal cell carcinoma, 27
Intraocular neoplasm, 102
Intraocular tumors, 150
choroidal haemangiomas, 92, 93








ocular metastasis, 91, 92
posterior segment incisional biopsy






primary intraocular lymphoma, 94, 95
retinal capillary haemangioma, 92, 93
retinoblastoma, 87–89
sclerochoroidal calcification, 94
uveal melanoma, 90, 91
vasoproliferative tumour, 94
Invasive conjunctival SCC, 71
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full-thickness grafts, 53, 54




standard surgical technique, 53
Lateral semicircular skin flap/tenzel flap, 39, 40
Lateral-based full-thickness advancement flap, 47–49
Lateral-based tarso-conjunctival flap, 49
Lower eyelid defects
cantholysis, adjunct procedure, 44–45
complications, 55
direct closure–wedge excision, 44
Hughes tarsoconjunctival flap, 45–46
lateral-based full-thickness advancement flap, 47–49
Mustarde’s cheek rotation flap, 48
periorbital flaps, 44
single-stage advancement flaps +/- free grafts, 46–47
skin flaps, 44
tenzel semicircular flap, 45
treatment, 44
M






forehead or glabellar tissue, 51
laissez-faire (spontaneous granulation), 50
nasolabial, cheek, and midfacial tissue, 51
paramedian forehead flap, 51
reconstruction options, 49–50
rhomboid transposition flap, 50
skin grafting, 52
upper eyelid anterior lamella, 51




Melanomas, 22, 23, 27
Merkel cell carcinomas (MCC), 3, 23, 24, 26
Moh’s micrographic surgery, 11
Mucinous carcinoma, 26
Mustarde’s cheek rotation flap, 48
N
Neurofibroma, 17






complete ophthalmic examination, 109
cystic basal cell carcinoma, 111
family history, 108
globes with Hertel’s exophthalmometer, 109, 110
laboratory tests, 111
motility dysfunction and diplopia, 109
normal anatomy, 110





computed tomography, 112, 113
incidence
metastatic tumors, 107
patient assessment process, 108
primary tumors, 107
magnetic resonance imaging, 111–113
PET CT, 113
ultrasonography, 113
Ocular adnexal tumors, 150–151
Ocular metastasis, 91, 92
Ocular pathology
ancillary investigations
chromosomal microarray analysis, 180
flow cytometry, 179–180
fluorescence in situ hybridisation (FISH), 180
immunohistochemistry, 176, 178
polymerase chain reaction, 178
post-analytical phase (see Post-analytical phase)
pre-analytical phase
conjunctival biopsy, 162
fresh tissue sample, 164–165
infection specimens, 168
mailed or couriered specimens, 168
pathology laboratory, 161–162
request forms, 162, 163




eyelid basal cell carcinoma, 180
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Ocular surface reconstruction, 81
Ocular surface squamous neoplasia, 70
Ophthalmic histopathology report















vascular and perineural invasion, 174
intraocular tumor, 175
orbital tumor, 175–176




orbital Brachy-Boost technique, 154
orbital brachytherapy
equipment and devices, 153
extrascleral uveal melanoma, 153–154
residual orbital melanoma, 152–153
post surgical procedures, 156
presurgical preparations
device preparations, 152
intraocular tumor imaging, 151








Russian Experience with Strontium-90, 155, 156
surgical indications
intraocular tumors, 150
ocular adnexal tumors, 150–151




Orbital Brachy-Boost technique, 154
Orbital brachytherapy
equipment and devices, 153
extrascleral uveal melanoma, 153–154
residual orbital melanoma, 152–153
Orbital exploration, 121, 122
Orbital implants
bio-ceramic implants, 142
hydroxyapatite ocular implant, 142
polyethylene (MEDPORE®) implant, 142















medial conjunctival approach, 120
orbital biopsy, 123
orbital inflammation, 119
reverse Trendelenburg position, 118





Orbital xanthogranuloma/systemic disease, 110
P
Pagetoid spread, 81
Paramedian forehead flap, 51
Partial scleroconjunctivectomy, 78
Partial thickness periocular defects, 35
Partially involuted infantile hemangioma, 18
Periocular reconstruction, 33–34
Peripunctal nevus, 15
Peri-tumoral limbal conjunctiva, 78
Photocoagulation, 100
Photodynamic therapy, 100
Pigmented basal cell carcinoma, 27
Pilomatrixoma, 14
Plaque radiotherapy, 76, 82
Polyethylene (MEDPORE®) implant, 142
Polymerase chain reaction (PCR), 178
Porous implants, 136
Post-analytical phase, ophthalmic histopathology report





Posterior segment incisional biopsy






Posterior segment incisional biopsy (cont.)
iris tumors, 102
vitrectomy, 101
Post excision with eyebrow preservation, 16
Post-reconstruction with suprapubic skin graft, 16
Premalignant lesions, 14, 20
Primary acquired melanosis (PAM), 72
Primary central system lymphoma (PCNSL), 94
Primary intraocular lymphoma (PIOL), 94, 95
Punch biopsy technique, 29, 30
R





Radioactive plaque placement, 155
Reactive lymphoid aggregates, 175, 176
Recurrent posterior melanoma, 132
Relaxed skin tension lines (RSTLs), 118
Residual orbital melanoma, 152–153
Retina and choroid tumor, 150
Retinal capillary haemangioma (RCH), 92, 93
Retinoblastoma, 87–89, 131, 181
Retropulsion, 111




Sebaceous gland carcinoma (SGC), 3, 7, 20–21
cheek rotation flap, 25
with loco-regional & systemic spread, 27
lower eyelid, 25
post reconstruction, 25




right upper eyelid, 24
Seborrheic keratosis, 13
Self-inflating tissue expanders, 143




immune check point inhibitors, 63








prospective, international, randomized trial, 62
regional lymph node metastasis, 59
risk factors, 60
surgical procedure, 60–62
Shave biopsy technique, 29–31
Simple limbal epithelial transplantation (SLET), 81
Single nucleotide polymorphism (SNP) chromosomal 
arrays, 180
Single-photon emission CT (SPECT-CT), 60, 61
Single-stage advancement flaps +/- free grafts, 46–47
Skin incisions, 118, 120, 121
Sliding upper eyelid tarsoconjunctival flap, 43
Snip biopsy, 31
Space-occupying lesions, 119








Upper eyelid anterior lamella, 51
Upper eyelid sliding tarsoconjunctival flap, 43
Upper lid full-thickness defect, 38–39










Xanthelasma post excision, 17
Xanthelasmas, 110
Xeroderma pigmentosa, 20
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